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Senescence is a state of proliferative arrest that is triggered through a range of harmful 
stimuli. Senescent cells are associated with the acquisition of an enhanced secretory profile 
known as the senescence-associated secretory phenotype (SASP), which has been 
demonstrated to confer a secondary senescence response upon neighbouring proliferating 
cells, in a process known as paracrine senescence. This work aims to characterise the 
contribution of a group of small lipid bilayer-bound particles, known as extracellular vesicles 
(EVs), to the induction of paracrine senescence, with a focus on emphasising the limitations 
of widely applied EV isolation methodologies in a senescence context.      
 
First, models of oncogene-induced (OIS) and replicative (RS) senescence were established in 
IMR90 and adult human mammary fibroblasts respectively, with phenotypic characterisation 
performed via a high content analysis (HCA) approach. EVs were then isolated from these 
models via differential ultracentrifugation (dUC), with increased EV release identified 
following senescence induction in both settings. Proteomic profiling via mass spectrometry 
(MS) indicated that soluble components of the SASP co-isolate during dUC based procedures, 
hindering the utility of this widely used technique within senescence research. Size-exclusion 
chromatography (SEC) was established to overcome this limitation, facilitating a further, 
more comprehensive assessment of OIS derived EVs via MS. Furthermore, SEC allowed 
demonstration that EVs isolated from OIS fibroblasts mediate the induction of paracrine 
senescence in both proliferating fibroblasts and breast cancer cells. Finally, in order to probe 
the mechanisms underlying these responses, potential mechanistic leads (NOTCH1 and 
ADAM10/17) were identified from EV proteomic profiles and validated to be constituents of 
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OIS derived EVs. The functional importance of these targets in paracrine senescence was also 
investigated.  
 
Overall, this work emphasises that EVs are distinct and functionally important mediators 
within the SASP, but that their investigation in a senescence setting requires careful attention 
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JAK Janus kinase 
Ki67 Antigen KI-67 
LFQ Label-free quantification 
LMK Lim Kinase 
LP Late passage 
M Mitotic phase 
M Molar 
MAML1 Mastermind like transcriptional coactivator 1 
MCH-II Major histocompatibility complex class II 
MDM2 Mouse double minute 2 homolog 
MEFs Mouse embryonic fibroblasts 
MIP1β Macrophage inflammatory protein-1 beta (CCL4) 
miR Micro RNA 
MISEV Minimum Information for the Study of Extracellular Vesicles 
ml Millilitre 
mM Millimolar 
MMP Matrix metalloproteinase 
MPF Mitotis-promoting factor (CDK1 and cyclin B complex) 
mRNA Messenger RNA 
MS Mass spectrometry 
mTOR Mammalian target of rapamycin 
MV Microvesicle 
MVB Multivesicular body 
N1ICD Notch-1 intracellular domain 
NF-κB Nuclear Factor kappa-light-chain-enhancer of activated B 
ng Nanogram 
NIS Notch Induced Senescence 
NK cell Natural Killer Cell 
nSMase Neutral sphingomyelinase-2 
NTA Nanoparticle tracking analysis 
OA Osteoarthritis 
OHT 4-Hydroxytamoxifen 
OIS Oncogene induced senescence 
p38MAPK P38 mitogen-activated protein kinases 
PAI-1 Plasminogen activator inhibitor-1 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PDGFAA Platelet-derived growth factor 
PDs Population doublings 
PEG Polyethylene glycol 





PGE2 Prostaglandin E2 
pH Power of hydrogen 
psen1 Presenilin-1 
PTX Paclitaxel 
qRT-PCR Quantitative Reverse Transcription PCR 
RA Rheumatoid arthritis 
RB Retinoblastoma 
RIPA Radio immunoprecipitation assay buffer 
RNA Ribonucleic acid 
ROCK RHO-associated protein kinase 
ROS Reactive oxygen species 
RPM Revolutions per minute 
RS Replicative senescence 
RT Room temperature 
S DNA synthesis 
SAHF Senescence-associated heterochromatin foci 
SASP Senescence-associated secretory phenotype 
SA-β-gal Senescence-associated beta-galactosidase 
SBB Sudan Black B 
SCAPs Senescent Cell Anti-Apoptotic Pathways 
SEC Size-Exclusion chromatography 
SF Synovial fluid 
shRNA Short hairpin RNA 
siRNA Small inhibitory RNA 
SIRT1 Sirtuin-1 
SP-IRIS Single-Particle Interferometric Reflectance Imaging Sensor 
TEAB Triethylammonium bicarbonate buffer 
TEM Transmission electron microscopy 
TEM Transmission electron microscopy 
TERRA Telomeric Repeat-containing RNA 
TGFβ Transforming growth factor beta 
TIS Therapy-induced senescence 
TRPS Tunable resistive pulse sensing 
TSAP6 Tumour suppressor-activated pathway 6 
u Unit 
uPA Urokinase-type plasminogen activator 
UPR Unfolded protein response 
VEGF Vascular endothelial growth factor 
VPS32 Vacuolar protein sorting-associated protein 32 
WCL Whole cell lysate 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
Y-EVs Young extracellular vesicles 
αSMA alpha smooth muscle actin 
γH2AX H2A histone family member X 






1.1.1 The Cell Cycle  
The division of eukaryotic cells is orchestrated in a highly regulated process known as the cell 
cycle (Figure 1.1). This is split into four distinct phases (G1, S, G2 and M) that are closely 
regulated at three key checkpoints (G1/S, G2/M and Spindle) (Schafer, 1998; Vermeulen, Van 
Bockstaele and Berneman, 2003). In vivo cells primarily exist in a reversible cell cycle arrest 
known as quiescence (G0) and only enter the cell cycle in G1 following sufficient mitogenic 
stimulation (Pardee, 1974). During G1, the cell is readied for DNA synthesis, which occurs 
during S phase. G2 then primes the cell for entry into the mitotic (M) phase (Malumbres and 
Barbacid, 2001; Massagué, 2004). During mitosis, chromosomes are sorted into daughter 
cells and cell division occurs through cytokinesis (Wieser and Pines, 2015). Progression 
through the cell cycle is driven by the interaction and complex formation between cyclin 
dependent kinases (CDKs) and cyclin sub-units (Satyanarayana and Kaldis, 2009; Lim and 
Kaldis, 2013). These allow advancement through regulatory checkpoints at which stage a cell 
is committed to the next phase of the cell cycle (Malumbres and Barbacid, 2001; Vermeulen, 
Van Bockstaele and Berneman, 2003). 
 
The progression of the cell cycle is transcriptionally controlled by the E2F family of 
transcription factors, which are frequently termed “master regulators”  (Dyson, 1998; 
Bertoli, Skotheim and De Bruin, 2013). In cells not under mitogenic stimulation, E2F mediated 
transcription is repressed though the binding of Retinoblastoma protein (RB) family 
members including RB, p130 and p107 (Dyson, 1998; Malumbres and Barbacid, 2001; 
Satyanarayana and Kaldis, 2009). Following sufficient mitogenic stimulation (including 
growth factor treatment), cells re-enter the cell cycle in G1, having advanced through the so-
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called restriction point (Pardee, 1974). This transition is governed by the synthesis of cyclin 
D in response to growth factor stimulation, which is not constitutively expressed in G0 cells 
(Assoian and Zhu, 1997; Vermeulen, Van Bockstaele and Berneman, 2003). CDK4/6 facilitates 
phosphorylation of RB through the formation of complexes with cyclin D, leading to 
dissociation of RB from E2F (Massagué, 2004; Bertoli, Skotheim and De Bruin, 2013). 
Transcription of E2F target genes marks progression though the restriction point and cells 
are now committed to S phase (Vermeulen, Van Bockstaele and Berneman, 2003; 
Satyanarayana and Kaldis, 2009). The G1/S transition is itself mediated by the E2F 
transcriptional target cyclin E, though complex formation with CDK2. This leads to 
hyperphosphoryaltion of RB (a state that is retained through the rest of the cell cycle) and 
further expression of E2F transcriptional targets, including cyclin E and A (Malumbres and 
Barbacid, 2001; Vermeulen, Van Bockstaele and Berneman, 2003; Moser et al., 2018). This 
feedback loop mediates the G1/S transition (Ohtsubo et al., 1995; Massagué, 2004). 
 
Following G1/S transition, cells are primed for DNA replication, with progress through S 
phase mediated by complexes of cyclin A and CDK2 (Girard et al., 1991; Walker and Maller, 
1991; Sherr, 2000). These complexes mediate both the activation of DNA synthesis and 
prevent further replication, ensuring DNA synthesis occurs only once per cell cycle (Coverley, 
Laman and Laskey, 2002; Woo and Poon, 2003). Progression through the G2/M phase 
checkpoint and entry into mitosis is governed by CDK1 and cyclin A complexes (Pagano et al., 
1992; Vermeulen, Van Bockstaele and Berneman, 2003). During mitosis, CDK1 and cyclin B 
complexes (also referred to as mitosis-promoting factor; MPF) regulate the initiation of both 
prophase and anaphase, with the latter leading to the degradation of cyclins and exit from 
mitosis into G1 of the following cell cycle (King, Jackson and Kirschner, 1994; Peters, 2006; 
Harashima, Dissmeyer and Schnittger, 2013).                    
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Whilst cyclins and CDKs represent key facilitators of the cell cycle, additional mechanisms 
exist that maintain regulatory control of the process. Key to the G1/S checkpoint, are the 
cyclin-dependent kinase inhibitor (CDKI) families INK4 and Cip/Kip, which act to inhibit the 
formation of cyclin-CDK complexes and thus impede cell cycle progression (Malumbres and 
Barbacid, 2001; Vermeulen, Van Bockstaele and Berneman, 2003). The INK4A family of 
cyclin-dependent kinase inhibitor (CDKI) tumour suppressors include p16INK4A (p16), p15INK4B 
(p15), p18INK4C (p18) and p14INK4D (ARF), which bind to CDK4/6 thus inhibiting complex 
formation with cyclin D (Malumbres and Barbacid, 2001). Cip/Kip CDKIs including p21WAF/CIP1 
(p21), p27KIP1 (p27) and p57KIP2 (p57) produce a less specific inhibition, attenuating CDK 
interactions with cyclins A, B, D and E (Figure 1.1), thus inhibiting progression though all 
phases of the cell cycle (Sherr and Roberts, 1999; Lim and Kaldis, 2013). The inhibition of 
CDK4/6 and CDK2 during G1 prevents the phosphorylation of RB. Consequently, this 
hypophosphorylated RB retains its inhibitory effect on E2F thus preventing transition from 
G1 to S phase. This arrest of the cell cycle is key to the process of senescence induction, with 
both p16 and p21 recognised as markers of a senescence response (Munoz-Espin and 





Figure 1.1: The Cell Cycle 
The cell cycle is comprised of four phases and dictates the growth and division of cells. In 
vivo, cells predominantly exist in a state of quiescence (G0), only entering the cell cycle 
following sufficient mitogenic stimulation. Entry into the cell cycle occurs during growth 
phase 1 (G1) and progresses through the DNA synthesis (S), growth 2 (G2) and mitotic phases 
successively. Advancement through the cell cycle is controlled at regulatory checkpoints by 
the formation of complexes between cyclin dependent kinases (CDKs) and regulatory cyclin 
sub-units. During senescence, exit from the cell cycle occurs, mediated by the action of INK4A 
(p16, p15, p18 and p19) and Cip/Kip (p21, p27 and p57) cyclin dependent kinase inhibitors. 
This predominantly occurs during G1, where hypophosphorylation of retinoblastoma protein 
(RB) leads to inhibition of E2F family transcription factors and failure to advance through the 





1.1.2 Pathways of Senescence Induction  
Senescence is a state of proliferative arrest typically characterised by exit from the cell cycle 
during G1 (Di Leonardo et al., 1994; Serrano et al., 1997; Campisi and D’Adda Di Fagagna, 
2007). This process was first described by Leonard Hayflick, who observed that primary 
fibroblasts possessed finite proliferative potential in vitro (Hayflick and Moorhead, 1961). 
This limited proliferative capacity was demonstrated to result from the shorting of telomeres 
with successive rounds of the cell cycle, leading to a DNA damage response (DDR) and what 
is now referred to as replicative senescence (Harley, Futcher and Greider, 1990; Olovnikov, 
1996; Bodnar et al., 1998). It has subsequently emerged that senescence may be induced 
prematurely through a variety of potentially harmful stimuli (described in detail in section 
1.1.7) (Sharpless and Sherr, 2015; Gorgoulis et al., 2019). Whilst the pathways through which 
senescence induction occurs are highly cell type and inducing stimulus specific, two pivotal 
effectors have been widely described as key to the initiation and maintenance of senescence 
– the CDKIs p16 and p21.  
 
Whilst not a universal requirement for the induction of senescence, many stimuli which 
trigger senescence initiate a DDR (Munoz-Espin and Serrano, 2014). This leads to the 
activation of kinases including ataxia-telangiectasia (ATM) and ataxia-telangiectasia and 
Rad3-related (ATR) that phosphorylate the checkpoint kinases CHK1 and CHK2 (Gire et al., 
2004; Campisi and D’Adda Di Fagagna, 2007). In turn, this leads to the phosphorylation of 
the transcription factor p53, attenuating the inhibitory binding of the ubiquitin ligase mouse 
double minute 2 homolog (MDM2; HDM2 human equivalent) which mediates the 
degradation of hypophosphorylated p53. Stabilisation of p53 leads to activation of the p21 
promoter and transcription of p21 (Espinosa, Verdun and Emerson, 2003; Campisi and 
D’Adda Di Fagagna, 2007). The role of p21 as a CDKI then leads to the inhibition of cyclin E 
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and CDK2 complex formation, preventing phosphorylation of RB. Consequently, E2F 
transcriptional activity is repressed and cessation of the cell cycle occurs during G1 as 
described above (section 1.1.1). 
 
Senescence induction may also occur through derepression of the CDKN2A locus. This has 
been observed in both ageing and following oncogene expression (Serrano et al., 1997; 
Krishnamurthy et al., 2004). This leads to expression of p16, which causes E2F inhibition 
though RB, via the blockade of cyclin D binding to CDK4/6 (Alcorta et al., 1996; Sherr, 2001). 
Furthermore, the gene product p14ARF (ARF) is also encoded at the CDKN2A locus (Sherr, 
2001). ARF contributes to the stabilisation of p53 and thus propagation of the p53/p21 
pathway, through inhibition of MDM2 (Sherr and McCormick, 2002).  
 
The relative contribution of the p21 and p16 pathways to the induction of senescence varies 
within specific cellular contexts. For example, epithelial cells have been demonstrated to 
undergo a p16 mediated senescence response before the critical shortening of telomeres 
(cellular senescence). Methylation of the p16 promoter then facilitates the reinstatement of 
cellular proliferation, which continues until telomere attrition triggers an exclusively p21 
driven senescence response (Brenner, Stampfer and Aldaz, 1998; Garbe et al., 2009). By 
contrast, both p21 and p16 have been demonstrated to contribute to the initiation and 
maintenance of senescence in fibroblasts. In fibroblast replicative senescence, p21 and p16 
expression occurs sequentially, with p21 levels reaching a maximum several passages before 
the population has reached proliferative arrest. This then begins to decline, accompanied by 
a concurrent increase in p16 expression (Alcorta et al., 1996). Furthermore, p16 has been 
demonstrated to maintain senescence-associated proliferative arrest following inhibition of 
the p53/p21 pathway, whilst inactivation of p53 reinstated proliferation in cells with low 
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levels of p16 (Beauséjour et al., 2003). Additionally, a secondary senescence response may 
be initiated in proliferating fibroblasts treated with conditioned media from oncogene-
induced senescence (OIS) cells. This occurs through activation of p21 and p15 pathways via 
transforming growth factor beta (TGFβ), a key component of the senescence-associated 
secretory phenotype (SASP) (section 1.1.4) (Coppe et al., 2008; Acosta et al., 2013). Models 
of replicative senescence and OIS are utilised within this work. 
 
In summary, the proliferative arrest which occurs during senescence is initiated and 
maintained primarily though the actions of the p16 and/or p21 tumour suppressor pathways 
(Figure 1.2). However, the relative importance of each of these varies between both cell 
types and senescence inducing stimuli. Consequently, senescence represents a diverse set 
of phenomena, each of which differ within the context of their initiation. This heterogeneity 
is reflected in the diverse set of markers that have emerged as so-called “hallmarks” of 





Figure 1.2: Pathways to Senescence Induction 
Senescence induction may occur in response to a range of potentially harmful stimuli. Many 
of these lead to instigation of a DNA damage response (DDR) and activation of kinases 
including ataxia-telangiectasia (ATM) and ataxia-telangiectasia and Rad3-related (ATR). 
These lead to a signalling cascade which results in the activation of the transcription factor 
p53, which facilitates transcription of the cyclin dependent kinase inhibitor (CDKI) p21. The 
transcription of p16, another CDKI may also be elicited by senescence inducting stimuli, 
including oncogenic signalling and derepression of the CDK2NA locus. The later of these can 
also facilitate p21 expression through increased ARF expression, leading to inhibition of 
MDM2 and disinhibition of p53. Furthermore, secreted cytokines including TGF-β have been 
demonstrated to facilitate activation of p53. Following expression, the CDKIs act to inhibit 
complex formation between cyclin dependent kinases (CDKs) and regulatory cyclin sub-units. 
This leads to hypophosphorylation of retinoblastoma protein (RB) and inhibition of E2F 
family transcription factors, leading to cessation of the cell cycle and induction of 
senescence. Based on (Munoz-Espin and Serrano, 2014).   
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1.1.3 Phenotypic Markers of Senescence 
As described in section 1.1.2, senescence represents a heterogeneous set of terminal cell 
fates that vary with cell type and senescence inducing stimuli. Whilst senescent cells share 
many common features, the diversity of potential cellular contexts has prevented the 
emergence of a universal “marker” of senescence. It is of particular importance to note that 
observation of a senescence phenotype must be carefully distinguished from other instances 
where cessation of cellular proliferation occurs, including quiescence and differentiation 
(Gorgoulis et al., 2019). To achieve this, a panel of senescence “hallmarks” are often utilised, 
in order to compliment an observed loss of proliferation (Hernandez-Segura, Nehme and 
Demaria, 2018). In order to comprehensively classify senescence induction, it has been 
proposed that a three-step multi-marker workflow be employed. This includes: 1) a general 
screen for senescence induction; 2) verification with additional markers; and 3) sub-type 
classification (Gorgoulis et al., 2019). The markers chosen within this framework will vary 
depending on the specific senescent context and are discussed in detail in this section (Figure 
1.3). The development of a senescence-associated secretory phenotype (SASP) is examined 
in section 1.1.4.          
 
1.1.3.1 Loss of Cellular Proliferation 
As described in section 1.1.1, a G1 cell cycle arrest is fundamental to the process of 
senescence. Therefore, loss of cellular proliferation is an intrinsic hallmark of senescence. 
The loss of cellular proliferation markers are often used to demonstrate this phenomenon. 
Bromodeoxyuridine (BrdU) is a thymidine analogue that is incorporated into DNA during 
synthesis in the course of S phase (Nowakowski, Lewin and Miller, 1989). BrdU 
immunofluorescence (IF) staining can be used to demonstrate a lack of progression to S 
phase and thus indicate that a population of cells has undergone a G1 arrest. Similarly, Ki67 
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is a proliferation marker whose expression greatly increases during S phase (Lawless et al., 
2010). Therefore, negative Ki67 IF staining can also be used to indicate cell cycle arrest. 
Reduced cellular proliferation can also be identified through quantitation of cell numbers, 
such as via nuclei counts following 4,6‐diamidino‐2‐phenylindole (DAPI) staining. Overall, 
whilst a key marker of senescence, loss of cellular proliferation alone is insufficient to 
distinguish senescence from cell fates such as quiescence and differentiation. It is also limited 
to in vitro assessment, as the vast majority of cells in vivo are in a state of G0 arrest 
(Vermeulen, Van Bockstaele and Berneman, 2003). Therefore, whilst an important marker, 
the loss of cellular proliferation alone cannot be considered an exclusive senescence marker.   
 
1.1.3.2 Cyclin Dependent Kinase Inhibitor Expression 
Closely linked to the loss of cellular proliferation described in section 1.1.2, senescence is 
associated with the engagement of the p16 and p21 tumour suppressor pathways. 
Therefore, identification of p16 and p21 upregulation are widely used to demonstrate the 
induction of a senescence response (Gorgoulis et al., 2019). However, the relative 
importance of these pathways varies between different types of senescence and neither can 
be considered a universal marker. Furthermore, p21 activation is not restricted to 
senescence, mediating DDR responses such as apoptosis and DNA repair (Jung, Qian and 
Chen, 2010). Paradoxically, p21 has also been demonstrated to promote cell cycle 
progression by facilitating CDK4/cyclin D complex formation (Cheng, 1999). This is an 
illustrative example of the wider issues regarding senescence marker identification, as whilst 
extremely useful in many settings, p21 is neither exclusive to senescence nor present in all 
senescence models. This underpins the requirement for a panel of senescence markers to 
confidently detect senescence induction.     
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1.1.3.3 Cellular Morphology 
Alterations in cell size and morphology were among the first phenotypic changes to be 
described as accompanying senescence (Cristofalo and Kritchevsky, 1969; Greenberg, Grove 
and Cristofalo, 1977; Wang and Gundersen, 1984). Phase contrast microscopy can readily 
visualise an increase in cell size following senescence induction, with heterogeneous size 
profiles emergent between different models of senescence (Hwang, Yoon and Kang, 2009). 
This increased size in vitro appears to be recapitulated in vivo, with senescence-associated 
beta-galactosidase (SA-β-gal) positive cells from a variety of mouse tissues demonstrating 
larger cell areas than negative counterparts following image-stream flow cytometry analysis 
(Biran et al., 2017). Interestingly, it has recently been demonstrated that increased cell size 
during G1 arrest hinders cellular proliferation. Pharmacological blockade of CDK4/6 via the 
p16 mimetic palbociclib leads to an increase in cell size and a decreased DNA:cytoplasmic 
ratio. This is hypothesised to contribute to a process of “cytoplasmic dilution” whereby 
nucleic acid and protein production cannot support an increased demand following excessive 
cell growth. This leads to fundamental changes in the biochemical properties of the 
cytoplasm such as diffusion rates and viscosity. Palbociclib treatment in combination with 
mitogenic stimulation leads to excessive cell growth and inhibition of cellular proliferation 
upon cessation of treatment. Crucially, palbociclib treatment in the absence of growth 
factors did not lead to impairment of cellular proliferation with removal of the drug. 
Together, this data indicates that a process of cytoplasmic dilution, resulting from excessive 
cell growth, may contribute to the proliferative arrest associated with senescence (Neurohr 
et al., 2019). This represents the first mechanistic implication of the widely reported increase 
in cell size that accompanies senescence, and indicates that excessive cell growth is a 




As well as increasing in size, senescent cells have also been widely reported to acquire 
alterations in cellular shape (Hernandez-Segura, Nehme and Demaria, 2018). The specific 
nature of these morphological changes is heavily dictated by the cell type under 
investigation. However, common features include an irregular flattened morphology, which 
is distinct from that of the proliferating counterpart cells (Hwang, Yoon and Kang, 2009). 
Such striking alterations in cell shape might be predicted to arise from cytoskeletal 
modifications with senescence. Expression of vimentin, an intermediate filament protein, 
has been demonstrated to increase with replicative senescence (Nishio et al., 2001; Nishio 
and Inoue, 2005). Moreover, reorganisation of vimentin from a disparate “fur” like network 
into discrete bundles that traverse the full length of the cell occurs (Nishio and Inoue, 2005). 
Senescence-associated changes in actin expression have also been investigated. However, 
contradictory studies have indicated that hydrogen peroxide (H2O2) and replicative 
senescence are not associated with changes in actin expression, but rather re-organisation 
(Chen et al., 2000) and that replicative senescence is associated with a decrease in actin 
expression (Nishio and Inoue, 2005). Therefore, vimentin currently represents the most 
comprehensively described cytoskeletal component that alters following senescence 
induction. Interestingly, small inhibitory RNA (siRNA) inhibition of Activating Transcription 
Factor 6 (ATF6α), part of the unfolded protein response (UPR), recovers a proliferative 
morphology in replicatively senescent fibroblasts without altering DNA damage markers of 
senescence (Druelle et al., 2016). Inhibition of cyclooxygenase-2 (COX-2) and prostaglandin 
E2 (PGE2), downstream effectors of the ATF6α, also leads to an uncoupling of senescence 
from morphological changes (Cormenier et al., 2018). However, the specific mechanisms via 
which these pathways influence senescent cell morphology have not been fully described 




1.1.3.4 Nuclear Alterations  
Changes in nuclear morphology have also been demonstrated to occur following senescence 
induction (Sadaie et al., 2015). Both a reduction in intensity of DAPI staining and increased 
nuclear area have been reported following induction of therapy-induced senescence (TIS) 
(Zhao et al., 2010; Studencka and Schaber, 2017). DAPI intensity has previously been used to 
stratify cell populations according to phase of the cell cycle and may provide a useful high 
throughput screening tool for demonstrating senescence induction (Zhao and Darzynkiewicz, 
2013; Roukos et al., 2015). These alterations in nuclear morphology have been attributed to 
changes in nuclear composition (Mehta et al., 2007; Hernandez-Segura, Nehme and 
Demaria, 2018). Lamin B1, a structural nuclear envelope protein, has been demonstrated to 
decrease in senescent fibroblasts induced by x-ray irradiation, replicative arrest and 
oncogenic-Ras expression (Freund et al., 2012). Impaired nuclear integrity following loss of 
Lamin B1 has been implicated in the emergence of cytoplasmic chromatin fragments (CCFs), 
which may underpin the reduced DNA content associated with senescence induction (Ivanov 
et al., 2013). Furthermore, irradiation induced senescence is also associated with a loss of 
DNA, demonstrated by reduced DAPI intensity, attributed to release of mitochondrial 
endonuclease G (EndoG) and the degradation of damaged DNA (Studencka and Schaber, 
2017). Therefore, alterations in nuclear morphology and reduced nuclear DNA content are 
widely reported in multiple models of senescence and these may arise from the loss of 
structural functionality of the nuclear envelope.  
 
By contrast, the emergence of DAPI-dense nuclear foci known as senescence-associated 
heterochromatin foci (SAHF) has been primarily associated with induction of OIS (Narita et 
al., 2003; Di Micco et al., 2011; Sharpless and Sherr, 2015). Heterochromatin describes a 
configuration of genomic DNA and regulatory histones that is tightly bound, thus repressing 
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access to transcriptional machinery (Parry and Narita, 2016). In OIS, it has been proposed 
that promoters of genes critical to the propagation of cellular proliferation, such as E2F 
targets, are associated with heterochromatin proteins, facilitating cell cycle arrest (Narita et 
al., 2003). However, if oncogenic RAS is expressed in cells that have been transduced with 
p53 short-hairpin RNA (shRNA), and consequently do not enter OIS, the appearance of SAHFs 
is retained (Di Micco et al., 2011). Interestingly, whilst the total presence of heterochromatin 
was unchanged, the localisation to E2F target promoters was dramatically reduced, 
accounting for the re-establishment of cellular proliferation and reinforcing the previously 
described role of SAHFs in proliferative arrest (Di Micco et al., 2011; Salama et al., 2014). 
Overall, SAHFs represent the only notable example of a senescence marker principally 
described in the context of a single form of senescence (Gorgoulis et al., 2019).  
 
1.1.3.5 Increased Lysosomal Activity 
One of the most widely reported markers of senescence is observation of increased 
lysosomal activity (Hernandez-Segura, Nehme and Demaria, 2018). In particular, the 
detection of increased SA-β-gal activity is often used to demonstrate acquisition of a 
senescence phenotype (Dimri et al., 1995). In senescence, due to high activity of SA-β-gal, a 
characteristic blue stain can be detected via use of the substrate 5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside (X-gal) at a pH of 6.0, which is not seen in proliferating cells. However, 
it has been demonstrated that SA-β-gal activity may be detected in quiescent cells, in 
conditions of contact inhibition and serum starvation (Yang and Hu, 2005). Therefore, whilst 
a notable and well-described marker of senescent cells, SA-β-gal must be considered a more 
general marker of increased lysosomal activity, which is not itself, exclusive to a senescence 
phenotype (Hwang, Yoon and Kang, 2009; Gorgoulis et al., 2019). 
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Despite the limitations that surround SA-β-gal, its popularity as a senescence marker has led 
to the emergence of other methods of lysosomal assessment. In particular, staining of 
lipofuscin aggregates (an indication of impaired lysosomal degradation) with Sudan Black B 
(SBB) stain has been reported as a method to demonstrate lysosomal accumulation 
(Georgakopoulou et al., 2013; Evangelou et al., 2017). A biotinylated SBB derivative (GL13) 
has recently become commercially available under the trade name SenTraGor™. These 
techniques provide some advantage over SA-β-gal as they are applicable to paraffin 
embedded tissue (Georgakopoulou et al., 2013; Hernandez-Segura, Nehme and Demaria, 
2018). However, the major limitation of SA-β-gal, that lysosomal accumulation is not 
exclusive to senescence, also applies to these techniques. Therefore, as discussed above, 
increased lysosomal activity must be applied in concert with other techniques in order to 
serve as a marker of senescence.  
 
1.1.3.6 DNA Damage Markers 
As described in section 1.1.2, the initiation of a DDR follows numerous senescence inducing 
stimuli (Munoz-Espin and Serrano, 2014). Senescent fibroblasts generated via both ionising 
radiation or replicative exhaustion demonstrate increased markers of DNA double strand 
breaks including p53 binding protein 1 (53BP1) and phosphorylated histone variant H2AX 
(γH2AX) (D’Adda Di Fagagna et al., 2003). H2AX is phosphorylated by ATM and ATR kinases 
during the DDR cascade and contributes to recruitment of DNA repair complexes to sites of 
double strand breaks (Celeste et al., 2002; Kuo and Yang, 2008). H2AX phosphorylation can 
also lead to the recruitment of 53BP1, which in turn promotes DNA repair of double strand 
breaks through non-homologous end-joining,  (Panier and Boulton, 2014; Kocyłowski et al., 
2015). As with other markers of senescence, the use of DNA damage is limited by a lack of 
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specificity to senescence and the existence of senescence models that do not engage a DDR 
(Hernandez-Segura, Nehme and Demaria, 2018).    
 
1.1.3.7 Mitochondrial Dysfunction 
Mitochondrial dysfunction has been proposed as a “hallmark” of ageing and has also been 
associated with senescence (López-Otín et al., 2013; Hernandez-Segura, Nehme and 
Demaria, 2018). Excessive reactive oxygen species (ROS) production by dysfunctional 
mitochondria has been described within replicative senescence (Passos et al., 2007) and is 
believed to lead to an accumulation of damaged proteins and other cellular waste, which 
overwhelms lysosomal degradative capacity (Gorgoulis et al., 2019; Vasileiou et al., 2019). 
This is fundamental to the “garbage catastrophe” theory of ageing, in which export or 
degradation of damaged products is overcome by excessive demand (Terman et al., 2010; 
Baixauli, López-Otín and Mittelbrunn, 2014; Picca et al., 2019). Furthermore, mitochondrial 
dysfunction has been observed following H2O2 treatment in fibroblasts, also leading to an 
increase in intracellular ROS production and instigation of a senescence phenotype (Tai et 
al., 2017). Therefore, mitochondrial dysfunction and the closely associated increase in ROS 






Figure 1.3: Common Markers of Senescence 
Senescence induction may be triggered through a range of stimuli. This results the 
emergence of a heterogeneous array of markers that also depends on the cell type under 
insult. As no single universal marker of senescence has been described, confident 
classification is determined through investigation of a range of markers. Aside from the 
intrinsic loss of proliferation, these include acquisition of an enlarged cellular and nuclear 
morphology, loss of nuclear Lamin B1, appearance of senescence-associated 
heterochromatin foci (SAHFs), expression of cyclin dependent kinase inhibitors (CDKIs) 
increased cytoplasmic chromatin fragments (CCFs), increased lysosomal activity, 
mitochondrial dysfunction, increased production of reactive oxygen species (ROS) and 




1.1.4 The Senescence-Associated Secretory Phenotype (SASP)  
The senescence-associated secretory phenotype (SASP) is an enhanced secretory profile of 
inflammatory cytokines, chemokines, growth factors and proteases that accompanies the 
development of senescence. Whilst individual factors, such as plasminogen activator type-1 
(PAI‐1), had previously been considered markers of senescence induction, Coppé et al., 
(2008) were the first to comprehensively describe the secretome of senescent cells (Mu and 
Higgins, 1995; Coppe et al., 2008). Through use of antibody arrays, investigators 
demonstrated that induction of senescence via both oncogenic-Ras expression and ionising 
radiation (IR) lead to secretion of a complex inflammatory secretome in both fibroblasts and 
epithelial cells (Coppe et al., 2008). The composition of the secretome varied between both 
cell types and inducing stimuli, reflecting the heterogeneity in senescence phenotypes within 
different cellular contexts (Coppe et al., 2008; Maciel-Barón et al., 2016).  
 
Whilst not present in all models of senescence, initiation of a DDR has been demonstrated 
to contribute to the development of the SASP (Rodier et al., 2009; Coppé et al., 2010). 
Interleukin 6 (IL-6) and IL-8 secretion, frequently used surrogate markers of the SASP, were 
demonstrated to increase following persistent DNA damage via both ionising radiation and 
proliferative arrest. This response was not recapitulated following transient DNA damage 
with low dose irradiation and was attenuated in cells depleted of ATM by shRNA. However, 
other identified factors (nine out of 14) were unaltered following ATM depletion 
demonstrating that a DDR is only partially involved in the development of the SASP (Rodier 
et al., 2009). Furthermore, SASP production has been demonstrated to occur independently 
of a DDR (Freund, Patil and Campisi, 2011). Interestingly, neither the p16 nor the p53/p21 
tumour suppressor pathways appear essential for SASP production. Senescent WI-38 
fibroblasts have been demonstrated to continue SASP production following p53 ablation by 
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shRNA. Furthermore, p53 may repress development of an exaggerated SASP, as WI-38 
fibroblasts induced by replicative exhaustion, irradiation and oncogenic-Ras develop a more 
potent SASP profile following p53 inactivation (Coppe et al., 2008). Additionally, senescence 
induction by ectopic expression of p21 or p53 is not accompanied by development of a SASP 
(Coppé et al., 2011). Moreover, SASP development occurs in WI-38s induced by both 
irradiation and oncogenic-Ras following p16 inhibition by shRNA. Therefore, whilst widely 
observed within a range of senescence models, SASP development appears to be uncoupled 
from tumour suppressor pathways (Coppé et al., 2010).               
   
Current understanding of the molecular pathways of the SASP are outlined in Figure 1.4. The 
mitogen-activated protein kinase p38 (p38MAPK) signalling cascade has been demonstrated 
to be essential to the induction of oncogenic-Ras induced senescence (Wang et al., 2002; 
Deng et al., 2004). The development of a potent SASP in these cells has also been linked to 
p38MAPK activity, as pharmacological inhibition was demonstrated to lead to a reduction in 
65 out 83 SASP factors in oncogenic-Ras induced HCA2 fibroblasts. This result was 
recapitulated in irradiation induced HCA2s, with 25 out of 37 factors reducing following 
p38MAPK inhibition. These emphasise that the SASP is variable between senescence models 
and, whilst 19 out of 23 common factors between both models reduced following p38MAPK 
inhibition, that SASP composition is likely be driven by more than one pathway (Freund, Patil 
and Campisi, 2011). Importantly, p38MAPK was also demonstrated to drive the activation of 
the transcription factor NF-κB, with NF-κB knockdown via shRNA sufficient to prevent 
p38MAPK induced SASP production (Freund, Patil and Campisi, 2011). 
 
NF-κB is a pro-inflammatory transcription factor that is upregulated during OIS and has been 
implicated as a major contributor to the direct transcription of many SASP factors (Chien et 
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al., 2011). As well as via p38MAPK, NF-κB activation occurs through interleukin-1α (IL-1α), 
an initiating factor within the SASP, which acts to regulate the development of a mature SASP 
composition, including both IL-6 and IL-8 (Orjalo et al., 2009). This occurs through a positive 
feedback loop, as IL-1α is a transcriptional target of NF-κB. Furthermore, this system is 
modulated by the microRNAs (miRs) miR-146a and miR-146b, which reduce expression of 
the IL-1α signalling cascade component interleukin 1 receptor-associated kinase (IRAK1), and 
are themselves upregulated via NF-κB (Bhaumik et al., 2009). IL-1α is also regulated by the 
molecular target of rapamycin (mTOR), a kinase whose pharmacological inhibition has been 
demonstrated to extend the life span of mice (Harrison et al., 2009). mTOR inhibition with 
rapamycin leads to reduced mRNA expression of NF-κB targets, including IL-6 and IL-8, as 
well as potent suppression of IL-1α signalling, whilst ectopic expression of IL-1α recovers 
rapamycin induced SASP suppression (Laberge et al., 2015; Faget, Ren and Stewart, 2019). 
Activation of NF-κB also occurs following cyclic GMP–AMP synthase (cGAS) / stimulator of 
interferon genes (STING) signalling in response to CCFs, which accumulate during senescence 
due to downregulation of cytoplasmic DNases (Dou et al., 2017; Glück et al., 2017; Takahashi 
et al., 2018). The initiation of a DDR (a key facet of many senescence models) has also been 
demonstrated to contribute to NF-κB activation. This occurs through stabilisation of GATA4, 
a transcription factor which upregulates IL-1α and thus contributes to the complex feedback 
loop that mediates the maturation of SASP composition (Kang et al., 2015; Faget, Ren and 
Stewart, 2019).    
 
Another key transcription factor activated though IL-1α signalling is CCAAT/enhancer-
binding protein beta (C/EBPβ) (Orjalo et al., 2009). Similar to IL-1α mediated activation of 
NF-κB, C/EBPβ is essential to the development of the full SASP composition including IL-6 
and IL-8 (Acosta et al., 2008; Kuilman et al., 2008). Factors within this developed SASP have 
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been demonstrated to reinforce senescence in an autocrine manner via the CXCR2 
chemokine receptor (Acosta et al., 2008). The contribution of C/EBPβ to SASP composition 
has also been demonstrated to depend on NOTCH1 signalling during OIS. Early during OIS, 
the composition of the SASP is geared towards TGFβ secretion, whilst activation of C/EBPβ is 
repressed. NOTCH1 mediates a switch to a C/EBPβ driven pro-inflammatory secretome, 
which is characterised by an increased IL-6 and IL-8 secretion.  
 
The vast majority of studies investigating the SASP have focused upon the soluble 
constituents. However, extracellular matrix components and shed ectodomains were also 
identified during early characterisation of the SASP (Coppé et al., 2010). It has since emerged 
that approximately 10% of the OIS SASP composition is comprised of shed ectodomains with 
a third of those released through cleavage by the sheddase A Disintegrin and 
metalloproteinase domain-containing protein 17 (ADAM17) (Morancho et al., 2015). 
Interestingly, reports into the activity of ADAM17 within senescence are not harmonious, 
with ADAM17 (and the closely related ADAM10) activity demonstrated to increase in 
oncogenic-Ras induced PC-3 prostate cancer cells (Effenberger et al., 2014), but not in MCF7 
breast cancer cells induced via oncogenic p95HER2 (Morancho et al., 2015). Whilst both 
reports demonstrated that ADAM17 contributed to SASP composition, the changes in both 
expression and activity of sheddases within senescence remain poorly described.        
 
In summary, the molecular controls of the SASP are complex and not fully appreciated. The 
SASP develops kinetically across the course of senescence induction and varies in both 
potency and composition between models of senescence and cell types. However, it is clear 
that the SASP comprises a plethora of soluble inflammatory factors as well as shed 




Figure 1.4: Molecular Pathways of the Senescence-Associated Secretory Phenotype (SASP) 
Acquisition of a senescence-associated secretory phenotype (SASP) occurs following 
senescence induction through a range of damaging stimuli. The composition of the SASP is 
not static and kinetically develops following senescence induction. SASP constituents also 
vary between cell types and following different senescence inducing stimuli. NF-κB and 
C/ERPβ are key transcription factors mediating SASP composition. Based on (Faget, Ren and 




1.1.5 Replicative Senescence 
As stated above, the phenomenon of senescence was first described by Hayflick and 
Moorhead in 1961, though observation of replicative exhaustion following ~50 “sub-
cultivations” of human fibroblasts in culture (Hayflick and Moorhead, 1961). This finite 
proliferative potential has since been termed the “Hayflick-limit” and is used to describe the 
number of population doublings required for cells to enter a state of replicative senescence 
(Figure 1.5). This process has been demonstrated to arise through initiation of a DDR in 
response to telomere shortening with consecutive rounds of the cell cycle (Herbig et al., 
2004).  
 
Telomeres are repetitive DNA sequences (5’ – TTAGGG – 3’) which serve as protective caps 
at the end of chromosomes (Blackburn and Gall, 1978; Blackburn, 2001). Telomeres are 
eroded with successive rounds of the cell cycle, due to the so called “end-replication 
problem”. This was first described in 1971 by Olovnikov in a Russian language publication 
(Olovnikov, 1971) where the author speculated that incomplete replication of DNA ends 
(“marginotomy”) could underpin the senescence responses observed by Hayflick (Olovnikov, 
1973, 1996). The distinction of being the first manuscript to describe this phenomenon is 
often attributed to (Watson, 1972), who independently described a similar phenomenon, 
albeit without linking to Hayflick’s work (Olovnikov, 1996; Greider, 1998). Regardless, the 
concept centres on fact that DNA synthesis occurs in a 5’ to 3’ direction. In order to 
synthesise the 3’ to 5’ lagging strand, short RNA primers are used to generate Okazaki 
fragments, which are in turn extended, and primers both removed and replaced by DNA 
polymerase. However, the primer of the final Okazaki fragment cannot be replaced with 
DNA, leading to incomplete replication following removal and overall shortening of the 
chromosome (Vega, Mateyak and Zakian, 2003; Chow et al., 2012). Telomeres serve a 
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protective function due to their position on the end of chromosomes, which allows them to 
be eroded rather than critical coding regions (Blackburn and Gall, 1978). This process occurs 
with each round of the cell cycle, with telomeres becoming progressively shorter (Harley, 
Futcher and Greider, 1990). Eventually, telomeres reach a critical length, where their role as 
a “buffer” against the end-replication problem can no longer be served, leading to instigation 







Figure 1.5: Replicative senescence of fibroblasts and the Hayflick Limit 
The finite proliferative capacity of cells in vitro was first demonstrated by Hayflick and 
Moorhead in 1961. Early proliferative (EP) cells are serially passaged reach until they reach a 
maximum cumulative number of population doublings. At this point they are considered to 
have entered replicative senescence (RS), having reached their Hayflick limit. The senescence 
response then develops into a stable phenotype known as deep senescence (DS). The 
initiation and maintenance of these responses is mediated by expression of the tumour 
suppressors p21 and p16, which have an inverse relative abundance during RS and DS. 
Furthermore, during the transition of RS to DS, the senescence-associated secretory 
phenotype (SASP) of the cells develops, from an early IL-1α composition to a developed, 




1.1.6 Oncogene-Induced Senescence 
Distinct from telomere dependent proliferative potential, senescence may be induced 
prematurely through expression of oncogenes including Ras (Serrano et al., 1997), MEK (Lin 
et al., 1998) and BRAF (Zhu et al., 1998) in a process termed oncogene-induced senescence 
(OIS). OIS was first described in normal human fibroblasts (IMR90 and WI-38), mouse 
embryonic fibroblasts (MEFs) and immortalised rat fibroblasts (REF52), through transduction 
with activated ras allele (HRasV12). This lead to supra-physiological expression of HRas 
protein, between 5 and 10 times greater than endogenous levels. Consequently, cellular 
proliferation was restricted through a G1 arrest characterised by reductions in 
hyperphosphorylated RB, cyclin A and CDK2 activity. This was accompanied by established 
senescence markers, including expression of both p16 and p21, along with increased SA-β-
gal activity and acquisition of an enlarged flattened morphology. Crucially, these phenotypes 
emerged within 10 days of transduction, demonstrating OIS to be a rapid, premature 
response (Serrano et al., 1997). Subsequently, initiation of OIS has been demonstrated to 
occur in response to the expression of other oncogenes including MEK and BRAF (Lin et al., 
1998; Zhu et al., 1998). These in vitro studies are supported by in vivo evidence that highlight 
a potential physiological role of OIS as an important tumour suppressor response (Campisi 
and D’Adda Di Fagagna, 2007). Mice expressing oncogenic KRasV12 acquire fewer malignant 
tumours (adenocarcinoma) and more pre-malignant tumours (adenoma) than control mice. 
The adenomas displayed characteristics of in vitro senescence markers including increased 
expression of p16, reduced expression of Ki67 and increased SA-β-gal activity, whereas 
adenocarcinomas did not. The authors speculated that initiation of OIS in vivo acts to inhibit 
tumour development, thus serving as a tumour suppressor mechanism (Collado et al., 2005; 
Campisi and D’Adda Di Fagagna, 2007). The physiological roles of senescence induction, 
including tumour suppression, are discussed further in section 1.1.9.             
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1.1.7 Other Types of Senescence 
Replicative exhaustion and oncogene expression represent two potential stressors that may 
elicit a senescence response. However, a wide range of other stimuli have also been 
demonstrated to induce senescence. Premature senescence may occur following challenge 
with a variety of deleterious agents including cytotoxic drugs (Petrova et al., 2016), 
irradiation (Studencka and Schaber, 2017), H2O2 (Chen and Ames, 1994), tumour suppressor 
loss (Chen et al., 2005), autophagy impairment (Tai et al., 2017) and mitochondrial 
dysfunction (Wiley et al., 2016). Senescence can also propagate between cells through 
processes of secondary senescence. This involves the transmission of senescence to 
neighbouring proliferating cells through a variety of mechanisms.  
 
The first indications that senescence could propagate through a population of cells was 
demonstrated by a so called “bystander effect”. Replicatively senescent MRC5 fibroblasts 
were demonstrated to induce a DDR in neighbouring proliferating cells, although this could 
not be recapitulated through use of conditioned media or trans-well co-culture experiments 
(Nelson et al., 2012). The breakthrough publication to investigate this bystander effect 
senescence was Acosta et al. (2013), who implicated paracrine signalling of the SASP as a 
major effector of secondary senescence (Acosta et al., 2013). Conditioned media collected 
from OIS (RAS, RAF and MEK) IMR90s was demonstrated to inhibit both cell proliferation and 
BrdU incorporation, as well as increase SA-β-gal activity. This inhibition of cellular 
proliferation was demonstrated up to 10 days following the cessation of treatment. 
Inhibition of p16, p21 and p53 by siRNA in treated cells attenuated this paracrine induction, 
indicating that both tumour suppressor pathways are involved in mediating paracrine 
senescence. Numerous factors were demonstrated to be critical to mediating this function 
of the SASP including TGFβ, VEGF, CCL2 and CCL20. Of these, the role TGFβ was identified as 
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the most uniquely paracrine, with a less significant role in the autocrine reinforcement of OIS 
than the other factors. Pharmacological TGFβ pathway inhibition was confirmed to attenuate 
paracrine senescence in a mechanism that relied upon both p15 and p21 (Acosta et al., 
2013).     
 
Understanding of secondary senescence has recently been extended to include a juxtacrine-
induced response through the expression of NOTCH1 ligands (Jagged 1, JAG1) on the surface 
of senescent cells (Hoare et al., 2016; Parry et al., 2018; Teo et al., 2019). This NOTCH-
induced senescence (NIS) was demonstrated to occur through lateral induction from both 
OIS IMR90s and senescent cells induced via ectopic expression of the intracellular domain of 
NOTCH1 (N1ICD; Figure 1.6) (Hoare et al., 2016; Hoare and Narita, 2018). Interestingly, 
expression of NOTCH1 and cleavage of its functional intracellular domain has been 
demonstrated to increase early during the induction of OIS, followed by a reduction in N1ICD 
cleavage from day 4. This is kinetically associated with a shift in secretome composition from 
a predominantly TGF-β high SASP, to an IL-6/IL-8 profile dependent on C/EBPβ (Hoare et al., 
2016). Ectopic expression of N1ICD also suppresses appearance of SAHFs in OIS cells, in an 
effect recapitulated though juxtacrine NOTCH1 signalling via JAG1 ligands on neighbouring 
cells (Parry et al., 2018). Therefore, the role of NOTCH1 signalling within senescence is 
complex. NOTCH1 expression increases in OIS and mediates the composition of the SASP. 
NOTCH1 ligands on senescent cells may drive neighbouring proliferating cells into a 
senescent phenotype in a juxtacrine mechanism of secondary senescence. Finally, the 
cleavage of N1ICD and activation of NOTCH1 signalling pathways supress development of a 
full OIS phenotype. Overall, senescent cells have been demonstrated to propagate 
senescence to neighbours through both paracrine and juxtacrine signalling. The physiological 




Figure 1.6: NOTCH induced senescence via canonical NOTCH1 signalling 
Expression of NOTCH1 ligands such as JAG1 and DLL4 on the surface of oncogene-induced 
senescent cells mediates induction of a form of secondary senescence referred to as NOTCH-
induced senescence (NIS). This occurs through canonical NOTCH1 juxtacrine signalling. 1) 
Binding of NOTCH1 ligands to the extracellular domain of the NOTCH1 receptor facilitates 2) 
Cleavage by ADAM10 and ADAM17 sheddases, which causes disengagement of the 
extracellular domain and leads to 3) cleavage of the NOTCH1 intracellular domain (N1ICD) by 
the γ-secretase complex (comprising PEN-2, PSEN-1, Nicastrin and APH-1). 4) N1ICD 
translocates to the nucleus leading to activation of MAML1 transcription factor and 
transcription of NOTCH1 responsive genes HES1 and HEY. This may be recapitulated 
experimentally though ectopic expression of N1ICD. Based on (Bray, 2016).  
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1.1.8 Senescence Reversal 
Senescence has widely been considered a terminal cell fate characterised by an irreversible 
cell cycle arrest. Whilst bypass of senescence has been demonstrated as a pro-tumorigenic 
effect that occurs following hypermethylation of the p16 promotor in epithelial cells (section 
1.1.2), these “bypassed” cells fundamentally differ from those early in their proliferative 
potential (Garbe et al., 2014; Lowe et al., 2015). Therefore, whilst these cells re-establish 
proliferation following cellular senescence, they are not considered “reversed” to an early 
proliferative state. However, this was recently achieved through the ablation of p16 via 
siRNA inhibition in adult human mammary epithelial cells (HMECs) (Lowe et al., 2015). This 
resulted in increased BrdU incorporation, reduced SA-β-gal activity and a reversion of DNA 
methylation profile to that of early proliferating cells. This work is supported by previous 
studies, which have demonstrated senescence reversal in MEFs (Dirac and Bernards, 2003; 
Sage et al., 2003) and human foetal fibroblasts (Gire and Wynford-Thomas, 1998; Beauséjour 
et al., 2003). A protocol for the reversal of senescence in adult fibroblasts has also recently 
been developed within the Bishop lab. by Elly Tyler, details of which are described within her 
PhD thesis (Thesis:(Tyler, 2016)) and section 2.6.  
 
1.1.9 Senescence in vivo 
Since Hayflick and Moorhead first described the proliferative arrest associated with 
replicative senescence, there has been widespread interest in determining the physiological 
purpose of senescence induction (van Deursen, 2014). An early concept proposed that 
senescence could serve as a protective function against the malignant transformation of cells 
by restricting proliferation (Campisi and D’Adda Di Fagagna, 2007). This was supported by 
both the observation that replicative senescence occurs as a consequence of telomere 
attrition, and by the discovery of OIS (Serrano et al., 1997; Bodnar et al., 1998). This would 
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position senescence as an evolutionarily beneficial process, which promotes organismal 
survival by providing a barrier to cancer development (Campisi, 2001). However, as first 
predicted by Hayflick and Moorhead, the loss of proliferation and long term persistence of 
senescent cells has also been proposed as a key mechanism to the tissue dysfunction and 
loss of regeneration that accompanies ageing (Campisi and D’Adda Di Fagagna, 2007). 
Furthermore, the secretion of SASP factors has been identified to contribute to an increased 
proliferation of premalignant cells (Krtolica et al., 2001). This paints a paradoxical picture of 
senescence in vivo, having both a bright, beneficial role in tumour suppression and a dark, 
detrimental role in ageing. These contradictory functions are harmonised in the evolutionary 
theory of “antagonistic pleiotropy”, which stipulates that, due to human lifespan being 
historically much shorter, mechanisms that are beneficial in early life may develop despite 
detrimental consequences with age. Individuals would be afforded protection by such 
mechanisms and thus reach reproductive age, before experiencing the harmful long-term 
effects in later life, where selection pressure is less (Rauser, Mueller and Rose, 2006; Campisi 
and D’Adda Di Fagagna, 2007). The physiological relevance of senescence has more recently 
been extended to include other key processes such as wound-healing (Demaria et al., 2014) 
and embryonic development (Muñoz-Espín et al., 2013). This is section will discuss the 
proposed physiological roles of senescence in turn.   
 
1.1.9.1 Senescence and Ageing 
As described in section 1.1.3, the classification of senescence is often hindered by a paucity 
of universally applicable markers. This is exacerbated in vivo, where the majority of cells are 
arrested, thus preventing characterisation of proliferative potential. Despite this, some in 
vitro markers may be observed in an in vivo setting, and have led to a clear association 
between senescence and ageing (Sharpless and Sherr, 2015). One widely applied method is 
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the identification of p16 positive cells, which has led to the detection of senescent cell 
accumulation in a variety of tissues from both mice and humans (Nielsen et al., 1999; 
Krishnamurthy et al., 2004; Ressler et al., 2006). This observation lead researchers to 
investigate if there was a causal link between the accumulation of senescent cells with aging 
and the development of age-related pathologies (van Deursen, 2014). This connection was 
first investigated in a progeroid mouse model of premature ageing (BubR1), where 
investigators utilised a transgene, INK-ATTAC, which contained a fragment of the p16 
promoter and was thus only transcribed in p16 positive (equated to senescent) cells. INK-
ATTAC encodes a caspase-8 containing fusion protein that dimerises (and becomes active) 
upon treatment with a small molecule AP20187. Therefore, this model triggers apoptosis in 
p16 positive cells, thus facilitating their clearance. Through the INK-ATTAC model, 
investigators demonstrated attenuation of age-related pathologies including loss of adipose 
tissue and skeletal muscle as well as reduced cataracts of the eye (Baker et al., 2011). Building 
on this work, the INK-ATTAC model was applied in naturally aged mice. In a seminal 
publication, Baker et al., (2016) demonstrated that clearance of p16 positive cells alleviated 
a range of age-related-pathologies and, strikingly, extended the median lifespan of 
experimental mice (Baker et al., 2016). This provided compelling evidence that the 
accumulation of senescent cells with age contributes to the development of age-related 
pathologies. There is now a growing interest in the therapeutic clearance of senescent cells 
through pharmacological methods, “senolytics”, which is discussed in section 1.1.10.1.             
  
1.1.9.2 Immune-Clearance of Senescent Cells  
The accumulation of senescent cells has been demonstrated to contribute to age-related 
pathologies as described above (Baker et al., 2016). However, the mechanisms through 
which this accumulation occurs are not entirely clear. It is conceivable that exposure to 
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stressful stimuli across an organism’s lifespan could lead to a general increase in senescent 
cell numbers (van Deursen, 2014). Alternatively, impairment of mechanisms responsible for 
the clearance of senescent cells could also contribute to the observed accumulation with 
age. Age has been previously been associated with a decline of immune function, referred 
to as immunosenescence, which renders the elderly more susceptible to infectious diseases 
and less responsive to vaccination (Nikolich-Žugich, 2008; Dewan et al., 2012; Boraschi and 
Italiani, 2014). This is believed to arise through compositional and functional alterations in 
immune cell sub-types, leading to a low level, chronic state of sterile inflammation known as 
“inflammageing” (Franceschi, 2007; Boraschi and Italiani, 2014). Interestingly, 
inflammageing has also been proposed to occur as a consequence of senescent cell 
accumulation, possibly through the SASP (Franceschi and Campisi, 2014). 
 
The clearance of senescent cells through immune function was first demonstrated by Xue et 
al., (2007), whereby p53 activation in hepatoblasts (liver progenitor cells), transplanted into 
mouse livers, led to the development of a senescence phenotype. These senescent cells were 
demonstrated to be cleared by innate immune cells (Xue et al., 2007). Krizhanovsky et al., 
(2008) developed this concept further, through use of macrophage inflammatory protein-1β 
(MIP-1β, also known as CCL4) induced fibrosis of mouse livers. This lead to accumulation of 
senescent hepatic stellate cells (HSCs), which were demonstrated to contribute to the 
restriction of fibrotic progression. The gene expression profile of the senescent HSCs was 
shown to be upregulated for factors that enhance natural killer (NK) cell function, including 
the chemokine IL-8 and the adhesion molecule CD58. NK cells were also demonstrated to 
selectively clear senescent IMR90s induced by replicative, therapy-induced and oncogene-
induced senescence in vitro. This was recapitulated in vivo, where use of an NK cell 
neutralising antibody led to an increase in senescent cell accumulation and stimulation of NK 
51 
 
activity reduced the number of senescent HSCs (Krizhanovsky et al., 2008). Further exploring 
the interaction between senescent cells and the immune system, oncogenic NRas induced 
senescence was investigated in hepatocytes (Kang et al., 2011). Immune cells were 
demonstrated to cluster around the senescent hepatocytes and the number of these 
senescent cells notably decreased from 12 days after NRas transduction. In transgenic mice 
with defective NK cell and macrophage responses, this reduction was not observed 
suggesting these cells are key mediators of the clearance of OIS cells in vivo (Kang et al., 
2011). Overall, these studies provide compelling evidence that senescent cells facilitate their 
own clearance through SASP signalling to immune cells. This integrated system of removal 
may represent a mechanism to prevent the deleterious effects of senescent cell 
accumulation observed in ageing, aligning closely to the antagonistic pleiotropy theory of 
ageing described above (Campisi and D’Adda Di Fagagna, 2007; van Deursen, 2014).    
                      
1.1.9.3 Wound Healing 
Whilst Baker et al., (2016) demonstrated that senescent cells contribute to the development 
of age-related pathologies, they also observed a beneficial effect of senescent cells to wound 
healing, as this was impaired following senescent cell clearance (Baker et al., 2016). This 
corroborated a previous a report, which utilised another p16 dependent model of senescent 
cell clearance (p16-3MR), which is inducible upon treatment with ganciclovir. Demaria et al., 
(2014) demonstrated transient accumulation of senescent cells in wounds, peaking 6 days 
after injury and returning to baseline by day 9. The clearance of senescent cells 24 hours 
after injury extended the time required for complete wound closure, and the final healed 
wound possessed increased levels of fibrosis characterised by increased collagen deposition. 
This was accompanied by alterations in MMP production (increased MMP-10 and -13; 
decreased MMP-2) and senescent cells induced via ionising radiation were demonstrated to 
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produce increased levels of collagen. Intriguingly, the SASP profile of senescent cells found 
in the wounds had an unusual composition, secreting very high levels of PDGF-A and VEGF, 
whilst not producing IL-6 or TGFβ. Interestingly, senescent cell clearance also depleted the 
number of myofibroblasts, an effect that could be rescued though PDGF-A treatment, along 
with normal wound closure kinetics. Overall, this study emphasised the nuances of SASP 
composition, implicating the development of a bespoke SASP to promote wound healing 
though stimulation of myofibroblast differentiation (Demaria et al., 2014). This critical role 
in a homeostatic process emphasises that senescence contributes to more than pathological 
ageing and suggests that therapeutic strategies of senescence clearance might be associated 
with adverse effects.    
 
1.1.9.4 Embryonic Development 
The majority of research into senescence has focused on a response to some form of insult, 
be that replicative exhaustion, DNA damage or oncogenic stimulation. A less widely 
described process involves the contribution of senescence to embryonic development, which 
occurs through a programmed system of senescent cell accumulation and clearance (Munoz-
Espin and Serrano, 2014). Senescence markers have been identified in embryos from mice, 
humans, chickens and quail, implicating senescence as a conserved feature across 
vertebrates during development (Nacher et al., 2006; Muñoz-Espín et al., 2013; Storer et al., 
2013). Of particular note is p21, without which morphological abnormalities occur during 
embryonic development. Importantly, developmental senescence does not appear to be 
associated with appearance of a DDR, emphasising the heterogeneous nature of senescence 




1.1.10 Therapeutic Modulation of Senescence  
1.1.10.1 Senolytics 
The compelling evidence for a causal role of senescent cells within the development of age-
related pathologies described above, has led to a rapidly increasing interest in the 
therapeutic modulation of senescence. Similar to the work of Baker et al., (2016), the 
selective clearance of senescent cells has become the focus of most therapeutic strategies, 
with the emergence of an array of “senolytic” agents (Kirkland et al., 2017). The first 
description of senolytics was made by Zhu et al., (2015), who identified the existence of pro-
survival anti-apoptotic pathways in senescent cells, termed senescent‐cell anti‐apoptotic 
pathways (SCAPs), through use of DNA microarrays and siRNA inhibition (Zhu et al., 2015; 
Kirkland et al., 2017). A targeted drug screen of 46 candidate molecules identified the 
compounds Dasatinib (a tyrosine kinase inhibitor) and Quercetin (a PI3 kinase inhibitor) as 
the most promising senolytic candidates in vitro. Dasatinib appeared to be more effective in 
the selective clearance of senescent preadipocytes, whereas Quercetin displayed 
preferential action in HUVECs. A combination treatment with both compounds overcame 
this cell type specificity, leading to a potent clearance of both cell types. Importantly, this 
effect appeared to translate in vivo where the combination treatment reduced the number 
of senescent adipose cells in aged mice along with improved cardiovascular function and 
extended the lifespan of progeroid mice (Zhu et al., 2015). More recently, Dasatinib and 
Quercetin were used to recover age-related physical decline of naturally aged mice and, 
strikingly, also caused an extension of lifespan (Xu et al., 2018). These seminal publications 
sparked an enormous research effort to discover more compounds that could selectively 




The third senolytic agent described was ABT263, more commonly referred to as Navitoclax, 
which was demonstrated to reduce the survival of senescent WI-38 fibroblasts induced by 
irradiation, replicative exhaustion and oncogenic-Ras expression (Chang et al., 2016). This 
was further validated in additional human and mouse cells in order to demonstrate a less 
cell type specific response than that of Dasatinib and Quercetin. The authors also 
demonstrated that oral delivery of Navitoclax cleared senescent cells in irradiated and 
naturally aged mice, with associated rejuvenation (Chang et al., 2016). This reported effect 
of Navitoclax was swiftly supported by a second publication, which was under review at the 
time of the first (Zhu et al., 2016). Navitoclax promotes apoptosis by inhibiting BCL-2 and 
BCL-xL anti-apoptotic proteins, continuing the SCAP focused development of senolytics. A 
similar SCAP mediated senolytic action was demonstrated through use of a FOXO4-peptide, 
which facilitates a p53 dependent apoptosis response (Baar et al., 2017). Subsequently, a 
range of other publications have found novel senolytics targeting SCAPs including the 
Quercetin analogue Fisetin  (Zhu et al., 2017) and the Navitoclax predecessor ABT-737 (Yosef 
et al., 2016). More recently, a new class of senolytic agent have been described, the cardiac 
glycosides (Guerrero et al., 2019; Triana-Martínez et al., 2019). These agents disrupt the 
electrochemical stability of senescent cells though binding of sodium/potassium pumps, 
leading to depolarisation and apoptosis. The membrane potential of senescence cells is 
higher than that of proliferating cells, making them more susceptible senolysis through this 
mechanism (Guerrero et al., 2019; Triana-Martínez et al., 2019). 
 
The rapid development of senolytics has already led to their clinical assessment. Senolytics 
are unlikely to represent a panacea against all possible age-related pathologies and are 
currently under clinical assessment for treatment of osteoarthritis (OA), idiopathic 
pulmonary fibrosis (IPF) and diabetic kidney fibrosis. Navitoclax, under the trade name 
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UBX0101, is currently in Phase II clinical trial (ClinicalTrials.gov Identifier: NCT04129944) to 
assess efficacy in the treatment of OA of the knee, having successfully navigated a Phase I 
tolerability trial (ClinicalTrials.gov Identifier: NCT03513016). This followed pre-clinical work 
in mice, which demonstrated that Navitoclax restricted the development of naturally 
occurring and traumatic OA (Jeon et al., 2017). Senescent cells have also been identified as 
mediators of IPF in mice (Schafer et al., 2017). Recently, a phase I clinical trial 
(ClinicalTrials.gov Identifier:  NCT02874989) demonstrated Dasatinib and Quercetin were 
well tolerated in IPF patients and some physical function benefits were demonstrated 
(Justice et al., 2019). Finally, Dasatinib and Quercetin have recently been demonstrated in a 
phase I clinical trial (ClinicalTrials.gov Identifier: NCT02848131) to reduce senescent cell 
numbers in humans. Intriguingly, the treatment also reduced circulating SASP factors, the 
suspected instigators of senescent cell driven age-related pathologies (Hickson et al., 2019). 
Overall, whilst promising, clinical research into senolytics is in its infancy and there are 
significant hurdles that must be overcome before senolytics emerge as therapeutically 
available agents.            
 
1.1.10.2  Therapy-induced senescence (TIS) 
Therapy-induced senescence (TIS) describes the induction of a senescence response in 
cancer cells through use of pharmacological agents. The bypass of senescence is an essential 
step in the malignant transformation of cells, with most cancer cells possessing mutations in 
key senescence effectors such as p21 and p16 (Hanahan and Weinberg, 2011). However, 
cancer cells have been identified which retain p16 expression and are, incidentally, often 
associated with a poor clinical outcome (Hui et al., 2000). Nevertheless, whilst cancer cells 
may bypass CDKI mediated cessation of proliferation, many retain the capacity to undergo 
senescence in response to chemotherapeutic agents, such as doxorubicin, suggesting that 
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the pathways which facilitate senescence induction may be repressed, as opposed to absent, 
within these cells (Ewald et al., 2010). Therefore, there is clinical interest in the induction of 
senescence as a therapeutic approach within cancer. This has led to the development of 
palbociclib, a p16 mimetic which inhibits CDK4/6 and which has shown clinical utility in the 
treatment of a subset of advanced breast cancer (Finn et al., 2009, 2016; Pernas et al., 2018). 
However, there are some concerns with such therapeutic approaches. These principally stem 
from the demonstration that senescent cells are deleterious in ageing (section 1.1.9.1) and 
that the SASP has the capacity to be pro-tumorigenic (section 1.1.9). Recently, an interesting 
novel use of senolytics in combination with senescence inducing agents in the treatment of 
cancer has been proposed. This “one-two punch” based approach utilises induction of 
senescence in order to render cancer cells vulnerable to senolytic clearance. This has recently 
been utilised in the clearance of liver cancer cells (Wang et al., 2019). Pharmacological 
inhibition of CDC7, a kinase involved in DNA replication, was demonstrated to induce 
senescence in liver cancer but not proliferating cells. This was then combined with an mTOR 
inhibitor, AZD8055, which led to apoptosis of the induced senescent cells in vitro. This was 
recapitulated in vivo where CDC7 inhibition in combination with AZD8055 restricted tumour 
growth to a greater extent than sorafenib, a current clinically used therapeutic (Wang et al., 
2019). Overall, this novel approach utilises the potent anti-tumorigenic action of senescence 
induction, without any potentially deleterious effects of senescent cell accumulation.  
 
1.1.10.3 Other Therapeutic Strategies 
Senolysis refers to the selective clearance of senescent cells. However, as described in 
section 1.1.9, senescence has been demonstrated to have beneficial effects, most notably in 
wound healing (Demaria et al., 2014). There is some concern that depletion of senescent 
cells may also cause dysfunction of tissue architecture, as the regenerative tissue capacity in 
geriatrics may be insufficient to restore these lost cells (Janzen et al., 2006). An alternative 
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to senolytic development is the search for “senomorphic” or “senostatic” agents, which 
modulate the senescence phenotype, in particular the SASP, whilst retaining the cell itself. 
As NF-κB is a significant driver of the SASP, its inhibition might be predicted to diminish the 
deleterious effects of the senescent cells. This was recently demonstrated through inhibition 
of the upstream kinase IκB kinase (IKK), which lead to restriction of age-related pathologies 
in progeroid mice (Tilstra et al., 2012). Similarly, inhibition of Janus kinases (JAK), a key 
component of canonical cytokine signalling pathways, attenuates the SASP of both 
preadipocytes and HUVECs. JAK inhibition also improved physical function in aged mice, not 
unlike that achieved with senolytic agents (Xu et al., 2015, 2018). However, in general, the 
field has committed more significant research effort to the development of senolytics. 
Nevertheless, it is prudent that an alternative strategy is also being actively pursued, in order 





1.2 Extracellular Vesicles (EVs) 
1.2.1 Classifications of Extracellular Vesicles 
Extracellular vesicles (EVs) is an umbrella term used to encompass the heterogeneous range 
of lipid bound particles secreted by cells (Witwer and Théry, 2019). EVs represent a diverse 
set of mediators, which are defined by both their size and route of biogenesis (Colombo, 
Raposo and Thery, 2014) (Figure 1.7). The term EV is often qualified to reflect a more context 
specific usage, such as inclusion of an indicator to the relative size (e.g. small EV) (Kowal et 
al., 2016). Historically, the nomenclature surrounding EVs has lacked standardisation and 
inconsistent usage across the literature has emerged (Gould and Raposo, 2013). Whilst EVs 
had been observed through electron microscopy previously (Aaronson et al., 1971), Trams 
et al., (1981) were the first to use the popular term “exosomes” to described vesicles 
“derived from specific domains of the plasma membrane” (Trams et al., 1981). Inconsistent 
usage of the term exosomes was then applied to vesicles derived from multivesicular bodies 
(MVBs) (Johnstone et al., 1987). These vesicles had been discovered earlier by two groups 
investigating the transferrin receptor in reticulocytes (Harding, Heuser and Stahl, 1983; Pan 
and Johnstone, 1983). Through immuno-gold labelling, trafficking of the receptor to 
multivesicular endosomes (equivalent to MVBs) was identified, and more specifically, 
tracked to the intraluminal vesicles (ILVs) which give MVBs their name. These vesicles were 
observed to be released by exocytosis through MVB fusion with the plasma membrane, 
hence their subsequent designation as exosomes (Johnstone et al., 1987). However, use of 
the term exosome did not remain exclusive to the description of endosome-derived vesicles 
and was often used to describe the second major subclass of EVs – microvesicles (MVs). 
These vesicles are shed directly from the plasma membrane and have been referred to 
previously as ectosomes (Witwer and Théry, 2019). A confounding factor that had added to 
this confusion is the paucity of accepted biomarkers of these vesicular subtypes. This has 
resulted in vesicles often being defined predominantly by size, with the vast majority of 
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experimental methods for their isolation also relying on size-separation (Gardiner et al., 
2016). Whilst exosomes have typically been regarded as smaller, ranging from 30-150nm in 
diameter, the broad size range of MVs, 50-1,000nm, makes this an imperfect solution, with 
experimental procedures considered to produce a varied set of vesicles. In order to achieve 
some level of standardisation, as well as to reflect the current uncertainties surrounding both 
biomarkers and experimental procedures, the International Society of Extracellular Vesicles 
(ISEV) has attempted to define a consensus position within the field with regard to 
nomenclature (Lotvall et al., 2014; Théry et al., 2018). As such, the broad term extracellular 
vesicle (EV) is generally preferred, unless specific determination of biogenesis can be 
demonstrated (Witwer and Théry, 2019). Therefore, EV is used throughout this thesis, with 





Figure 1.7: Classification of Microvesicles and Exosomes   
Extracellular vesicles (EVs) is a term to describe small lipid bilayer bound particles secreted 
by cells. There has been inconsistent usage of nomenclature within the field, but EVs are 
widely considered to predominantly comprise two main subclasses. These may be 
distinguished by both their size and biogenesis. Microvesicles (MVs) are shed directly from 
the plasma membrane and have a broad size range of 50-1,000nm. In contrast, exosomes 
are small vesicles (30-150nm) and have an endosomal origin. They form as intraluminal 
vesicles (ILVs) within multivesicular bodies (MVBs). These may be trafficked to lysosomes for 
degradation or to the plasma membrane where they are released as exosomes. Adapted 




1.2.2 Extracellular Vesicle Biogenesis 
As described above, one of the defining characteristics of EV subtypes is variation between 
the routes to biogenesis. Two main varieties of EV have been described within the literature, 
exosomes and microvesicles, although considerable heterogeneity is likely to exist within 
these subsets in terms of both composition and function (Kowal et al., 2016; van Niel, 
D’Angelo and Raposo, 2018). In the broadest sense, these two categories are divided by the 
endosomal origin of exosomes, whilst MVs are directly shed from the plasma membrane 
(Colombo, Raposo and Thery, 2014). 
 
1.2.2.1 MVB and ILV Biogenesis 
The generation of MVBs is fundamental to the process of exosomal biogenesis (Figure 1.8). 
This first requires endosome formation, which occurs via inward budding of the plasma 
membrane (Klumperman and Raposo, 2014). Subsequent budding of the endosomal 
membrane leads to formation of ILVs contained within larger a MVB, with the ILV membrane 
orientation matching that of the plasma membrane (Stoorvogel et al., 1991; Colombo, 
Raposo and Thery, 2014). The formation of MVBs is mediated by the endosomal sorting 
complex required for transport (ESCRT), which is a group of ~30 proteins that act in sequence 
to recruit other ESCRT members or accessory proteins (Hurley, 2008; Colombo, Raposo and 
Thery, 2014). ESCRT-0 has been demonstrated to facilitate the recruitment of ubiquitinated 
membrane cargos, which allows clustering in the regions of the endosomal membrane fated 
for ILV formation (Wollert and Hurley, 2010). A component of ESCRT-0, hepatocyte growth 
factor regulated tyrosine kinase substrate (HRS), then recruits the ESCRT-I component 
TSG101, which is subsequently responsible for the recruitment of the ESCRT-II protein 
Apoptosis-Linked Gene 2-Interacting Protein X (ALIX; Gene Name: PDCD6IP), which in turn 
leads to recruitment of ESCRT-III (Colombo, Raposo and Thery, 2014). ESCRT-I and ESCRT-II 
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also possess ubiquitin binding domains, which maintains the recruited cargos within regions 
of the endosomal membrane, facilitating sorting into ILVs (Baietti et al., 2012). Both ESCRT-I 
and ESCRT-II have been demonstrated to lead to curvature and budding of the endosomal 
membrane, which encloses cytoplasmic cargo within what will subsequently become the ILV 
lumen (Wollert and Hurley, 2010). ESCRT-III components are responsible for the final scission 
event that disengages the bud from the endosomal membrane, by acting to draw the 
membrane across the “neck” of the bud, thus leading to ILV formation (Wollert et al., 2009; 
Wollert and Hurley, 2010). Additionally, it has been demonstrated that the presence of the 
proteoglycan syndecan within the endosomal membrane may lead to ILV formation through 
complexing with ALIX via the adaptor protein syntenin. ALIX then promotes recruitment of 
vacuolar protein sorting-associated protein 32 (VPS32) a component of ESCRT-III, which leads 
to ILV generation (Baietti et al., 2012). However, whilst the ESCRT-dependent pathway is the 
most clearly described process of ILV formation, evidence suggests that it may also occur in 
an ESCRT-independent manner (van Niel, D’Angelo and Raposo, 2018). 
 
The first indication of a ESCRT-independent route for ILV generation came through 
demonstration that knockdown of the ESCRT components HRS (ESCRT-0), TSG101 (ESCRT-I), 
VPS22 (ESCRT-II) and VPS24 (ECRT-III) via siRNA, was insufficient to prevent ILV formation 
within MVBs (Stuffers et al., 2009). This supported a previous finding by Trajkovic et al., 
(2008), who demonstrated that knockdown of ESCRT components including ALIX and TSG101 
did not lead to a complete impairment of exosome release. Instead, the investigators 
identified that exosomes were enriched for several types of lipid, including cholesterol, 
sphingolipids and, crucially, ceramide. Ceramide is generated from sphingomyelin via the 
enzymatic activity of sphingomyelinases. Use of the neutral sphingomyelinase (nSMase) 
inhibitor GW4869 led to a reduction in exosome release, corroborated via use of two 
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additional nSMase inhibitors. The authors speculated that the cone-like shape of ceramide 
may contribute to curvature of endosomal membranes thus facilitating the formation of ILVs 
(Trajkovic et al., 2008). The work of Trajkovic et al., (2008) was carried out in oligodendroglial 
cells but has subsequently been contradicted in a MNT-1 melanoma cell line, where use of 
GW4869 did not inhibit ILV generation. These investigators identified the tetraspanin CD63 
as a crucial mediator of ILV formation, as siRNA inhibition led to a dramatic reduction in the 
number of ILVs observed by electron microscopy (van Niel et al., 2011). Other tetraspanins, 
including CD9, have also been implicated in exosome biogenesis, with particular regard to 
sorting of specific cargos (Chairoungdua et al., 2010). It has been proposed that the structure 
of the tetraspanins may facilitate invagination of the endosomal membrane following their 
clustering within micro-domains (van Niel, D’Angelo and Raposo, 2018). Therefore, whilst 
the pathways that underpin the formation of exosomes have not been fully elucidated, there 





Figure 1.8: Mechanisms of ILV Biogenesis 
The formation of intraluminal vesicles (ILVs) is critical to the biogenesis of exosomes. This 
process occurs through inward budding of endosomal membranes leading to subsequent 
designation as multivesicular bodies (MVBs). The process of ILV formation has been 
demonstrated to occur via two main pathways. The first, the ESCRT dependent pathway, 
sees clustering of ubiquitinated membrane proteins on the endosomal surface via the 
subunit ESCRT-0. A series of subsequent ESCRT subunits then facilitate membrane curvature 
and scission, leading to formation of an ILV. This process has also been demonstrated to 
occur via an ESCRT independent route, with tetraspanins clustering within microdomains on 
the endosomal membrane facilitating ILV generation. The ESCRT-II component ALIX may has 
also been demonstrated to facilitate the generation of ILVs through binding to syntenin 
adaptor proteins that are in turn bound to syndecan membrane domains. The accumulation 
of luminal cargos such as miRNA and cytoplasmic proteins is less well described and may 
occur due to proximity to the endosome or through active trafficking.  Adapted from (van 




1.2.2.2 ILV Trafficking and Release  
Following their generation within MVBs, ILVs face one of two main fates. The first is 
trafficking to the plasma membrane, where they may be released by exocytosis as exosomes. 
The second is to undergo degradation following fusion of the MVB with lysosomes. Indeed, 
exosome secretion increases in cells treated with the lysosome inhibitor Bafilomycin A1 
(Eitan et al., 2016; Villarroya-Beltri et al., 2016). The processes that determine the fate of 
MVBs have not been well described, however, the lipid composition of the MVB membrane 
may contribute, as enrichment of cholesterol leads to a bias towards exosome secretion 
(Möbius et al., 2003). Furthermore, those MVBs that form through the syndecan–syntenin–
ALIX axis appear to exclusively release ILVs as exosomes (Baietti et al., 2012; van Niel, 
D’Angelo and Raposo, 2018). This is mediated by RAB7, as inhibition via siRNA led to a 
reduction in exosome secretion (Baietti et al., 2012). RAB7 has previously been 
demonstrated to play a role in the development of endosomal compartments and is a 
member of the wider RAB superfamily of small GTPases, which are crucial effectors of ILV 
trafficking and release (Rink et al., 2005; Colombo, Raposo and Thery, 2014). For instance, 
the RAB27 isoforms A and B were identified as mediators of exosome production through an 
shRNA screen in HeLa cells, where they were demonstrated to facilitate MVB fusion with the 
plasma membrane (Ostrowski et al., 2010). Similarly, RAB35 was shown to act in a similar 
manner to RAB27 in mouse oligodendroglial cells, promoting the secretion of exosomes by 
facilitating plasma membrane fusion (Hsu et al., 2010). Furthermore, RAB11 has also been 
demonstrated to contribute to exosome production from K562 erythroleukemia cells 
(Savina, Vidal and Colombo, 2002; Colombo, Raposo and Thery, 2014). Overall, the 
intracellular trafficking of ILVs, as well as their subsequent release as exosomes, appears to 




1.2.2.3 Microvesicle Biogenesis 
The processes that lead to MV generation have been less clearly described than those of 
exosomes. The most obvious distinction is that MVs are shed directly from the plasma 
membrane, contrasting the endosomal origin of exosomes. Changes in lipid organisation 
within the plasma membrane have been demonstrated to promote curvature thus 
facilitating MV formation (Piccin, Murphy and Smith, 2007; van Niel, D’Angelo and Raposo, 
2018). Furthermore, RHO small GTPases and RHO-associated protein kinase (ROCK) have 
been implicated as crucial effectors of MV generation via regulation of actin in cancer cells. 
MV production requires extension of actin filaments and formation of a ring-like structure, 
in order to be released from the plasma membrane. This is impaired by the regulatory 
protein cofilin, which usually facilitates the disassembly of actin filaments. Lim kinase (LIMK) 
activation by ROCK, facilitates phosphorylation and inactivation of cofilin, thus leading to 
actin filament elongation and MV production (Li et al., 2012). Interestingly, despite being 
widely considered markers of exosomal biogenesis, ESCRT complex members have also been 
demonstrated to contribute to MV formation. TSG101 and the ESCRT recycling ATPase VPS4 
were demonstrated to facilitate MV generation in HEK-293T cells (Nabhan et al., 2012). 
Furthermore, ESCRT-0 and ESCRT-I depletion in C. elegans embryos was demonstrated to 
inhibit MV release from the plasma membrane (Wehman et al., 2011). This common 
contribution of ESCRT proteins to the biogenesis of both MVs and exosomes prevents their 
confident usage as unique markers of exosome biogenesis, contributing to the widespread 
difficulty in identifying subclasses of extracellular vesicles (Hurley, 2015; van Niel, D’Angelo 




1.2.3 Extracellular Vesicle Cargo and Composition  
By virtue of their origin, EVs are compositionally dependent upon their producing cell. 
Therefore, all cargos and constituents are derived directly from the parental cell. As such, 
EVs have been described as “miniature versions of the cell”, representing the cellular 
composition at the precise point of biogenesis (Saleem and Abdel-Mageed, 2015). However, 
this is not entirely accurate, as EVs are preferentially enriched in a range of cargos, and also 
possess a heterogeneous composition between subtypes (Willms et al., 2016). Of particular 
note, is an identified enrichment in a range of factors involved in EV biogenesis, notably the 
ESCRT components ALIX and TSG101, as well as the tetraspanins CD9, CD63 and CD81 (Théry 
et al., 2001). These have been observed widely and are considered general EV markers 
(Lotvall et al., 2014). However, due to heterogeneity across EV subtypes, no single marker is 
considered truly universal, as no marker has been described as common within all EVs (Kowal 
et al., 2016). This underpins the use of more general terminology to describe bulk 
populations of vesicles, as specific subtypes cannot currently be confidently identified 
(Witwer and Théry, 2019).  
 
Because EVs derive both membrane and luminal cargos directly from producing cells, their 
potential compositional components are as varied as that of the cells themselves, as well as 
all the specific contexts those cells may be in. In general, EVs have been demonstrated to 
contain a range of protein and nucleic acid cargoes, as well as a variety of compositional lipid 
components (Colombo, Raposo and Thery, 2014). Lipids are a fundamental constituent of 
EVs, given that they are considered lipid bilayer bound particles (Witwer and Théry, 2019). 
Work by Llorente et al., (2013), demonstrated that PC-3 prostate cancer cell derived EVs, 
comprised a distinct lipid profile compared to their producing cells. Specifically, EVs were 
associated with enrichment of cholesterol, glycosphingolipids, phosphatidylserine and 
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sphingomyelin (Llorente et al., 2013). It is not clear whether these changes are specific to PC-
3 cell derived EVs or represent a more widely associated EV profile. Lipids have, in general, 
garnered significantly less research attention than the other predominant EV cargos – 
proteins and nucleic acids (Colombo, Raposo and Thery, 2014).     
 
Many EV protein constituents are involved in surface interactions with recipient cells. These 
are considered in more detail in section 1.2.4. In fact, the proteomic composition of EVs has 
been characterised in such a variety of circumstances, that several online compendiums 
(such as www.ExoCarta.org) exist to catalogue the data. To date, approximately 25% of 
proteins have been identified in human EVs in some context (Mathivanan et al., 2012; 
Keerthikumar et al., 2016). Therefore, it is prudent to assess the protein content of EVs within 
specific circumstances, such as within senescence and ageing (described in detail – section 
1.3). Generally, profiling of the proteomic content of EVs is performed through mass 
spectrometry (MS), due to the high level of sensitivity, low required sample volume and 
extensive data sets produced (Bandu, Oh and Kim, 2019). MS has proved a critical tool within 
EV research and was utilised in the detection of the majority of proteins now considered 
canonical EV “markers” (Théry et al., 2001). However, its utility within EV research is 
hindered by the inherent limitations of EV isolation techniques, many of which are subject 
to non-vesicular protein contamination (section 1.2.5). Furthermore, the huge variety in 
producing cells, as well as subtypes of EV, has led to enormous diversity in the proteomic 
characterisation of EVs (Willms et al., 2016).  
 
Nucleic acids have received widespread research attention since they were first identified as 
EV cargos. This was demonstrated by Valadi et al., (2008), who showed that messenger RNA 
(mRNA) and miRNA could be transferred between murine mast cells. Importantly, these 
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nucleic acids were demonstrated to have functional potential, as the delivered mRNA 
possessed the capacity to facilitate translation in recipient cells (Valadi et al., 2007). This was 
built upon by Pegtel et al., (2010), who further demonstrated that miRNAs from B-cell 
derived EVs could regulate protein expression in treated dendritic cells (Pegtel et al., 2010). 
These studies have prompted significant research interest, as EV mediated transfer of nucleic 
acids represents a form of cellular communication that is distinct from the wider soluble 
secretome. However, in order to fully appreciate these differences, it is important to 
understand the mechanisms through which EVs may engage recipient cells.       
 
1.2.4 Extracellular Vesicle Uptake and Signalling 
Following their release, EVs may interact with recipient cells through a number of 
mechanisms (Figure 1.9). These include endocytosis, macropinocytosis, phagocytosis, 
clathrin/caveolin mediated endocytosis, direct membrane fusion and receptor/ligand 
binding (Figure 1.9) (Mulcahy, Pink and Carter, 2014; van Niel, D’Angelo and Raposo, 2018). 
There is some distinction to be made between the binding of EVs with a recipient cell through 
a combination of receptors and ligands, compared to the internalisation of the entire vesicle 
itself. However, the two concepts intersect, as EV uptake is facilitated by binding to specific 
surface receptors (van Niel, D’Angelo and Raposo, 2018). This has been demonstrated via 
the loss of EV uptake following proteinase K treatment of ovarian cancer cells (Escrevente et 
al., 2011). Such mechanisms may allow a more specific route to signalling, than could be 
achieved through general uptake systems. This is likely facilitated by heterogeneity in EV and 
cell membrane compositions (Mulcahy, Pink and Carter, 2014). Indeed, integrins on the 
surface of EVs have been demonstrated to facilitate uptake through interaction with 
adhesion molecules on the surface of dendritic cells (Morelli et al., 2004; van Niel, D’Angelo 
and Raposo, 2018). Furthermore, different cells uptake EVs with different levels of efficiency, 
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such as a demonstrated reduction in T-cell uptake compared to peritoneal exudate cells 
(Zech et al., 2012; Mulcahy, Pink and Carter, 2014). The actual mechanisms through which 
cells internalise EVs are broadly covered by the term “endocytosis”, although greater 
specificity has been widely demonstrated (Figure 1.9) (Doherty and McMahon, 2009; 
Mulcahy, Pink and Carter, 2014). Vesicles may also directly fuse with the plasma membrane, 
leading to cytoplasmic delivery of luminal cargos (Parolini et al., 2009). This represents a 
potential route through which vesicular payloads may be delivered to a target cell. 
Alternatively, following endocytosis, “back-fusion” of the EV with the endosomal membrane 
could facilitate a similar cytoplasmic delivery (van Niel, D’Angelo and Raposo, 2018). The 
engagement of such mechanisms currently underpin our understanding as to the routes 
through which functional delivery of luminal EV cargos, such as nucleic acids, occurs (Valadi 
et al., 2007; Mulcahy, Pink and Carter, 2014). 
 
Contrasting vesicular uptake, engagement of EVs with receptors on the surface of recipient 
cells has been demonstrated to activate intracellular signalling cascades in a variety of 
contexts (van Niel, D’Angelo and Raposo, 2018). This was first demonstrated through the 
observation of augmented T-cell IL-2 secretion following antigen presentation by MHC-II 
molecules on the surface of B-lymphocyte derived EVs (Raposo et al., 1996). Furthermore, 
Cossetti et al., (2014) demonstrated that interferon gamma (IFN-γ) bound to its receptor, 
interferon gamma receptor 1 (Ifngr1), on the surface of EVs, could engage STAT1 signalling 
in recipient NIH 3T3 fibroblasts. Investigators noted that a greater response was elicited in 
cells treated with EVs compared to soluble IFN-γ at a 100 times greater concentration than 
that measured in the EVs by ELISA. This suggests that EVs may augment the activity of soluble 
mediators, possibly by conferring additional stability than the soluble form (Cossetti et al., 
2014).This was supported by Webber et al., (2015), who demonstrated that EV-associated 
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TGFβ1 promoted the differentiation of lung fibroblasts into myofibroblasts, characterised by 
expression of alpha smooth muscle actin (αSMA). Whilst this also occurred in response to 
soluble TGFβ1, the EV-associated form of the cytokine produced an altered secretory profile, 
with increased expression of several growth factors (uPA and HGF) and downregulation of 
others (PDGF-AA and IGFBP-3). Furthermore, increased proliferation of HUVECs was 
demonstrated through treatment with conditioned media (CM) from the EV treated 
fibroblasts, compared to media derived from cells treated with a concentration-matched 
level of soluble TGFβ1. Importantly, the fibroblast differentiation (and derived CM effect) 
could be attenuated by TGFβ1 receptor inhibition, through use of the small molecule 
SB431542 (Webber et al., 2015). Together, these studies demonstrate that activation of 
intracellular signalling pathways can occur in response to EV engagement with cell surface 
receptors. Clearly, these responses will be highly context specific, relying on the composition 
of both producing and recipient cell, as well as any heterogeneity within EV subtypes. 
However, through both uptake mechanisms and receptor signalling, EVs have been 
demonstrated to be functionally relevant contributors to cellular communication (Mulcahy, 





Figure 1.9: Mechanisms of Extracellular Vesicle Signalling 
Extracellular vesicles (EVs) may engage with recipient cells through interactions with the cell 
surface or internalisation of the vesicle itself. Receptors and ligands on the surface of EVs can 
interact with corresponding counterparts of the cell surface and trigger intracellular 
signalling cascades. Furthermore, EVs may fuse with the plasma membrane, leading to direct 
cytoplasmic delivery of luminal cargo. Alternatively, EVs may be taken up through a range of 
mechanisms broadly falling under the term endocytosis. These may be mediated though 
formation of clathrin pits or caveolae on the cell surface, or through more general uptake 
mechanisms such as macropinocytosis and phagocytosis. Once internalised within 
endosomes, EVs may “back-fuse” with the endosomal membrane leading to cytoplasmic 
delivery of luminal cargo. Conversely, the endosome may be fated for lysosomal 
degradation, leading to breakdown of the internalised EVs. Adapted from (van Niel, D’Angelo 




1.2.5 Influence of the 3D Environment on EV Production and Function 
The vast majority of research investigating EVs has been performed in two-dimensional (2D) 
cell culture models. This is perhaps unsurprising, as these systems are the fundamental 
backbone of biomedical research and are generally considered the “standard” for in vitro 
investigations (Tibbitt and Anseth, 2009; Thippabhotla, Zhong and He, 2019). However, it is 
now widely appreciated that these 2D systems fail to fully represent the three dimensional 
(3D) conditions in which cells are found in vivo, leading to inconsistencies between 
physiological conditions and the experimental systems that aim to model them (Tibbitt and 
Anseth, 2009). In particular, cells in 2D lack the complex interactions with the surrounding 
extracellular matrix (ECM) that are found in vivo, which have been demonstrated to alter 
fundamental cellular processes including morphology, proliferation and differentiation 
(Baker and Chen, 2012). Recently, this has been extended to include the rate of EV 
production, with several investigations identifying an increase in EV production from cells 
cultured using 3D cell culture models (Rocha et al., 2019; Thippabhotla, Zhong and He, 2019). 
Furthermore, both the protein and RNA cargo of EVs has been demonstrated to alter with 
3D cell culture, suggesting that 2D systems may provide inaccurate representation of EV 
composition in vivo (Rocha et al., 2019). This provides an important caveat to the work 
presented in this thesis, as only 2D cell culture was utilised and thus may be restricted by the 
inherent limitations associated with this form of cell culture. In the context of senescence, it 
would represent interesting future work to investigate the changes in EV production and 
function in 3D, particularly given the potential for ECM remodelling afforded by components 
of the SASP, such as matrix metalloproteinases (MMPs) (Ghosh et al., 2020). However, this 
work aims to explore the biological fundamentals of EVs within senescence by utilising a 




1.2.6 Methods of Extracellular Vesicle Isolation 
As discussed above, significant heterogeneity exists between subtypes of EVs. Furthermore, 
no marker can be considered exclusively vesicular, as all cargos are derived from parental 
cells (van Niel, D’Angelo and Raposo, 2018). This makes both confident classification of EV 
subtypes and distinction from cellular material difficult, hence the use of generic, all-
encompassing terminology (Witwer and Théry, 2019). Current understanding of EVs broadly 
separates subclasses into plasma membrane shed MVs and endosome derived exosomes 
(Colombo, Raposo and Thery, 2014). One commonly reported distinction between these 
groups is a disparity in size profile, with exosomes generally considered smaller. However, 
the extensive range of possible MV sizes, many of which overlap those of exosomes, makes 
this a flawed means of distinction (Lotvall et al., 2014). Indeed, it has been proposed that EVs 
should be classified according to their size (e.g. small, medium and large), without any 
attempt to describe their route of biogenesis, as this cannot confidently be attributed to bulk 
isolates (Kowal et al., 2016). This proposal stems from the fact that the majority of methods 
for the isolation of EVs are based upon the separation of particles according to size (Gardiner 
et al., 2016). However, within these size-based classifications, enrichment will occur for 
particular groups of EVs. For example, a population of small EVs may be described as 
enriched for exosomes, whilst a population of large EVs may be enriched for MVs. This 
concept of enrichment as opposed to isolation is helpful, particularly when combined with 
appropriately cautious nomenclature, as it allows the nuances of EV heterogeneity to be 
accurately represented. It is important to note that any employed isolation technique should 
be tailored to the experimental questions and downstream applications. Equally, all 
techniques will have some level of bias towards a particular population of EVs and results 
observed are unlikely to be universally applicable to all other settings. With these caveats in 




1.2.6.1 Differential Ultracentrifugation (dUC) 
Application of a series of increasingly fast centrifugation steps, the final of these being an 
ultracentrifugation step, is comfortably the most widely applied method for the isolation of 
EVs (Gardiner et al., 2016). The general principle behind this technique is that larger particles 
will sediment at slower speeds, allowing them to be removed in the early stages, whilst 
smaller particles will be pelleted in the final steps (Figure 1.10) (Livshits et al., 2015). Within 
the field, the number, speed and duration of centrifugation steps employed to isolate EVs 
have ranged widely. Furthermore, variation exists between different centrifugation rotors, 
particularly in the clearance factor (K-factor), which is a measure of the efficiency with which 
the rotor pellets particles at its maximum speed (this may be adjusted for any given 
revolutions per minute (RPM). Additionally, each individual particle within a sample has a 
specific sedimentation coefficient, which dictates its movement within a liquid based upon 
the physical characteristics of both particle and medium. Through a combination of both K-
factor and sedimentation co-efficient, a particular particle will pellet from a given medium 
within a specific time using a specific rotor (Cvjetkovic et al., 2014). This is overviewed in 
Figure 1.11. These variables present a problem, as direct comparison between protocols 
requires detailed information about rotor specifications, which have not been consistently 
reported within the literature. Therefore, comprehensive methodological reporting is now a 
minimal experimental requirement, as determined by ISEV (Lotvall et al., 2014). As a general 
principle, at least three steps are usually employed to pellet vesicles according to size, largely 
based on a protocol described by Théry et al., (2006). A step of approximately 2000 x g is 
used to remove large MVs (such as apoptotic bodies) as well as any other cellular debris. A 
second 10,000 x g step is employed to pellet MVs and a final 100,000 x g step used to pellet 
exosomes (Théry et al., 2006). As described above, overlap between the sizes of these 
vesicles makes each of these steps an enrichment for the intended subtype rather than a 
true isolation, with use of the terms large, medium and small EVs more appropriately 
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describing the composition of the final pellets (Kowal et al., 2016). Through dUC, EVs have 
been successfully obtained from a wide range of biological fluids and cell culture 
supernatants (Gardiner et al., 2016).  
 
Despite its widespread popularity, dUC has several drawbacks as a method of EV isolation. 
The first of these is the physical disruption of the vesicles due to the high forces involved 
with ultracentrifugation, which hinders yield and can lead to a broad range of particle sizes 
(Lobb et al., 2015; Taylor and Shah, 2015). It is also a technique not suitable for clinical 
application, due to a high level of user variability and complications resulting from variable 
viscosity of patient samples (e.g. plasma) (Lamparski et al., 2002; Lobb et al., 2015). However, 
perhaps the most significant drawback to dUC is its relative lack of purity. One proposed 
method of purity assessment is to observe the ratio of particles and protein within an EV 
sample. By this measure, dUC performs poorly compared to methods such as sucrose 
gradient separation (Webber and Clayton, 2013). This effect may be driven by the co-
isolation of proteins alongside EVs during dUC and may be a more significant problem 
depending on both the starting material (e.g. cell culture supernatant vs patient plasma) or 
intended downstream applications (Van Deun et al., 2014). Recently it has been 
comprehensively demonstrated by Foers et al., (2018) that dUC EV preparations are 
associated with considerable soluble protein contamination. Electron microscopy of EVs 
isolated from the synovial fluid (SF) or rheumatoid arthritis (RA) patients, demonstrated 
significant isolation of non-vesicular material by dUC. Immunoblotting demonstrated that, 
whilst EV markers were enriched, presence of contaminating serum albumin, apolipoprotein 
A-I and the extracellular matrix (ECM) component fibronectin were also identified. 
Furthermore, application of size-exclusion chromatography (SEC) largely avoided these 
centrifugation-related issues (Foers et al., 2018). Therefore, whilst a popular technique that 
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has been demonstrated to successfully isolate EVs from starting material, dUC is associated 
with significant limitations with regard to the purity of the final EV product, in particular due 





Figure 1.10: Principles of Differential Centrifugation 
Extracellular vesicles (EVs) may be isolated from a starting medium by subjecting it 
centrifugation spins of increasingly faster speeds (differential ultracentrifugation, dUC). This 
separates vesicles into pellets based upon their size, allowing broad separation between 
large, medium and small EVs including apoptotic bodies, microvesicles and exosomes. 






Figure 1.11: Principles of Particle Sedimentation 
The particles that are isolated by a particular rotor is determined by: 1) The K-factor (K) of 
that rotor, which corresponds to the revolution per minute (RPM) and minimum/maximum 
radii from the centre of rotation (rmax and rmin), and 2) the sedimentation coefficient (S) of 
the particles, which is dependent of the mass (m) and radii (r) of the particles, and the 
viscosity (η) of the medium. 3) The time of centrifugation (T) required for any individual 
particle by a specific rotor can then be determined via the K-factor and sedimentation co-
efficient. Adapted from (Cvjetkovic et al., 2014).        
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1.2.6.2 Size-Exclusion Chromatography (SEC)  
As described above, size-exclusion chromatography (SEC) presents some advantages over 
dUC as an isolation technique, mainly in the form of a greater separation of vesicles from 
soluble proteins (Foers et al., 2018). SEC generally involves use of a column comprising 
sepharose beads, which in turn contain a pore of 30-70nm. This pore increases the path 
length through the column for any loaded particles smaller than the pore size. This means 
large particles pass straight through the column and are often eluted in the void volume. By 
contrast, smaller particles pass through the column more slowly, distributing in fractions 
according to size (Böing et al., 2014). In general, EVs are eluted in earlier fractions than 
soluble proteins, and SEC has been demonstrated to provide excellent separation between 
vesicles and protein (Benedikter et al., 2017; Koh et al., 2018). However, as with dUC, 
because SEC utilises size to separate vesicles, it does not provide any sort of indication to the 
class of EVs obtained. Furthermore, SEC columns are not readily scalable, which may present 
problems depending on the volume of starting material. One solution to this issue is to 
incorporate SEC as a purification step following concentration through techniques such as 
dUC or filtration (Nordin et al., 2015; Gardiner et al., 2016). Overall, SEC represents a useful 
alternative or complimentary technique to the widely employed dUC, due to greater overall 
purity in the final EV product.              
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1.2.6.3 Density Gradient Separation (DGS) 
As discussed above, a key aim of EV isolation methodologies is the separation of a pure 
vesicular population from an initial medium, without the co-isolation of non-vesicular 
factors. Density gradient separation (DGS) employs ultracentrifugation to separate EVs 
within a gradient comprised of either sucrose or iodixanol (OptiPrepTM) (Tauro et al., 2012). 
This often employs a multi-step process where EVs are initially isolated via dUC and then 
purified by DGS. During this process, EVs of different densities (a physical property largely 
dependent on size) separate within the gradient, which can then be collected in fractions 
(Iwai et al., 2016). This also leads to separation of vesicles and protein, with little overlap 
between fractions (Foers et al., 2018). However, as with all isolation techniques, DGS 
possesses limitations. For example, the high osmotic pressure associated with sucrose 
gradients may cause structural damage to the isolated vesicles, although this problem may 
be circumvented through use of iodixanol (Iwai et al., 2016). Furthermore, the density of EVs 
has been demonstrated to overlap significantly with that of high-density lipoprotein (HDL), 
which is a significant contaminant of DGS preparations, particularly those derived from 
biological fluids (Foers et al., 2018; Onódi et al., 2018). Additionally, due to the use of 
multiple centrifugation steps, isolation recovery yield is often low with DGS, limiting 
potential downstream processes (Tauro et al., 2012; Onódi et al., 2018). Whilst DGS has been 
used with some success in combination with SEC, this also suffered from issues of yield 
(Karimi et al., 2018). Overall, DGS should be considered a complimentary technique to be 
paired with other methods of EV isolation where downstream applications require a high 
level of purity.          
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1.2.6.4 Precipitation Based Assays  
Numerous kits are commercially available that are intended to provide a quick and easy 
method of EV isolation (Rider, Hurwitz and Meckes  Jr., 2016). These often comprise volume-
excluding polymers such as polyethylene glycol (PEG), which precipitate biological material 
by sterically excluding them from regions of solvent occupied by the polymer (Atha and 
Inghamg, 1981; Rider, Hurwitz and Meckes  Jr., 2016; Brennan et al., 2020). Acetate based 
assays have also been employed, in which negatively charged components of the EV 
membrane, such as phosphatidylserine, are neutralised, leading to hydrophobic interaction, 
aggregation and subsequent precipitation of the vesicles (Brownlee et al., 2014). However, 
these precipitation-based assays are associated with significant limitations, which principally 
stem from the fact that the underlying principles employed are not exclusive to EVs. For 
instance, high concentrations of albumin were co-precipitated with EVs isolated from human 
plasma samples (Lobb et al., 2015). Furthermore, precipitation-based techniques were 
demonstrated to produce less enrichment for EV markers, despite having a higher overall 
protein concentration (Van Deun et al., 2014). This supports the concept that precipitation 
of non-vesicular proteins occurs alongside EVs, potentially compromising downstream 









1.2.7 Methods of Extracellular Vesicle Characterisation  
As described throughout section 1.2.5, current understanding of EV biology is hampered by 
technical limitations in both isolation and characterisation. The latter of these is particularly 
hindered by the small size of EVs, which limits application of standard microscopy and flow 
cytometry techniques. Nevertheless, a range of approaches have been employed to visualise 
and characterise EVs.    
 
1.2.7.1 Electron Microscopy (EM) 
The first studies to identify the existence of EVs did so through application of electron 
microscopy techniques (Trams et al., 1981; Harding, Heuser and Stahl, 1983; Pan and 
Johnstone, 1983). The majority of investigations utilise transmission electron microscopy 
(TEM), which has a resolution of around 1-3nm, thus allowing clear visualisation of even the 
smallest EVs (Coumans et al., 2017). TEM requires the fixation and dehydration of samples 
before imaging, which has been demonstrated to alter EV morphology, resulting in a “cup 
shape” that has been erroneously reported as an EV specific characteristic (Raposo et al., 
1996; van Niel, D’Angelo and Raposo, 2018). This issue is avoided through use of cyro-EM, 
where samples may be maintained in a hydrated state, thus retaining their conventional 
spherical morphology (Coumans et al., 2017). EM may also be combined with immuno-gold 
labelling, whereby gold particles are conjugated to an antibody, thus allowing identification 
of specific surface proteins. This technique was used in early EV investigations to follow the 
trafficking of the transferrin receptor to ILVs (Harding, Heuser and Stahl, 1983; Pan and 
Johnstone, 1983; Coumans et al., 2017). Whilst EM may be considered the gold standard for 
characterisation of individual EVs, it is not high-throughput, requires significant operator 
training and does not provide a measurement of sample concentration (Rikkert et al., 2019). 
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Therefore, it is often used to validate the successful isolation of EVs and combined with 
additional methods of characterisation.  
 
1.2.7.2 Nanoparticle Tracking Analysis (NTA) 
Nanoparticle tracking analysis (NTA) is a technique that aims to determine the size of 
particles based upon their Brownian motion, a characteristic whereby particles in suspension 
randomly move (Dragovic et al., 2011). NTA utilises a laser beam, the light of which is 
scattered by the suspended particles and detected by a microscope. This scattering of light 
is recorded by a video camera, whilst tracking software is employed to follow the 
displacement of particles between frames. This is combined with the physical characteristics 
of the suspension fluid (temperature and viscosity) and allows determination of the size of 
each tracked particle via the Stokes-Einstein equation (Figure 1.12) (Filipe, Hawe and Jiskoot, 
2010; Dragovic et al., 2011; Gardiner et al., 2013). In simple terms, smaller particles have 
greater Brownian motion than larger particles in the same fluid, thus tracking movement 
allows an estimation of size to be made (Gardiner et al., 2014). Because the microscope 
visualises a suspension chamber of a known volume, a concentration of tracked particles can 
also be determined (Dragovic et al., 2011). Therefore, NTA has become a widely employed 
technique to characterise the size and concentration of EV preparations (Gardiner et al., 
2016). 
 
However, NTA is not without limitations. The most glaring of these, is that NTA is simply a 
measurement of light scattered by particles of a specific size and cannot confidently separate 
EVs from any contaminating materials (Coumans et al., 2017). In this sense, it is a 
measurement of a physical property of EVs, as opposed to any biological characteristic. 
However, NTA can be combined with fluorescent probes, such as lipid binding dyes, that 
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allow some level of confidence that measured particles are EVs (Gardiner et al., 2013). 
However, NTA is not able to determine the subcellular origin of the detected EVs and thus 
cannot be used to define EV subtypes. It has also been suggested that NTA may be less 
reproducible than other techniques (Filipe, Hawe and Jiskoot, 2010; Hole et al., 2013; 
Bachurski et al., 2019). However, with these caveats in mind, NTA does provide a relatively 
simple technique to determine the concentration and size of EVs, without the need for 
labelling or sample processing. Many of the limitations posed may be offset through 
combination with other techniques such as immunoblotting and EM. This approach is 
recommended by ISEV in order to minimise the relative limitations of each individual 
technique (Lotvall et al., 2014). Therefore, NTA is a widely accepted method for EV 




     
Figure 1.12: Principles of Nanoparticle Tracking Analysis (NTA)  
Nanoparticle tracking analysis (NTA) is based on the principle of Brownian motion, the 
movement of particles based upon size. A laser beam is applied to particles in suspension, 
the movement of which causes light to be scattered. This is then detected by a microscope 
and the light scatter is tracked by software such as that in the NS300 system. The scattered 
light is dependent on the relative speed that at which the particles are moving, which is in 
turn dependent on the size of the particles. Therefore, by tracking the scattered light the 
Stokes-Einstein equation may be applied to calculate the diameter of the particles (d) using 
the temperature (T) of the sample and the viscosity (η) of the suspension fluid using 







1.2.7.3 Tunable Resistive Pulse Sensing 
Tunable resistive pulse sensing (TRPS) involves continuous measurement of a current across 
a pore, which can be used to calculate the electrical resistance of the pore itself. As vesicles 
are forced through the pore by both voltage and pressure, the resistance in the pore 
increases, recorded as a decrease in current. This is proportional to the volume of vesicles 
traversing the pore, which can then be calculated (Coumans et al., 2014). Furthermore, the 
count of current-decrease events may also be used to determine the particle concentration 
of a sample. However, as with NTA, this system does not distinguish between EVs and non-
vesicular material (Coumans et al., 2017). Furthermore, the system also relies heavily on the 
pore size, as inclusion of particles or contaminants larger than the pore may clog and damage 
the system, leading to unreliable results (Coumans et al., 2014). Finally, the system has no 
facility to determine any compositional characteristics of the measured EVs.  
 
1.2.7.4 Flow Cytometry (FCM) 
In conventional flow cytometry (FCM), cells are passed sequentially through a laser beam 
leading to the scattering of light, which allows determination of cell size (forward angle 
scatter) and granularity (side scatter) (Adan et al., 2017). Early attempts to evaluate EVs by 
FCM utilised polystyrene beads to construct calibration curves against which EV samples 
could be compared (Coumans et al., 2017). However, this is a flawed approach, as EVs have 
a different refractive index to the calibration beads, resulting in inaccurate comparisons (van 
der Pol et al., 2014). Furthermore, the small size of EVs produces an issue of sensitivity, as 
the EV scattered light is often indistinguishable from background noise. This means that 
often only the largest EVs are detected, leading to inaccurate size measurements (Harrison 
and Gardiner, 2012). Additionally, due to their small size, multiple vesicles are often included 
as one “event”, leading to coincidence artefacts and inaccurate data output (Van Der Pol et 
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al., 2012; Coumans et al., 2017). Finally, the use of fluorescent FCM in an EV setting is limited, 
as antigen availability is much lower on the surface of EVs than on cells. This once again limits 
the intensity of signal generated, thus hindering detection (Coumans et al., 2017). Overall, it 
is a consequence of repurposing a technique designed for cells that limits the utility of FCM 
as a method of EV characterisation.  
 
However, recently, a purpose built form of EV FCM has become commercially available – 
nanoFCM. This system overcomes many of the limitations of the standard technique as it has 
a lower resolution limit of 40nm for EVs, as opposed to 1000nm reported for FCM (Van Der 
Pol et al., 2012; Tian et al., 2020). Furthermore, EV subpopulations may be assessed through 
fluorescent staining for the EV markers CD9, CD63 and CD81 (Tian et al., 2018). Recently, this 
technique was used to assess EVs isolated by dUC, SEC, ultrafiltration and several 
precipitation based kits successfully (Tian et al., 2020). Overall, this system would appear to 
have several advantages over techniques such as NTA as it is capable of determining particle 
size, concentration and, more importantly, potential heterogeneity with EVs based upon 
fluorescently detected markers. Whilst an exciting new technology, its relative infancy has 








1.2.7.5 Single particle interferometric reflectance imaging sensing (SP-IRIS) 
The development of new technologies to characterise EVs has begun to address some of the 
major limitations within the field. This can be seen with nanoFCM and greater elucidation of 
EV subtype compositions. Similarly, single particle interferometric reflectance imaging 
sensing (SP-IRIS) has recently been deployed in the form of the ExoView system (Daaboul et 
al., 2016; Bachurski et al., 2019). This technique utilises a micro-array of capture spots, which 
is able to immune-capture EVs positive for the tetraspanins CD9, CD63 and CD81. 
Furthermore, additional fluorescent antibodies may be incorporated to identify other 
surface markers of interest. The resolution limit is 50nm but, crucially, those EVs detected 
will have an associated profile of all three tetraspanins (Bachurski et al., 2019). This is 
important as it has previously been indicated that sub-populations of EVs may be identified 
by the combination of tetraspanins expressed (Kowal et al., 2016). An obvious limitation of 
this technique is that it is not suitable for EVs that do not express any of the tetraspanins. 
However, this is also a strength, as it overcomes the misidentification of non-vesicular 
particles that confounds other systems (Bachurski et al., 2019). Another important 
advantage is that, depending on the sample, no EV isolation method need be pre-applied 
(Daaboul et al., 2016). This overcomes a major hurdle in terms of practicality and yield that 
has hindered EV research to date. Overall, it is encouraging to see the emergence of new 
technologies that attempt to overcome many of the issues that have hampered EV research. 
Whilst widespread adoption is likely to take time, the application of more rigorous 






1.3 Extracellular Vesicles in Senescence and Ageing  
1.3.1 Changes in Extracellular Vesicle Production in Senescence 
As described in section 1.1.4, the secretory phenotype of the SASP has become a hallmark of 
senescent cells (Coppe et al., 2008; Hernandez-Segura, Nehme and Demaria, 2018). This 
enhanced secretome has typically been regarded as comprising predominantly soluble 
factors, complemented by shed ectodomains (Coppe et al., 2008; Morancho et al., 2015). 
However, recent reports have described a vesicular component to the secretory profile of 
senescent cells, which is exaggerated from that associated with proliferating or quiescent 
counterparts (Takasugi, 2018; Wallis, Mizen and Bishop, 2020). This was first reported by 
Lehmann et al., (2008), who observed that EV secretion increased in human prostate cancer 
cells that had undergone premature senescence in response to ionising radiation. The 
authors also described an increase in EV release from replicatively senescent human dermal 
fibroblasts (HDFs), which suggested that this may be a feature of multiple types of 
senescence (Lehmann et al., 2008). A previous report had established that tumour 
suppressor-activated pathway 6 (TSAP6) and vacuolar protein sorting-associated protein 32 
(VPS32), both p53 targets, were responsible for an increase in EV secretion following p53 
activation in response to ionising radiation in non-small cell lung cancer cell lines (Yu, Harris 
and Levine, 2006). Expanding on this, EV secretion was demonstrated to increase following 
DNA damage, triggered by ionising radiation or actinomycin D treatment, in MEFs and bone 
marrow-derived dendritic cells (BMDCs), respectively. This was demonstrated to occur in a 
p53 dependent manner, as the increased production of EVs was lost in cells from TSPAN6 
knockout mice, indicating a possible link between this key effector of senescence and EV 
production (Lespagnol et al., 2008). Whilst a less explicit association, p53 has also been 
reported to mediate an increase in Rab27b expression in senescent SVts8 fibroblasts, once 
again linking p53 to EV biogenesis. More recently, Takasugi et al., (2017) demonstrated that 
EV production increased in TIG-3 human fibroblasts in response to replicative, oncogene 
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induced and therapy-induced senescence (Takasugi et al., 2017). This work has been 
followed by a flurry of publications reporting increased EV secretion in models of replicative 
(Mensà et al., 2020; Riquelme et al., 2020), oncogene-induced (Borghesan et al., 2019), 
therapy-induced (Kavanagh et al., 2017), H2O2-induced (Terlecki-Zaniewicz et al., 2018) and 
irradiation-induced (Basisty et al., 2020) senescence. Overall, in a phenotype reminiscent of 
the SASP, senescence has been widely associated with an increase in EV production (Wallis, 
Mizen and Bishop, 2020).       
 
It is currently unclear how the establishment of a senescence phenotype may lead to an 
increase in EV secretion. Choi et al., (2020) have sought to provide some clarity using HDFs, 
which have undergone senescence in response to replicative exhaustion. The authors 
demonstrated that RS HDFs are associated with increased nSMase activity. As described in 
section 1.2.2.1, this enzyme has been shown to be a crucial mediator of EV production and 
its inhibition with GW4869 was demonstrated to reduce EV release by HDFs (Choi, Kil and 
Cho, 2020). Furthermore, increased nSMase activity has been linked to excessive ROS 
production, another senescence-associated phenomenon, with antioxidant treatment 
demonstrated to attenuate EV production from senescent HDFs (Hernandez-Segura, Nehme 
and Demaria, 2018; Choi, Kil and Cho, 2020). Additionally, the authors postulated that 
dysfunctional lysosomal activity in senescent cells is directly linked with increased EV 
secretion. Pharmacological restoration of lysosomal function in senescent HDFs, through 
lowering of lysosomal pH, reduced EV production. Furthermore, increasing lysosomal pH in 
proliferating HDFs conferred a vesicular secretory level equitable to that of senescent cells 
(Choi, Kil and Cho, 2020). Together, this suggests a link between the altered lysosomal 
activity of senescent cells and an increased rate of EV production.           
92 
 
1.3.2 Changes in Extracellular Vesicle Cargoes in Senescence 
The biogenesis of EVs necessitates that they derive all compositional components directly 
from their producing cell (van Niel, D’Angelo and Raposo, 2018). Therefore, alterations in 
cellular composition can lead to subsequent changes in EV cargoes. Senescent cells are 
compositionally distinct from their proliferating counterparts and a growing body of 
evidence suggests the same is true of the EVs produced by these cells (Takasugi, 2018; Wallis, 
Mizen and Bishop, 2020). This section will discuss the alterations in senescent cell derived EV 
cargos in the context of proteins, nucleic acids and lipids, as well as the associated functional 
consequences of these constituents.  
 
1.3.2.1 Proteins   
EVs have recently emerged as an additional layer of complexity to the predominantly soluble 
secretome of senescent cells (Takasugi, 2018; Basisty et al., 2020). Whilst identification of 
EVs themselves has become more routine as a result of techniques such as NTA (Bachurski 
et al., 2019) and EM (Rikkert et al., 2019), as well as the identification of widely accepted 
biomarkers (Théry et al., 2018), distinction between EV constituent proteins and other 
secreted factors remains technically challenging (Foers et al., 2018). Nevertheless, efforts to 
characterise the change in EV protein content following senescence induction have recently 
escalated. Having described an increase in EV production in four distinct models of 
senescence, Takasugi et al., (2017) assessed the proteomic composition of therapy-induced 
senescent RPE-1 epithelial cells following doxorubicin treatment. The ephrin receptor A2 
(EphA2) was identified as the second most abundantly enriched protein, the first being 
histone H4, which the authors attributed to the presence of CCFs in senescent cells. EphA2 
was further demonstrated to increase in both RS and OIS TIG-3 fibroblasts. The investigators 
also established that the proliferation of MCF7 breast cancer cells could be potentiated by 
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treatment with TIS RPE-1 derived EVs, as well as CM from TIS RPE-1s and RS TIG-3s, an effect 
which was lost if the CM was depleted of EVs. EphA2 was demonstrated to be crucial to these 
EV mediated effects, with shRNA ablation of EphA2 attenuating the increase in cancer cell 
proliferation elicited by both TIS RPE-1 EVs as well as TIS RPE-1 and TIG-3 CM. EphA2 was 
demonstrated to act via ephrin A1 on the surface of the cancer cells in a reverse signalling 
mechanism that was not recapitulated in non-cancerous RPE-1s, as ephrin A1 expression was 
lower in those cells. Recombinant EphA2 could not recapitulate the effect of the EV-
associated form, suggesting that incorporation within EVs potentiated its function. This is 
reminiscent of studies that describe a more potent effect of EV-associated factors than a 
soluble form of the same protein, specifically interferon gamma (IFN-γ) (Cossetti et al., 2014) 
and TGFβ (Webber et al., 2015). This opens the possibility that EVs may augment the 
signalling properties of soluble proteins, including SASP components (Takasugi, 2018).  
 
The role of EVs within TIS has recently been explored further in Cal51 triple negative breast 
cancer cells. Kavanagh et al., (2017) demonstrated that following senescence induction with 
paclitaxel (PTX), EV secretion increased. Furthermore, proteomic analysis of these EVs 
demonstrated increased expression of 142 proteins. Of these, authors validated the 
increased expression of annexin V, sodium/potassium ATPase and α-tubulin, involved in 
apoptosis/chemoresistance, ATP regulation and PTX mediated senescence induction 
respectively. Pathway analysis also indicated that 69/142 of the proteins with increased 
abundance in EVs were predicted to enhance cellular proliferation. The investigators 
suggested that cells might preferentially sort proteins into EVs for removal, in order to 
maintain survival following stressful stimuli. Furthermore, as the fluorescent PTX analogue 
Flutax-2 was observed in EVs, and as EV biogenesis inhibition with GW4869 decreased 
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cellular proliferation, it was proposed that EVs might also represent a route through which 
cancer cells enforce chemoresistance and maintain proliferation (Kavanagh et al., 2017). 
 
The process of paracrine senescence, described in section 1.1.7, is one of the key functions 
of the SASP, as well as a suspected contributor to the age-related pathologies associated 
with senescence (Acosta et al., 2013; Baker et al., 2016). Whilst previous studies had 
demonstrated that senescent cell derived EVs were functionally active, given they could 
increase the proliferation of cancer cells, Borghesan et al., (2019) were the first to directly 
describe a contribution to paracrine senescence. The investigators demonstrated that HFFF2 
human foreskin primary fibroblasts treated with OIS cell derived EVs had reduced cellular 
proliferation, as well as increased expression of p16, p53 and DNA damage foci. Supporting 
this finding, conditioned media and trans-well investigations demonstrated that OIS 
mediated paracrine senescence could be attenuated by treating conditioning cells with 
nSMase inhibitors. The implication of this finding is that EVs are a major contributor to the 
paracrine senescent effects of the SASP. In order to characterise the composition of EVs 
derived from senescent cells, HFFF2s induced by both OIS and DNA damage following 
etoposide treatment were investigated by mass spectrometry. Among common factors 
differentially expressed in both models, as well as unique to the EVs, interferon-induced 
transmembrane protein 3 (IFITM3) was identified as a possible functional EV cargo through 
a CM siRNA screen. This was validated through both IFITM3 siRNA and shRNA inhibition of 
EV producing HFFF2s, which attenuated the upregulation of p16 and IL-8 in cells treated with 
the EVs (Borghesan et al., 2019). Overall, this data indicates that EVs are contributors to 




A key issue when establishing the composition of senescent cell derived EVs, is the context 
dependent nature of their constituents. This mirrors the SASP, where components vary with 
both cell type and inducing stimuli (Coppe et al., 2008). Recently, a solution to this 
heterogeneity has been produced through development of a SASP “Atlas”. Investigators 
collated mass spectrometry data from CM derived from fibroblasts stimulated by therapy, 
oncogene and irradiation-induced senescence, as well as epithelial cells stimulated by 
irradiation. This was supported by proteomic profiling of EVs derived from the OIS and IR 
fibroblast models (Basisty et al., 2020). This work confirmed that EV composition varied with 
senescence model, emphasising this fundamental challenge with both senescence and EV 
research. Whilst a commendable endeavour, the utility of the SASP Atlas would be greatly 
enhanced if it were to have a facility for submission. This could allow the development of a 
collaborative repository of datasets similar to that of ExoCarta (Simpson, Kalra and 
Mathivanan, 2012), which would facilitate a more comprehensive record of the 
heterogeneity in SASP composition. As it stands, the SASP Atlas allows comparison of an 
inputted gene list and the stored data sets. It is interesting to note that neither EphA2 nor 
IFITM3 were identified in any of the SASP Atlas components, highlighting the challenge facing 
the field when attempting to compose a complete SASP profile across models and cell types. 
It is also important to note that without standardisation of variables such as EV isolation, CM 
incubation time and cell numbers, the number of potentially confounding factors is 
extensive. However, the SASP Atlas clearly corroborates previous studies, which indicate that 
EVs are compositionally distinct from the from the soluble proteins that have canonically 




1.3.2.2 Nucleic Acids 
Having been established as abundant components within the secretome of senescent cells, 
understanding whether EVs carry out functions distinct from those of the soluble SASP has 
become a key research question. The EV mediated transfer of nucleic acids represents a 
potential route through which such discrete functional roles may occur. This principle was 
first described by Valadi et al., (2007), with demonstration of EV mediated transfer of 
functional mRNA between mast cells (Valadi et al., 2007). Subsequently, the role of EV 
facilitated transfer of nucleic acids has become widely investigated in the senescence field. 
This section will address these studies according to the subtype of nucleic acid investigated: 
miRNA, DNA and Telomeric repeat containing RNA (TERRA). 
 
1.3.2.3 miRNA   
Within senescence, miRNAs have been described as contributors to the maintenance of p16 
dependent cellular senescence in epithelial cells (Overhoff et al., 2014). More recently, 
miRNAs have also been observed to stimulate the development of RS in MEFs (Xu et al., 
2019). Therefore, EV resident miRNAs have become the focus of significant research 
attention in order to explore potential roles in the modulation of senescence responses. This 
was first investigated by Weiner-Gorzel et al., (2015) who identified that miR-433 expression 
in ovarian cancer cells instigated a senescence response through ablation of CDK6. 
Investigators identified that EVs isolated from three ovarian cancer cell lines expressing miR-
433 were associated with increased levels of the miRNA. Furthermore, confocal microscopy 
demonstrated that EVs were delivered to treated cells, raising the possibility that EVs may 
facilitate a route to secondary senescence induction (Weiner-Gorzel et al., 2015). This initial 
study was recently expanded upon by Fulzele et al., (2019), through demonstration that 
oxidative stress induced senescence in both mouse myoblasts and human myotubes 
97 
 
contained increased levels of miR-34a, which the authors also demonstrated to be elevated 
with age in mice. Importantly, the myoblast EVs were shown to elicit a paracrine senescence 
response in treated bone-marrow stem cells (BMSCs), determined through increased SA-β-
gal activity. The investigators also observed that the p53 suppressor Sirtuin 1 (SIRT1) could 
be downregulated in BMSCs following treatment with EVs from miR-34a overexpressing 
cells, suggesting a possible mechanism for the proposed senescent cell derived EV mediated 
paracrine senescence (Yamakuchi and Lowenstein, 2009; Fulzele et al., 2019). This has since 
been elaborated by Mensa et al., (2020), through investigation of the “MiRome” in senescent 
HUVECs and derived EVs. Investigators first established that EVs were released in greater 
quantities from RS HUVECs than from the proliferating counterparts. Comprehensive 
analysis of all miRNAs in proliferating and senescent HUVECs, as well as the derived EVs, 
identified five that were differentially expressed in both senescent HUVECs and their EVs, a 
number that was reduced to two following qRT-PCR validation. These were miR-21-5p and 
miR-217. This was further validated through a demonstrated increase in expression of both 
miRNAs in human aortic endothelial cells (HAECs) induced by replicative exhaustion, as well 
as HAECs and HUVECs following TIS. These miRNAs had previously been established as 
inhibitors of both SIRT1 and DNA Methyltransferase 1 (DNMT1). The investigators 
demonstrated that treatment of proliferating HUVECs with senescent HUVEC derived EVs led 
to a reduction of both SIRT1 and DNMT1, accompanied by reduced Ki67 expression and 
increased expression of p16, IL-6 and IL-8 (Mensà et al., 2020). Together, this data indicates 
that functional transfer of miRNAs via replicatively senescent cell derived EVs is a contributor 
to paracrine senescence, in a process dependent on the inhibition of SIRT1 and DNMT1. This 
suggests EVs may have a role as mediators within the “dark” detrimental effects of the SASP 




By contrast, miRNAs transported by EVs have also been suggested to contribute to the 
beneficial side of the SASP, in particular in wound healing (Fafián-Labora and O’Loghlen, 
2020; Wallis, Mizen and Bishop, 2020). Terlecki-Zaniewicz et al., (2019) demonstrated that 
miR-23a-3p encapsulated within EVs was responsible for an enhanced wound healing effect 
upon treatment of keratinocytes in scratch assays. These EVs had been isolated from HDFs 
induced by oxidative stress through H2O2 treatment (Terlecki-Zaniewicz et al., 2019). The 
same investigators had previously established that under these conditions, HDFs secrete 
more EVs than quiescent cells maintained under contact inhibition (Terlecki-Zaniewicz et al., 
2018). In this earlier report, it was demonstrated that senescent cell derived EVs possessed 
a distinct miRNA profile, which kinetically developed with the long-term maintenance of 
senescence. Target prediction of the top 20 most abundant EV miRNAs implicated a potential 
role as negative regulators of apoptosis. Indeed, the senescent cell derived EVs were 
demonstrated to confer an anti-apoptotic effect upon treated fibroblasts that were exposed 
to acute stress through H2O2 treatment, although this was not explicitly attributed to the 
miRNA cargo (Terlecki-Zaniewicz et al., 2018). Together, these studies indicate that 
senescent cell derived EVs are functionally relevant contributors to the SASP and, 
importantly, have a diverse set of both beneficial and detrimental roles, with many of these 
effects mediated by the transfer of functional miRNAs (Wallis, Mizen and Bishop, 2020).  
 
1.3.2.4 Telomeric Repeat-Containing RNA (TERRA) and Telomeric DNA 
As described in section 1.1.5, replicative senescence occurs as a direct consequence of the 
erosion of telomeres due to the end-replication problem. Telomere attrition has been 
demonstrated to lead to an increase in the presence of TERRA within cells, although a direct 
link to senescence has not currently been demonstrated (Cusanelli, Romero and Chartrand, 
2013; Takasugi, 2018). EVs isolated from human lymphoblastoid cells have been 
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demonstrated to contain TERRA, whilst cells treated with these EVs display an upregulation 
in inflammatory cytokines, including the canonical SASP factor IL-6 (Wang et al., 2015; Wang 
and Lieberman, 2016). However, a limited number of research publications have investigated 
this phenomenon and a clear link directly to senescence is still lacking. Indeed, contradictory 
evidence has proposed that cytoplasmic telomere repeats may exert anti-inflammatory 
response through inhibition of cGAS/STING (Bonafè, Sabbatinelli and Olivieri, 2020). 
Therefore, the presence and consequences of telomeric components within senescent cell 
derived EVs remains unclear.  
 
1.3.2.5 DNA 
As described in section 1.1.4, the increased presence of CCFs has become an established 
hallmark of senescence, with an intrinsic link to SASP modulation through cGAS/STING 
mediated activation of NF-κB (Ivanov et al., 2013; Dou et al., 2017; Glück et al., 2017). The 
potential secretion of these DNA fragments within EVs has recently been investigated by 
Takahashi et al., (2017). Investigators demonstrated that inhibition of EV secretion via siRNA 
ablation of ALIX and Rab27a, as well use of nSMase inhibitors, lead to increased apoptosis of 
RS and OIS TIG-3 fibroblasts. The use of the same treatments also caused an increase in DNA 
damage in proliferating fibroblasts, whilst knockdown of DDR response kinases ATM and ATR 
via siRNA was sufficient to attenuate this effect. The authors concluded that EVs were thus 
functioning as a homeostatic mechanism to prevent DDR activation. In order to demonstrate 
that this occurred through the removal of damaged cytoplasmic DNA fragments, immuno-
gold labelling was used to identify double stranded DNA (dsDNA) in EVs via EM, as well as 
the histone proteins H3 and H4. This was supported by rescue of DNA damage through use 
of a dsDNA endonuclease, following inhibition of EV secretion. The authors went on to 
demonstrate that the cGAS/STING/IFN-γ axis was key to mediating the onset of the aberrant 
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DDR following blockade of EV secretion (Takahashi et al., 2017). This elegantly returns to 
some of the earliest concepts surrounding the biological function of EVs, namely their role 
as a mechanism of “waste disposal” (Johnstone, 1992; Wallis, Mizen and Bishop, 2020). 
Finally, the investigators demonstrated that the CCF containing EVs could evoke a DDR in 
treated fibroblasts, suggesting a more malign influence in the form of paracrine senescence 
than the predominantly beneficial contribution to cellular homeostasis demonstrated within 
the producing cells. 
 
1.3.2.6 Lipids  
There is a paucity of research investigating the lipid composition of senescent cell derived 
EVs, particularly when compared to the abundance of publications investigating constituent 
proteins and nucleic acids (Wallis, Mizen and Bishop, 2020). Recently, lipidomic assessment 
of OIS fibroblast derived EVs has been performed by several groups. Buratta et al., (2017) 
demonstrated that EVs possessed a distinct lipid profile from the cells from which they were 
derived. Investigators highlighted EV enrichment of lyso-phospholipid and reduced 
abundance of phosphatidylserine (Buratta et al., 2017). A subsequent study supported this 
proposed differential lipid content, with EVs from OIS fibroblasts possessing greater levels of 
saturated and polyunsaturated fatty acids compared to the producing cells (Sagini et al., 
2018). Complimenting previous reports, the lipid profile of EVs has also been described to 
contribute to EV mediated paracrine senescence. Khayrullin et al., (2019) demonstrated that 
C24:1 ceramide was abundantly present in EVs isolated from elderly volunteers. Mouse 
serum derived EVs were then loaded with this very long chain ceramide, which were then 
used to treat BMSCs. These EV treatments lead to a paracrine senescence effect, 
demonstrated by increased SA-β-gal staining. The authors indicated that this may suggest 
that EVs contribute to secondary senescence induction (Khayrullin et al., 2019). Overall, it 
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remains unclear as to how the lipid profile of EVs changes following senescence induction 
and to what extent the lipid composition of EVs determine their functional effects.   
 
1.3.3 Changes in Extracellular Vesicle Production with Age 
The emerging consensus across multiple models of senescence, investigated in a variety of 
cell types, suggests that EV production increases following senescence induction (Takasugi, 
2018; Fafián-Labora and O’Loghlen, 2020). However, a less clear picture has developed in 
terms of the change in EV production during ageing. Alberro et al., (2016) noted that in 
subjects aged 79-92, the level of serum IL-6 was greater than that seen in individuals aged 
21-50. However, this was not the case with EVs isolated from the same volunteers, with no 
change across any age-groups observed (Alberro et al., 2016). A subsequent investigation 
noted a decrease in the plasma EV concentration with age, assessed in 74 participants 
ranging from 30 – 65 (Eitan et al., 2017). The investigators also demonstrated that both 
smoking and increased body mass index (BMI) had some correlation to an increased level of 
plasma EVs. Interestingly, both these factors are also associated with enhanced levels of 
senescence induction (Nyunoya et al., 2006; Ogrodnik et al., 2019). The range in ages 
assessed between these conflicting studies makes assessment difficult and may be a 
contributing factor to the differences observed. More recent investigations also contradict 
these early findings, with Im et al., (2018) demonstrating an increase in EV secretion in 
elderly volunteers aged 63-90, compared to young volunteers aged 23-45 (Im et al., 2018). 
This observation was supported by recent work in a mouse model of normal ageing, which 
demonstrated a correlation between increased age and the level of plasma EV like particles 
positive for TSG101, CD63 and CD81, acquired from either young (3 months) or old (18-21 
month) mice. The investigators made an important observation in that depending on their 
selected method of EV characterisation, an entirely contrary result was observed. In this 
102 
 
case, use of NTA demonstrated a decrease in EV concentration, contradicting western blot 
and flow cytometry data (Alibhai et al., 2020). This emphasises the importance of utilising 
multiple methodologies when investigating EVs, as contaminants (in this case lipoproteins) 
can often obfuscate the true nature of the EVs present. Determination of the level of EV 
production may also be confounded by age-related pathologies. The investigation by Im et 
al., (2018) describe above, also noted that young patients with gastric cancer secreted more 
EVs than healthy volunteers of a comparable age (Im et al., 2018). Increased EV levels have 
also been observed in the plasma of patients with COPD, as well as from isolated 
chondrocytes derived from the cartilage of osteoarthritis patients (Tan et al., 2017; Jeon et 
al., 2019). Overall, due to the array of potentially confounding factors that undermine 
comparison between these studies, it is difficult to draw as firm a conclusion as to the change 
in EV production with age, as that which can be drawn for senescent cells.                        
 
1.3.4 Changes in Extracellular Vesicle Cargoes with Age 
To understand the consequences of altered levels of EV secretion within both age and age-
related pathology, it is also important to appreciate any compositional changes that may also 
occur in these circumstances. EVs isolated from healthy elderly subjects have been 
demonstrated to possess a reduced capacity to facilitate osteogenic differentiation of 
adipose tissue‐derived mesenchymal stem cells (ASCs) compared to EVs of young donors. 
This was attributed to an increase in miR-31 content, demonstrated by a rescue of 
differentiation through use of an anti-miR-31 nucleic acid inhibitor (Weilner, Schraml, et al., 
2016). The same group also demonstrated that the carbohydrate binding protein Galectin-3 
is present at reduced levels in EVs isolated from the plasma of elderly volunteers (older than 
55) compared to young participants (younger than 25). The EVs from the old subjects were 
also less efficient at stimulating the osteogenic differentiation of ASCs than those from the 
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young volunteers (Weilner, Keider, et al., 2016). Further supporting these findings, is 
evidence that osteogenic differentiation of mouse BMSCs may be attenuated through 
treatment with EVs isolated from the bone marrow of aged mice. These EVs were shown to 
be associated with increased levels of miR-183-5p, which could independently cause 
comparable inhibition of osteogenic differentiation. Whilst not direct evidence that this 
miRNA is the effector of the EV mediated response, investigators did demonstrate EV uptake, 
thus providing a rationale that delivery miR-183-5p may be a feasible underlying mechanism 
(Davis et al., 2017). Further evidence to indicate that EV cargo change with age comes 
through the demonstration that macrophage derived EVs are associated with increased 
mRNA levels of IL-6 and IL-12, when isolated from old subjects aged 65-90 compared to 
young volunteers aged 21-45 (Mitsuhashi et al., 2013). Changes in the nucleic acid content 
of EVs derived from the plasma of frail aged (71–89 years) individuals has also been 
demonstrated when compared to that of healthy aged and young (23–35 years) subjects, 
with 8 miRNAs (miR-10a-3p, miR-92a-3p, miR-185–3p, miR-194–5p, miR-326, miR-532–5p, 
miR-576–5p, and miR-760) identified to be differentially expressed (Ipson et al., 2018). 
Further supporting these observations is evidence from Alibhai et al., (2020) who 
demonstrated that six miRNA increased (miR‐146a, miR‐21, miR‐22, miR‐223, miR‐145, and 
let‐7a) and two decreased (miR‐212 and miR‐455) in EVs isolated from elderly mice 
compared to young counterparts. Several of the increased miRNA were able to recapitulate 
an immunomodulatory effect on macrophages that had been observed following treatment 
with the old EVs, specifically an increased production of TGFβ and IL-10, suggesting that they 
may be functionally delivered cargos in ageing (Alibhai et al., 2020). 
 
Mirroring the observation above from Ipson et al., (2018), that fragility associated with 
pathological ageing is accompanied by changes in EV cargo, diseases associated with 
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advanced age have also been observed to lead to alterations in EV composition and function. 
EVs isolated from acute coronary syndrome patients (43-93 years) have been demonstrated 
to contribute to a process of secondary senescence, characterised by endothelial dysfunction 
and oxidative stress (Abbas et al., 2017). EVs isolated from the plasma of elderly volunteers 
aged 75-83, were demonstrated to contribute to increased calcification of human aortic 
smooth muscle cells compared to EVs isolated from young subjects aged 20-28. The EVs from 
aged individuals were demonstrated to be enriched for proteins considered pro-calcific 
including annexin A2, annexin A6 and BMP2 (Alique et al., 2018). Furthermore, OA is a 
pathology closely associated with ageing. Work by Jeon et al., (2019) demonstrated that EVs 
derived from chondrocytes isolated from OA patients contributed to a paracrine senescence 
response in treated non-senescent chondrocytes, demonstrated by an increase in SA-β-gal 
staining. Investigators attributed these effects to reduced levels of EV associated miR-140-
3p and increased miR-34a-5p, which are associated within increased chondrocyte 
dysfunction and the onset of senescence respectively. Furthermore, EVs isolated from 
elderly healthy and OA subjects aged (70-80) were demonstrated to contain 22 differentially 
expressed miRNAs, which the authors postulated as potential biomarkers of OA. 
Additionally, the investigators demonstrated that young mice treated with EVs from aged 
mice displayed increased pain and less leg function than controls, indicating that EVs may act 
to propagate the development of OA. 
 
Finally, two recent studies have focused on the inverse situation to the majority of 
investigations described here, namely the contribution of EVs from young individuals or 
proliferating cells upon old subjects or senescent cells. The first publication by Yoshida et al., 
(2019), demonstrated that an extracellular form of nicotinamide phosphoribosyltransferase 
(eNAMPT) was exclusively contained in EVs and that the levels of this decreased with age in 
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both humans (37-80 years) and mice (young, 4-6 months; old, 18-26 months). Furthermore, 
old mice treated with EVs isolated from the plasma of young mice were demonstrated to 
display increased levels of physical activity and, remarkably, had an extended median 
lifespan of 10% (Yoshida et al., 2019). Supporting this finding is recent work by Fafián-Labora 
et al., (2020), who investigated the functions of EVs isolated from primary fibroblasts derived 
from young individuals (Y-EVs; 1-4 years). Treatment of fibroblasts from old individuals (67-
81 years) with Y-EVs reduced the appearance of senescence markers including p16, p21, SA-
β-gal and IL-8, along with increasing expression of BrdU and increased cellular proliferation. 
Furthermore, OIS HFFF2s treated with EVs derived from proliferating control cells displayed 
reduced mRNA expression of several SASP components as well as both p16 and p21. Through 
the proteomic assessment described in Borghesan et al., (2019), glutathione-related protein 
(GSTM2) was identified as a potential functional candidate, validated by western blot to be 
increased in both EVs from control HFFF2s and Y-EVs. Treatment of old fibroblasts with Y-
EVs was also demonstrated to prevent accumulation of 8-Oxo-2'-deoxyguanosine (8-oxo) 
and γH2AX, indicating inhibition of oxidative stress. The EV-associated GSTM2 was 
demonstrated to be functional, increasing the formation of glutathione (GSH) in treated old 
fibroblasts, which was positioned as key component of the rejuvenating properties of Y-EVs. 
Finally, in vivo investigation demonstrated that aged mice (22-25 months) treated with Y-EVs 
displayed reduced levels of SA-β-Gal in kidney, lung and adipose tissues. Furthermore, these 
tissues were also associated with reduced ROS levels and increased GST activity. Overall, this 
work elegantly demonstrated the potential of EVs isolated from young cells to ameliorate 
senescence in vitro and in vivo, at least partially through the action of EV-associated GSTM2 
(Fafián-Labora, Rodríguez-Navarro and O’Loghlen, 2020). The work presented in these two 
studies presents EVs from proliferating cells as an intriguing avenue for the development of 




1.4 Thesis Hypothesis  
This work aims to explore the change in composition and function of extracellular vesicles 
(EVs) following the induction of senescence. It was hypothesised that EVs derived from 
senescent cells contain a distinct profile of protein constituents from those isolated from 
proliferating cells. Furthermore, it was hypothesised that these cargos facilitate the 
propagation of a secondary senescence response, so called paracrine senescence, to 
proliferating cells, in a distinct manner from that of the canonical soluble SASP. Additionally, 
it was hypothesised that application of rigorous EV isolation methodologies are essential to 
the accurate functional and compositional profiling of senescent cell derived EVs, due to the 
previously reported obstacle of co-isolating soluble proteins.  
 
1.5 Project Aims 
 Establish and validate experimental models of senescence 
o Induction of oncogene-induced senescence (OIS) in IMR90 fibroblasts 
o Induction of replicative senescence (RS) in adult human mammary 
fibroblasts (HMFs) 
o Investigation of the senescent secretome using an established model of 
senescence reversal in HMFs 
 
 Establish methodology for the isolation and compositional assessment of EVs from 
senescent cells 
o Validate isolation of EVs through differential ultracentrifugation (dUC) 
o Validate isolation of EVs through size-exclusion chromatography (SEC) 




 Characterise contribution of EVs to the process of paracrine senescence  
o Investigate paracrine senescence through conditioned media and EV 
treatment investigations 
o Probe potential mechanisms identified during compositional 




2 Material and Methods  
 
2.1 Cell Culture and Reagents 
Unless otherwise indicated, all reagents were sourced from Sigma UK. All cells were 
maintained under conditions of 37°C with 5% CO2 and demonstrated to have a negative 
mycoplasma status regularly. Cells were cultured in T25/75/150 flasks (Corning, UK). Unless 
otherwise stated, cells were medium changed every two to three days. Cells were frozen at 
densities not exceeding 1e6 cells/ml in 2ml cryovials using 1ml freezing medium comprising 
90% foetal bovine serum (FBS, Labtech.com, UK) and 10% dimethyl sulfoxide (DMSO). 
Antibiotics were not used in culture media aside from experiments utilising EV treatments. 
In these cases, 50units/ml penicillin and 50μg/ml streptomycin (Life Technologies, UK) were 
included in the media.  
 
IMR90 ER:STOP (vector) or ER:RAS (OIS) foetal lung fibroblasts were kindly donated by Juan 
Carlos Acosta (MRC Institute of Genetics & Molecular Medicine, Edinburgh), having been 
generated according to this group’s published protocol (Hari et al., 2019). Cells were cultured 
using Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies, UK) containing 10% FBS 
and 2mM L-Glutamine (Life Technologies, UK). Cells were thawed from stocks as required, 
seeded at a density of 2,000-10,000 cells/cm2, passaged on a weekly basis. These cells were 
used in experiments investigating OIS, which are described further in section 2.2. OIS was 
selected as a model due to the expedient nature of senescence induction and the previously 
reported potency of the OIS SASP, thus providing potential advantage over other models of 
premature senescence e.g. IR induced senescence (Coppe et al., 2008). As these cells are not 
immortalised, all investigations were carried out within three passages of thawing to prevent 
the confounding influence of replicative senescence.     Normal adult human mammary 
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fibroblasts (HMFs) were donated by Elly Tyler (Bishop Lab, Blizard Institute) having previously 
been acquired from Martha Stampfer (Lawrence Berkeley National Laboratory, Berkeley). 
Cells were derived from tissue collected from a 16-year-old donor following a reduction 
mammoplasty procedure (Stampfer et al., 1981). Cells were cultured in the same medium as 
IMR90s with the addition of 10μg/ml bovine pancreas insulin using a seeding density of 
10,000 cells/cm2. These cells were serial passaged every seven days until observation of 
replicative senescence, as described in section 2.3. This model was selected due to its 
previous comprehensive characterisation within the group (Thesis:(Tyler, 2016)). It is 
important to note that these cells were derived from a single patient and the associated 
Hayflick proliferation profiles of cells from other individuals may vary significantly. This is 
discussed further in section 3.7.  
 
MDA-MB-468 triple negative basal-like breast cancer cells (468s) were purchased from ATCC 
(HTB-132). These were cultured using high glucose DMEM supplemented with 10% FBS, 
2mM L-Glutamine and 1mM Sodium Pyruvate. Cells were seeded at a density of 10,000 
cells/cm2, passaged weekly for a maximum of 10 passages and used in the experiments 
described in sections 5.3, 5.5 and 5.6. These cells were selected due to previous 
characterisation of senescence induction via High Content Analysis (HCA) within the group 
(Preprint(Moore et al., 2018)). The cells were used to serve as a means of assessing the 
potential pro-/anti-tumorigenic effects of the SASP that has been previously reported 
(Campisi and D’Adda Di Fagagna, 2007). 
 
2.1.1 Antibodies  
For the immunoblotting and immunofluorescence procedures described in sections 2.5 and 
2.12, the antibodies utilised are described in Table 1.  
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Target Antibody Supplier Dilution 
p21 12D1 Cell Signalling, UK 
IF: 1:2,000 
WB: 1:1,000 
p16 10883-1-AP Protein-Tech, UK 
IF: 1:2,000 
WB: 1:1,000 
Ki67 NCL-Ki67p Novocastra, UK IF: 1:1,000 
IL-6 AB-206-NA R and D Systems, UK 
IF: 1:500 
WB: 1:250 
IL-8 AF-208-NA R and D Systems, UK 
IF: 1:500 
WB: 1:500 
GAPDH ab9485 Abcam, UK WB: 1:5,000 
β-Tubulin E1C601-1 EnoGene, UK WB: 1:20,000 
Lamin B1 ab16048 Abcam, UK WB: 1:1,000 
CD9 CD9-A1 System Biosciences, UK WB: 1:1,000 
TSG101 ab30871 Abcam, UK WB: 1:1,000 
Calnexin ab22595 Abcam, UK WB: 1:1,000 
NOTCH1 4147 Cell Signalling, UK WB: 1:1,000 
N1ICD 4380 Cell Signalling, UK WB: 1:1,000 
ADAM10 14194 Cell Signalling, UK WB: 1:1,000 
ADAM17 ab2051 Abcam, UK WB: 1:1,000 
HRP goat anti-rabbit 
65-6120 
Invitrogen, UK WB: 1:5,000 
HRP rabbit anti-goat 
P0160 
Dako, UK WB: 1:5,000 
Goat anti-rabbit-Alexa 546 A11035 Thermo-Fisher, UK IF: 1:500 
Rabbit anti-goat-Alexa 546 A21446 Thermo-Fisher, UK IF: 1:500 
Table 1: Antibody List  
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2.2 Oncogene-Induced Senescence Induction  
OIS induction was carried out through use of ER:RAS IMR90 fibroblasts. These cells express 
a fusion protein comprising oncogenic HRas coupled to an oestrogen receptor (ER) hormone 
binding domain. This construct is activated through treatment with 4-Hydroxytamoxifen 
(OHT) (Reuter and Khavari, 2006). Control ER:STOP cells were utilised as a proliferating 
control, which express a constuct comprising the ER hormone binding domain alone 
(Boumendil et al., 2019). In the interest of clarity, ER:RAS cells are refered to as OIS and 
ER:STOP as vector throughout this report. 
 
In the course of this project several induction schedules were optimised, with the final 
protocol used for the majority of experiments presented here. This is summarised in Figure 
2.1, along with an explanation of the initial protocols and corresponding experiments. In the 
final schedule (schedule three), vector and OIS IMR90s were seeded at 10,000 cells/cm2. One 
day post seeding, these were treated with 200nM OHT prepared in DMEM with 10% FBS. 
Cells were cultured for 72 hours to day four at which point media was changed to one 
comprising DMEM, 200nM OHT and 1% “exosome-depleted FBS” (Gibco, UK). Media was 
collected on day eight for downstream experiments and EV isolation. Concurrently, cells 
were passaged and seeded into 96-well plates. These were cultured for a further five days at 






Figure 2.1: Optimisation of OIS Induction Schedule 
Throughout the course of this work, the schedule used for the induction of oncogene-
induced senescence has undergone several optimisations (schedule 1, 2 and 3). The bulk of 
the work has been performed using the optimised schedule 3. However, several key 
experiments (including the first and second rounds of mass spectrometry – MS1 and MS2) 
were performed using earlier iterations. This figure illustrates the three schedules in detail 
along with which experiments (and figures) correspond to which schedule.      
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2.3 Replicative Senescence Induction  
Validation of RS induction in HMFs using a panel of senescence markers has previously been 
established within the Bishop Lab (section 3.5) and is employed here as a complimentary 
system to OIS. HMFs were serially passaged from a variety of initial cell stocks (provided by 
Elly Tyler) at passages ranging from nine to 22. Cells were considered to have reached 
replicative senescence (RS) at passage 29, as this was the point at which an increase in 
population doublings was no longer observed. To allow development of a deep senescence 
(DS) phenotype, with an elaborated and mature SASP, experiments were conducted at 
passage 29 + three weeks (Passos et al., 2010; Tyler, 2016). By contrast, cells were considered 
early proliferative (EP) between passages 10 and 16, where cells were readily proliferating, 
with population doublings (PDs) remaining consistent between weekly passages. For 
phenotypic assessment, cells were seeded at 10,000 cell/cm2 and cultured for six days. At 
this point fixation and immunofluorescence, staining was performed according to section 
2.4. For other experiment specific culture conditions, see sections 2.8 and 2.10.     
 
2.4 Immunofluorescence Staining  
Immunofluorescence staining was performed in either 6-well or 96-well plates depending on 
experimental requirements. Cells in culture were fixed through use of 3.7% 
paraformaldehyde (PFA) comprising 5% sucrose. Fixation occurred at room temperature (RT) 
for 15 minutes and was both preceded and followed by a Phosphate Buffered Saline (PBS) 
wash. Permeabilisation of cell membranes was then performed for 15 minutes at RT via a 
solution of 0.1% Triton X-100, followed by a further PBS wash. In experiments where cellular 
proliferation and morphology measurements were investigated alone, this was followed by 
a two hour incubation with both 4’,6 -diamidino-2 phenylindole (DAPI) (Sigma UK, D8417, 
1µg/µl) and HCS Cell Mask Deep Red (Cell Mask 0.1µg/ml) (Thermo-Fisher UK, C10046, 
114 
 
1:50,000). Where antibody staining was required, an initial 30 minute blocking step using 
0.25% (w/v) bovine serum albumin in PBS (PBS/BSA) was employed following 
permeabilisation. Primary antibody incubations were then carried out overnight at 4°C in 
working dilutions of PBS/BSA. The following morning, cells were washed at RT with PBS/BSA 
for 30 minutes followed by RT incubation for two hours with DAPI, Cell Mask and the relevant 
Alexa Fluor-546 conjugated secondary antibody (1:500, Invitrogen). Final wash steps were 
then applied, including a 30 minute PBS/BSA incubation followed by three washes in PBS. 
Plates were then imaged using an IN Cell 2200 automated microscope (GE). A full list of 
antibodies is included in section 2.17 as a table.  
 
2.5 High Content Analysis (HCA) 
Images were acquired through the IN Cell 2200 using magnifications of 10-20X and four fields 
of view. The images were assessed via the IN Cell Developer software version v1.9.2. (GE) 
high content analysis (HCA) system. DAPI and Cell Mask staining were used to develop 
nuclear and cellular image masks respectively. The individual targets comprising these masks 
were then linked to create a “nucleated cell” target set, upon which subsequent analyses 
were applied (Figure 2.2). The morphology of nucleated cells was then assessed, according 
to the measures described in Table 2. Values from each individual measure were used to 
generate Z-scores relative to the proliferating control. This was performed according to the 
equation: Score = (mean value of three independent experiments for senescent experimental 
condition – mean value of three independent experiments for proliferating control condition) 
/ Standard Deviation (SD) of proliferating control condition. The Z-scores were combined in 
heat maps, in order to illustrate the morphological profile of the imaged cells. In heat maps, 
forced maximum (+/- five Z-scores) and minimum (+/- one Z-scores) thresholds were applied 
to facilitate comparison between measures. It is important to emphasise that Z-scores were 
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not used to determine statistically significant change but rather as an indication of positive 
or negative modulation of each measure by providing a means of scaling. An overview of the 
HCA morphology workflow is outlined in Figure 2.3.  
 
Immunostaining for changes in the senescence markers p16, p21, Ki67, IL-6 and IL-8. A 
comparison between proliferating and senescence conditions was determined by calculating 
percentage positivity of each marker. This was based upon the raw grey-scale values 
detected and thresholded based on signal detected in the secondary only control. The 
presence of senescence-associated heterochromatin foci (SAHFs) was determined through 
quantitation of nuclei positive for DAPI foci as a percentage of the total nuclear count.  
 
Figure 2.2: Principle of High Content Analysis (HCA) 
 
Following immunofluorescence staining with A) DAPI (blue) and B) Cell Mask (red) (section 
2.4) cells were assessed by high content analysis (HCA). Staining was used to generate C) 
nuclear mask (green) and D) cellular mask (pink) to quantitate nuclei and cells, respectively. 
These targets were linked into E) “nucleated cell” target set upon which all analysis, including 




Table 2: HCA Morphology Measures    
Measure Name Measure Explanation 
Cell Number Mean Count of Nucleated Cells  
Cell Area Mean Area of Nucleated Cells 
Nuclear Area Mean Area of  Nuclei in Nucleated Cells 
Cytoplasmic/Nuclear Ratio Mean Cell Area / Nuclear Area 
DAPI Density Mean DAPI Grey Levels in Nuclear Mask  
Nuclear Form Factor Mean Nuclear Circularity (Ranging 0 -1 where 1 is a circle)  
Cellular Protrusions Mean Count of End Nodes within Nucleated Cells 
Cellular Form Factor Mean Cellular Circularity (Ranging 0 -1 where 1 is a circle) 
Major Axis Length Longest Axis within Nucleated Cell 
Minor Axis Length Shortest Axis within Nucleated Cell 




Figure 2.3: Schematic of HCA Morphology Analysis Workflow 
Morphological analysis by HCA was used to assess senescence induction. Proliferating and 
senescent cells from three independent experiments were imaged via the InCell 2200 
microscope and images subject to HCA using the InCell Developer software. Morphology 
measures were quantitated and mean values used to determine Z-Scores (change in 
standard deviation from the proliferating condition). These were displayed as heat maps with 
red indicating positive modulation and blue negative modulation from the proliferating 
condition. White indicates no change.    
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2.6 Senescence Reversal  
The reversal of senescence in RS cells has been demonstrated within the Lab (Lowe et al., 
2015) and all siRNAs employed have been previously validated (Table 3) (Thesis:(Tyler, 
2016)). Here, both reversal and downstream analysis was carried out in DS HMFs by Kishan 
Vara, a supervised MSc student. Senescent HMFs seeded at 15,000 cells/cm2 in 6 well format 
and were treated with 30nM siRNA using 6.5µl of the transfection reagent Dharmafect 2 (GE 
Healthcare, UK). Two siRNAs, targeting p16 and p21 respectively, were used in combination 
for senescence reversal, whilst a fluorescently tagged negative control siRNA targeting 
cyclophilin B (siGLO) was also employed, having been demonstrated not to alter either the 
EP or DS phenotype. Cells were reverse transfected on the day of seeding and media changed 
24 and 48 hours later. After a further 72 hours had elapsed, cells and associated conditioned 
media were collected for immunoblotting, qRT-PCR and ELISA assessment.  
 
Table 3: siRNAs Used in Senescence Reversal Protocol  
  
siRNA (Target) Accession number Supplier siRNA Target sequence 
siGLO (PPIB)  NM_000942  Dharmacon, UK GAGCCCAGAUCAACCUUUA 
p16 (CDKN2A) NM_000077 QIAGEN, UK TACCGTAAATGTCCATTTATA 
p21(CDKN1A) 
 




















2.7 Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) 
As with the senescence reversal investigations, all qRT-PCR experiments were carried out 
through supervision of Kishan Vara. Following either application of the reversal protocol or 
using EP and DS cells, cell lysis was performed using 400μl of QIAzol lysis reagent (Qiagen, 
UK). RNA extraction was performed using miRNeasy Mini Kit according to manufacturer’s 
instructions (Qiagen, UK). RNA Reverse transcription reactions were carried out using a 
starting RNA concentration of 100ng/μl prepared in RNase-free water. 3μl of RNA was added 
to a reaction mixture comprising 1ul each of oligo(dT)18 (50μM; Millipore, UK) and 
deoxynucleotides triphosphate (10mM; Thermo Scientific, USA) and made up to 13μl with 
RNase-free water. This reaction was performed at 65°C for 5 minutes, followed by a 5 minute 
incubation on ice. This reaction mixture was then made up to 20μl through addition of 4μl 
5x first strand buffer (Invitrogen, UK), 1μl dithiothreitol (0.1M; Invitrogen, UK), 1μl RNase 
inhibitor (40u/μl; Invitrogen, UK) and 4 μl superscript III reverse transcriptase (200u/μl; 
Invitrogen, UK). This mixture was incubated at 50°C for 45 minutes and then at 70°C for 15 
minutes to produce cDNA. Standard curve serial dilutions were then prepared for target 
genes described in Table 3, alongside a previously validated housekeeper control, 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 2μl cDNA was added to reaction 
mixtures comprising 12.5μl 2x SYBR Green PCR Master-mix (Applied Biosystems, UK), 0.2μl 
forward and reverse primers (20μM; Eurofins Genomics, UK) and made up to 25μL using 
ultrapure water. qRT-PCR was carried out via using 7500 Real-time PCR system (Applied 
Biosystems, UK) according to the schedule in Table 4. CT values for each target gene was 
normalised to the GAPDH, which was validated to remain constant between samples.  
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Table 4: qRT-PCR Primer Sequences  











































Step  Temperature (°C) Time Cycles 
Denature 95 10 minutes 1 
Denature 












15 seconds  
1 minute 
15 seconds  







2.8 Extracellular Vesicle Isolation  
2.8.1 Differential Ultracentrifugation (dUC) 
EVs were isolated from conditioned media generated through a range of conditions. 
However, in all cases, culture medium was prepared with “exosome-depleted FBS”, which 
was established to contain negligible levels of EVs (Section 4.3). In the OIS model, three 
induction schedules were utilised as described above, with a range of media volumes 
collected from varied final cell numbers (Schedule 1, 20ml collected from one T150 flask 
(30ml total), Vector: 8.9e6 cells, OIS: 1.7e6 cells ; Schedule 2, 160ml collected from six T150 
flasks (180ml total), Vector 5.1e7 cells, OIS: 1.6e7 cells; Schedule 3, 80ml collected from 
three T150 flasks (90ml total), Vector: 6.1e6 cells, OIS: 4.3e6 cells; mean cell numbers).  
 
In the HMF model, a single protocol was used, in which cells were seeded at day zero and 
cultured to day four. At this point cells were changed to medium containing ExoFBS and 
cultured for a further 72 hours. At day seven, medium was collected for EV isolation (20ml 
collected from two T75 flasks or one T150 flask (30ml total), EP: 4.9e6 cells; LP: 1.6e6 cells; 
mean cell numbers). EP HMFs seeded at 7,500 cell/cm2 were used alongside cells that were 
between passage 26 and 28 seeded at 15,000 cells/cm2. RS was imminent in these cells, 
having reached close to the maximum number of population doublings observed in HMFs 
(i.e. passage 29). However, as some level of cellular proliferation persisted, these passages 
cannot be considered senescent. Therefore, they have been designated as late passage (LP), 
likely comprising a significant proportion of cells that have entered RS.  
 
The collected media was centrifuged (2,000 x g; 4°C; 10 minutes) in order to pellet large EVs 
such as apoptotic bodies. The resultant supernatant was decanted into 50ml polypropylene 
tubes (Nalgene UK, 3118-0050) and subject to a high speed centrifugation (10,000 x g; 4°C; 
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30 minutes) in order to remove medium sized EVs including MVs (Sorvall RC6+ High Speed 
Rotor: SS-34; RPM: 9130; k-factor: 3,598.4). The cleared supernatant was then decanted into 
30ml Oak Ridge polycarbonate tubes (Thermo Scientific, UK) and ultracentrifuged (100,000 
x g; 4°C; one-hour 30 minutes) in order to achieve a population of small EVs enriched for 
exosomes (Sorvall Discovery 100 SE Rotor: T-865; RPM: 31,300; k-factor: 223.1). The final 
pellet was resuspended in 250µl sterile PBS. 
 
2.8.2 Size-Exclusion Chromatography (SEC) 
In order to concentrate EVs from a large starting volume, dUC was performed according to 
the protocol described, apart from a modified final resuspension volume of 500µl PBS. This 
dUC product was then loaded onto qEV original size-exclusion chromatography columns, 
which were first equilibrated with 10ml sterile PBS (Izon Science, UK). Twenty fractions of 
500µl were then collected consecutively as per the manufacturer’s instructions, with the first 
six comprising void volume. Columns were washed with 10ml sterile PBS in-between 
experiments, and reused a maximum of five times. However, for preparations used in EV 
treatment experiments, samples were prepared from fresh columns.   
 
2.9 Nanoparticle Tracking Analysis (NTA) 
NTA was carried out using the Nanosight NS300 system (Malvern-Panalytical, UK). EV 
dilutions were prepared in sterile PBS to produce a final volume of 1ml. The magnitude of 
this dilution was determined by the final particles per frame of captured videos, which were 
required to be between 15 and 80 particles/frame in order to both generate sufficient 
particle tracks and avoid particle masking. However, in order to preserve sample volume and 
enable other methods of analysis, a maximum dilution of 1:50 was used. A minimum of three 
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60-second videos were acquired at camera level 15, whilst analysis was performed at 
detection threshold 3 in software version NTA 3.2.  
 
2.10 “Exosome-Depleted FBS” Growth Rate Experiment 
EP HMFs were seeded in 6-well plates at 10,000 cell/cm2. These cells were maintained in 
standard culture medium until day 4, at which point cells were changed into medium 
containing 10% “exosome-depleted FBS” or standard FBS as a control. Cells were cultured 
for a further two days at which point fixation and immunofluorescence staining was 
performed (section 2.4). Cellular proliferation and morphology characterisation was then 
carried out according to the processes in section 2.5.   
 
2.11 Freezing Stability Experiment  
In order to assess the optimum storage conditions of isolated EV preparations, DMEM 10% 
FBS was subjected to the dUC EV isolation procedure. Samples were analysed by NTA on the 
day of isolation in order to determine the concentration of newly prepared samples. 
Remaining sample volume was then aliquoted and stored at either 4°C or -80°C. After one 
week, an aliquot from each condition was thawed and assessed by NTA. Following a further 
4 weeks, remaining aliquots from each temperature were also assessed by NTA. Samples 
were disposed of following thawing to avoid the confounding issue of multiple freeze/thaw 
cycles.  
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2.12 Western Blotting 
2.12.1 Sample Preparation 
Whole cell lysates (WCL) were collected through the resuspension of cell pellets using a lysis 
solution comprising RIPA buffer and 4% protease cocktail inhibitor (Roche, UK). These pellets 
contained a known cell number via use of a haemocytometer. The lysate was vortexed for 
30 seconds and incubated on ice for five minutes, followed by an additional 30 second vortex. 
Lysate protein concentration was then measured through use of a DC protein assay kit and 
BSA standard curve (Bio-Rad, UK). Protein concentrations between 2-5µg were then 
combined with 6X Laemmli sample buffer (Alfa Aesar, UK) and boiled at 95°C for 5 minutes. 
WCL samples were then ready for loading. Importantly, whilst the majority of WCL samples 
were prepared with standardised protein concentrations as described, in a number of 
experiments protein from an equal number of cells was prepared. This was to account for 
the size differential between proliferating and senescent cells, which results in an equal 
protein level from a lower number of senescent cells. In such instances, Lamin B1 is used as 
a loading control in order to demonstrate that observed changes are not due to excessive 
loading in the senescent condition (Freund et al., 2012). This is not the preferred method of 
analysis and is clearly indicated where used.  
 
In order to determine the protein concentration of EV samples, microBCA protein assays 
were performed (Thermo-Fisher, UK). However, as there was no intention to draw direct 
comparison to WCL samples, EV preparations isolated via dUC were used to produce samples 
containing an equal number of particles (3e9 particles) prior to loading. In situations where 
EV particle numbers were limited, such as in preparations isolated by SEC, an equal volume 
(25µl) of sample was prepared, determined by the maximum loading volume of the gel. EV 
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samples were then combined with sample buffer and boiled at 95°C for 5 minutes. No direct 
lysis step was used.  
 
2.12.2 SDS-PAGE and Immunoblotting 
Following sample preparation, gels were constructed, and used to separate protein 
according to size, via the Mini-PROTEAN III system (Bio-Rad, UK). The same system was used 
to transfer protein to a nitrocellulose membrane (GE, UK). This was then blocked at RT in 
0.05% (v/v) Tween-20, 5% (w/v) Marvel semi-skimmed milk in PBS (PBS-T-milk) for one hour. 
Membranes were then incubated overnight at 4°C with primary antibody prepared in PBS-T-
M on a roller. The following morning, HRP-conjugated secondary antibodies appropriate for 
the primary were then used to incubate the membranes, both preceded and followed by a 
wash step comprising three PBS-T washes for five minutes on a roller. Membranes were then 
incubated with Enhanced Chemiluminescence reagent (GE Healthcare, UK) and used to 
expose photographic film (GE Healthcare, UK). Densitometry was performed using ImageJ 











2.13 Mass Spectrometry (MS) Analysis  
 
2.13.1 Sample Preparation  
All steps described here were performed in collaboration with Natasa Josipovic and Argyris 
Papantonis (Institute of Pathology, Göttingen) through the CECAD proteomic facility 
(University of Cologne). EV or CM samples were prepared according to the protocols 
described in sections 2.8. Samples were combined in an equal ratio with a solution 
comprising 8M Urea, 50mM Tetraethylammonium bromide (TEAB) and protease cocktail 
inhibitor. This then underwent a series of 30 second sonication steps, with 30 second rest 
intervals for 10 minutes. Samples were then centrifuged at 20,000 x g for 15 minutes. 5mM 
Dithiothreitol (DTT) was then added to the collected supernatant, followed by a one-hour 
incubation at 25°C. Subsequently, 40mM chloroacetamide (Merck, Germany) was added for 
30 minutes at 25°C in the absence of light. A 4-hour incubation with 0.1µg/µl of Lysyl 
Endopeptidase (Wako, Germany) at RT was then performed, followed by 0.1µg/µl Trypsin 
(Serva, Germany) overnight. The following morning, addition of 1% of formic acid (FA; 
Honeywell, Germany) was carried out. Sequential washes with methanol (VWR, Germany), 
0.1% FA in 80% acetonitrile (Merck, Germany) and 0.1% FA in water were then used to 
activate stage tips, followed by sample loading. The tips then underwent additional wash 
steps with 0.1% FA in water and 0.1% FA in 80% Acetonitrile, were left to dry and 
subsequently stored at 4°C. Label-free mass spectrometry was performed using a nanoHPLC 
coupled to a Thermo Q-exactive MS/MS. Protein quantification and annotation was 
performed via MaxQuant, using default settings for label-free detection (Cox and Mann, 
2008). For each detected protein, iBAQ intensity values were then converted to LFQ 
intensities using the Perseus software platform (Tyanova et al., 2016). 
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2.13.2 Data Analysis 
MS data was generated from vector and OIS samples according to the senescence induction 
schedules described in section 2.2. MS1 utilised triplicate EV samples prepared by dUC from 
both OIS and vector cells. Generated gene lists were ranked in each condition according to 
mean label-free quantification (LFQ) values in order to indicate the abundance of each 
protein. These were also used to determine fold change values from the vector condition. 
FunRich version 3.1.3 was then used to explore Gene Ontology (GO)  terms associated with 
each sample, with cellular compartment terms ranked based upon the percentage of genes 
identified. In MS2, CM, SEC fraction 8 and SEC fraction 20 samples isolated from OIS cells 
were investigated in triplicate. Mean LFQ intensities were calculated for all identified genes 
in each sample and GO terms were then examined using FunRich as in MS1. In order to 
further examine the compositional makeup of each sample, localisation classifications were 
attributed to each gene according to those described in Protein Atlas 
(www.proteinatlas.org). Each gene was designated as intracellular, membrane or secreted, 
with genes able to receive multiple designations. Genes identified in each sample were then 
collated in lists according to Protein Atlas categorisation. Fraction 8 genes were then 
assessed using the PANTHER DB pathway analysis tool (http://www.pantherdb.org/) in order 
probe potential functional targets. MS3 utilised the same sample types as MS2 but were 
collected from both OIS and vector cells. Mean LFQ intensity values were compared through 
principal component and hierarchical clustering analysis using R version 3.6.3. Each sample 
type (CM, Fraction 8, Fraction 20) were also compared between vector and OIS conditions in 
order to calculate mean LFQ intensity fold changes. Finally, GO terms were explored in 
fraction 8 samples according to predicted cellular compartment within the gene ontology 
database. MS1, MS2 and M3 data are found in appendices 1, 2 and 3 respectively and a 





Figure 2.4: Overview of Mass Spectrometry Proteomic Investigations 
Three rounds of mass spectrometry were performed (MS1, MS2 and MS3). MS1 investigated 
EV samples isolated by differential ultracentrifugation (dUC) from vector and OIS IMR90s. 
MS2 investigated conditioned media (CM) and size-exclusion chromatography (SEC) fractions 
8 and 20 (F8 and F20) isolated from OIS IMR90s only. MS3 investigated CM, F8 and F20 from 
both vector and OIS IMR90s. OIS induction schedules 1-3 are described in Figure 2.1.   
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2.14 Enzyme-Linked Immunosorbent Assay (ELISA) 
Conditioned media samples were generated according to the senescence induction and EV 
isolation schedules described in sections 2.2, 2.3 and 2.8. Following a clearance 
centrifugation step of 2000 x g, media was analysed through use of commercial ELISA sets 
(R&D Systems, Human IL-6 DuoSet ELISA DY206; R&D Systems, Human IL-8 DuoSet ELISA 
DY208). EV samples were prepared according to the protocols in section 2.8 and analysed 
with the same ELISA kits without pre-application of lysis. Analytes were assessed at an 
absorbance of 450/570nm via a CLARIOstar Plus multi-mode plate reader (BMG Labtech). 
 
2.15 Conditioned Media and EV Treatment Investigations  
Treatment experiments were performed with conditioned media and EV samples in several 
contexts. Figure 2.5 summarises the treatment regimens, including dosing schedule and 
treatment volumes.  
 
2.15.1 Conditioned Media Investigations  
Conditioned media (CM) samples were prepared from OIS cells according to the conditioning 
and clearance protocols described in section 2.8. For HMFs, EP cells were seeded at 6,785 
cell/cm2 and DS at 25,477 cell/cm2  in order to achieve a final cells per microlitre of condition 
media comparable to that described in (Acosta et al., 2013). In investigations using IMR90s 
and HMFs, the CM was combined in a 3:1 ratio with a 4X cocktail of medium components 
comprising 40% FBS DMEM and 8mM L-glutamine, in accordance with the protocol described 
in (Acosta et al., 2013). Control medium was composed of serum free DMEM supplemented 
with the 4X cocktail. Vector IMR90 or EP HMFs were seeding in 96 well plates at 10,000 
cells/cm2. These were treated with 120µl of CM + 4x cocktail. Treatment was performed one 
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day after cell seeding and repeated following an additional 72 hours. After cells were 
cultured for a further 48 hours, fixation and staining was carried out according to the 
protocol described in section 2.4. Due to differences in standard culture medium, the MDA-
MB-468 treatment experiments were performed with some modification. The vector and OIS 
media was collected and cleared as described in section 2.8. However, a dose of 10µl CM 
was added to each well of 468s seeded at 10,000 cells/cm2 with an identical dose regime to 
the IMR90/HMF investigations.   
 
2.15.2 Extracellular Vesicle Treatment Investigations  
Following isolation through SEC, EV samples were used to treat IMR90 or 468 cells cultured 
in 96-well plates. In all cases cells were seeded at 10,000 cells/cm2 and doses of 10µl per well 
were applied in addition to 120µl of appropriate standard culture media. Dosing regimens 
were identical to those of conditioned media investigations, with doses at 24 and 96 hours 
post-seeding. Assessment by HCA was then performed following the standard fixation 
procedure. EV samples used in these experiments included fraction 8 and 20 from OIS and 










2.16 NOTCH1/ADAM Inhibitor Conditioned Media Experiments 
IMR90 vector and OIS cells were cultured in 6-well plates and subject to the final OIS 
induction schedule described in section 2.2 with some modification. At day four, cells were 
treated with either 500nM of the ADAM17 inhibitor TMI005, 10µM of the γ-secretase 
inhibitor DAPT or DMSO vehicle control. DAPT was selected as a potent inhibitor of NOTCH1 
signalling that has previously been utilised in a senescence setting (Hoare et al., 2016). 
TMI005 has been reported as a potent inhibitor of ADAM17 but it important to acknowledge 
that the compound also inhibits MMPs (Shu et al., 2011; Richards et al., 2012). Cells were 
cultured for a further four days at which point conditioned media was collected and prepared 
in accordance with the protocol described in section 2.15.1. MDA-MB-468 cells were then 
treated with conditioned media according to the schedule also described in section 2.15.1. 
It is important to note that this experiment was only performed with N=1, with one technical 
replicate on conditioning plate and four on treatment plate.   
 
2.17 Statistical Analysis  
GraphPad Prism version 7 was used to conduct all statistical tests, details of which may be 
found in figure legends. As standard, unpaired Student’s t-test and Ordinary One-way ANOVA 
analyses were used, in order to compare means between two and multiple conditions, 
respectively. Tukey’s post-hoc tests were performed following ANOVA, in order to make 
multiple comparisons between conditions. Statistical significance was defined according to 
the following p value representations: ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p <0.0001. 
Unless otherwise stated, error bars represent standard deviation (SD) of ≥3 independent 
experiments with at least three technical replicates throughout.  
 
2.18  Diagrams and Schematics 
All diagrams and schematics have been prepared using BioRender – www.biorender.com  
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3 Results 1: Establishing Models of Senescence and 
Characterising Phenotype 
3.1 Introduction 
As described in section 1.1, senescence is a terminal cell fate characterised by a loss of 
cellular proliferation in response to a variety of potential harmful stimuli. These stimuli have 
been demonstrated to drive a context dependent response, with the emergent phenotype 
dependent not only on the particular senescence trigger, but also on the cell type under 
insult. Consequently, this leads to varied secretory profiles emerging between different 
models of senescence, with the SASP driven by both cell type and senescence inducer. Whilst 
this is true of in vitro models of senescence, it becomes of greater significance when 
considering the consequences of senescence in vivo, where specific types of senescence in 
specific cells/tissues contribute to a diverse range of biological responses (section 1.1.9). 
Therefore, senescence cannot be considered a single uniform phenomenon and, as such, it 
is useful to employ a variety of experimental models when investigating it.  
 
Oncogene-induced senescence (OIS) is one of the most widely applied models of senescence 
and has a well-characterised and potent SASP (section 1.1.6). A popular system for studying 
OIS involves expression of oncogenic HRas in IMR90 foetal lung fibroblasts, often coupled to 
the oestrogen receptor (ER) in an inducible fusion protein system (section 2.2). This allows 
investigation of OIS in an expedient manner, whilst also generating a robust and well-
described phenotype. By contrast, the induction of replicative senescence (RS) in primary 
adult cells is a more laborious endeavour and less widely used. These cells must be serially 
passaged over many months until observable population doublings stop as cells reach their 
Hayflick limit (section 1.1.5). The rationale for investigating senescence in this protracted 
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experimental system is to recapitulate a phenotype reflective of ageing in adult cells. 
Therefore, both models have advantages and limitations but provide useful complimentary 
systems in which to study the broad phenomena of “premature” and “replicative” 
senescence. The ER:RAS model of OIS and a primary adult human mammary fibroblast (HMF) 
model of RS are used here.  
 
Finally, as a potentially useful experimental tool, the process of senescence reversal was also 
investigated (section 1.1.8).  In conjunction with the model of RS, siRNA inhibition of key 
tumour suppressors p16 and p21 were used to rejuvenate deeply senescent cells. This work 
was performed through supervision of a Regenerative Medicine MSc student, Kishan Vara 
and based upon work established previously within the lab by Elly Tyler (Thesis:(Tyler, 2016)).  
 
Overall, by setting up these experimental systems and characterising the senescence 
phenotypes, the next set of experiments investigating the extracellular vesicle (EV) 









3.2 Chapter Hypothesis and Aims 
The aim of this chapter was to establish models of senescence in order to facilitate the 
subsequent isolation of EVs. Expression of an inducible HRas construct in IMR90 fibroblasts 
and serial cultivation of adult human mammary fibroblasts (HMFs) were hypothesised to 
generate models of oncogene-induced (OIS) and replicative (RS) senescence, respectively. 
Validation of senescence induction was performed through characterisation of canonical 
senescence markers along with a high content analysis (HCA) based screening assessment of 
senescence-associated morphological changes. The acquisition of a senescence-associated 
secretory phenotype (SASP) was also investigated in both models. Finally, use of a previously 
validated siRNA reversal protocol in RS HMFs was hypothesised to attenuate expression of 
the SASP and investigated though supervision of an MSc student.  
 
The aims of this chapter are as follows: 
 To characterise oncogene-induced senescence (OIS) in IMR90 HRas:ER 
fibroblasts.  
o To validate loss of cellular proliferation and changes in canonical 
senescence markers by high-content analysis (HCA) microscopy  
o To establish a high-throughput, unbiased set of morphological measures 
to characterise senescence induction 
o To validate the OIS SASP 
 
 To characterise replicative senescence (RS) in primary adult human mammary 
fibroblasts (HMFs)  
o To validate RS induction by HCA  
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o To establish the SASP of RS HMFs 
 To characterise senescence reversal in RS HMFs through use of siRNA 
o To validate the re-establishment of cellular proliferation and ablation of 
canonical senescence markers 




3.3 Characterising the Oncogene- Induced Senescence (OIS) Phenotype of 
IMR90 HRas:ER Fibroblasts  
Oncogene-induced senescence (OIS) has been widely modelled through use of an inducible 
HRas:ER fusion protein construct in IMR90 foetal lung fibroblasts. The validation of 
senescence induction generally requires the observation of changes in a panel of senescence 
markers, as no single marker is considered universal. Here, the expression of tumour 
suppressor proteins (p21 and p16) were combined with assessment of cellular proliferation 
(reduction in cell number and Ki67 expression) as well as the acquisition of senescence-
associated heterochromatin foci (SAHFs). These canonical markers of senescence induction 
were complimented with an unbiased high-content analysis assessment of changes in 
cellular and nuclear morphology. Cell area has been widely reported to increase with 
senescence induction, with senescent cells previously described as having an enlarged, 
flattened morphology (section 1.1.3.3). Furthermore, acquisition of enlarged irregular nuclei 
with low DAPI staining have been previously used to identify senescent cells (section 1.1.3.4). 
Here, these features were assessed using a range of morphological measures, in order to 
establish a senescence-associated morphological profile. Overall, these markers were 
considered as a collective in order to assess the induction of OIS.  
 
Firstly, whole cell lysate (WCL) was collected from vector control and OIS cells at day eight of 
the OIS induction schedule. Day eight was selected following extensive optimisation of the 
OIS induction schedule (section 2.2), which sought to balance the seeding density and 
proliferation of the vector control cells (and thus prevention of contact inhibition) with 
development of an OIS phenotype. In particular, the elaboration of a SASP (section 3.4). 
Immunoblotting was then performed in order to assess the expression of the tumour 
suppressors p21 and p16. The OIS WCL was associated with an increased expression of both 
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these canonical senescence markers compared to the vector control (vector p21, 0.07 ± 0.01 
a.u.; OIS p21, 0.72 ± 0.10 a.u.; vector p16, 0.02 ± 0.01 a.u.; OIS p16, 0.43 ±  0.10; Figure 3.1 
A-D). This provided evidence that the senescence induction protocol led to an increase in 
tumour suppressor expression, as previously reported (Serrano et al., 1997). The next step 






Figure 3.1: Western blot analysis of canonical senescence markers p21 and p16 
Immunoblot analysis of whole cell lysate (WCL) from vector and OIS IMR90s for senescence 
markers p21 and p16. A-B) Immunoblot and densitometry quantitation for p21 and GAPDH 
loading control. C-D) Immunoblot and densitometry quantitation for p16 and β-tubulin 
loading control. Each lane contains a sample prepared during an independent experiment. 
N=3 independent experimental replicates (1 technical replicate per experiment). 
Quantitation performed via Image J with normalisation to loading control in each lane. 







Next, vector and OIS cells were passaged into 96 well plates on day eight of the induction 
schedule. These were then cultured to day 13 at which point the plates were fixed. 
Immunofluorescence staining was then used to assess the induction of senescence. HCA 
assessment demonstrated a reduction in cell number in the OIS cells compared to the vector 
control (vector, 4631 ± 535.7; OIS, 909.8 ± 184.4; Figure 3.2A). Cellular morphology was 
visualised using the nucleic acid dyes DAPI and Cell Mask. HCA analysis was used to 
unbiasedly assess a panel of 10 morphological measures (Figure 3.2B): cell area (vector, 
922.2 ± 63.64µm2; OIS, 3951±695.6 µm2), nuclear area (vector, 206.6 ± 0.7219 µm2; OIS, 
303.2 ± 10.53 µm2), cytoplasmic/nuclear ratio (vector, 3.514 ± 0.2925; OIS, 12.76 ± 2.449 ) , 
DAPI density (vector, 4760 ± 216.9 a.u.; OIS, 3173 ± 170.6 a.u.), Nuclear form factor (vector, 
0.7936 ± 0.01385; OIS, 0.7514 ± 0.01378), cellular protrusions (vector, 4.403 ± 0.3185; OIS, 
16.82 ± 0.695), cellular form factor (vector, 0.6371 ± 0.278; OIS, 0.3085 ± 0.01248), Major 
axis length (vector, 42.11 ± 1.4 µm; OIS, 86.29 ± 6.877 µm), minor axis length (vector, 24.41 
± 0.5097 µm; OIS 42.43, ±3.525 µm) and cellular elongation (vector, 0.58 ± 0.008918 ; OIS, 
0.49 ± 0.002648), all of which were found to significantly change in the OIS cells compared 
to the vector control. This demonstrates that the use of HCA allows assessment of a large 
number of morphological parameters, of which OIS cells produced a district profile. To 
increase the applicability of this to other models of senescence induction, as well as compare 
between different measures, Z-scores were calculated based on the standard deviation from 
the control cells for each parameter (section 2.5). This method of analysis allows a broad 
assessment of senescence induction to be made based upon “senescence-associated” 
changes in morphological characteristics (Figure 3.3). In order to validate this approach, it 




Figure 3.2: High Content Analysis (HCA) of oncogene-induced senescence proliferation and 
morphology  
HCA analysis was performed on vector and OIS IMR90s to assess a panel of morphological 
measures. A) Representative immunofluorescence images for DAPI (blue) and Cell Mask (red) 
staining in OIS and vector control IMR90s following senescence induction. B) Quantitation of 
HCA cell number and morphology measures. N=3 independent experimental replicates (3 
technical replicates per experiment).  Statistical analysis performed via unpaired Student’s t-
test per measure (section 2.17). Scale bars = 250µm. Four fields of view. 
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Figure 3.3: Heat map showing from morphological measure Z-scores following oncogene-
induced senescence induction in IMR90 fibroblasts  
HCA morphological measures were converted to Z-scores according to the change from the 
vector control condition (section 2.5). Positive and negative modulation of each measure is 
demonstrated by a change of at least +/- one Z-score (standard deviation) from the vector 
condition and indicated as red (increase) or blue (decrease), respectively. White indicates no 






Having established through immunoblotting that the tumour suppressors p21 and p16 were 
upregulated in the OIS cells following induction, immunofluorescence staining was 
performed in order to visualise the localisation of these proteins. Both nuclear p21 and p16 
were demonstrated to increase within the OIS cells (p21, 72.83 ± 9.835 percentage positive; 
p16, 99.05 ± 0.686 percentage positive; Figure 3.4 and 3.5) when compared to the 
proliferative control (p21, 29.11 ± 3.291 percentage positive; p16, 28.27 ± 10.35 percentage 
positive; Figure 3.4 and 3.5). Impaired cellular proliferation had been established in the OIS 
cells, as demonstrated by a reduction in cell number, and was further supported by a 
reduction in Ki67 staining compared to the vector control (vector, 45.35 ± 4.853 percentage 
positive; OIS, 4.755 ± 3.68 percentage positive; Figure 3.6). Finally, the presence of SAHFs 
was investigated, as these are often seen as a more specific marker of OIS. The number of 
foci was assessed per nuclei in brackets of 1-3 (vector, 1.29 ± 0.89%; OIS, 26.41 ± 1.57%), 4-
6 (vector, 0.25 ± 0.23%; OIS, 23.54 ± 1.62%), 7-9 (vector, 0.06 ± 0.06%; OIS, 17.67 ± 0.80%) 
and 10+ (vector, 0.02 ± 0.02%; OIS, 9.15 ± 1.23%) (Figure 3.7). Each group saw significantly 
more foci in the OIS cells than the vector control. Therefore, assessment of canonical 
senescence markers demonstrated the successful induction of OIS. Importantly, these were 
supported by a HCA based morphological panel, which was employed to establish the 
induction of a senescence-associated morphology in subsequent experiments. Overall, it was 
concluded that the OIS induction schedule was successful in producing a canonical 





Figure 3.4: Immunofluorescence staining by high-content microscopy of senescence 
marker p21 
Immunofluorescence staining for p21 was assessed in vector and OIS IMR90s. A-B) 
Representative images for DAPI (blue) and p21 (green) staining in OIS and vector control 
IMR90s following senescence induction. C) Frequency distribution of p21 density levels in all 
targets, including secondary only control conditions (2nd). D) Quantitation of p21 nuclear 
staining percentage positivity compared to secondary only control. N=3 independent 
experimental replicates (3 technical replicates per experiment). Statistical analysis 






Figure 3.5: Immunofluorescence staining by high-content microscopy of senescence 
marker p16   
Immunofluorescence staining for p16 was assessed in vector and OIS IMR90s. A-B) 
Representative images for DAPI (blue) and p16 (green) staining in OIS and vector control 
IMR90s following senescence induction. C) Frequency distribution of p16 density levels in all 
targets, including secondary only control conditions (2nd). D) Quantitation of p16 nuclear 
staining percentage positivity compared to secondary only control. N=3 independent 
experimental replicates (3 technical replicates per experiment). Statistical analysis 






Figure 3.6: Immunofluorescence staining by high-content microscopy of proliferation 
marker Ki67   
Immunofluorescence staining for Ki67 was assessed in vector and OIS IMR90s. A-B) 
Representative images for DAPI (blue) and Ki67 (green) staining in OIS and vector control 
IMR90s following senescence induction. C) Frequency distribution of Ki67 density levels in all 
targets, including secondary only control conditions (2nd). D) Quantitation of Ki67 staining 
percentage positivity compared to secondary only control. N=3 independent experimental 
replicates (3 technical replicates per experiment). Statistical analysis performed via unpaired 





Figure 3.7: Immunofluorescence staining by high-content microscopy of senescence-
associated heterochromatin foci (SAHF) 
Immunofluorescence staining for SAHF was assessed in vector and OIS IMR90s. A-B) 
Representative images for DAPI (blue) staining in OIS and vector control IMR90s following 
senescence induction. C) Quantitation of nuclei positive for at least one foci as a percentage 
of the total nuclei in that condition. N=3 independent experimental replicates (3 technical 
replicates per experiment). Statistical analysis performed via unpaired Two Way ANOVA with 





3.4 Characterising OIS Senescence Associated Secretory Phenotype (SASP) 
One of the key hallmarks of senescence induction is the acquisition of an enhanced secretory 
phenotype, the SASP. The SASP of OIS cells has been extensively investigated, with IL-6 and 
IL-8 frequently described as canonical markers (section 1.1.4). WCL from vector and OIS cells 
was assessed for these SASP components by immunoblotting. Both IL-6 and IL-8 were 
exclusively seen in the WCL from OIS cells. Whilst the IL-8 can confidently be described as 
increasing with senescence induction (vector, 0.02 ± 0.01 a.u.; OIS, 2.36 ± 1.08 a.u.; Figure 
3.8), the IL-6 blot must be treated with some caution. This is because Lamin B1 was also 
assessed as the IL-6 blot loaded according to cell number. As Lamin B1 is downregulated in 
senescence, the rationale for its use as a loading control is to demonstrate that wells have 
not been overloaded (section 2.12). As this downregulation was not demonstrated, a 
conclusion cannot be drawn concerning the change in IL-6 based on this blot.  
 
Next, immunofluorescence staining was performed, in order to determine the localisation of 
SASP proteins within the OIS cells. Whilst IL-8 was demonstrated to increase in OIS (vector, 
2.256 ± 2.701 percentage positive; OIS, 31.95 ± 7.107 percentage positive; Figure 3.10), there 
was no observable difference between the OIS and vector cells in terms of IL-6 expression 
(vector, 23.72± 13.68 percentage positive; OIS, 33.49 ± 21.56 percentage positive; Figure 
3.9). However, analysis was confounded by intra-experimental variability, so conclusions 
regarding IL-6 expression in OIS were not drawn. Whilst IL-8 data had thus far supported the 
literature, increased in IL-6 with OIS induction has not yet been demonstrated. Therefore, 




Figure 3.8: Western blot analysis of the canonical SASP markers IL-6 and IL-8  
Immunoblot analysis of whole cell lysate (WCL) from vector and OIS IMR90s for senescence-
associated secretory phenotype (SASP) markers IL-6 and IL-8. A-B) Immunoblot and 
densitometry quantitation for IL-6 and Lamin B1 loading control. C-D) Immunoblot and 
densitometry quantitation for IL-8 and GAPDH loading control. Each lane contains sample 
prepared during an individual experiment. N=3 independent experimental replicates (1 
technical replicate per experiment). Quantitation performed via Image J with normalisation 
to loading control in each lane. Statistical analysis performed via unpaired Student’s t-test 







Figure 3.9: Immunofluorescence staining by high-content microscopy of SASP marker IL-6 
Immunofluorescence staining for IL-6 was assessed in vector and OIS IMR90s. A-B) 
Representative images for DAPI (blue) and IL-6 (green) staining in OIS and vector control 
IMR90s following senescence induction. C) Frequency distribution of IL-6 density levels in all 
targets, including secondary only control conditions (2nd). D) Quantitation of IL-6 staining 
percentage positivity compared to secondary only control. N=3 independent experimental 
replicates (3 technical replicates per experiment).  Statistical analysis performed via unpaired 







Figure 3.10: Immunofluorescence staining by high-content microscopy of SASP marker IL-
8 
Immunofluorescence staining for IL-8 was assessed in vector and OIS IMR90s. A-B) 
Representative images for DAPI (blue) and IL-8 (green) staining in OIS and vector control 
IMR90s following senescence induction. C) Frequency distribution of IL-8 density levels in all 
targets, including secondary only control conditions. D) Quantitation of IL-8 staining 
percentage positivity compared to secondary only control. N=3 independent experimental 
replicates (3 technical replicates per experiment).  Statistical analysis performed via unpaired 





The secretion of IL-6 and IL-8 by the OIS cells was assessed by ELISA. Here, both IL-6 and IL-8 
were demonstrated to increase compared to the proliferating control (vector IL-6, 57 ± 29.44 
pg/ml; OIS IL-6, 8192 ± 981.1pg/ml; vector IL-8, 189.3 ± 259.6 pg/ml; OIS IL-8, 30978 ±  4248 
pg/ml; Figure 3.11 A-B). It was notable, that the IL-8 concentration was substantially greater 
than that observed for IL-6. When combined with the immunoblotting and 
immunofluorescence data, IL-8 was selected as reliable marker of the OIS SASP that could be 
confidently assessed in subsequent experiments.   
 
It was proposed that the difficulties in IL-6 characterisation might be due to variability within 
the composition of the SASP. Therefore, the levels of IL-6 and IL-8 were assessed across the 
course of OIS induction (schedule two), with samples collected at two day intervals between 
day four and day 16. This demonstrated that both IL-6 and IL-8 increased between day four 
and day 12. However, this was followed by a subsequent reduction from day 14, dramatically 
in the case of IL-8 (Figure 3.12). The kinetics of SASP development are incompletely 
understood and represent an intriguing area for future work (section 6.2). Despite not being 
the point of maximum SASP production during schedule two, a conditioning period between 
day four and day eight was selected for EV isolation experiments. This balanced the level of 
SASP production with the proliferation of vector cells, as well as a higher seeding density 
used in protocol three. In order to prevent contact inhibition and quiescence, this earlier 
time-point was selected. However, this data indicates that characterisation of later time-





Figure 3.11: ELISA analysis of conditioned media from OIS and vector cells for canonical 
SASP markers IL-6 and IL-8   
Conditioned media was collected from vector and OIS IMR90s between day four and day 
eight of the OIS induction schedule three. This media was assessed by ELISA for A) IL-6 and 
B) IL-8. N=3 independent experimental replicates (3 technical replicates per experiment).  







Figure 3.12: ELISA analysis of conditioned media from OIS cells collected between days 4-
16 
Conditioned media was collected from OIS IMR90s every two days between day four and day 
16 following OIS induction (schedule two). This media was assessed by ELISA for A) IL-6 and 




3.5 Characterising the Replicative Senescent (RS) Phenotype of Human 
Mammary Fibroblasts (HMFs)  
 
Having successfully validated the induction of OIS in IMR90s, a model of replicative 
senescence (RS) was then pursued. Primary adult human mammary fibroblasts were 
selected, as these had already been extensively characterised within the lab (Thesis:(Tyler, 
2016)). Importantly, the SASP of the RS HMFs has not been previously established. HMFs 
were serially passaged on a weekly basis until the point of replicative senescence (RS). This 
was established to occur at passage 29, at which point the cells had undergone ~35 
population doublings (PDs), in line with previous investigations (Romanov et al., 2001). Cells 
were then maintained for a further 3 weeks to allow for the establishment of a long-term 
stable state of deep senescence (DS). The HMF Hayflick curve (Figure 3.13A) demonstrated 
relatively consistent population doublings until around passage 16. Therefore, passages up 
to this point were considered to be “early proliferative” (EP). With these parameters 
established, the phenotype of the DS cells could characterised.  
 
Given that the model of RS had been previously well established within the lab and that the 
cells were considered precious given they take ~200 days to generate, limited 
characterisation was performed. Immunofluorescence demonstrated a loss of proliferation 
in the DS cells compared to the EP, characterised by a reduced cell number (EP, 15572; DS, 
2948). The panel of senescence-associated morphological changes also suggested induction 
of senescence, with alterations in cell area (EP, 1571; DS, 5600.137 µm2), nuclear area (EP, 
206; DS, 297µm2), cytoplasmic/nuclear ratio (EP, 6.64; DS, 18.78), DAPI density (EP, 9579; DS, 
3370 a.u.), nuclear form factor (vector, 0.901; DS, 0.853), cellular protrusions (EP, 3.88; DS, 
9.10), cellular form factor (EP, 0.710; DS, 0.549), major axis length (EP, 53.58; DS, 99.31 µm), 
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minor axis length (EP, 33.91; DS, 60.41 µm) and cellular elongation (EP, 0.633; DS, 0.608) all 
observed (Figure 3.14). Importantly, this data must be viewed with caution as it represents 
only N=1 with technical replicates. However, it indicates that the cells which underwent 
serial passaging to passage 29 +3 weeks are morphologically distinct from the EP HMFs and 
that they have impaired proliferative capacity. Furthermore, this data is supported by 
previous evidence that HMFs at passage 29+3 weeks are positive for canonical senescence 
markers, reinforcing the assertion that a DS phenotype has been established (Stampfer et 
al., 1981; Tyler, 2016). Therefore, whilst not definitively demonstrated to the highest 
possible standard here, it is reasonable to consider the likely establishment of RS. 
Throughout this work, this model has been predominantly used in a supportive capacity, to 
compliment evidence from OIS. If future work were to focus on the cells generated here, it 
would essential to comprehensively validate the induction of RS beforehand. With these 




Figure 3.13: Hayflick curve and phase images of primary human mammary fibroblasts 
(HMFs) during culture from early proliferation (EP) to deep senescence (DS) 
Human mammary fibroblasts (HMFs) were serially passaged to replicative senescence, 
having been previously passaged by Elly Tyler (Bishop Lab; Red line) and were acquired at 
passage nine. A) Hayflick curve demonstrating cumulative population doubling with passage 
number. Cells were defined as replicatively senescent (RS) at passage 29 and deeply 
senescent (DS) at 29 +3 weeks. N≥2 all passage apart from N=1 passage 18-21. Red line 
indicates cells cultured by Elly Tyler. B) Brightfield phase images of EP (passage 10) and DS 





Figure 3.14: High Contentment Analysis (HCA) of Replicative Senescence in Human 
Mammary Fibroblasts (HMFs) – Proliferation and Morphology 
HCA analysis was performed on early proliferative (EP) and deeply senescent (DS) human 
mammary fibroblasts (HMFs) to assess a panel of morphological measures. A) 
Representative immunofluorescence images for DAPI (blue) and Cell Mask (red) staining in 
EP and DS HMFs. B) Quantitation of HCA cell number and morphology measures. N=1 




Whilst well described as a model, the secretome of RS HMFs has not been established 
previously. In order to parallel the work in the OIS model, IL-6 and IL-8 were once again 
investigated as canonical markers of the SASP. Through immunoblotting (carried out through 
supervision of MSc student Kishan Vara), it was observed that IL-6 expression increased in 
the DS cells compared to the EP control (EP IL-6, 1 ± 0 fold change; DS IL-6, 30.39 ± 3.77; 
Figure 3.15). Intriguingly, this was not the case for IL-8, despite it being the more prominent 
marker of the OIS SASP (EP IL-8, 1 ±-0; DS IL-8, 0.57 ± 0.11; Figure 3.15). It should be noted 
that cells were loaded based upon cell numbers with Lamin B1 serving as a loading control 
with OIS samples included for reference. Interestingly, IL-6 in the OIS samples was observed 
to increase compared to the vector, which had not been fully demonstrated in section 3.4 
(vector, 1.069 ± 0.06 fold change; OIS, 18.82 ± 3.83 fold change; Figure 3.15). The OIS lysates 
were collected at day 11 post-seeding (schedule two), which may account for this observed 
difference. Therefore, it appears that IL-6 forms a part of the RS HMF SASP whereas IL-8 does 
not. This highlights the context dependent nature of the SASP, with the RS and OIS models 
appearing quite different in composition. This also emphasises the benefit of utilising 
multiple senescence models, as senescence cannot be considered a homogenous 




Figure 3.15: Assessment of the senescence-associated secretory phenotype (SASP) of 
replicatively senescent human mammary fibroblasts (HMFs) 
Immunoblot analysis of whole cell lysate (WCL) from early proliferative (EP) and deeply 
senescent (DS) human mammary fibroblasts (HMFs) and vector and OIS IMR90s for the 
senescence-associated secretory phenotype (SASP) markers IL-6 and IL-8. A-B) 
Representative immunoblot and densitometry quantitation for IL-6 and Lamin B1 loading 
control. C-D) Immunoblot and densitometry quantitation for IL-8 and Lamin B1 loading 
control. N=2 independent experimental replicates (1 technical replicate per experiment). 




3.6 Senescence Reversal in HMFs 
Senescence has previously been described as an irreversible arrest of the cell cycle. However, 
this concept has recently been challenged, with the demonstration that RS reversal can be 
initiated through use of siRNA knockdown of p16 and p21 (Thesis:(Tyler, 2016)). This system 
presents opportunities to investigate pathways that are intrinsic to the senescence process, 
as well as potential to uncouple senescence hallmarks, such as loss of proliferation and SASP 
production. The secretome of reversed HMFs has not been previously explored, although 
that of reversed HMECs indicates that senescence reversal sees ablation of SASP production 
(Lowe et al., 2015). The work presented within this section was carried out through 
supervision of a Regenerative Medicine MSc student – Kishan Vara. The objectives were to 
establish the p16+p21 siRNA reversal protocol in RS HMFs and characterise the SASP of the 
reversed cells. It is important to acknowledge that all work in this section used only two 
independent experimental replicates and has not, therefore, been statistically assessed.    
 
Firstly, it was important to assess the successful reversal of RS in the HMFs. Senescence 
reversal was demonstrated through re-establishment of cellular proliferation. This was 
observed through an increase in cell number in p16+p21 siRNA cells compared to the 
untreated DS cells and the siGLO control (DS, 1 ± 0 fold change; siGLO, 1.00 ± 0.03 fold 
change; 1.89 ± 0.27 fold change; Figure 3.16). Next, p21 and p16 were assessed by qRT-PCR. 
In the p16+21 siRNA treated cells, the level of both p16 (DS, 1 ± 0 fold change; siGLO, 1.176 
± 0.09 fold change; p16+p21, 0.2684 ± 0.03 fold change; Figure 3.17A) and p21 (DS, 1 ± 0 fold 
change; siGLO, 1.159 ± 0.08 fold change; p16+p21, 0.161 ± 0.14 fold change; Figure 3.17B) 
mRNA were lower than that of DS and siGLO conditions. When taken with previously 
generated data, RS reversal in the HMFs was concluded to have been successful. Therefore, 




Figure 3.16: Assessment of siRNA senescence reversal via immunofluorescence through re-
establishing cellular proliferation 
Deeply senescent (DS) human mammary fibroblasts (HMFs) were treated with siGLO or 
p16+p21 siRNA or left as an untreated control. A) Timeline for siRNA reversal protocol B) 
Schematic indicating previously established reversal of HMF RS senescence via use of 
p16+p21 siRNA 3) HCA assessment of cell numbers. Normalisation to untreated DS control 





Figure 3.17: qRT-PCR analysis of p21 and p16 expression in human mammary fibroblasts 
(HMFs) following siRNA senescence reversal 
Deeply senescent (DS) human mammary fibroblasts (HMFs) were treated with siGLO or 
p16+p21 siRNA and compared to early proliferating (EP) and DS controls. Assessment of A) 
p16 and B) p21 mRNA expression was then made by qRT-PCR. Relative expression was 
calculated through normalisation to a GAPDH housekeeper and fold change relative to the 
DS condition was determined. N=2 independent experimental replicates (2 technical 
replicate per experiment).   
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As described previously, the SASP varies between cells types and senescence triggers, as 
emphasised by the lack of IL-8 production in the RS HMFs observed through immunoblotting. 
This was once again demonstrated, as negligible IL-8 mRNA was observed in either EP or DS 
samples by qRT-PCR and did not change following siRNA treatments (EP, 1 ± 0 fold change; 
DS, 1.742 ± 0.71 fold change; siGLO, 1.131 ± 0.45 fold change; p16+p21, 5.646 ± 3.00 fold 
change; Figure 3.18A). By contrast, IL-6 mRNA was observed in both the DS and siGLO 
conditions, and was found to decrease with use of p16+p21 siRNA (EP, 1 ± 0 fold change; DS, 
258.4 ± 39.5 fold change; siGLO, 232.5 ± 30.41 fold change; p16+p21, 52.92 ± 34.68 fold 
change; Figure 3.18A). In order to explore the effect of reversal on the SASP further, IL-1α 
and IL-1β were also assessed by qRT-PCR. IL-1α was demonstrated to remain unchanged 
from the levels observed in the DS and siGLO conditions, significantly above that of the EP 
cells (EP, 1 ± 0 fold change; DS, 50.93 ± 5.87 fold change; siGLO, 43.01 ± 2.70 fold change; 
p16+p21, 48.53 ± 3.769 fold change; Figure 3.18B). Intriguingly, IL-1β was seen to increase 
dramatically in the reversed cells (EP, 1 ± 0 fold change; DS, 64.1 ± 0.08 fold change; siGLO, 
54.3 ± 1.71 fold change; p16+p21, 234.9 ± 5.82 fold change; Figure 3.18B). This suggests that 
the reversed secretory phenotype may be more complex than simply reverting to that of the 
EP condition.  
 
As IL-6 has thus far been considered the most well described marker of the RS HMF SASP, 
the abundance of protein secretion was then investigated in the rejuvenated cells. The level 
of IL-6 secretion appeared to decrease in the p16+p21 conditioned verses the siGLO control, 
although this was not a statistically significant response (siGLO, 138.8 ± 91.71pg/ml; 10.82, 
± 3.08pg/ml; Figure 3.19). The high variability between experiments highlights the 
importance of sufficiently powered experiments and producing at least one further replicate 




Figure 3.18: qRT-PCR analysis of IL-6, IL-8, IL-1α and IL-1β expression in human mammary 
fibroblasts (HMFs) following siRNA senescence reversal  
Deeply senescent (DS) human mammary fibroblasts (HMFs) were treated with siGLO or 
p16+p21 siRNA. Assessment of A) IL-6 and IL-8 and B) IL-1α and IL-1β mRNA expression was 
then made by qRT-PCR. Relative expression was calculated through normalisation to a 
GAPDH housekeeper and fold change relative to the DS condition was determined.  N=2 





Figure 3.19: ELISA analysis of conditioned media from human mammary fibroblasts (HMFs) 
following siRNA senescence reversal  
Deeply senescent (DS) human mammary fibroblasts (HMFs) were treated with siGLO or 
p16+p21 siRNA. Conditioned media was collected and assessed by ELISA for IL-6. N=2 






In this chapter, two models of senescence have been investigated. The first, OIS in IMR90s, 
is one of the most extensively characterised models within the literature. Here, senescence 
induction was confirmed through the characterisation of multiple orthogonal markers 
including tumour suppressor expression (p16 and p21), loss of cellular proliferation (cell 
number and Ki67) and the appearance of SAHFs. This data was complimented by an HCA 
morphological assessment, which allowed unbiased characterisation of a panel of measures 
assessing cellular and nuclear shape. This panel demonstrated that OIS was associated with 
an overall increased cellular area, whilst this enlarged shape was also more irregular than 
that of the proliferating vector control. These cellular changes were also reflected in the 
nuclear morphology, where OIS was associated with large irregularly shaped nuclei, which 
possessed weak DAPI staining. The morphological alterations that accompany senescence 
induction were some of the first phenotypes identified in senescent cells (Hwang, Yoon and 
Kang, 2009). More recently, this increased size has been mechanistically linked to senescence 
induction through a process of “cytoplasmic dilution” (Neurohr et al., 2019). This is 
corroborated here, by the observed increase in cytoplasmic to nuclear ratio. Together, this 
data demonstrates that HCA is a powerful tool when assessing the induction of a senescence 
phenotype. Whilst not representing a comprehensive characterisation, it allows a reliable 
“first pass” with which to classify senescence induction (section 6.4). Therefore, this was 
used in combination with proliferation data in section 5, in order to determine paracrine 
senescence induction.       
 
Whilst the OIS model represents an expedient method of investigating senescence, RS 
(occurring as a result of telomere attrition) has been positioned as an important contributor 
to ageing (Lee et al., 1998). RS was investigated by culturing adult HMFs to their Hayflick 
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limit, the point at which population doublings are no longer observed. This has previously 
been determined to occur at ~35 PDs, an observation reproduced here. This model takes 
>200 days to produce and is both labour and resource intense. Therefore, these cells were 
considered extremely precious and not used to reproduce characterisation experiments that 
had been conducted previously, apart from a preliminary validation via HCA comparison of 
proliferation and morphology (Thesis:(Tyler, 2016)). Overall, throughout this project, the OIS 
model was used as the primary experimental setting. This is in part due to the relative 
availability of senescent cells within each model, but also due to the exaggerated phenotype 
in OIS. The intended workflow was to develop experimental protocols and validate reagents 
in OIS, then moving into the complimentary RS system. However, OIS was eventually taken 
forward as the sole model of investigation as the project developed (sections 5 and 6). The 
use of a comprehensively characterised RS model would support many of the overall project 
conclusions, as a model that more faithfully recapitulates an ageing phenotype. However, 
this was reprioritised as future, complimentary work (section 6.2). It is important to 
acknowledge that the proliferation profile of comparable HMF samples from different 
biological donors may differ significantly from that investigated here. As such, future work 
would benefit from the investigation of cells from different donors to account for the 
potential heterogeneity in senescence responses. The broader implications of such sources 
of heterogeneity are discussed further in section 6.2. 
 
The SASP is a defining hallmark of senescence induction and has been well characterised in 
OIS. Here, the canonical SASP factor IL-8 was validated by immunoblotting, 
immunofluorescence and ELISA. IL-6 was also investigated in each of these settings but was 
only fully validated by ELISA. Therefore, IL-8 was considered a more reliable marker of the 
OIS SASP and utilised as such in subsequent investigations. Preliminary exploration of the 
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kinetics of OIS induction were also carried out. It has previous been demonstrated that SASP 
composition varies during OIS induction (Hoare et al., 2016). When selecting a protocol for 
EV isolation in section 5, this data was intended to establish a point at which the cells were 
producing the most potent secretome, as this was hypothesised to be a point in which EVs 
may also be produced. However, as the OIS induction schedule was optimised, with 
particular regard to initial seeding densities, the issue of contact inhibition and quiescence 
in the control condition became a more significant priority. Therefore, a conditioning time 
between day four and eight was selected, in line with previous studies (Acosta et al., 2013). 
However, the time-course data here indicates that future work investigating the 
development of the OIS SASP, particularly at later time-points, would be valuable. 
Furthermore, the differences in RS and OIS SASP composition, particularly in terms of IL-8, 
further support the context dependent nature of the SASP, justifying further investigation in 
additional models (section 6.2).               
 
The reversal of replicative senescence via siRNA has previously been established within the 
group (Thesis:(Tyler, 2016)). However, the secretome of reversed HMFs has not previously 
been established. Through supervision of an MSc student, this was explored using a 
previously validated combination of p16+p21 siRNA, with cellular proliferation successfully 
reinstated. Successful knockdown of p16 and p21 mRNA was confirmed by qRT-PCR, 
validating the experimental approach. Finally, SASP production was assessed by both qRT-
PCR and ELISA. qRT-PCR corroborated immunoblotting data, which demonstrated that the 
RS SASP comprised IL-6 but not IL-8. IL-6 expression was also demonstrated to decrease upon 
senescence reversal. Interestingly, IL-1α and IL-1β expression did not decrease with reversal. 
This is intriguing, as it suggests the cells retain a “senescent” secretory profile, although one 
that comprises only certain factors. As IL-1α has been described as an early SASP factor, it 
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may be that cells have been reverted to an early part of the senescence induction process, 
or are re-entering senescence. However, it may also indicate that certain factors are more 
important within the SASP and warrants further investigation. 
 
Overall, this chapter has established two models of senescence in which to study 
extracellular vesicles (EVs). OIS was comprehensively characterised and will form the basis 
of the majority of subsequent experiments. Importantly the OIS SASP was also characterised 
and demonstrated to contain a significant IL-8 component. Whilst a model RS was also 
established, this will serve as a complimentary system to the main OIS focus. Future work 
from this chapter includes further exploration of the kinetics of SASP production (section 6.2) 
and use of siRNA senescence reversal in order to explore the mechanisms behind SASP 









As discussed in section 1.2, extracellular vesicles (EVs) represent a heterogeneous set of lipid 
bound nanoparticles that can be defined based on their size and route of biogenesis. These 
are most commonly broken down into two main groups: microvesicles and exosomes. 
However, the process of practically separating EVs into these distinct populations is hindered 
by the lack of unique, subset specific markers. Consequently, isolation methodologies 
broadly focus on separating EVs based upon physical characteristics, with the most common 
methods using size. However, due to overlapping size profiles, this is imperfect, and cannot 
confidently be considered to produce homogenous vesicle preparations. Therefore, the 
generic term “extracellular vesicle” is employed to reflect this ambiguity. However, each 
particular isolation methodology is usually aimed towards the enrichment of a specific EV 
subtype. Here, the isolation methods employed are done so with the intention of enriching 
for exosomes, but it important to acknowledge that a mixed EV population will in fact be 
produced.    
 
This chapter focusses on the isolation and characterisation of EVs from senescent cells. 
Differential ultracentrifugation (dUC) was initially used to isolate EVs from both the OIS and 
RS senescence models. Nanoparticle-tracking analysis (NTA) was then employed to 
characterise both the size and concentration of the EVs produced. Next, proteomic 
assessment was performed, with the aim of characterising the cargo and composition of 
senescent cell derived EVs.  
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In order to explore the limitations of dUC, size-exclusion chromatography (SEC) was then 
employed as a complimentary isolation technique. This highlighted advantages and 
limitations of both methodologies, whilst a second round of proteomics was performed in 
order to emphasise the advantages of SEC in a senescence setting. This primarily stemmed 
from a greater separation between the soluble and vesicular portions of the senescent 
secretome, allowing more robust characterisation of EV composition to be made. Finally, a 
third round of proteomics was performed in order to confidently profile the changes in EV 
protein content following OIS induction.      
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4.2 Chapter Hypothesis and Aims 
The aim of this chapter was to establish a rigorous protocol for the isolation of extracellular 
vesicles from senescent cells in order to facilitate compositional profiling via mass 
spectrometry (MS). It was hypothesised that differential ultracentrifugation (dUC) 
represents an effective method of EV isolation, albeit one potentially hindered by a lack of 
separation between EVs and co-isolated soluble proteins. Size-exclusion chromatography 
(SEC) was hypothesised to represent a purification method to serve as a useful adjunct to 
dUC. MS was employed as a method of global proteomic profiling in order characterise the 
change in EV composition following senescence induction, as well asses the relative 
suitability of each EV isolation technique.      
 
The aims of this chapter are as follows: 
 To validate that differential ultracentrifugation (dUC) can be used to isolate 
extracellular vesicles (EVs) 
 To isolate extracellular vesicles (EVs) from senescent cells by dUC 
o To validate the presence of canonical EV markers by immunoblotting 
o To assess the change in EV production in senescence by nanoparticle 
tracking analysis (NTA)   
 To isolate EVs from senescent cells by size-exclusion chromatography (SEC) 
o To establish the optimal isolation methodology for the assessment of 
EVs from senescent cells  
 To characterise the cargo and composition of senescent cell derived EVs by mass 




4.3 Establishing a Protocol of EV Isolation via Differential Centrifugation 
4.3.1 Use of Exosome Depleted FBS (ExoFBS) 
Differential ultracentrifugation (dUC) is the most widely applied method for the isolation of 
EVs and was selected as a starting point to generate preparations from senescent cells 
(Figure 4.1) (Gardiner et al., 2016). However, before culture media is conditioned in advance 
of EV isolation, it is important to ensure that there are no vesicles from any other source that 
may contaminate the final preparation. It has previously been demonstrated that foetal 
bovine serum (FBS) represents a potential source of these contaminating vesicles (Tosar et 
al., 2017). This is a complication, as it requires cells to be cultured in either serum free or EV 
depleted media. Following application of the dUC protocol, a high number of EVs were 
confirmed to be present within DMEM supplemented with 10% FBS (DMEM 10%; 4.3E+10 ± 
4.9E+09 Particles/ml; Figure 4.2) in comparison to the serum free control (DMEM 0%; 
1.2E+08 ± 7.2E+07 Particles/ml; Figure 4.2). Extensive attempts to deplete this through 
longer ultracentrifugation procedures (up to 6 hours) were unsuccessful and so strategy 
turned towards use of commercially available products. DMEM supplemented with 10% 
“exosome-depleted FBS” (ExoFBS) was demonstrated to contain a negligible number of 
vesicles (1.8E+08 ± 3.1E+07 Particles/ml; Figure 4.2) compared to standard FBS (4.3E+10 ± 
2.0E+09 Particles/ml; Figure 4.2) and was comparable to the serum free media (DMEM 0%; 
1.2E+08 ± 7.2E+07 Particles/ml; Figure 4.2). Therefore, DMEM supplemented with ExoFBS 
was considered a viable alternative to standard FBS and taken forward for further validation.  
 
A possible alternative to commercially depleted FBS is the use of a chemically defined cell 
culture medium. This was not pursued for three reasons: 1) A lack of established defined 
media for the cells used in both senescence models; 2) The need to move between multiple 
cell types and senescence models; and 3) The extensive characterisation of the RS model 
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with media containing FBS previously. The later of these points was also an important 
consideration when optimising the use of ExoFBS. In particular, there was a concern that 
during the manufacturing process, factors other than EVs may also be depleted. As 
comparisons between proliferating and senescent cells would constitute many subsequent 
experimental objectives, it was important to establish that use of ExoFBS did not stimulate a 
senescence response, particularly in the EP HMFs. To assess this, EP cells were cultured with 
DMEM supplemented with 10% FBS or 10% ExoFBS (Figure 4.3) and incubated for 48 hours. 
No differences were observed in either cell number (10% FBS, 14,963 ± 615; 10% ExoFBS, 
13,482 ± 920; Figure 4.3) or any morphological measure between conditions. Importantly, 
the OIS phenotype was also demonstrated to be robust following culture with ExoFBS 
between days four and eight as described in section 3.3. Whilst not a comprehensive 
assessment of the possible changes in proliferation with ExoFBS in all following experimental 
conditions, the advantage of ExoFBS demonstrated by NTA, combined with an absence of 
growth impairment in the EP HMFs, was considered sufficient to justify the use of ExoFBS as 








Figure 4.1: Schematic of EV Isolation Procedure by Differential Centrifugation (dUC)  
As described in section 1.2.5.2, EVs may be isolated from cell culture medium by differential 
ultracentrifugation (dUC). This facilitates the clearance of large and medium sized EVs (such 
as apoptotic bodies and microvesicles) from the supernatant in earlier steps. A final 100,000 
x g product is then produce, which is enriched for small EVs (such as exosomes) but may 




Figure 4.2: Nanoparticle Tracking Analysis (NTA) of DMEM culture medium containing 
foetal bovine serum (FBS) or exosome-depleted FBS (ExoFBS) 
Extracellular vesicles (EVs) were isolated by differential ultracentrifugation (dUC) from serum 
free media (DMEM 0%), media containing 10% foetal bovine serum (DMEM 10% FBS) and 
media containing a commercial EV depleted FBS (DMEM 10% ExoFBS). These preparations 
were assessed by nanoparticle tracking analysis (NTA) alongside a PBS vehicle control. N=3 
independent experimental replicates (1 technical replicate per experiment). Statistical 




Figure 4.3: Immunofluorescence high content analysis (HCA) of human mammary 
fibroblasts (HMFs) cultured with medium containing foetal bovine serum (FBS) or EV-
depleted FBS (ExoFBS) 
Early proliferating human mammary fibroblasts (HMFs) were cultured for 48 hours in media 
containing 10% foetal bovine serum (10% FBS) or media containing a commercial EV 
depleted FBS (10% ExoFBS) and assessed by HCA. A) Representative immunofluorescence 
images for DAPI (blue) and Cell Mask (red) staining in HMFs. B) HCA morphology measures 
were converted to Z-scores according to the change from the FBS 10% control condition (see 
methods). Positive and negative modulation of each measure is demonstrated by a change 
of at least +/- one Z-score from the FBS 10% condition and indicated as red or blue 
respectively. White indicates no change from the control. N=3 independent experimental 
replicates (2 technical replicates per experiment).  Statistical analysis performed via One-way 
ANOVA with Tukey’s post-hoc test (section 2.17). Scale bars = 200µm. Four fields of view. 
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4.3.2 Assessing the Long Term Stability of EVs 
In order to assess the optimum method for long-term storage of EV preparations, EVs were 
isolated from DMEM supplemented with 10% FBS. These were then aliquoted and stored at 
either 4°C or -80°C. Consistency of both particle concentration and size were then assessed 
by NTA. Measurements were taken at zero days, one week and five weeks post-isolation. No 
concentration changes were observed at zero days (4.3E+10 ± 4.9E+09 Particles/ml; Figure 
4.4A), one week (4°C, 3.92E+10 ± 3.45E+09; -80°C, 4.54E+10 ± 5.08E+09 Particles/ml; Figure 
4.4A) or five weeks (4°C, 4.34E+10 ± 2.09E+09; -80°C, 4.41E+10 ± 6.25E+09 Particles/ml; 
Figure 4.4A). Size differences were also not seen at zero days (88 ± 2.5 nm; Figure 4.4B), one 
week (4°C, 82 ± 4.0; -80°C, 84 ± 5.1 nm; Figure 4.4B) or five weeks (4°C, 87 ± 7.2; -80°C, 81 ± 
1.7 nm; Figure 4.4B). Consequently, it was decided that long-term storage would be 
performed at -80°C as this has been described previously in the literature (Witwer et al., 
2013). It is important to emphasise that this work utilises FBS derived EVs and there is an 
assumption that those from cells will behave in a similar manner. Equally, no analysis of 
freeze-thaw cycles has been made. However, from a logistical perspective the use of freshly 
isolated preparations was not feasible for all experiments. Despite this, the NTA data 
suggests that preparations are reasonably robust and steps were taken to minimise freeze-




Figure 4.4: Nanoparticle Tracking Analysis (NTA) of EVs isolated from foetal bovine serum 
(FBS) and stored at either 4°C or -80°C 
Extracellular vesicles (EVs) were isolated by differential ultracentrifugation (dUC) from 
unconditioned media containing 10% foetal bovine serum and assessed by nanoparticle 
tracking analysis (NTA). Aliquots were stored at either 4°C or -80°C for one and five weeks 
with NTA assessment at these time points. A) NTA particle concentration measurements. B) 
NTA particle size measurements. N=3 independent experimental replicates (1 technical 
replicate per experiment). Statistical analysis performed via One-way ANOVA with Tukey’s 
post-hoc test (section 2.17). 
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4.4 Isolating EVs from Models of Oncogene-Induced and Replicative 
Senescence 
Having established that particles of ~100nm could be isolated from FBS, the dUC protocol 
was then applied to conditioned media from vector control and OIS cells in order to isolate 
EVs. Here, an increase in particle concentration was observed in OIS samples (4.48E+11 ± 
9.57E+09 Particles/ml; Figure 4.5A) compared to those from vector cells (2.13E+11 ± 
2.06E+10 Particles/ml; Figure 4.5A), with the modal sizes also observed at ~100nm (vector, 
85.3 ± 5.3 nm; OIS, 102.5 ± 14.3 nm; Figure 4.5B). This size profile reflects that which would 
be anticipated for a population of EVs enriched for exosomes, supporting previous data that 
suggests senescent cells have an increased rate of EV production (Section 1.3.1). Next, the 
same dUC protocol was applied to conditioned media from early proliferating (EP; P12-13) 
and late passage (LP; P26-29) HMFs. The LP cells have a very slow PD rate but are not 
considered to have reached the point of replicative senescence. However, an observable 
increase in particle concentration (per cell) was identified in the LP derived samples (4630 ± 
969.7 Particles/ml; Figure 4.6A) compared to those from EP cells (603 ± 636.9 Particles/ml; 
Figure 4.6A). Once more, these displayed a modal size broadly consistent with EVs enriched 
for exosomes (EP, 86.27 ± 11.98; DS, 86.33 ± 5.508; Figure 4.6B). This suggests that RS is also 
associated with an increased production of EVs. However, due to the relative expediency of 
the OIS model, coupled with greater availability of senescent cells, it was decided at this point 
to focus on further validation of EV isolation in OIS and return to the RS model at a later point 







Figure 4.5: Nanoparticle Tracking Analysis (NTA) of EVs isolated from vector or oncogene-
induced senescent (OIS) IMR90 fibroblasts by differential centrifugation 
Extracellular vesicles (EVs) were isolated by differential ultracentrifugation (dUC) from vector 
control and OIS IMR90s. Nanoparticle tracking analysis (NTA) was then performed to 
determine A) particle concentration and B) particle size measurements. N=4 independent 
experimental replicates (1 technical replicates per experiment). Statistical analysis 




Figure 4.6: Nanoparticle Tracking Analysis (NTA) of EVs isolated from early or late passage 
human mammary fibroblasts (HMFs) by differential centrifugation 
Extracellular vesicles (EVs) were isolated by differential ultracentrifugation (dUC) from early 
proliferative (EP) and late passage (LP) human mammary fibroblasts (HMFs). Nanoparticle 
tracking analysis (NTA) was then performed to determine A) particle concentration and B) 
particle size measurements. N=3 independent experimental replicates (1 technical replicate 
per experiment). Statistical analysis performed via unpaired Student’s t-test (section 2.17).    
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Much like senescence, there is no universal marker of EVs. This makes it difficult to classify 
preparations as containing exclusively one subclass of vesicle confidently. However, as stated 
above (section 4.1), the dUC protocol is aimed at producing an EV population that is enriched 
for exosomes. Therefore, markers of the exosomal biogenesis pathway may be used to 
identify the presence (if not exclusivity) of exosomes within the final EV pellet. 
Immunoblotting was carried out to determine the presence of the ESCRT I protein TSG101, 
as well as the tetraspanin CD9. Both of these were identified in dUC EV preparations from 
both the vector and OIS cells (Figure 4.7). The blots were loaded with matched particle 
numbers based upon NTA data. However, only TSG101 gave consistent band intensity 
between the proliferating and OIS samples. This may reflect heterogeneity within the 
isolated vesicles, as EVs have previously been described which lack CD9 (Kowal et al., 2016). 
Next, in order to establish that the majority of isolated EVs were derived from an endosomal 
origin, the endoplasmic reticulum (ER) protein calnexin was investigated (Figure 4.7). 
Proteins from non-endosomal organelles are often employed as “negative” exosome 
markers, in order to demonstrate the absence of additional EV subclasses, which are 
proposed to be more susceptible to incorporation of such “contaminating” protein (Théry et 
al., 2018). Interestingly, calnexin was detectable in EV samples from both vector and OIS 
cells, indicating the presence of EVs other than exosomes. However, the most pertinent 
comparison that should be made is that between the relative abundance of calnexin and 
TSG101 within the EV and WCL samples. In the WCL, there is strong expression of calnexin 
with no observable detection of Tsg101 at this exposure. Conversely, in the EV samples, there 
is greater expression of Tsg101 than that seen for calnexin. This suggests that the EV samples 
are enriched for exosomal markers and have lower abundance of non-exosomal protein than 
observed in the WCL. Together with the NTA data, which suggests that the isolated particles 
are ~100nm in diameter, this indicates that the dUC protocol has successfully isolated a 




Figure 4.7: Western blot analysis of EVs and whole cell lysate (WCL) from vector or 
oncogene-induced senescent (OIS) IMR90 fibroblasts by differential centrifugation 
Immunoblot analysis of extracellular vesicles (EV) isolated by differential ultracentrifugation 
(dUC) and whole cell lysate (WCL) from vector and OIS IMR90s for TSG101 and calnexin. CD9 
was investigated in the EV samples only. Each lane contains sample prepared during an 
individual experiment. EV: N=3 independent experimental replicates (1 technical replicate 






4.5 Proteomic Analysis 1: Differential Centrifugation OIS and Vector (EVs) 
Following validation that the dUC protocol isolated EVs, attention turned to characterising 
the overall composition of the vesicles, as well as exploring any changes that occurred with 
the induction of OIS. Proteomic analysis was performed by MS, with an initial proof-of-
principle experiment aimed at understanding the feasibility of characterising the EVs in this 
manner. As such, whilst the starting cell number was consistent, following senescence 
induction, EVs were generated from fewer OIS cells than those from the vector control. 
Equally, given the reported lack of precision associated with NTA as a technique, no attempt 
was made to match for particle numbers as with immunoblotting. Therefore, for clarity, 
more EVs from fewer OIS cells were analysed than from the vector control and, 
unsurprisingly, differential expression was observed between the two conditions (Figure 
4.8A). Overall, 571 proteins were detected in both samples, with increased abundance of 
131 and decreased abundance of 80 in OIS. Importantly, proteins with increased abundance 
included key markers of senescence (HRAS), endosomal biogenesis (PDCD6IP/ALIX) as well 
as the validated tetraspanin CD9. Interestingly, several proteins previously identified in the 
OIS SASP were also identified at increased levels (CXCL8; PLAU; MMP1; MMP14). This 
highlighted the potential that EVs may have the capacity to act as “carriers” or “facilitators” 
of the SASP. However, it also demonstrated the possibility that components of the secretome 
other than EVs may be isolated during the dUC process. Indeed, gene-ontology assessment 
of cellular compartments indicated that of the top 50 most abundantly expressed proteins 
in each condition, a significant portion were associated with either the “extracellular region” 
or “extracellular space” (Figure 4.8B). These terms suggested that there was the potential 
for soluble protein contamination of the final EV pellet, a limitation of dUC that has been 
reported previously (Foers et al., 2018). In a senescence setting, this may represent a 
significant limitation, as the SASP represents a major source of potential soluble 
contamination. Therefore, in order to validate the presence of SASP factors within the EV 
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samples, IL-8 was assessed by ELISA. This clearly demonstrated an increased IL-8 content in 
the OIS EV samples (885.9 ± 128.2pg/ml; Figure 4.9) compared to the vector control (13.63 
± 14.91pg/ml; Figure 4.9). Therefore, it was concluded that this preliminary round of 
proteomic assessment had to be treated with caution, as the identified factors could not 
confidently be designated as either cargo or contaminant. Consequently, attention turned to 
whether an alternative or complimentary isolation method would be more appropriate in a 




Figure 4.8: Volcano Plot and Gene Ontology Cellular Compartment Terms for EV Samples 
Isolated from vector or oncogene-induced senescent (OIS) IMR90 fibroblasts by differential 
centrifugation (dUC) 
Extracellular vesicles (EV) isolated by differential ultracentrifugation (dUC) from vector and 
OIS IMR90s were analysed by mass spectrometry. A) Volcano plot demonstrating Log2 fold 
change (Log2FC) in protein expression between OIS and vector samples. B) Gene ontology 
cellular compartment terms in vector and OIS samples. N=3 independent experimental 




Figure 4.9: IL-8 ELISA analysis for extracellular vesicle (EV) samples isolated from vector or 
oncogene-induced senescent (OIS) IMR90 fibroblasts by differential centrifugation 
Extracellular vesicles (EV) isolated by differential ultracentrifugation (dUC) from vector and 
OIS IMR90s were assessed by ELISA for the senescence-associated secretory phenotype 
(SASP) marker IL-8. N=3 independent experimental replicates (3 technical replicates per 




4.6 Purification of EV Isolation procedure via Size Exclusion Chromatography 
(SEC) 
4.6.1  Assessing EVs Isolated by SEC by NTA and Immunoblotting 
One key advantage of dUC is the ability to concentrate EVs from a large starting volume into 
a small final preparation. Given that dUC had also been established as successfully isolating 
EVs from senescent cells, it was not abandoned as a technique outright. However, as 
described in the previous section, the final dUC preparations required further assessment, 
and possibly further purification. Size-exclusion chromatography (SEC) was selected as a 
complimentary, adjunct technique, as one of the main purported advantages is the 
separation of soluble and vesicular material. Commercially available Izon qEV columns were 
selected, as there is significant literature support for their use (Lobb et al., 2015). The final 
dUC pellet was loaded into these columns and twenty sequential fractions were collected, 
as per the manufacturer’s instructions (Figure 4.10). Previous reports suggest that Fractions 
7-10 (particularly Fraction 8), should contain the vesicles, whilst the later fractions 
(particularly Fraction 20), should contain soluble contaminants. As a starting point, Fraction 
8 was collected from vector control and OIS samples. Particle concentration and size 
measurements were assessed by NTA in the same manner as those from the dUC protocol. 
Whilst modal sizes in both samples remained ~100nm (vector, 92.28 ± 7.667 nm; OIS, 107.2 
± 11.06 nm; Figure 4.11B) the particle yield was impaired, with the OIS sample approximately 
five times lower following SEC (dUC, 4.48E+11 ± 9.57E+09 Particles/ml; SEC, 8.79E+10 ± 
2.11E+10 Particles/ml). Despite this, there was still a significantly higher production of 
particles in the OIS sample (8.79E+10 ± 2.11E+10 Particles/ml; Figure 4.11A) compared to the 
vector control (1.65E+10 ± 8.35E+09 Particles/ml; Figure 4.11A). In order to validate that the 
isolated particles were EVs, immunoblotting was once again performed for TSG101, CD9 and 
calnexin (Figure 4.12). However, due to the lower particle numbers observed by NTA, loading 
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was performed based on the maximum volume of sample that could be added per well, in 
order to increase the probability of observable bands. This decision appears to have been 
prudent, as the particle, concentration in the vector samples was too low for marker 
detection. However, in the OIS samples, clear CD9 expression could be observed, along with 
weaker (but detectable) TSG101 expression. Interestingly calnexin bands could still be 
observed (albeit faintly) and the relative difference to TSG101 expression between EV and 
WCL was maintained. When coupled with the NTA data, it was concluded that the addition 
of SEC to the dUC protocol still allowed the isolation of a population of small EVs enriched 






Figure 4.10: Schematic of EV Isolation Procedure by Size-Exclusion Chromatography  
The differential ultracentrifugation (dUC) protocol employed in section 2.3 was adjusted to 
include a final size-exclusion chromatography step. This involved the loading of the dUC 
product (EVs + co-isolated protein) into a SEC column, from which 20 sequential fractions 
were then collected. Manufacturer’s suggested EVs should be anticipated within Factions 7-




Figure 4.11: Nanoparticle Tracking Analysis (NTA) of EVs isolated from vector or oncogene-
induced senescent (OIS) IMR90 fibroblasts by size-exclusion chromatography  
Extracellular vesicles (EVs) were isolated by size-exclusion chromatography (SEC) from vector 
control and OIS IMR90s. Nanoparticle tracking analysis (NTA) was then performed on 
Fraction 8 samples to determine A) particle concentration and B) particle size 
measurements. N=4 independent experimental replicates (1 technical replicate per 




Figure 4.12: Western blot analysis of EVs and whole cell lysate (WCL) from vector or 
oncogene-induced senescent (OIS) IMR90 fibroblasts by size-exclusion chromatography  
Immunoblot analysis of extracellular vesicle Fraction 8 (EV) isolated by size-exclusion 
chromatography (SEC) and whole cell lysate (WCL) from vector and OIS IMR90s for CD9, 
TSG101 and calnexin. Each lane contains sample prepared during an individual experiment. 
EV: N=3 independent experimental replicates (1 technical replicate per experiment) WCL: 




4.6.2 Further Analysis of All SEC Fractions in Vector and OIS Samples 
In order to further assess SEC as an isolation technique, all fractions from vector and OIS 
samples were assessed for particle concentration by NTA, as well as protein concentration 
by microBCA. In the vector samples (Figure 4.13), there was a small increase in protein 
concentration in Fractions 7-10, which was associated with a modest increase in particle 
concentration, peaking in Fraction 8. In later fractions, there was a steady increase in protein 
concentration between Fractions 15-20. Importantly, this was not associated with an 
increase in particle concentration, with the Fraction 8 particle concentration (7.73E+09 ± 
2.10E+09 Particles/ml; Figure 4.13B) significantly higher than that of Fraction 20 (7.33E+08 ± 
5.92E+08 Particles/ml; Figure 4.13B). In the OIS samples, a similar trend was observed, with 
an overall increased protein and particle concentration in the EV Fractions 7-10 than those 
observed in the vector samples. Once again, whilst protein concentration increased steadily 
between Fractions 15-20, this was not associated with an increase in particle number. As 
such, the particle concentration in OIS Fraction 20 (3.73E+09 ± 1.66E+09 Particles/ml; Figure 
4.14B) was significantly lower than that seen in the in Fraction 8 (4.63E+10 ± 1.76E+10 
Particles/ml; Figure 4.14B). The Fraction 8 concentration is not comparable to that seen in 
Figure 4.11, as a different OIS isolation schedule had been (schedule 2). Overall, analysis of 
all fractions in both the vector and OIS samples indicates that SEC is efficient at separating 
EVs into Fractions 7-10 (with the highest concentration in Fraction 8), whilst soluble, non-EV 
protein, which is co-isolated during the dUC process, is confined to Fractions 15-20. 
Therefore, it become important to explore whether the SASP proteins identified in dUC EV 
samples by MS and ELISA, were associated with the SEC “EV” or “soluble” fractions. 
Consequently, all fractions from the OIS samples were assessed for IL-8 concentration by 
ELISA. A modest peak in IL-8 concentration was observed in Fractions 7-10 (most prominently 
in Fraction 8). However, a far greater IL-8 content was observed in the later fractions, with a 
steady increase between Fractions 15-20. This resulted in a significantly greater IL-8 content 
196 
 
in Fraction 20 (190.1 ± 45.43 Particles/ml; Figure 4.15) than Fraction 8 (36.77 ± 24.47 
Particles/ml; Figure 4.15B). The implication of this finding was that whilst some IL-8 may be 
associated with the EVs, the vast majority could be considered a soluble, contaminating by-
product of the dUC isolation procedure. Therefore, this would represent a major advantage 
of SEC by providing a means of dissecting the vesicular and soluble portions of the senescent 
secretome. However, as the relative loss of yield represented a substantial limitation of SEC, 
it was decided to explore the composition of Fraction 8 and Fraction 20 in more detail, in 






Figure 4.13: microBCA and nanoparticle tracking analysis (NTA) of EV fractions from vector 
IMR90 fibroblasts isolated by size-exclusion chromatography (section 2.8.2)  
Extracellular vesicles (EVs) were isolated by size-exclusion chromatography (SEC) from vector 
control IMR90s. A) Nanoparticle tracking analysis (NTA) was performed on Fractions 6-20 
and microBCA protein concentration measured in Fraction 1-20. B) Comparison of NTA 
concentration data for Fractions 8 and 20. N=3 independent experimental replicates (NTA, 1 
technical replicate per experiment; microBCA, 3 technical replicates per experiment). 




Figure 4.14: microBCA and nanoparticle tracking analysis (NTA) of EV fractions from 
oncogene-induced senescent (OIS) IMR90 fibroblasts isolated by size-exclusion 
chromatography (section 2.8.2) 
Extracellular vesicles (EVs) were isolated by size-exclusion chromatography (SEC) from OIS 
IMR90s. A) Nanoparticle tracking analysis (NTA) was performed on Fractions 6-20 and 
microBCA protein concentration measured in Fraction 1-20. B) Comparison of NTA 
concentration data for Fractions 8 and 20. N=3 independent experimental replicates (NTA, 1 
technical replicate per experiment; microBCA, 3 technical replicates per experiment). 




Figure 4.15: IL-8 ELISA analyses of EV fractions from oncogene-induced senescent (OIS) 
IMR90 fibroblasts isolated by size-exclusion chromatography (section 2.8.2)  
Extracellular vesicles (EVs) were isolated by size-exclusion chromatography (SEC) from OIS 
IMR90s. A) All Fractions 6-20 were assessed by ELISA for the senescence-associated secretory 
phenotype (SASP) component IL-8 B) Comparison of IL-8 concentration data for Fractions 8 
and 20. N=3 independent experimental replicates (3 technical replicates per experiment). 




4.7 Proteomic Analysis 2: Size-Exclusion OIS (Conditioned Media, Fraction 8 and 
Fraction 20) 
Analysis of SEC fractions indicated that, whilst producing a lower overall EV recovery yield 
than dUC, greater separation between the vesicular and soluble secretomes was also 
achieved. Fraction 8 was designated as the primary EV fraction, whilst Fraction 20 was 
designated as representing the co-isolated, soluble contaminating protein. Along with total 
conditioned media samples, these fractions were analysed by MS, in order to further explore 
the relative compositions between sample types, as well as provide justification for use of 
SEC over dUC. Because these samples were fundamentally different, no attempt was made 
to normalise based on protein or particle concentrations. The first, and perhaps most striking 
finding, were the differences in total unique proteins identified within the different samples. 
(Fraction 8, 698; Fraction 20 14; Conditioned Media, 78; Figure 4.16). In order to explore this 
further, GO pathway analysis was performed (Figure 4.17). Cellular compartment terms 
indicated that whilst the CM and Fraction 20 samples had enrichment for EV proteins, they 
also possessed significant representation from the extracellular region and extracellular 
space, i.e. secreted protein. In contrast, Fraction 8 was associated with strong enrichment 
for EVs but also for proteins of the plasma membrane and cytosol. This reinforces the 
concept that Fraction 8 contains small membrane bound vesicles, which include cytoplasmic 
contents derived from the parental cell, validating SEC as an isolation procedure. This was 
supported by protein localisation data from Protein Atlas (Figure 4.18),  which demonstrated 
that proteins considered membrane bound or intracellular were primarily enriched into 
Fraction 8, accounting for the disparity in total unique proteins seen in that fraction. 
Conversely, secreted proteins displayed little enrichment between samples, which was also 
the case for a list of canonical SASP factors identified from (Coppé et al., 2010) (Figure 4.19). 
This highlights the benefits of SEC as an isolation technique, as without it, these secreted 
proteins would be a confounding influence in all subsequent proteomic and functional 
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experiments. Therefore, it was accepted that SEC provided sufficient benefits over dUC to 
accept the loss of yield. Consequently, efforts turned to producing a comprehensive and 
rigorous assessment of the changes in EV composition following OIS induction, by using SEC 





Figure 4.16: Schematic of conditioned media (CM), SEC Fraction 20 and SEC Fraction 8 from 
oncogene-induced senescent (OIS) IMR90 fibroblasts 
Conditioned media (CM), SEC Fraction 20 and SEC Fraction 8 samples from oncogene-
induced senescent (OIS) IMR90 fibroblasts were assessed by mass spectrometry (MS). 
Proteins are identified within each sample type are indicated in the Venn diagram. N=3 




Figure 4.17: Gene ontology cellular compartment terms for conditioned media (CM), SEC 
Fraction 20 and SEC Fraction 8 from oncogene-induced senescent (OIS) IMR90 fibroblasts  
Conditioned media and size-exclusion chromatography (SEC) Fractions 8 and 20 from OIS 
IMR90s were analysed by mass spectrometry. Gene Ontology cellular compartment terms 
were then assessed for all proteins identified in each sample type. N=3 independent 




Figure 4.18: Heat maps showing Protein Atlas localisation data for conditioned media (CM), 
SEC Fraction 20 and SEC Fraction 8 from oncogene-induced senescent (OIS) IMR90s 
Size-exclusion chromatography (SEC) was utilised as a means of EV isolation from OIS IMR90s 
according to the procedure described in section 2.8.2. SEC fractions 8 (EVs) and 20 (co-
isolated protein) were analysed by mass spectrometry, along with conditioned media that 
was not subject to the EV isolation procedure. Protein localisations were then assessed via 
Protein Atlas (www.proteinatlas.org) for all proteins identified in each sample. Proteins were 
defined as either intracellular, membrane or secreted, with proteins able to receive multiple 
designations. For each localisation category, a heat map was produced that displays the 
mean LFQ intensity from three independent experimental replicates per sample for each 
protein. Proteins not identified in a sample appear white. N=3 independent experimental 




Figure 4.19: Canonical SASP Factors (and related) from (Coppé et al., 2010)  
Size-exclusion chromatography (SEC) was utilised as a means of EV isolation from OIS IMR90s 
according to the procedure described in section 2.8.2. SEC fractions 8 (EVs) and 20 (co-
isolated protein) were analysed by mass spectrometry, along with conditioned media that 
was not subject to the EV isolation procedure. Proteins considered canonical SASP markers 
were identified based upon classification in (Coppé et al., 2010). Non-soluble extracellular-
matrix components (collagens, laminins and fibronectin) were omitted. A heat map was 
produced that displays the mean LFQ intensity from three independent experimental 
replicates per sample for each protein. Proteins not identified in a sample appear white. N=3 
independent experimental replicates (1 technical replicate per experiment). N=3 
independent experimental replicates (1 technical replicate per experiment). 
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4.8 Proteomic Analysis 3: Size-Exclusion OIS and Vector (Conditioned Media, 
Fraction 8 and Fraction 20) 
Following the establishment that SEC represented a more appropriate isolation methodology 
than differential centrifugation alone, a final round of proteomic analysis was employed in 
order to compare the conditioned media, Fraction 8 and Fraction 20 from both vector and 
OIS samples. Principal component analysis demonstrated that the different sample types 
were the primary determinant of protein expression. However, in all samples there was also 
distinct separation between the vector and OIS conditions along at least one principal 
component (Figure 4.20). Supporting this, hierarchical clustering analysis demonstrated that 
the soluble samples (CM and Fraction 20) had distinct expression profiles compared to the 
vesicular Fraction 8 samples (Figure 4.21). Here, the vector and OIS conditions also clustered 
separately, with the OIS samples demonstrating higher expression in many proteins. To 
explore this further, mean LFQ intensities were compared between vector and OIS conditions 
within each sample type (Figure 4.22). Differential expression was observed within all 
samples with increased abundance of 298, 144 and 374 proteins in OIS conditioned media, 
Fraction 20 and Fraction 8 respectively (Figure 4.23A). Of these, 256 were unique to Fraction 
8 and GO analysis indicated that these comprised predominantly vesicular, membrane and 
cytosolic proteins (Figure 4.23B). These included the validated EV marker CD9 and the 
previously reported functional senescence cell-derived EV protein EphA2. This profile of 
Fraction 8 is not unexpected, as it would be anticipated to be enriched for EV proteins given 
the higher particle concentration compared to the vector identified by NTA. However, it is 
encouraging that those proteins with uniquely increased abundance in Fraction 8 appear 
predominantly vesicular, as this provides a clear distinction from the soluble Fraction 20 and 
CM. This list of 256 proteins (Appendix 4) represents a rich data set for probing any potential 




Figure 4.20: Principal component analysis (PCA) of conditioned media (CM), SEC Fraction 
20 and SEC Fraction 8 from vector and oncogene-induced senescent (OIS) IMR90 fibroblasts 
Conditioned media and size-exclusion chromatography (SEC) Fractions 8 and 20 from vector 
and OIS IMR90s were analysed by mass spectrometry. Principal component analysis was 
performed using mean LFQ intensity values for each identified protein within each sample. 





Figure 4.21: Hierarchical clustering analysis of conditioned media (CM), SEC Fraction 20 and 
SEC Fraction 8 from vector and oncogene-induced senescent (OIS) IMR90 fibroblasts 
Conditioned media and size-exclusion chromatography (SEC) Fractions 8 and 20 from vector 
and OIS IMR90s were analysed by mass spectrometry. Hierarchical clustering analysis was 
performed using mean LFQ intensity values for each identified protein within each sample. 
Purple block identifies OIS samples and red block vector samples. N=3 independent 






Figure 4.22: Volcano plots of conditioned media (CM), SEC Fraction 20 and SEC Fraction 8 
from vector and oncogene-induced senescent (OIS) IMR90 fibroblasts  
Conditioned media and size-exclusion chromatography (SEC) Fractions 8 and 20 from vector 
and OIS IMR90s were analysed by mass spectrometry. Volcano plots demonstrating Log2 fold 
change (Log2FC) in protein expression between OIS and vector conditions for each sample 
type were then prepared and the number of proteins present at increased levels highlighted. 




Figure 4.23: Schematic showing number of proteins with increased abundance in 
conditioned media (CM), SEC Fraction 20 and SEC Fraction 8 from oncogene-induced 
senescent (OIS) IMR90 fibroblasts and GO terms for those unique to OIS Fraction 8.   
Conditioned media (CM), SEC Fraction 20 and SEC Fraction 8 samples from oncogene-
induced senescent (OIS) and vector control IMR90 fibroblasts were assessed by mass 
spectrometry (MS). A) Proteins with increased abundance in OIS conditions were then 
identified (figure 4.22) within each sample type and are indicated in the Venn diagram. B) 
Gene Ontology cellular compartment terms were then assessed for proteins unique to OIS 
Fraction 8. N=3 independent experimental replicates (1 technical replicate per experiment).  
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4.9 Summary  
EV research represents a burgeoning field, in which no single isolation technique or 
characterisation methodology has emerged as a universal gold standard. This is in part due 
to the ubiquity of EVs, which have been isolated and studied from a plethora of biological 
fluids and cell types, each of which require application of a context specific approach. 
Furthermore, the small size and lack of subset specific markers represent technical 
challenges that have hindered EV research, leading to attempts to achieve consensus and 
reporting standardisation (Lotvall et al., 2014). However, this remains an issue within the 
field and in a senescence setting, a diverse set of isolation methodologies, characterisation 
methods and senescence models have been employed (Wallis, Mizen and Bishop, 2020). 
Therefore, it was important to establish that the isolation methodologies selected were 
appropriate and robust. 
 
In this chapter, the process of setting up a rigorous workflow for EV isolation and 
characterisation from senescent cells has been described. This required numerous technical 
challenges to be overcome, simply to confidently isolate a population of EVs. Firstly, a 
solution was found to the issue of contaminating bovine EVs from FBS. Several alternatives 
were considered, but the use of a commercial “exosome” depleted FBS (ExoFBS) was 
demonstrated to produce negligible bovine EV contamination, whilst not compromising EP 
cellular proliferation. This was specifically aligned to the current isolation time-line, which 
subsequently underwent further optimisation. However, as the use of ExoFBS allowed 
interchange between multiple models of senescence, a balance between EV depletion, 
proliferation maintenance and logistical practicality justified its use. Similarly, investigations 
into the most appropriate storage conditions were made under the assumption that FBS 
derived EVs would behave in a similar manner to those from cultured cells. The decision to 
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store at -80°C was made by weighing the lack of experimentally observed degradation with 
literature recommended best practice. As with use of ExoFBS, this had to be considered 
alongside the practicality of working in multiple models of senescence. Therefore, whilst not 
conclusive, these initial experiments provided confidence that EV preparations could be 
produced which were free from contaminating bovine EVs and which could be stored long 
term without compromising integrity. 
 
Having established these fundamentals, dUC was then used to isolate EVs from both the OIS 
and HMFs models. In both cases, the number of EVs produced increased in the senescent 
population (although the HMFs had yet to reach the point RS). This finding supports previous 
literature reports of EV production increasing in senescence (section 1.3.1). At this point, 
given the expediency of the OIS model, the decision was made to focus on EV isolation in 
OIS. This model was considered more appropriate for isolation methodology development, 
given the relative availability of senescent cells. As the project developed, the OIS model 
continued to facilitate research questions and the RS model was not explored further. 
However, given the context dependent nature of the SASP, recapitulating work in RS would 
support the conclusions drawn. Therefore, this has been included as a suggestion for follow 
up investigations (section 6.2).    
 
Immunoblotting supported NTA data in validating that the dUC protocol isolated a 
population of EVs enriched for exosomes. MS was then applied in order to characterise the 
change in EV composition with the induction of OIS. One initial hypothesis was that EVs could 
act as “carriers” of SASP factors and potentially facilitate paracrine senescence. Therefore, 
the observation of multiple SASP factors within the more abundant proteins in OIS was 
encouraging. However, given the reported limitation of dUC in co-isolating soluble protein, 
213 
 
these could not be considered a true “cargo”. So far, achieving the maximum yield of isolated 
EVs had been a priority, as the required thresholds for each analysis technique had not been 
established. However, as these appeared robust, the purity of the isolated EV preparations 
began to take precedence and the use of PBS washes was initially considered as a purification 
step. However, whilst this may have diluted contamination due to relative centrifugation 
efficiencies, the potential for factors that had co-isolated once to do so again was considered 
too high (Coumans et al., 2017). Therefore, SEC was selected as a complimentary technique.    
 
Initial characterisation of Fraction 8 indicated that, whilst successfully able to isolate EVs, SEC 
was associated with a significant loss of yield. However, when all fractions were analysed, 
the potential advantages of SEC became evident. NTA and protein analysis indicated that a 
clear distinction could be made between fractions containing EVs and those containing the 
co-isolated soluble contaminating protein. This was further highlighted by the observation 
that the vast majority of IL-8 that had been associated with EV preparations generated by 
dUC was likely to constitute a contaminant rather than a cargo, as this was now primarily 
associated with the later SEC fractions. This made a compelling case for the use of SEC, as 
the SASP represented a potent source of potential contamination if dUC was employed 
alone. However, in order justify the compromised recovery yield a second round of MS was 
performed. 
 
This second round of MS compared the CM, Fraction 8 and Fraction 20 from the OIS cells, in 
order to identify the relative composition of each sample type. Because this exercise 
compared fundamentally different samples, it was felt that normalising for protein or particle 
concentration would not be appropriate. As such, all proteins detected were included in the 
analysis, as opposed to only those that appeared in both samples, as in MS1. This highlighted 
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that there were many more proteins within the Fraction 8 samples, suggesting a more 
complex composition. GO analysis of the cellular compartments indicated that the CM and 
Fraction 20 samples were predominantly extracellular (i.e. secreted) whilst Fraction 8 
contained enrichment for both membrane and cytosolic proteins. This was supported by 
localisation data from a second source (Protein Atlas), which indicated that secreted proteins 
were present across all samples, whereas membrane and intracellular proteins were 
enriched in Fraction 8. Overall, the MS analysis supported the previous data. Fraction 8 
contained membrane bound vesicles that in turn contained cytosolic proteins. SEC allowed 
these to be separated from the predominantly soluble content of the conditioned media that 
is confined to Fraction 20. This major benefit of SEC was considered to outweigh the loss of 
yield when selecting the most appropriate isolation technique. Therefore, a final round of 
MS was performed to more accurately profile the change in EV composition with the 
induction of OIS.    
 
MS3 was intended to represent a comprehensive characterisation of the change in EV 
composition with the onset of OIS, taking into account the considerations of isolation 
methodology discussed above. For completeness, the total CM, Fraction 8 and Fraction 20 
was analysed from both vector and OIS cells. Principal component and hierarchical clustering 
analysis demonstrated that samples clustered according to sample type, with the soluble 
samples clustering away from the vesicular Fraction 8. Within the Fraction 8 clusters, 
distinction between the proliferating and senescent conditions could be made, emphasising 
that EVs are a reflection of their parental cell. In all samples, OIS was associated with 
differential protein expression, with proteins of increased abundance in each condition. Of 
these, 256 were uniquely present at increased levels in the OIS Fraction 8, representing the 
proteins most distinctly “vesicular” and thus of functional interest to the pursuit of 
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senescence cell derived EV mediated paracrine signalling. Interestingly, these included the 
EV marker CD9 and the previously reported senescence-associated functional EV cargo 
EphA2 (Takasugi et al., 2017). In combination with the findings of MS2, MS3 facilitated the 
identification of functional leads for further mechanistic exploration. These are described in 
section 5.6 and further discussed in section 6.3. 
 
Overall, this chapter highlights the technical challenges involved in the isolation and 
characterisation of EVs, as well as the particular considerations that are involved when 
bringing this into a senescence setting. dUC was demonstrated to be efficient at isolating EVs 
from the conditioned media of senescent cells, but limited through the co-isolation of 
secreted proteins. SEC provided a complimentary purification technique, which allowed 
separation of the soluble and vesicular components of the senescent secretome. This 
facilitated the characterisation of changes in EV cargo following the onset of senescence, 





5 Results 3: Characterising the Role of Small Extracellular 
Vesicles to the Paracrine Signalling of the SASP 
5.1 Introduction  
One of the defining characteristics of senescence is the acquisition of an enhanced 
secretome – the SASP. As discussed above (sections 1.1.4), the composition of the SASP is 
dependent on both the cell type and specific trigger of senescence. The SASP has also been 
described as having a “bright” and “dark” side, with beneficial or detrimental effects based 
upon the specific cell context (Campisi and D’Adda Di Fagagna, 2007). Furthermore, the SASP 
can act paradoxically, having contradictory effects depending on the setting (for example 
being both pro- and anti-tumorigenic). Perhaps the most widely described role of the SASP 
is the process of paracrine senescence, the ability to confer senescence on proliferating cells 
in the local microenvironment. In this chapter, the contribution of EVs to the phenomenon 
of paracrine senescence is assessed in both IMR90 fibroblasts and MDA-MB-468 basal-like 
breast cancer cells (468s). 
 
Initially, the SASP was investigated through conditioned media investigations, in order to 
establish the functional effect of the total senescence secretome. Next, building on the 
principles established in chapter 4, EV preparations isolated by SEC were used to investigate 
the specific contribution of EVs to the signalling of the SASP. Finally, preliminary 
investigations are carried out, with the aim of identifying pathways that may be functionally 




5.2 Chapter Hypothesis and Aims 
The aim of this chapter was to characterise the contribution of EVs to the signalling 
properties of the SASP. It was hypothesised that EVs represent discrete mediators of 
paracrine senescence, capable of inducing a secondary senescence response independent 
from that of the soluble SASP. This was investigated by first benchmarking the OIS paracrine 
senescence response through conditioned media investigations. EV treatment experiments 
were then performed with senescence induction characterised by high content analysis 
(HCA). Potential mechanistic targets were selected according to the proteomic profiling in 
Results 2, with the NOTCH1 and ADAM10/17 pathways hypothesised to be potential routes 
of EV mediated paracrine senescence.  
 
The aims of this chapter are as follows: 
 To characterise the paracrine senescence effect of the entire senescence 
secretome  
o To validate previously reported OIS paracrine senescence response 
through conditioned media investigations 
o To replicate paracrine senescence effect in a model of RS  
o To investigate the effect of OIS SASP on MDA-MB-468 basal-like breast 
cancer cells  
 
 To characterise the contribution of EVs to the paracrine senescence effects of 
the SASP 
o To implement principles of SEC established in chapter 4 to explore the 
specific role of OIS cell derived EVs  
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 To explore potentially functional routes through which EVs may contribute to 
the paracrine senescence effects of the SASP  
o Investigate functional relevance of targets identified through proteomic 





5.3 Assessing the Paracrine Effects of the OIS SASP 
The paracrine senescence effect of conditioned media from OIS IMR90s has been reported 
previously (Acosta et al., 2013). It was important to reproduce this effect in order to provide 
a benchmark against which other paracrine senescence experiments could be assessed. 
Media was conditioned with OIS or vector control cells between day four and day eight, at 
which point it was collected, centrifuged at 2000 x g and supplemented with additional FBS 
and L-glutamine to ensure these would not be limiting (section 2.15). Vector control IMR90 
fibroblasts were treated with this conditioned media (CM) one and four days post-seeding. 
The OIS CM produced a reduction in cell number compared to that from the vector cells 
(vector, 4504 ± 224.3; OIS, 1652 ± 73.2; Figure 5.1). This was accompanied by senescence-
associated changes in a panel of morphological measures assessed by HCA, previously 
established in section 3.3. Taken together, this indicates that a paracrine senescence 
response from OIS CM was successfully produced. 
 
The functional role of the SASP is highly context dependent and has been demonstrated to 
produce a variety of often-contradictory effects. This is particularly the case in cancer, where 
the SASP has been demonstrated to be both pro and anti-tumorigenic (Rao and Jackson, 
2016; Saleh et al., 2018). Therefore, the effect of the OIS CM in MDA-MB-468 basal-like 
breast cancer cells was investigated. These p16 positive cells have previously been 
extensively investigated within the lab, with a particular emphasis on the induction of 
senescence and phenotypic assessment using HCA morphological measures 
(Preprint:(Moore et al., 2018)). The 468s are maintained in a different media to that used for 
the fibroblasts and so an alternative dosing regime was used. Rather than culture entirely in 
CM, 10µl conditioned fibroblast media was added per well, with standard 468 media making 
up the remaining volume. Here, it was identified that the OIS CM produced a reduction in 
220 
 
cellular proliferation compared to the vector control, demonstrated by a reduction in cell 
number (vector, 10606 ± 923.3; OIS, 7237 ± 593.2; Figure 5.2). Importantly, this was 
accompanied by potent morphological changes similar to those achieved by senescence 
induction through other means (Preprint:(Moore et al., 2018)). Interestingly, the vector CM 
produced an increase in cellular proliferation compared to the unconditioned control media 
(8749 ± 378.7; Figure 5.2) and there was no difference between this control and the OIS. This 
may reflect heterogeneity within the SASP, with individual factors producing contradictory 
effects. However, the clear differences in response between vector and OIS CM indicates 





Figure 5.1: Immunofluorescence high-content analysis (HCA) of IMR90 fibroblasts treated 
with conditioned media from vector or oncogene-induced senescent (OIS) IMR90s  
Vector IMR90 cells were treated with conditioned media (CM) collected from vector or OIS 
IMR90s and assessed by HCA. A) Representative immunofluorescence images for DAPI (blue) 
and Cell Mask (red) staining. B) Quantitation of HCA cell number. C) HCA morphology 
measures were converted to Z-scores according to the change from the vector control 
condition (see methods). Positive and negative modulation of each measure is demonstrated 
by a change of at least +/- one Z-score from the vector condition and indicated as red or blue 
respectively. White indicates no change from the control. N=3 independent experimental 
replicates (4 technical replicates per experiment). Statistical analysis performed via One-way 




Figure 5.2: Immunofluorescence high-content analysis of MDA-MB-468 basal-like breast 
cancer cells treated with conditioned media from vector or oncogene-induced senescent 
(OIS) IMR90s  
MDA-MB-468 cells were treated with conditioned media (CM) collected from vector or OIS 
IMR90s and assessed by HCA. A) Representative immunofluorescence images for DAPI (blue) 
and Cell Mask (red) staining. B) Quantitation of HCA cell number. C) HCA morphology 
measures were converted to Z-scores according to the change from the vector control 
condition (see methods). Positive and negative modulation of each measure is demonstrated 
by a change of at least +/- one Z-score from the vector condition and indicated as red or blue 
respectively. White indicates no change from the control. N=3 independent experimental 
replicates (4 technical replicates per experiment). Statistical analysis performed via One-way 
ANOVA with Tukey’s post-hoc test (section 2.17). Scale bars = 500µm. Four fields of view. 
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5.4 Assessing the Paracrine Effects of the RS SASP 
Having established that the OIS CM produced a potent paracrine senescence response, the 
RS model was then investigated. As previously, CM was collected from EP or DS cells, albeit 
here for 72 hours. This time-point was selected before the OIS experiment had been fully 
optimised and it would be an improvement to repeat this with a 96 hour conditioning time-
point to allow for more accurate comparison. The CM was centrifuged at 2000 x g and 
supplements added. It is important to note that inter-experimental variability hindered 
statistical assessment, as final control cell numbers were variable. Therefore, proliferation 
data has been assessed using a block ANOVA (equivalent to a two-way ANOVA with 
experiment and treatment as factors) as described in (Lew, 2007). EP HMFs were then 
treated at day one and four post seeding and subsequently fixed on day six. The DS CM was 
demonstrated to produce a reduction in cell number compared to the EP CM (EP, 8110 ± 
2742; DS, 5693 ± 1414; Figure 5.3). This was accompanied by modest changes in several 
components of the morphological panel. However, the effect of the RS media appeared less 
potent than that seen previously in the OIS investigations, which may be attributed to the 
reduced conditioning time. As with the EV investigations in section 4, in terms of workflow, 
the OIS model was prioritised in order to establish investigatory frameworks into which the 





Figure 5.3: Immunofluorescence high-content analysis of proliferating human mammary 
fibroblasts (HMFs) treated with conditioned media from early proliferative (EP) or deeply 
senescent (DS) HMFs  
Early proliferative (EP) human mammary fibroblasts were treated with conditioned media 
(CM) collected from EP or deeply senescent (DS) HMFs and assessed by HCA. A) 
Representative immunofluorescence images for DAPI (blue) and Cell Mask (red) staining. B) 
Quantitation of HCA cell number for Control (black), EP (red) and DS (green). C) HCA 
morphology measures were converted to Z-scores according to the change from the EP 
control condition (see methods). Positive and negative modulation of each measure is 
demonstrated by a change of at least +/- one Z-score from the EP condition and indicated as 
red or blue respectively. White indicates no change from the control. N=3 independent 
experimental replicates (4 technical replicates per experiment). Statistical analysis 
performed via Block ANOVA (equivalent to a two-way ANOVA with experiment and 
treatment as factors). Scale bars = 500µm. Four fields of view. 
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5.5 Assessing the Paracrine Effect of OIS EVs  
Having established that the SASP from OIS cells produced a paracrine senescence response 
in both proliferating IMR90 fibroblasts and MDA-MB-468 cancer cells, the contribution of 
EVs to these effects was investigated. First, EVs were isolated using SEC, as this had been 
established to be crucial in dissecting the soluble and vesicular secretomes. 10µl treatments 
from PBS vehicle, vector Fraction 8, OIS Fraction 8 and OIS Fraction 20 were then 
administered to vector IMR90s on day one and four post seeding. It was demonstrated that 
whilst neither vector Fraction 8 or OIS Fraction 20 produced a change in cellular proliferation, 
OIS Fraction 8 produced a reduction in cell number compared to all other samples (Control, 
3841 ± 112.7; Vector Fraction 8, 3683 ± 406.7; OIS Fraction 20, 3917 ± 168.6; OIS Fraction 8, 
2805 ± 21.81; Figure 5.4). Importantly, this was accompanied by characteristic changes in 
cellular morphology, albeit notably less dramatic than those seen in previous investigations. 
Interestingly, OIS Fraction 20 appeared to be slightly pro-proliferative, causing inverse 
morphological changes to those typically seen with senescence induction. It is important to 
note that the vector Fraction 8 contains fewer EVs than the OIS Fraction 8 and so the 
observable differences may be driven by the “dose” of EV as opposed to a specific functional 
cargo. However, the differences in OIS Fractions 8 and 20 again emphasise the advantages 
of SEC as an isolation methodology.  
 
Next, the same treatments were investigated in the 468 cancer cells. As in the RS CM 
investigation, inter-experimental variability necessitated use of block ANOVA analysis (Lew, 
2007). With this caveat in mind, the OIS Fraction 8 reduced proliferation in comparison to 
the OIS Fraction 20 (OIS Fraction 8, 8567 ± 1482; OIS Fraction 20, 10569 ± 1847; Figure 5.5). 
Contrasting the IMR90 experiments, both OIS Fraction 20 and Fraction 8 produced 
morphological changes indicative of senescence, albeit more potently in Fraction 8. 
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However, OIS Fraction 20 once again produced a slight pro-proliferative effect compared to 
the PBS vehicle (9717 ± 1165; Figure 5.5). Ideally, this work would be repeated to produce 
replicates with more consistent final cell numbers in the control condition, thus allowing use 
of more standard statistical analysis. However, treatment with SEC fractions demonstrates a 










Figure 5.4: Immunofluorescence high-content analysis of IMR90 fibroblasts treated with 
EVs from vector or oncogene-induced senescent (OIS) IMR90s  
Vector IMR90 cells were treated with size-exclusion chromatography (SEC) Fraction 8 or 
Fraction 20 collected from vector or OIS IMR90s and assessed by HCA. A) Representative 
immunofluorescence images for DAPI (blue) and Cell Mask (red) staining. B) Quantitation of 
HCA cell number. C) HCA morphology measures were converted to Z-scores according to the 
change from the vector control condition (see methods). Positive and negative modulation 
of each measure is demonstrated by a change of at least +/- one Z-score from the vector 
condition and indicated as red or blue respectively. White indicates no change from the 
control. N=3 independent experimental replicates (4 technical replicates per experiment). 
Statistical analysis performed via One-way ANOVA with Tukey’s post-hoc test (section 2.17). 




Figure 5.5: Immunofluorescence high-content analysis of MDA-MB-468 basal-like breast 
cancer cells treated with EVs from vector or oncogene-induced senescent (OIS) IMR90s  
MDA-MB-468 cells were treated with size-exclusion chromatography (SEC) Fraction 8 or 
Fraction 20 collected from vector or OIS IMR90s and assessed by HCA. A) Representative 
immunofluorescence images for DAPI (blue) and Cell Mask (Red) staining. B) Quantitation of 
HCA cell number. C) HCA morphology measures were converted to Z-scores according to the 
change from the vector control condition (see methods). Positive and negative modulation 
of each measure is demonstrated by a change of at least +/- one Z-score from the vector 
condition and indicated as red or blue respectively. White indicates no change from the 
control. N=3 independent experimental replicates (4 technical replicates per experiment). 
Statistical analysis performed via Block ANOVA (equivalent to a two-way ANOVA with 
experiment and treatment as factors) (section 2.17). Scale bars = 500µm. Four fields of view. 
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5.6 Investigating Mechanistic Lead Candidates 
Having established that OIS derived EVs could contribute to the paracrine senescence effects 
of the SASP, attention turned to exploring this on a mechanistic level. Importantly, 
understanding whether EVs act through a distinct mechanism from canonical soluble 
paracrine senescence was a key objective. Candidate pathways were selected by identifying 
leads from the proteomic assessments that also had a level of literature support for a feasible 
contribution to secondary senescence. PANTHER DB pathway analysis initially identified 
NOTCH1 signalling constituents within the OIS F8 EVs in MS2, including both the NOTCH1 
receptor and the sheddase ADAM17. Importantly, both NOTCH1 and ADAM17 are 
membrane proteins, which were considered to represent a major compositional distinction 
of EVs from soluble factors (as emphasised in MS3 – section 4.8). NOTCH1 has recently been 
implicated in the induction of senescence in several ways. A juxtacrine senescence effect 
may be induced in proliferating cells through the display of NOTCH1 ligands on the surface 
of neighbouring senescent cells (section 1.1.7). These include DLL4 and JAG1, both of which 
were identified in the OIS Fraction 8 during the second round of proteomics (MS2). Secondly, 
ectopic expression of the cleaved intracellular NOTCH1 domain N1ICD, leads to induction of 
a senescence phenotype. As NOTCH1 was identified in the OIS F8 in both the second and 
third rounds of MS, the potential for transfer of NOTCH1 to recipient cells was of interest. 
Finally, the kinetics of NOTCH1 in OIS have not been fully elucidated. NOTCH1 expression 
increases in OIS up to day eight. However, expression of the functional cleaved intracellular 
domain is lost from day four. It was hypothesised that this crucial signalling domain could be 
packaged and released as an EV cargo, with potential for NOTCH1 induced responses in 
recipient cells. Overall, several canonical members of NOTCH signalling pathways were 
identified in the OIS EVs and, supported by a literature rationale, were pursued as a potential 




Figure 5.6: Heat Map Demonstrating Expression of NOTCH Pathway Associated Proteins in 
conditioned media, OIS SEC Fractions 20 and 8 
Conditioned media and size-exclusion chromatography (SEC) Fractions 8 and 20 from OIS 
IMR90s were analysed by mass spectrometry. Genes related to NOTCH signalling pathways 
were identified by PANTHER DB pathway analysis. N=3 independent experimental replicates 




PANTHER DB pathway analysis of OIS F8 in MS2 identified numerous components of the 
NOTCH1 signalling pathway (described above). This included ADAM17, an important 
initiating enzyme in the NOTCH1 signalling cascade, mediating the cleavage and 
disengagement of NOTCH1 and its ligand following binding (section 1.1.7 – Figure 1.6). The 
presence of ADAM17 in OIS derived EVs led exploration of other ADAMs including the closely 
related family member ADAM10, which was strongly represented in all three rounds of MS, 
along with several other proteins associated with sheddase activity (Figure 5.7). ADAM10 has 
also previously been identified as a potential marker of EVs (Kowal et al., 2016). However, 
there is has been limited research into the role of sheddases in a senescence setting. The 
role of shed ectodomains from the surface of senescent cells has also received relatively little 
research attention, although they have been described as components within the SASP 
(Coppe et al., 2008). The potential identification of ADAMs within the composition of OIS EVs 
led to a broader consideration of the make-up of the senescence secretome. It was 
hypothesised that composition of the SASP could be broken down into three distinct parts: 
secreted soluble protein (secretome), secreted EVs (vesiculome) and shed ectodomains 
(sheddome). Of these, few studies have been conducted that focus on the functional 
contribution of these shed factors to the SASP. Furthermore, the presence of numerous 
ectodomains on the EV surface were hypothesised to represent a potential “reservoir” of 
these ectodomains, which could be mobilised by ADAMs on the EV. Therefore, the 
contribution of ADAM sheddases to both the composition of the SASP and the function of 






Figure 5.7: Heat Map Demonstrating Expression of ADAM10/17 Sheddase Pathway 
Associated Proteins in conditioned media, OIS SEC Fractions 20 and 8 
Conditioned media and size-exclusion chromatography (SEC) Fractions 8 and 20 from OIS 
IMR90s were analysed by mass spectrometry. Genes related to ADAM10/17 sheddase 
pathways signalling pathways were identified. N=3 independent experimental replicates (1 





In order to investigate the potential for an EV mediated NOTCH1 driven signalling pathway, 
it was important to establish the presence of NOTCH1 in both the parental cell and the 
isolated EVs. This was carried out by immunoblotting, firstly in the WCL (Figure 5.9). It was 
established that NOTCH1 was present in both the vector and OIS cells. Interestingly, the 
cleaved intracellular domain N1ICD was detected in both vector and OIS WCL. This disputes 
previous reports in the literature, which have suggested that N1ICD expression is no longer 
present at day eight in OIS. It is important to note that whilst these western blots were 
loaded with the same amount of protein, they were intended as antibody validation blots 
and a loading control was not included. Therefore, despite indicating that NOTCH1 
expression increases in OIS, that conclusion cannot be confidently supported based on these 
blots.     
 
The presence of NOTCH1 was then assessed in SEC Fraction 8 samples form vector and OIS 
cells. As described in section 4, vector Fraction 8 contained insufficient vesicles to observe 
expression of the EV marker CD9. By contrast, CD9 was clearly expressed in the OIS EVs, as 
was NOTCH1 (Figure 5.10). The NOTCH1 antibody recognises both the full-length protein 
(300 kDa) as well as a “transmembrane” section (short transmembrane domain + 
intracellular domain; 120 kDa) both of which were observed in the OIS EVs (Figure 5.8). 
Attempts to detect the cleaved N1ICD protein in EVs via western blot were unsuccessful and 
it would represent useful follow up work to utilise increased amounts of EV protein and a 
form of loading control to more thoroughly explore this potential cargo. Therefore, this data 
indicated that NOTCH1 expression was present in the OIS cells and derived EVs, at least in 






Figure 5.8: Schematic indicating epitopes detected by NOTCH1 and N1ICD Antibodies  
The NOTCH1 antibody (4147, Cell Signalling UK) recognises both the full-length NOTCH1 
protein (300 kDa) and a “transmembrane” section comprising a short transmembrane 
domain and the NOTCH1 intracellular domain (120Kda). The N1ICD antibody exclusively 




Figure 5.9: Western blot analysis of whole cell lysate (WCL) from vector or oncogene-
induced senescent (OIS) IMR90 fibroblasts for Notch1 and cleaved NOTCH1 intracellular 
domain (N1ICD) 
Immunoblot analysis of whole cell lysate (WCL) from vector and OIS IMR90s for NOTCH1 full 
length (FL), NOTCH1 transmembrane domain (TMD) and NOTCH1 intracellular domain 





Figure 5.10: Western blot analysis of EVs from vector or oncogene-induced senescent (OIS) 
IMR90 fibroblasts for Notch1 and CD9 
Immunoblot analysis of size-exclusion chromatography (SEC) Fraction 8 (EV) from vector and 
OIS IMR90s for NOTCH1 full length (FL), NOTCH1 transmembrane domain (TMD) and CD9. 

















Mirroring the validation of NOTCH1 expression in OIS WCL and EVs, immunoblotting was also 
performed for ADAM10 and ADAM17. ADAM10 expression was observed in the WCL from 
OIS samples (Figure 5.11). Once again, direct comparisons to the vector WCL are difficult as 
loading based on cell number was also being investigated using these blots. Therefore, Lamin 
B1 was used as a loading control as it has previously been demonstrated to decrease in 
senescence and can thus serve as a proof of principle for demonstrating that lanes have not 
been overloaded (section 2.12). However, the anticipated decrease in Lamin B1 was not 
observed (possibly due to the day eight time point) and, as such, additional data is needed, 
with more conventional loading controls, to determine the change in ADAM10 expression 
with senescence. Next, OIS EV samples isolated by both dUC and SEC were assessed, with 
ADAM10 expression detected in both cases (Figure 5.12). Interestingly, ADAM10 expression 
was also observed in vector EV samples isolated by dUC, once again highlighting the loss of 
yield with SEC. Intriguingly, the observed band height in the WCL samples were at 90kDa, 
whilst in the EV samples were at 68kDa. The manufacturer’s website indicated that the 
90kDa band represented the pro- form of ADAM10, whilst the 68kDa band represented the 
active cleaved form. Therefore, this data indicates that ADAM10 is present in EVs from OIS 
cells but possibly predominantly in its active form.  
 
ADAM17 was then assessed in Fraction 8 EVs and WCL from OIS and vector samples (Figure 
5.13). Once again, this was observed in a pro- form in WCL samples from both vector and OIS 
cells. In the EVs, this was also seen in the OIS samples but the active form of ADAM17 
appeared to be more extensively expressed. Overall, this data indicates that both ADAM10 





Figure 5.11: Western blot analysis of whole cell lysate (WCL) from vector or oncogene-
induced senescent (OIS) IMR90 fibroblasts for ADAM10 and Lamin B1 
Immunoblot analysis of whole cell lysate (WCL) from vector and OIS IMR90s for ADAM10 (P, 
precursor) and Lamin B1 as a loading control. Each lane contains sample prepared during an 





Figure 5.12: Western blot analysis of EVs from vector or oncogene-induced senescent (OIS) 
IMR90 fibroblasts for ADAM10 
Immunoblot analysis of extracellular vesicles (EVs) isolated by size-exclusion 
chromatography (SEC) and differential ultracentrifugation (dUC) from vector and OIS IMR90s 
for ADAM10 (A, active). Each lane contains sample prepared during an individual experiment. 





Figure 5.13: Western blot analysis of EVs from vector or oncogene-induced senescent (OIS) 
IMR90 fibroblasts for ADAM17 
Immunoblot analysis of size-exclusion chromatography (SEC) Fraction 8 (EV) and whole cell 
lysate (WCL) from vector and OIS IMR90s for ADAM17 (P, precursor; A, active). Each lane 




Having established that both NOTCH1 and ADAM10/17 were present in both the OIS cells 
and the derived EVs, the functional relevance of the pathways was then pursued. A 
preliminary experiment was carried out which investigated the effect of perturbing these 
pathways in cells from which conditioned media was then collected. This would allow 
assessment of the relative contribution of each pathway to the production of the SASP. 
DAPT, a γ-secretase inhibitor, was used to attenuate cleavage of the N1ICD domain and thus 
inhibit the NOTCH1 pathway. TMI005 was selected with the intention of inhibiting ADAM17, 
although it must be acknowledged that this compound also been reported to have an 
inhibitory effect on MMPs (Shu et al., 2011; Richards et al., 2012). Whilst DAPT appeared to 
have little effect on either vector or OIS CM, the TMI005 appeared to rescue the paracrine 
senescence effect of the OIS media. This was demonstrated through an observed increase in 
cell number (vector DMSO, 14407; vector TMI005,13435; OIS DMSO, 8831; OIS TMI005, 
12114) with alterations in cell area (vector DMSO, 324.1 µm2; vector TMI005,329.7 µm2; OIS 
DMSO, 587.8 µm2; OIS TMI005, 411.9 µm2), nuclear area (vector DMSO, 142.4 µm2; vector 
TMI005,141.5 µm2; OIS DMSO, 200.3 µm2; OIS TMI005, 164.7 µm2), cytoplasmic/nuclear 
ratio (vector DMSO, 1.25; vector TMI005,1.28; OIS DMSO, 1.92; OIS TMI005, 1.45), DAPI 
density (vector DMSO, 9752 a.u.; vector TMI005, 9634 a.u.; OIS DMSO, 7981 a.u.; OIS 
TMI005, 9042 a.u.), Nuclear form factor (vector DMSO, 0.88; vector TMI005, 0.89; OIS DMSO, 
0.92 OIS TMI005, 0.89), cellular protrusions (vector DMSO, 3.84; vector TMI005, 3.68; OIS 
DMSO, 5.52; OIS TMI005, 3.90), cellular form factor (vector DMSO, 0.74; vector TMI005, 
0.74; OIS DMSO, 0.70; OIS TMI005, 0.74), Major axis length (vector DMSO, 23.3 µm; vector 
TMI005, 23.5 µm; OIS DMSO, 31.9 µm; OIS TMI005, 26.2 µm), minor axis length (vector 
DMSO, 16.06 µm; vector TMI005, 16.15 µm; OIS DMSO, 21.7 µm; OIS TMI005, 18.0 µm). 
However, there was no obvious change cellular elongation (vector DMSO, 0.69; vector 
TMI005, 0.69; OIS DMSO, 0.68; OIS TMI005, 0.68). It is important to note that this is a 
preliminary finding and replication is important. Furthermore, additional controls are 
242 
 
required to account for the transfer of drug along with the media. However, it indicates that 
of the two pathways selected, the sheddases may represent a more interesting mechanistic 
route to pursue. Additionally, the relative contribution of ADAM10/17 to the paracrine 
effects of the SASP could be investigated further via the use of other inhibitors including 
GI254023 (ADAM10) and GW280264X (ADAM10/17) in a similar manner to that described 




Figure 5.14: HCA of MDA-MB-468 basal-like breast cancer cells treated with conditioned 
from vector or oncogene-induced senescent (OIS) IMR90s following treatment with 
NOTCH1 pathway inhibitor (DAPT) or ADAM17 inhibitor (TMI005) 
MDA-MB-468 cells were treated with conditioned media (CM) collected from vector or OIS 
IMR90s that had been treated with the γ-secretase inhibitor (DAPT), ADAM17 inhibitor 
(TMI005) or DMSO control and assessed by HCA. A) Representative immunofluorescence 
images for DAPI (blue) and Cell Mask (red) staining. B) Quantitation of HCA cell number and 
morphology measures. N=1 independent experimental replicates (4 technical replicates per 
experiment. Scale bars = 500µm.  
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5.7 Summary  
The concept of the SASP has traditionally been associated with soluble factors and, as such, 
functional investigations have primarily focused on the use of conditioned media 
investigations in order to probe the associated functional effects. These conditioned media 
experiments have demonstrated that a secondary senescence effect can be initiated in 
treated proliferating cells through a mechanism of paracrine senescence. Recently, the role 
of EVs in this effect has been explored, but often not in combination with the highest levels 
of isolation rigor (Wallis, Mizen and Bishop, 2020). In this chapter, the advantages of SEC 
have been emphasised, with a particular focus on dissecting the relative contribution of 
soluble and vesicular constituents of the SASP to paracrine senescence. 
 
Successful reproduction of OIS paracrine senescence conditioned media investigations from 
the literature was an important first step, as it provided a benchmark against which other 
models could be compared. This also demonstrated the advantages of the HCA 
morphological senescence characterisation, as a paracrine senescence response could be 
validated without extensive antibody staining. The use of complimentary senescence 
markers would have provided supporting evidence that a true “senescent” phenotype had 
been induced. However, this was considered to have more value as future work (section 6.5) 
to compliment the current objective, which was to demonstrate that senescent cell derived 
EVs produced a distinct functional effect from the soluble SASP, and that SEC allowed this to 
be more confidently determined than dUC alone. The use of dUC samples was not pursued, 
as the co-isolation of soluble factors would limit interpretation of the contribution of EVs. 
SEC provided confidence that Fraction 8 was primarily vesicular, and could thus be compared 
with the soluble Fraction 20. Given, the relative concentration of SASP factors between 
samples (section 4.6.2; Figure 4.15), it was intriguing that Fraction 8 and not Fraction 20 
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produced a paracrine response. However, the observable response in Fraction 8 suggests a 
mechanism distinct from canonical soluble factor signalling, hence the focus on membrane 
proteins. It is important to emphasise that the “dose” of EVs (10µl) was optimised based 
upon the volume of PBS vehicle which cells could tolerate without compromising final cell 
numbers. This also means that the difference in vector and OIS samples could be accounted 
for by the number of vesicles applied as much as any functionally relevant cargo. Therefore, 
comparisons between Fraction 8 and Fraction 20 are the most relevant to the work 
presented here, whilst dose responses would provide interesting complimentary data. 
However, the doses applied reflect the relative production of EVs that occur following OIS 
induction. Therefore, the experimental procedures are appropriate to describe the 
functional consequences of increased EV production in OIS and the capacity to illicit a 
paracrine senescence response. 
 
Given the context dependent role of the SASP, the capacity of OIS EVs to produce paracrine 
senescence in additional cell types was also explored, given the paradoxical roles of the SASP 
reported previously. Here, the OIS SASP was demonstrated to inhibit the proliferation of 468 
breast cancer cells, whilst inducing morphological changes indicative of senescence. This 
observation provided an additional model of paracrine senescence in which to assess the 
relative contribution of OIS EVs. However, further characterisation of the OIS paracrine effect 
in 468s (for example additional doses) would support this work. The observation that the OIS 
EVs recapitulate a paracrine senescence response in a second cell type supports their 
functional relevance within the SASP. However, the 468 EV experiments were hindered by 
inter-experimental variability and a block ANOVA statistical analysis approach was taken. 
This prevents the effects of each sample type from being masked by variability between 
experiments. Whilst this is an appropriate statistical approach, for consistency, additional 
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replicates would be useful support the conclusion that OIS EVs contribute to the paracrine 
effect of the OIS SASP on 468 cells. Overall, these functional experiments demonstrate that 
EVs derived from OIS can contribute to the paracrine signalling of the SASP and that SEC is 
an effective methodology for dissecting this effect from that of the soluble secretome. 
 
The functional data described above suggests that EVs may contribute to paracrine 
senescence through a mechanism that is distinct from the soluble SASP. It was postulated 
that any alternative mechanism was likely to revolve around inherent compositional 
differences between the vesicular and soluble SASP. The presence of membrane proteins 
represent one such potential distinction, as these are fundamental to the structure of the 
EVs but would not be expected in the soluble SASP. This hypothesis was supported by MS2, 
which indicated enrichment in OIS Fraction 8 for membrane proteins and MS3, which 
indicated that those proteins uniquely present at increased levels in OIS Fraction 8 comprised 
a significant membrane component. Intracellular proteins derived from the cytoplasm of the 
parental cell could also represent a candidate route and would be interesting to explore 
during future work (Section 6.3). PANTHER pathway analysis identified NOTCH family 
proteins, as well as members of associated signalling cascades, as constituents of the OIS 
EVs. This was intriguing when combined with recent evidence for the role of NOTCH1 in 
secondary senescence. The ability of NOTCH1 ligands to elicit a juxtacrine senescence 
response in neighbouring cells was considered of interest, as the presence of these ligands 
on the surface of EVs may represent a potential route for “paracrine-juxtacrine” senescence 
induction (Sheldon et al., 2010; Tan, Asada and Ge, 2018). Furthermore, NOTCH1 signalling 
is evidently important in both NIS and OIS, so the delivery of NOTCH1 and its intracellular 
domain to recipient cells represented another potential mechanistic route. However, JAG1 
expression could not be validated by ELISA in either OIS WCL, CM or EV samples. Coupled 
247 
 
with the lack of observable change in OIS paracrine senescence with DAPT inhibition, 
preliminary data provides limited support to NOTCH1 (or its ligands) as a significant 
contributor to EV mediated paracrine senescence. However, it is important to note that DAPT 
inhibition was only used in CM experiments and thus not assessed directly in a vesicular 
context. Equally, NOTCH1 inhibition in treated cells rather than conditioning cells may should 
also be explored. These would be a useful additional experiment before discounting a 
NOTCH1 mediated role.    
 
The decision to explore ADAM sheddases was a natural extension of the NOTCH1 
investigations. ADAM10/17 facilitate cleavage of the N1ICD by γ-secretase and are thus 
essential in the activation of the NOTCH1 pathway (Bray, 2016). ADAM10 has also been 
previously reported as a specific marker of small EVs (Kowal et al., 2016). The role of ADAMs 
within senescence has not been widely investigated but the presence in EVs would require 
expression in the producing cell. Interestingly, many ectodomains that are shed in ADAM 
dependent process have also been described as SASP factors (Coppé et al., 2010; Morancho 
et al., 2015). Coupled with EVs, this would represent an additional layer of complexity to the 
SASP that could be considered to comprise canonical soluble factors (secretome), EVs 
(vesiculome) and non-soluble shed ectodomains (sheddome). Given that EVs appear to have 
a distinct role within paracrine senescence, the relative contribution of the senescent 
sheddome was also explored. The potential for interplay between these two facets of the 
SASP is also worthy of investigation, as ectodomains on the EV surface may represent a 
potential “reservoir” which could be shed by EV-ADAMs. In order to explore this, the role of 
the sheddome within the composition of the SASP was explored though pharmacological 
inhibition of ADAM17 by TMI005. Although this experiment was only performed with one 
replicate, the OIS CM paracrine senescence effect appeared to be rescued by blocking 
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ADAM17 in the conditioning cells. This was an intriguing finding and suggests that shed 
ectodomains may be functionally important mediators within the SASP. Future work should 
explore the relative contribution of ADAM10/17 to this effect through use of inhibitors 
including GI254023 (ADAM10) and GW280264X (ADAM10/17). This would support 
preliminary findings and provide a clear rationale for exploring the sheddases as a 
mechanistic route. This could be achieved by using the same inhibitors to pharmacologically 
attenuate the EV mediated paracrine senescence response.  
 
To conclude, in this chapter, the role of EVs within OIS paracrine senescence has been 
explored. The use of SEC allows distinction between the soluble and vesicular portions of the 
secretome, supporting the rationale for its use in Chapter 2. Whilst characterisation of the 
mechanisms underpinning this effect had proved beyond the scope of this project, 
preliminary investigations indicate that ADAM10/17 sheddases may represent a functionally 
relevant pathway that is worthy of further investigation.  




6 Discussion and Future Work  
The principal findings of the work set out here, regard demonstration of the technical 
challenges that underpin the study of EVs within a senescence setting, which have facilitated 
the thorough profiling of the change in EV composition following the induction of OIS. Whilst 
demonstrably evidenced to concentrate EVs from cell culture supernatant, dUC was also 
shown to be limited by the co-isolation of soluble SASP factors including IL-8. SEC served as 
a means by which to overcome this limitation, by providing separation between the vesicular 
and soluble divisions of the SASP. Through this process, it was demonstrated that EVs 
contribute to the phenomenon of paracrine senescence, in a process distinct from that of 
the soluble secretome. Interrogation of the senescent cell derived EV composition has 
provided avenues for future investigations to probe the functional role of the SASP, with 
preliminary results identifying the senescent “sheddome” as an unappreciated facet of the 
SASP. Therefore, through a dedication to isolation rigor, this work provides a framework in 
which to explore the potential mechanisms that underpin the EV mediated paracrine effects 
of senescent cells.  
    
6.1 Overcoming the Technical Challenges of EV Isolation in Senescence 
The study of EVs has long been hindered by the technical challenges of investigating these 
nanoscale sized mediators (Ramirez et al., 2018). This includes a lack of utility for standard 
microscopy and flow cytometry techniques, the paucity of EV specific markers and shortfalls 
in the specificity of widely applied methods of EV characterisation (sections 1.2.5 and 1.2.6) 
(Coumans et al., 2017). These issues are further compounded when studying EVs in a 




The lack of efficiency in recovery yield is a widely described problem within EV research 
(Cvjetkovic et al., 2014). This varies between different methods of EV isolation but generally 
sees techniques targeted towards either a high purity or high yield (Van Deun et al., 2014; 
Mateescu et al., 2017). Indeed, in this work, dUC was demonstrated to produce an 
approximately five-fold greater particle concentration than that observed with SEC. This was 
offset by the co-isolation of soluble factors alongside the final dUC pellet, limiting its value 
as an isolation technique upstream of proteomic or functional analysis. Therefore, this 
positioned dUC as a high-yield low-purity technique, whilst the opposite was true of SEC. In 
some settings, it could be possible to overcome the SEC-associated loss of yield by scaling up 
cell culture, increasing the number of cells and flasks used. However, the loss of cellular 
proliferation intrinsic to senescence induction restricts the feasibility of this solution, 
particularly in models of replicative senescence, where large numbers of flasks would have 
to be maintained for weeks or months depending on the associated Hayflick curves. An 
alternative solution is the application of bioreactor cell-culture systems, which have been 
successfully used generate higher concentrations of EVs than standard cell culture flasks 
(Webber and Clayton, 2013; Watson et al., 2016). This would require optimisation of 
senescence induction within these systems, but may represent a useful technology to pair 
with SEC. Such a workflow would facilitate elaboration of the change in EV composition in 
further models of senescence, which is an important consideration given the heterogeneity 
between types of senescence. Furthermore, it could facilitate the exploration of the changes 
in EV composition in both the stages immediately preceding RS, and as the senescent 
phenotype matures to one of DS.    
       
Alongside yield, the issue of purity is of particular concern when investigating EVs within 
senescence, due to the SASP, which represents a potent source of potential protein 
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contamination. Here, it was demonstrated that SASP factors were co-isolated with the final 
dUC product. This was overcome through use of SEC, where the majority of IL-8 was 
identified in fractions that did not contain EVs. However, it cannot be discounted that the 
modest amount of IL-8 still associated with the EV fractions may represent a limitation of 
SEC, as there may be incomplete removal of all soluble protein from the EV fractions. 
Regardless, SEC provides a significant advantage over dUC in terms of purity and should be 
considered a more appropriate isolation technique within a senescence setting. This extends 
beyond proteomic assessment of EV composition and into the challenges of more general EV 
characterisation approaches. In particular, NTA is a technique limited by its ability to detect 
non-vesicular material (Coumans et al., 2017). It is feasible that a high level of SASP 
contamination within dUC preparations could produce an erroneously high concentration 
measurement, thus exacerbating the perceived loss of yield associated with SEC. However, 
the concurrent reduction in EV markers observed by immunoblotting suggest this to be a less 
important consideration. Finally, when determining SASP contamination of the EV products, 
it is important to acknowledge that IL-8 has been utilised as a surrogate marker of the OIS 
SASP throughout this work. It would represent a potential improvement to directly measure 
additional factors by ELISA, in order to demonstrate that the observed effects encompass a 
range of SASP components. However, the evidence presented in MS2 suggests that 
numerous proteins typically considered SASP factors are associated with the final OIS 
Fraction 20 samples (Coppé et al., 2010). This provides evidence that the observed co-
isolation is not IL-8 specific and can be considered associated with the senescent secretome 
more generally. It is also important to emphasise that due to the heterogeneity in SASP 
composition between models and cell types, the selection of any individual markers can be 
considered somewhat arbitrary. Therefore, IL-8 detection in the late SEC fractions served as 
justification for a more comprehensive assessment by mass spectrometry, than could be 
achieved by the analysis of several individual factors by ELISA. However, further validation 
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of MS2 could subsequently have been performed, with an emphasis on investigating the 
relative abundance of factors common between samples. This would reinforce the assertion 
that specific factors of the SASP were co-isolating during dUC and provide additional weight 
for the recommended use of SEC.   
 
The presence of numerous SASP factors in OIS Fraction 20 is compelling evidence for the use 
of SEC within senescence, overcoming a major hurdle to accurate characterisation. It is 
important that these concerns become more widely appreciated, as there has been an 
apparent nescience within the field surrounding such considerations. This is emphasised in 
Figure 6.1, which depicts the relative usage of EV isolation techniques within the senescence 
and ageing literature (Introduction section 1.3). Use of dUC and precipitation based kits, 
widely considered the methodologies least weighted towards purity, have been the most 
popular techniques in the field, suggesting that much of the compositional and functional 
assessments of EVs may have been hindered by co-isolation of the SASP. Therefore, it is 
hoped that by explicitly investigating the importance of research methodology to the 
characterisation of senescent cell derived EVs, this work will contribute to the promotion of 





Figure 6.1: Use of EV Isolation Methodologies within senescence and ageing literature 
Summary of the papers within section 1.3, which investigate extracellular vesicles (EVs) with 
senescence and ageing according to isolation methods. Isolation methods were included if 
they were utilised at any point within the publications. Abbreviations: differential 
ultracentrifugation (dUC), size-exclusion chromatography (SEC), sucrose gradient separation 
(SG), precipitation-based assays (PPT).   
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6.2 EV Heterogeneity – A Limitation Compounded in Senescence   
It is important to emphasise some key limitations of the work presented here, in order to 
provide suggestion on where future investigations could build to support the conclusions 
drawn. One of the clearest limitations is the focus on a single model of senescence induction 
— OIS. Whilst RS was intended to serve as a complimentary model, as the focus of the project 
moved towards methodology comparisons, OIS emerged as the more appropriate setting 
due to the greater availability of senescent cells. Whilst the magnitude of EV production and 
the paracrine effect of conditioned media was examined in the RS model, further analysis of 
the RS derived EVs would be beneficial, in order to provide an insight into whether the 
observations made in OIS are consistent in other senescence models. This is an important 
consideration, as it is widely accepted that the SASP consists of a heterogeneous set of 
mediators, dependent on both cell type and senescence inducer. Indeed, the RS model was 
demonstrated to lack an IL-8 component and it may be anticipated that EV composition will 
also vary between models. Therefore, in order to probe the heterogeneity of EV composition 
between models of senescence, a round of proteomics similar to MS3 (performed in the RS 
model) would provide valuable interrogation of the composition of senescent cell derived 
EVs beyond the specific profiling of OIS presented here. Furthermore, investigation of 
senescence induction and EV composition in a cell type other than fibroblasts may also be 
beneficial, in order to improve the applicability of the work to senescence more generally. 
For example, investigation within TIS in cancer cells would be interesting, as the SASP has 
been proposed as a major limitation of this potential therapeutic strategy (section 1.1.10.2). 
Therefore, it would be prudent to explore any potentially deleterious effects of EVs within 
this setting, utilising the methodological considerations presented here. Additionally, further 
exploration of the kinetic development of the SASP and, in particular, its vesicular content, 
was not investigated in depth. Analysis of media collected regularly during the OIS induction 
schedule indicated that the SASP is far from a static phenotype. Indeed, it has previously 
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been demonstrated that the OIS SASP undergoes a NOTCH1 mediated switch, leading to its 
late inflammatory composition (Hoare et al., 2016). There have been no reports to date 
describing a change in secretion of EVs across the course of senescence and it would be 
worthwhile to investigate whether the dynamic development of the SASP is reflected in a 
similar change in EV production. Furthermore, conditioned media and EV preparations 
collected across a time-course could be used in secondary senescence investigations, in 
order to understand how senescent cells modulate their microenvironment beyond a single 
time-point. Such investigations would only be worthwhile where confident attribution of EV 
dependent effects could be made, emphasising the value of the methodological 
development that was the focus of this work. 
 
Another source of potential heterogeneity not explored here, is that between sub-types of 
EVs. This may occur between both classes of EV (i.e. MVs vs exosomes) or from heterogeneity 
within these broad classifications (e.g sub-populations of exosomes). Given the diverse set 
of potential functions indicated to occur through senescent cell derived EVs (section 1.3), 
understanding the heterogeneity of EV composition is essential to uncovering their 
contribution to the signalling of senescent cells. The current limitations in isolation 
methodology make this an ambitious goal. However, the emergence of new technologies, 
such as nanoFCM and ExoView, provide opportunities for characterisation of single EVs, as 
opposed to the bulk analysis provided by NTA and mass spectrometry. However, whilst these 
techniques provide single particle resolution, they must be tailored for predefined targets of 
interest and do not provide the “global profiling” offered by mass spectrometry. Therefore, 
it is feasible that a two-step workflow may be useful, with initial identification of potential 
targets by bulk proteomics, followed by a refined characterisation on a single vesicle level by 
either nanoFCM or ExoView. This approach could be applied in concert with the proteomic 
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investigations here, to explore the heterogeneity in NOTCH1 and sheddase expression within 
the SEC isolated EVs. Development of such experimental approaches represent the most 
likely avenue towards understanding the nuances and heterogeneity in EV composition and 
function. At present, it is important to acknowledge that all conclusions are drawn from a 
mixed population of EVs and that these may be contributing to the observed effects to 
varying degrees. Equally, individual isolation schedules will enrich for specific populations of 
EVs, which may confound comparisons of both function and composition. This is emphasised 
by the lack of IFITM3 identification in any proteomic assessment made here, despite it having 
previously been identified as a key mediator of EV driven paracrine senescence in OIS 
(Borghesan et al., 2019). Interestingly, this particular factor was also not identified in the 
recent SASP Atlas investigation, emphasising the challenges of achieving standardisation 
within the field (Basisty et al., 2020). Mirroring the approach of EV research more broadly, 
the most likely way to achieve consensus is to adhere to the MISEV guidelines and appreciate 
the potential sources of heterogeneity between studies, including final cell numbers, 
incubation times, senescence models, cell types and isolation schedules (Lotvall et al., 2014; 
Théry et al., 2018). Moreover, development of a system equivalent to the EV-TRACK initiative 
could provide value in the senescence field, by standardising reporting and ensuring details 
of the above sources of potential heterogeneity are explicitly described within publications 
(Van Deun et al., 2017). This could be extended beyond an EV specific remit to a more general 
“SASP-Track” system, which would facilitate comprehensive reporting of experimental 
parameters and thus more straightforward comparison between investigations (Figure 6.2). 
Furthermore, this could be paired with a repository similar to ExoCarta, in order to develop 
an extensive database of SASP compositions within specific, well described, senescent 
contexts (Simpson, Kalra and Mathivanan, 2012). This seems to have been the broad aim of 
the SASP-Atlas, but that was limited (quite naturally) by the relatively few models that could 
be studied in a single publication. The value of such comparative databases relies on the 
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collation of a large number of data sets. Through a community driven approach, there is 
potential to develop an extensive database that may facilitate our understanding of the 
heterogeneity of the SASP, in terms of both its soluble and vesicular constituents. Overall, it 
is important to build on a firm foundation when assessing the role of EVs within senescence, 
which requires use stringent methodologies and an acknowledgment that even these are 
limited by the specificity of experimental parameters along with current technological 





Figure 6.2: Proposal for Developing a SASP-Track Database 
In order to develop a community driven database of context specific SASPs, a reporting 
interface would be useful within the field. This could facilitate standardisation of reporting, 
including parameters that underpin sources of heterogeneity in SASP composition. From a 
senescence perspective, clear identification of cell types, senescence models, cell numbers 
and conditioning times would be beneficial. From a vesicular outlook identification of 
isolation schedules, particles numbers and characterisation techniques would also be 
valuable. Collation of gene lists with the above experimental parameters clearly stated could 
help identify sources of heterogeneity and provide a rich database in which to explore the 
complex composition of the SASP.    
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6.3 Profiling the Composition of EVs in Senescence  
Having established SEC as an appropriate technique for the isolation of EVs, in combination 
with an acknowledgment of the limitations inherent to studying senescence in one model at 
a single time point, the work set out here has mobilised the development of a rigorous 
isolation methodology to comprehensively characterise the composition of EVs derived from 
OIS IMR90 fibroblasts at day eight. The profiling performed in MS3, identified 374 proteins 
present at increased levels in the OIS EVs compared to those from the vector control. Of 
these, 256 were uniquely increased in the EVs, suggesting they may constitute functional 
candidates that could underpin a distinction from the soluble SASP. These included both 
NOTCH1 and ADAM10, which had been identified in the previous MS2 round of proteomic 
assessment, and had already been selected as candidates for functional exploration (sections 
4.7 and 5.6). Additional validation included identification of increased levels of CD9, an EV 
marker that had been identified through immunoblotting, as well as EphA2, previously 
described as a functionally active component of senescent cell derived EVs (Takasugi et al., 
2017). These all represent membrane bound components, which account for a significant 
portion of those proteins uniquely present at increase levels in the OIS EVs. It is perhaps 
unsurprising that membrane proteins should be overexpressed within this data set, due to 
the higher particle numbers loaded (hence the abundance of CD9) and the inherent property 
of EVs as discrete membrane bound units, contrasting the soluble Fraction 20 and CM. 
Therefore, this dataset also provides a level of confidence that the preparations investigated 
were indeed EVs. This is corroborated further by the correspondingly high abundance of 
intracellular proteins, which should not be neglected in future work seeking to expand upon 
this initial profiling. Indeed, the diverse functional roles of EVs described previously in the 
literature have been have been demonstrated to occur through cargos with varied vesicular 
localisations (Wallis, Mizen and Bishop, 2020). In order to appreciate the broad range of 
potential EV mediated effects (described further below – section 6.4), it is crucial that 
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appreciation of all potential vesicular cargos be made. Therefore, whilst the MS3 proteomic 
assessment provides a rich source of data for future work to build upon, it should be 
acknowledged that it does not profile the entirety of EV composition. In particular, 
supporting such proteomic assessment with analysis of nucleic acid constituents would 
provide a more complete assessment of EV cargo and could reveal other avenues in which 
to explore the functional role of senescent cell derived EVs. However, within the scope of 
this work, the data within MS3 provides a thorough assessment of the proteomic cargo of 
OIS derived EVs and, in the context of SEC, serves as a demonstration of recommended 
practice when profiling EV proteomic composition within senescence.  
 
6.4 Exploring the Contribution of EVs to Paracrine Senescence   
One of the primary aims of this project has been to explore the contribution of EVs to the 
paracrine signalling of the SASP and, in particular, the induction of secondary senescence in 
proliferating cells. This is a crucial aspect of the SASP, as it has been widely hypothesised to 
contribute to the accumulation of senescent cells within ageing and age-related pathologies 
(section 1.3). Here, SEC was utilised to demonstrate that paracrine senescence could be 
facilitated through EVs in a manner distinct from that of the soluble SASP. This was evidenced 
by the reduced proliferation of IMR90 fibroblasts following OIS Fraction 8 treatment, which 
could not be recapitulated with Fraction 20. This was important, as it demonstrated that SEC 
did not preclude paracrine senescence investigation, which had been a possibility given the 
associated lack of yield. Furthermore, it supported literature evidence that EVs were 
important modulators of this secondary senescence effect (section 1.3.2.1). Most crucially, 
this effect could be confidently attributed to the EVs, due to the extensive compositional 
characterisation between Fraction 8 and Fraction 20. Together, this demonstrates that SEC 
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is a useful technique to apply in advance of EV treatment investigations, in order to 
convincingly demonstrate EV mediated outcomes. 
 
This was utilised here to explore a novel role of OIS derived EVs to the induction of paracrine 
senescence in MDA-MB-468 breast cancer cells. This effect was demonstrated by both the 
EVs and total conditioned media. Interestingly, whilst senescence is predominantly 
considered an anti-tumorigenic effect, the SASP has been reported to promote the 
proliferation of cancer cells (Campisi and D’Adda Di Fagagna, 2007) in an effect recapitulated 
with senescent cell derived EVs (Takasugi et al., 2017). By contrast, EVs derived from 
palbociclib-induced senescent cells have also been demonstrated to inhibit the proliferation 
of MCF-7 breast cancer cells (Borghesan et al., 2019). Therefore, the classification of both 
the SASP and EVs as either pro- or anti-tumorigenic is currently uncertain (Rao and Jackson, 
2016; Saleh et al., 2018). In order to explore this further, some adjustment to the EV isolation 
experiments may be prudent. For example, use of a range of EV doses would facilitate a more 
compelling case for the observed loss of proliferation. Furthermore, use of co-culture or 
transwell experiments could be more representative of in vivo conditions than the discrete 
dose administrations utilised here. However, this work serves as a demonstration that the 
use of SEC may facilitate functional investigation of EVs in a senescence setting, providing a 
foundation for more comprehensive future investigation.  
 
Whilst the work here has predominantly focused on the phenomenon of paracrine 
senescence, this is not the only function of the SASP, albeit one considered “dark” or 
detrimental within ageing (Wallis, Mizen and Bishop, 2020). As described in section 1.1.9, 
the SASP also contributes to homeostatic processes, including wound healing (Demaria et 
al., 2014). Interestingly, EVs derived from senescent cells have also been implicated in a 
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similar role, suggesting they mediate some of the “bright” beneficial effects of senescence 
(Terlecki-Zaniewicz et al., 2019). One underexplored role of EVs within senescence is the 
potential interaction with immune cells. Therefore, it would be interesting to utilise the 
methodologies optimised here, within experiments investigating the contribution of EVs to 
immune meditated responses. These could include investigations utilising NK cells, 
previously established as key effectors of senescent cell clearance via the SASP (section 
1.1.9.2). In such investigations, it would be critical to minimise the contamination of EVs with 
SASP components, making a SEC based approach ideal. Furthermore, as described above, 
EVs have been implicated in a diverse set of functional roles, on both sides of the bright/dark 
dichotomy of the SASP. In order to uncover the relative contribution of EVs to these complex 
and contradictory functions, it is essential that effects can be convincingly credited to 
vesicles, emphasising the importance of diligence when selecting isolation methodologies.        
 
6.5 Senescence Characterisation – A role for morphology 
The characterisation of senescence has long been hindered by the lack of universally 
expressed markers with which to identify senescent cells. Consequently, best practice sees 
application of several markers, identifying hallmarks commonly observed following 
senescence induction (Hernandez-Segura, Nehme and Demaria, 2018). This requires 
significant optimisation, to find both markers and experimental conditions appropriate for 
the particular model and cell type under investigation. Therefore, there is significant 
research interest in identifying screening methods that may characterise senescence in a 
high-throughput manner, in a variety of cell types and models (Lahtela et al., 2013; Sadaie et 
al., 2015). Here, canonical markers of OIS were paired with a HCA based morphological panel 
in order to demonstrate the utility of this approach. Each individual morphology measure 
was selected in accordance with literature evidence that supported a potential senescence-
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associated change. Cell number was assessed, in order to demonstrate the inherent 
reduction in proliferation that accompanies senescence induction (Munoz-Espin and 
Serrano, 2014). Additionally, cell area and axis lengths were measured in order to facilitate 
demonstration of the widely described increase in senescent cell size (Hwang, Yoon and 
Kang, 2009). Similarly, nuclear area was assessed, as identification of enlarged nuclei has 
been used successfully as a screening tool to characterise the induction of senescence 
(Sadaie et al., 2015). Furthermore, measures assessing the uniformity of both cellular 
(cellular protrusions, cell form factor, cell elongation) and nuclear (nuclear form factor) 
morphology were also employed, as senescence has also been associated with irregularly 
shaped cells and nuclei (Hwang, Yoon and Kang, 2009; Sadaie et al., 2015). Additionally, the 
ratio between cytoplasmic and nuclear areas was also measured, as cytoplasmic dilution 
resulting from a reduced DNA/cytoplasmic ratio has been demonstrated to occur in 
senescent cells previously (Goldstein, 1990; Neurohr et al., 2019). Finally, assessment of DAPI 
intensity was made, as this has been successfully used to identify G1 arrested cells and as a 
screening tool for senescence assessment (Zhao et al., 2010; Roukos et al., 2015). Overall, 
the combination of these measures allowed a comprehensive assessment of OIS morphology 
to be made, supported by a panel of more conventional markers. This HCA approach was 
then applied to both replicative and secondary senescence investigations, emphasising its 
utility for characterising senescence in numerous settings.  
 
However, it is important to acknowledge the limitations of utilising morphology as the sole 
method of senescence characterisation, as without the support of additional markers, it 
cannot conclusively be determined that senescence induction has occurred. Nevertheless, 
the context in which analysis has been performed is also relevant, as are the hypotheses 
being interrogated. Here, where morphological assessment has been employed in isolation, 
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it has not been done to characterise a previously unreported phenomenon, but rather to 
support the established principles of conditioned media and EV mediated paracrine 
senescence. HCA was used to provide distinction between treatments, rather than 
demonstrate a novel effect. Therefore, it has provided value by allowing exploration into the 
suitability of SEC as a method of EV isolation upstream of functional analysis. Future work 
characterising additional markers of senescence induction would further support the 
conclusions drawn. It would be prudent to begin by assessing markers previously associated 
with paracrine senescence (both in conditioned media and EV investigations), including p21, 
p16 and DNA damage foci (Acosta et al., 2013; Borghesan et al., 2019). However, HCA 
morphological analysis has merit as a first pass, proof of principle assessment, similar to that 
previously described for SA-β-gal (Gorgoulis et al., 2019). It should be noted that selection of 
senescence markers always requires tailoring for the specific context. For example, SAHFs 
are predominately associated with OIS and thus would not be a suitable readout in the RS 
model (Di Micco et al., 2011). Similarly, the p16 positive nature of MDA-MB-468 cells would 
limit the utility of this marker in secondary senescence investigations. This emphasises the 
more general challenges surrounding senescence characterisation, as well as the need for 
identification of novel senescence markers. The HCA based approach used here is well 
supported in the OIS model and has been employed to provide useful characterisation in 
several additional settings.  
 
6.6 Senescence Reversal Investigations  
In section 3.6, a protocol investigating the reversal of RS in HMFs was investigated. This has 
been extensively characterised in the lab previously, and presents a useful system in which 
to explore the phenotypes associated with senescence (Thesis:(Tyler, 2016)). In this work, a 
particular emphasis was placed on characterising the secretome of these reversed cells. IL-6 
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was demonstrated, through both qRT-PCR and immunoblotting, to be a major constituent of 
the RS SASP, whereas IL-8 was not. Following siRNA-induced reversal of RS, IL-6 was observed 
to decrease vs the siGLO control, albeit not to the level of EP cells. Interestingly, this was not 
recapitulated with the early SASP marker IL-1α, whilst IL-1β mRNA expression appeared to 
be dramatically increased following reversal. Together, this suggests that the secretome of 
reversed cells may be more complex than that of the EP counterparts. It may also indicate 
that the proliferative arrest associated with senescence may be uncoupled from the 
production of the SASP, as has been demonstrated elsewhere (Coppé et al., 2011). The model 
of senescence reversal also presents the possibility to interrogate similar changes in EV 
production, which was demonstrated in this work to increase during RS. Whether this can be 
attenuated by the reversal protocol may provide an insight into the association of 
senescence with EV production, as the increased rate of production has been observed in all 
settings investigated (Section 1.3.1). However, some obstacles exist that preclude immediate 
exploration of this association, not least the transient nature of siRNA inhibition. This could 
be overcome through development of constitutive or inducible shRNA inhibitory systems, 
which would provide a stable knockdown in which to apply EV isolation protocols. 
Furthermore, exploration into compositional differences in EVs derived from EP, DS and 
reversed cells could provide insight into which cargos are of most functional significance 
within RS. Initial inquiries would focus on whether reversal attenuates RS-associated 
paracrine senescence, which would in turn lead to investigations pursing the EV mediated 
component of this response. Overall, whilst not the focus of this project, the senescence 
reversal investigations presented here, demonstrate the potential for further investigation 





6.7 Proposed Mechanisms of EV Mediated Paracrine Senescence  
Having developed a robust workflow establishing isolation of EVs from OIS cells via SEC, the 
previously reported role of senescent cell derived EVs in mediating paracrine senescence was 
assessed. It was confirmed that EVs isolated by SEC contribute to paracrine senescence and, 
importantly, do so in way that appears distinct from that of the soluble SASP, given the lack 
of recapitulation with Fraction 20 treatments. It is possible that EVs may augment signalling 
of SASP factors previously demonstrated to contribute to senescence induction, in a similar 
manner to that of TGFβ1 and IFN-γ described previously (Cossetti et al., 2014; Webber et al., 
2015). However, it is also feasible that components of the EV membrane may directly engage 
recipient cells in a manner reminiscent of IFITM3 and EphA2 (Takasugi et al., 2017; Borghesan 
et al., 2019). Alternatively, delivery of an EV cargo to the cytoplasm of a recipient cell could 
engage a distinct set of pathways inaccessible to the soluble factors of the SASP. Here, it was 
chosen to focus on the latter two scenarios, as the proteomic analysis performed in 
MS2/MS3 indicated that the EV preparations comprised heavy enrichment of membrane and 
cytosolic proteins, which were felt to possess more potential for engagement of distinct 
mechanisms compared to soluble factors.       
         
6.7.1  NOTCH1 Investigations   
One intriguing set of membrane constituents identified in MS2, were factors associated with 
NOTCH signalling, in particular NOTCH1 and its associated ligands JAG1 and DLL4. It was 
hypothesised that JAG1/DLL4 ligands on the surface of EVs may engage receptors on 
recipient cells, instigating a NOTCH1 dependent form of secondary senescence similar to that 
described between senescent and proliferating cells (Parry et al., 2018; Teo et al., 2019). This 
engagement of NOTCH signalling through ligands on the surface of EVs has been described 
elsewhere (Sheldon et al., 2010; Sharghi-Namini et al., 2014; Tan, Asada and Ge, 2018) and 
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would constitute an intriguing mechanism for a form of signalling traditionally considered 
juxtacrine. Additionally, the presence of NOTCH1 on EVs was also considered of functional 
interest, as a non-canonical form of NOTCH signalling facilitated by EV delivery has previously 
been described (Wang and Lu, 2017). Briefly, EVs are able to mediate the delivery of NOTCH 
to recipient cells, resulting in engagement of canonical NOTCH signalling cascades, whilst 
bypassing the requirement for binding of NOTCH ligands. Interestingly, this process has been 
demonstrated to require γ-secretase activity in the recipient cells, suggesting that the N1ICD 
is only cleaved following EV mediated delivery. It was considered that delivery of NOTCH1 
and, in particular, the N1ICD intracellular domain, could facilitate similar signalling in the EV 
treatment experiments presented here, facilitating the instigation of a secondary senescence 
response. Furthermore, the previously reported loss of N1ICD expression from OIS cells after 
day four post-induction was also a source of interest (Hoare et al., 2016). Whilst the previous 
report of non-canonical signalling suggested that N1ICD is not cleaved before incorporation 
into EVs, it was hypothesised that this could account for the observed loss in OIS. 
Alternatively, identification of critical components of the NOTCH signalling cascade within 
EVs, including members of the γ-secretase complex, as well as ADAM10 and 17, could 
account for reduced cleavage of the intracellular domain. Together, this provided a rationale 
for exploring the expression of NOTCH1 and N1ICD in OIS cells and EVs. NOTCH1 and N1ICD 
were both identified in the OIS cells, but only NOTCH1 was identified in the EVs. However, 
as the NOTCH1 antibody recognises an epitope also comprising N1ICD, this indicated that 
NOTCH1 was present within the EVs but had not been cleaved into its active form. 
Additionally, preliminary work investigating JAG1 by ELISA suggested it too was not present 
on OIS EVs. This could be accounted for by the change in OIS induction schedule, as JAG1 was 
also not observed in the MS3 round of proteomics. Overall, when coupled with the 
ineffectual DAPT treatment during preliminary conditioned media investigation, initial 
exploration of potential NOTCH1 mediated mechanisms provided minimal support for this 
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hypothesis. However, before entirely abandoning this line of investigation, it would be useful 
to utilise the DAPT inhibitor during EV treatment investigations, as this is would be a more 
appropriate scenario in which to assess modulation of an EV specific effect. Furthermore, 
treatment of recipient cells with DAPT may be a more prudent strategy for inhibition, given 
the previous report of EV delivered N1ICD cleavage only occurring in recipient cells (Wang 





Figure 6.3: Hypotheses for routes of EV mediated paracrine senescence through NOTCH1 
NOTCH1 and its ligands JAG1 and DLL4 were identified in OIS derived EVs by mass 
spectrometry (MS2). It is hypothesised that EVs may instigate a NOTCH1 mediated form of 
secondary senescence in proliferating cells through either binding NOTCH1 on the surface of 
recipient cells (canonical NOTCH1 signalling) or through delivery of NOTCH1 itself, which 
then may be cleaved in the recipient cell thus facilitating NOTCH signalling.    
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6.7.2 ADAM10/17 Sheddases    
In the course of developing a rationale for the NOTCH1 mediated hypotheses discussed 
above, the sheddase ADAM17 was identified in the MS2 assessment of OIS Fraction 8. 
ADAM17, as well as the closely related ADAM10, are sheddases that mediate the initial 
cleavage events the follow NOTCH1 biding to it its ligands. Beyond this, these sheddases have 
a broad action, responsible for the shedding of membrane bound ectodomains, which 
subsequently come to comprise a significant part of the secretome. In senescence, shed 
ectodomains have been described to constitute around 10% of the total secreted factors 
(Morancho et al., 2015). Furthermore, ADAM10 has been proposed as a marker of EVs, 
possibly serving as the elusive specific marker of small EVs (or exosomes) that has eluded the 
field (Kowal et al., 2016). Therefore, it was decided to explore the role of both ADAM10 and 
ADAM17 within the development of the senescent secretome, particularly because the 
former appeared consistently present at increased levels in all three rounds of mass 
spectrometry. Immunoblotting demonstrated the presence of both sheddases in the OIS 
cells and derived EVs. However, for both proteins, epitopes of different sizes appeared to be 
identified depending on the type of sample examined. Communications from antibody 
manufacturers suggested that the lower molecular weight bands detected in the EVs 
represented cleaved, active forms of the sheddases, suggesting these forms to be 
preferentially trafficked during EV biogenesis or that EVs possessed the appropriate 
machinery to facilitate such activation. Additionally, proteomic data suggested that ADAM 
accessory proteins including IRHOM1, IRHOM2, TSPAN5 and TSPAN14 were also associated 
with the EVs. These proteins mediate the cleavage and shedding of specific ectodomains, 
tailoring the specificity of the sheddases (Matthews et al., 2017). Together, these data 
suggested that further investigation of ADAM sheddases within senescence was worthwhile 
and, in particular, led to further consideration regarding the composition of the senescent 
secretome more broadly. It was hypothesised that alongside the canonical soluble SASP, and 
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the more recently accepted vesicular component, the less frequently described “sheddome” 
from senescent cells may represent an important and underexplored facet. Furthermore, it 
was considered that functionally active ADAMs on the surface of EVs could constitute a 
mechanism through which mobilisation of a “reservoir” of EV membrane ectodomains could 
occur, adding an additional layer of complexity (Effenberger et al., 2014; Folkesson et al., 
2015; Schumacher et al., 2015). In order to investigate this, modulation of both composition 
and function of the SASP could be investigated through use of ADAM inhibitors, including 
GW280264X (ADAM10/17), GI254023 (ADAM10) and TMI005 (ADAM17). The latter of these 
was the subject of preliminary investigation here, with modulation of OIS conditioning cells 
with TMI005 seeming to ablate the paracrine senescence effect of the collected media. 
Whilst a preliminary finding, this result suggests that further exploration of the role of 
sheddases in determining the composition of the SASP is worthwhile, along with further 
interrogation of potential activity of EV constituent sheddases. Overall, identification of this 
potentially underexplored dimension of the SASP was only feasible given the application of 
a high purity EV isolation workflow, reinforcing the primary finding of this work, that isolation 
methodology is essential to the evaluation of the extracellular vesicle component of the 





Figure 6.4: Composition of the Senescent Secretome  
The secretome of senescent cells is complex, with the composition of the SASP dependent 
on both cell type and senescent inducing stimulus, as well as altering temporally within the 
course of senescence induction. The majority of studies investigating the SASP have focused 
on characterising the action of soluble factors but extracellular vesicles (EVs) are becoming 
widely appreciated a functionally relevant constituents. Whilst there have been 
investigations characterising the shedding of ectodomains from the surface of the senescent 
cells, which thus become part of the soluble SASP, their distinction from the rest of the 
secretome is not widely appreciated. Here, proteomic profiling of OIS derived EVs has led to 
the proposal that EVs possessive of the sheddases ADAM10/17 may be important 
contributors to the composition of the “sheddome”. This may involve mobilisation of 
ectodomains from the surface of EVs, which, in turn, may contribute to the process of 
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8 Appendix  
8.1 Mass Spectrometry 1: Proteomic assessment of EVs isolated by dUC from 
vector and OIS IMR90s 
This data forms the basis of section 4.5 and is referred to throughout as MS1. EV samples 
were isolated in triplicate by dUC from vector and OIS IMR90s. These were analysed by mass 
spectrometry through collaboration with the CECAD proteomic facility (University of 
Cologne). Gene lists detailing the label-free quantitation intensities (LFQ) for each sample 
were produced and analysed according to section 2.13.2. Mean LFQ intensity values (Mean 
LFQ) from vector (orange) and OIS (purple) replicates are detailed, along with positive or 
negative fold change (FC). Unpaired Student’s t-tests were also performed, with the p-value 
described in the final column for each gene (-Log10 p-value).    












HRAS 25.70 32.51 6.81 3.00359 
PLAT 24.92 30.18 5.26 3.16908 
STC1 24.94 29.84 4.90 1.71936 
SLC16A6 23.83 28.58 4.75 2.95297 
PLAU 27.21 31.96 4.75 2.08836 
ESR1 25.09 29.47 4.38 1.16622 
NRG1 23.84 28.18 4.33 2.29246 
ANPEP 26.85 31.07 4.22 1.68092 
ITGA6 25.28 29.45 4.17 1.77055 
CDCP1 24.02 28.14 4.12 2.85444 
FAT1 24.66 28.71 4.05 1.58854 
ANGPTL4 23.94 27.94 4.01 1.48653 
CXCL8 24.17 28.09 3.92 1.09485 
ITGB5 23.94 27.83 3.89 2.1631 
CD81 28.19 32.05 3.86 0.697259 
ITGA2 29.87 33.58 3.71 2.7326 
ADAM10 26.88 30.58 3.70 0.969503 
SRPX 25.00 28.58 3.58 2.3039 
AREG 23.67 27.19 3.52 1.93028 
CD9 29.96 33.47 3.51 1.92014 
MMP1 29.60 33.09 3.49 3.63488 
MMP14 26.19 29.59 3.39 1.30072 
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ICAM1 24.61 27.83 3.23 1.34471 
ITGA5 26.03 29.25 3.22 1.35397 
CD82 24.34 27.56 3.21 0.844971 
NT5E 29.90 33.11 3.21 2.29579 
VGF 23.83 27.04 3.21 1.60946 
TSPAN9 23.88 27.06 3.17 1.08192 
EPHB2 23.95 27.12 3.17 1.36677 
ANTXR2 24.03 27.12 3.09 1.72921 
F3 24.97 28.04 3.08 1.91424 
CD46 23.98 26.91 2.94 2.20242 
ATP1A1 27.55 30.48 2.93 1.57059 
MARCKSL1 25.39 28.27 2.89 1.64189 
EPHA2 25.40 28.27 2.87 1.28975 
INHBA 24.50 27.24 2.74 0.836981 
IGSF8 26.04 28.77 2.73 0.821364 
PSMA1 24.51 27.22 2.71 1.17663 
TFPI2 24.12 26.82 2.70 1.75395 
SERPINB2 24.03 26.73 2.69 2.0259 
PRSS23 25.76 28.44 2.68 1.49614 
ITGB3 24.81 27.45 2.64 1.78118 
ITGA3 27.79 30.37 2.58 1.68267 
GPX3;GPX6;GPX5 23.99 26.55 2.55 3.12507 
AKAP12 24.32 26.86 2.54 1.4676 
SERPINE2 24.10 26.63 2.53 1.32185 
TPBG 24.40 26.92 2.51 1.37937 
EMILIN1 25.15 27.66 2.51 1.23251 
CD276 24.00 26.51 2.50 1.92512 
TPP2 26.91 29.35 2.44 0.685864 
GNB1 25.89 28.33 2.44 0.871749 
GNAI3 24.06 26.43 2.36 1.04047 
CD151 26.02 28.37 2.35 1.21775 
MAP4K4;TNIK;MINK1 24.11 26.46 2.35 1.39218 
WNT5A 26.93 29.27 2.34 1.8858 
PTGES3 26.79 29.13 2.34 0.499642 
SCUBE3 24.23 26.55 2.32 0.902257 
S100A13 26.15 28.37 2.22 0.735764 
ITGAV 26.64 28.85 2.21 1.30962 
SLC39A10 23.53 25.73 2.21 2.56138 
HGF 27.03 29.23 2.20 1.00574 
SDCBP  26.24 28.42 2.18 0.545436 
SEMA7A 25.10 27.27 2.17 0.829803 
GNG5 23.40 25.57 2.17 1.9908 
ITGB1 31.47 33.59 2.12 2.16295 
GNG2 24.18 26.22 2.05 1.1095 
TGM2 27.52 29.54 2.02 2.7114 
PSMC2 24.25 26.27 2.02 0.846803 
300 
 
PLXNB2 25.28 27.29 2.01 1.26521 
COLEC10 24.19 26.19 2.00 2.2834 
RAB13 24.97 26.95 1.98 0.961604 
MME 24.82 26.79 1.96 1.36464 
PAPPA 27.11 29.07 1.96 1.00374 
PSMC6 24.29 26.25 1.96 0.814239 
RALA 24.99 26.94 1.95 0.930667 
PDCD6IP 27.73 29.68 1.95 0.511703 
POSTN 25.26 27.20 1.94 0.590062 
EGFR 26.74 28.66 1.91 1.96907 
TIMP1 29.50 31.40 1.90 1.78323 
ANP32B 24.34 26.19 1.85 0.786356 
PSMA5 26.64 28.48 1.84 1.34325 
BSG 26.21 28.05 1.84 1.86716 
GSTO1 25.73 27.56 1.82 0.483914 
ITGA1 25.00 26.81 1.82 0.576688 
HMGB2 28.26 30.07 1.81 0.66992 
CD59 29.91 31.72 1.81 1.0804 
PHLDA1 24.00 25.78 1.78 0.873278 
PSMA6 25.45 27.20 1.75 0.810143 
COL6A3 34.52 36.27 1.75 1.30193 
COL6A2 32.11 33.84 1.73 1.55027 
GNAI2 27.88 29.57 1.69 1.00008 
FAM129B 25.04 26.71 1.67 0.68106 
CD44 29.63 31.30 1.67 2.36033 
GNAS 24.21 25.87 1.66 1.21263 
CCT8 27.58 29.24 1.66 0.951109 
NRP1 26.57 28.22 1.65 0.848592 
TFRC 26.54 28.18 1.64 0.293772 
PLOD3 25.06 26.65 1.59 0.827253 
EIF3I 24.37 25.96 1.59 0.579586 
CTNNA1 26.56 28.13 1.57 0.717302 
BZW1 24.17 25.73 1.56 0.465704 
THBS1 32.97 34.52 1.55 1.26771 
SLC16A3 25.24 26.73 1.48 1.17785 
FARP1 23.96 25.44 1.48 0.592974 
GDF15 24.27 25.73 1.45 0.950164 
PSMD3 24.93 26.35 1.42 1.35659 
CCT3 26.12 27.53 1.41 0.459598 
EPRS 25.71 27.09 1.39 0.440838 
DYNC1H1 28.02 29.40 1.37 0.569275 
FASN 25.78 27.15 1.37 0.469999 
PSMD11 25.22 26.59 1.37 0.589214 
RAB5C 25.41 26.77 1.36 0.844313 
HINT1 24.58 25.93 1.35 0.474625 
ACTR1B 24.15 25.49 1.34 0.48229 
301 
 
APOB 25.07 26.41 1.34 0.575553 
COL6A1 33.31 34.63 1.33 1.28906 
SRSF1 24.48 25.80 1.32 0.462412 
PSMD2 25.44 26.75 1.32 0.49747 
LRP1 29.51 30.83 1.32 0.93725 
DNAJA1 24.34 25.65 1.31 0.915416 
ILK 24.52 25.82 1.31 0.850565 
ARF1;ARF3 25.28 26.57 1.30 0.912451 
PSMA7 26.08 27.37 1.29 0.887924 
RPS9 25.65 26.94 1.29 0.424107 
CST3 26.10 27.38 1.28 0.524208 
PPP2CA;PPP2CB 23.78 25.05 1.28 1.4527 
DCTN2 24.50 25.76 1.26 0.509573 
TUBB4B;TUBB4A 25.16 26.41 1.24 0.376553 
HTRA1 28.27 29.49 1.22 0.681053 
PTMA 26.76 27.98 1.22 0.211827 
CTNND1 24.93 26.15 1.22 0.522061 
NPTN 25.53 26.74 1.22 1.09229 
CCT4 27.63 28.84 1.21 0.650055 
PSMA2 26.58 27.77 1.20 0.418715 
HLA-A 28.13 29.32 1.19 2.40925 
CDH13 27.75 28.93 1.18 1.32598 
AHCY 28.43 29.59 1.16 0.789628 
LGALS3BP 31.04 32.21 1.16 0.429142 
WNT5B 25.21 26.36 1.15 0.480317 
IGF2R 26.76 27.91 1.15 0.668061 
TNFRSF10D 24.43 25.57 1.14 0.633442 
COL4A2 25.67 26.80 1.13 0.398245 
SOD1 26.86 27.99 1.13 0.361085 
HSPH1 25.27 26.39 1.12 0.428672 
SLC3A2 29.01 30.12 1.11 0.669216 
TUBA4A 27.24 28.33 1.09 0.894038 
EIF3C;EIF3CL 24.92 25.98 1.06 0.577071 
ST13;ST13P4;ST13P5 25.90 26.95 1.05 0.316926 
CTTN 24.53 25.57 1.05 0.347846 
S100A16 26.78 27.83 1.05 0.801921 
PPP1R12A 25.39 26.44 1.04 0.266924 
PLEK 27.76 28.77 1.02 0.640661 
PLOD1 27.20 28.21 1.01 0.693833 
RAC1;RAC3 28.34 29.34 1.00 0.612795 
PXDN 31.12 32.10 0.98 1.00496 
PSMC3 25.78 26.73 0.96 0.531628 
EHD1 27.11 28.07 0.95 0.439226 
CORO1C 25.07 26.00 0.93 0.212913 
RFTN1 25.47 26.40 0.93 0.383035 
TCP1 27.64 28.55 0.91 0.615714 
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SSC5D 25.78 26.68 0.90 0.284664 
TOP1 25.94 26.83 0.89 0.183879 
THBS2 24.21 25.10 0.89 1.4964 
SLC1A5 27.80 28.69 0.89 0.543108 
GREM1 28.40 29.27 0.87 0.749457 
WARS 24.54 25.41 0.87 0.264027 
SUB1 25.37 26.24 0.86 0.246806 
MAPRE2 26.14 27.00 0.86 0.638382 
LAMA2 25.94 26.79 0.85 0.224028 
ABCA1 24.50 25.35 0.84 0.625254 
SARS 25.48 26.32 0.84 0.388223 
HGFAC 27.01 27.85 0.84 0.291945 
EEF1D 25.36 26.19 0.83 0.204186 
TNFRSF11B 25.13 25.95 0.82 0.502863 
CCT2 27.88 28.70 0.82 0.632221 
CDC42 27.52 28.33 0.81 0.970418 
CCT5 27.88 28.69 0.81 0.659863 
RP2 25.72 26.52 0.80 0.314374 
PSMC4 24.46 25.25 0.79 0.509526 
HSPA4 25.20 25.98 0.79 0.773002 
SET 27.11 27.88 0.76 0.16743 
RAP1B 28.85 29.61 0.76 0.311871 
CSPG4 25.89 26.65 0.76 1.41211 
HMGB1;HMGB1P1 30.04 30.79 0.75 0.645217 
CACNA2D1 26.65 27.40 0.75 1.15293 
EPB41L3 25.79 26.54 0.75 0.250794 
LTBP1 27.68 28.43 0.75 1.85941 
CCT7 26.90 27.64 0.74 0.511763 
HEXB 25.38 26.11 0.73 0.209121 
ARPC1B 25.52 26.25 0.73 0.237469 
ACLY 26.95 27.67 0.73 0.568308 
CCT6A 27.49 28.22 0.73 0.876551 
ATP2B1 26.49 27.21 0.72 0.219917 
PSMD13 25.13 25.83 0.70 0.369156 
BMP1 25.91 26.60 0.69 0.501979 
TGFBI 31.14 31.82 0.68 0.439882 
PSMD12 25.57 26.24 0.67 0.495602 
SDF4 25.20 25.87 0.67 0.214607 
RAB7A 27.63 28.30 0.67 0.36919 
STIP1 26.33 26.99 0.67 0.379733 
CD99 25.91 26.58 0.67 0.204738 
GDI2 28.82 29.48 0.66 0.580201 
C1QTNF3 28.91 29.57 0.65 0.217595 
ANXA11 24.72 25.37 0.65 0.295833 
CAND1 26.43 27.05 0.63 0.248474 
ATIC 26.86 27.49 0.63 0.60159 
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RPS27 24.97 25.58 0.61 0.212732 
AKR1B1 25.55 26.16 0.61 0.315674 
PAFAH1B1 26.38 26.98 0.60 0.233236 
RPLP2 28.10 28.70 0.60 0.67797 
SPON2 27.94 28.52 0.58 0.351167 
RPS5 25.48 26.03 0.56 0.161835 
HABP2 26.12 26.66 0.54 0.683673 
CAPZA1 25.95 26.48 0.53 0.314111 
RPL22 25.30 25.83 0.53 0.133922 
RAB11B;RAB11A 27.52 28.05 0.53 1.2255 
BASP1 30.26 30.79 0.52 0.229193 
ALDOA 30.35 30.87 0.52 0.440168 
RPL14 26.21 26.72 0.52 0.132009 
RPSA 25.48 25.99 0.51 0.176139 
YWHAG 29.24 29.75 0.51 0.435627 
CA2 24.80 25.31 0.51 0.367952 
DBN1 24.46 24.96 0.51 0.129592 
HSPA8 31.61 32.12 0.51 0.417437 
RPL8 26.75 27.25 0.50 0.11295 
CTSB 29.19 29.68 0.49 0.282859 
FKBP1A 26.67 27.15 0.48 1.74158 
YWHAZ 30.01 30.48 0.47 0.543776 
ARPC3 25.89 26.36 0.47 0.186757 
EIF3A 26.26 26.72 0.46 0.128273 
TPM3 25.43 25.89 0.46 0.124284 
ARHGDIA 28.07 28.53 0.46 0.318973 
RPL29 25.90 26.35 0.45 0.105135 
PGK1 29.94 30.39 0.45 0.632015 
AP2B1;AP1B1 25.84 26.28 0.44 0.227905 
RPLP1 25.82 26.25 0.43 0.208585 
SRSF3 25.49 25.91 0.42 0.163422 
STRAP 24.51 24.93 0.42 0.174418 
COPB2 25.08 25.50 0.42 0.135874 
FN1 34.95 35.36 0.42 0.336002 
IARS 25.10 25.51 0.41 0.184804 
CLIC1 28.97 29.38 0.41 0.576218 
MYO1C 26.03 26.43 0.40 0.0820101 
RHOA 27.17 27.57 0.40 0.270317 
ANXA1 30.46 30.86 0.40 0.271405 
RPLP0P6;RPLP0 28.14 28.53 0.40 0.130873 
RPS16 26.41 26.80 0.39 0.152499 
TPT1 26.89 27.28 0.39 0.356123 
YWHAH 25.82 26.20 0.38 0.138328 
OTUB1 24.81 25.17 0.36 0.542483 
RAB1A 28.36 28.72 0.36 0.265624 
GPI 27.30 27.65 0.35 0.394229 
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GDI1 23.93 24.27 0.34 0.472831 
UCHL1 27.97 28.30 0.32 0.194818 
MSN 31.54 31.85 0.31 0.384454 
NAP1L1 27.02 27.33 0.31 0.172464 
ATP2B4 26.56 26.87 0.31 0.183344 
PKM 30.88 31.18 0.30 0.239856 
ECE1 25.44 25.74 0.30 0.115338 
ACTR2 26.81 27.11 0.30 0.158494 
YWHAB 28.19 28.48 0.29 0.288171 
TNC 30.26 30.55 0.29 0.245831 
S100A11 29.64 29.93 0.29 0.256068 
LDHA 28.60 28.88 0.28 0.134582 
PRPS1;PRPS1L1 24.31 24.58 0.26 0.147803 
LGALS1 30.17 30.42 0.24 0.227005 
LAMA4 30.18 30.42 0.24 0.0795321 
NPTX1 28.97 29.21 0.24 0.0909086 
CAP1 28.85 29.09 0.24 0.106257 
RPL5 29.00 29.23 0.23 0.0772643 
PABPC1;PABPC3 26.85 27.08 0.23 0.136421 
ANXA6 29.97 30.21 0.23 0.131209 
RPL10 26.97 27.19 0.23 0.0595955 
WDR1 28.84 29.07 0.22 0.224048 
RPL19 26.04 26.25 0.21 0.0693246 
LRRC17 28.71 28.92 0.20 0.0704307 
DCD 29.90 30.10 0.20 0.0934322 
TLN1 30.78 30.98 0.20 0.207952 
TWF2 24.25 24.45 0.20 0.0783927 
GAPDH 31.73 31.93 0.20 0.121278 
CDH6 26.18 26.36 0.18 0.300873 
YWHAE 30.34 30.50 0.16 0.0946144 
ACTR3 26.46 26.62 0.16 0.0816506 
NME2;NME2P1 26.13 26.29 0.16 0.0601313 
ADK 26.07 26.23 0.16 0.0847547 
RPS4X 28.07 28.22 0.15 0.100176 
RPS23 27.18 27.32 0.14 0.0562509 
ACTR1A 25.94 26.08 0.14 0.106344 
TPI1 29.96 30.09 0.13 0.140454 
SH3BGRL3 28.40 28.53 0.13 0.114869 
F10 28.93 29.06 0.12 0.0862334 
ECM1 29.23 29.35 0.12 0.0680848 
RPS11 27.11 27.23 0.12 0.0671045 
HSP90AB1 31.44 31.55 0.11 0.0519229 
GNB2L1 27.06 27.17 0.11 0.0228686 
STOM 26.38 26.49 0.11 0.0279364 
ERP29 26.07 26.17 0.10 0.03449 
NPC2 25.59 25.67 0.08 0.0207312 
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TUBB3 26.60 26.66 0.06 0.0375343 
EIF4A1 26.73 26.79 0.06 0.0210235 
ANXA2;ANXA2P2 32.76 32.82 0.06 0.0333452 
EEF2 29.91 29.96 0.05 0.0307063 
HSP90AA1 30.73 30.76 0.04 0.020694 
TFPI 26.44 26.47 0.04 0.0290542 
RPS6 28.97 28.99 0.02 0.00851102 
PARK7 27.41 27.43 0.02 0.0121102 
THY1 28.66 28.67 0.02 0.00990806 
RPS21 26.32 26.33 0.01 0.00291367 
ENO1 30.85 30.85 0.00 0.000354674 
CCDC66 26.87 26.87 0.00 0.00428466 
NCL 28.94 28.93 -0.01 0.00368642 
IGFBP2 29.40 29.37 -0.02 0.0112548 
HSPE1 27.95 27.93 -0.02 0.00556022 
RSU1 26.91 26.87 -0.05 0.0772534 
RPS20 26.52 26.47 -0.05 0.0177527 
EEF1G 27.33 27.28 -0.05 0.0237647 
RPS28 26.28 26.22 -0.05 0.0139397 
RPL7A 27.38 27.33 -0.06 0.0176945 
RPL24 25.54 25.49 -0.06 0.0172507 
TUBA1B 31.32 31.27 -0.06 0.0440691 
CLSTN1 26.74 26.68 -0.06 0.0530084 
RPS15 24.62 24.55 -0.07 0.0179801 
RPS15A 24.47 24.40 -0.08 0.0213376 
RARS 24.61 24.53 -0.08 0.0485728 
RPL26;RPL26L1 27.99 27.91 -0.08 0.0256395 
S100A6 28.06 27.97 -0.09 0.0174966 
IGF2 27.70 27.61 -0.09 0.0599356 
NCAM1 25.37 25.28 -0.09 0.0586614 
RPL17 27.84 27.74 -0.10 0.0262326 
RPS8 29.20 29.09 -0.11 0.0450309 
PRDX1 30.13 30.00 -0.13 0.0893899 
NACA 25.40 25.27 -0.13 0.0405686 
CALM3 28.93 28.81 -0.13 0.0531057 
MARCKS 29.21 29.08 -0.13 0.0640214 
HSPB1 28.00 27.85 -0.14 0.107225 
GSTP1 27.84 27.69 -0.15 0.0691929 
PFN1 30.34 30.19 -0.15 0.105744 
S100A10 28.09 27.93 -0.16 0.109671 
CFL1 31.01 30.85 -0.16 0.170014 
LDHB 29.09 28.92 -0.17 0.19321 
VIM 32.33 32.16 -0.17 0.0586126 
CSRP1 27.43 27.25 -0.17 0.109845 
VCP 29.64 29.47 -0.17 0.0785448 
SEPT7 25.87 25.69 -0.18 0.0505022 
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COL5A1 29.43 29.24 -0.18 0.187057 
PFKP 26.89 26.70 -0.19 0.180536 
MYDGF 26.40 26.21 -0.19 0.0515471 
PHGDH 27.86 27.67 -0.20 0.225723 
EEF1A1;EEF1A1P5 32.01 31.80 -0.21 0.302323 
LOXL2 29.27 29.06 -0.21 0.395992 
RPS3 26.64 26.43 -0.21 0.0989594 
TXN 30.02 29.80 -0.22 0.227291 
VCL 29.96 29.74 -0.22 0.395569 
GSN 26.12 25.89 -0.23 0.374697 
RPL27 26.27 26.03 -0.24 0.0556283 
LAMB1 32.06 31.82 -0.24 0.103977 
FABP5 28.51 28.26 -0.25 0.106413 
RBP4 28.56 28.31 -0.25 0.0984198 
CNTN1 24.93 24.66 -0.27 0.2489 
G6PD 25.76 25.48 -0.28 0.335083 
CLTC 29.91 29.63 -0.28 0.222965 
PSAP 28.82 28.53 -0.29 0.132761 
TKT 28.05 27.75 -0.30 0.139845 
RPL23A 25.97 25.67 -0.30 0.0818649 
ACTN4 30.96 30.65 -0.31 0.238159 
RPS17 25.46 25.14 -0.32 0.296155 
NPM1 29.01 28.68 -0.32 0.159817 
FBN1 28.63 28.30 -0.33 0.619871 
BGN 28.93 28.59 -0.34 0.69703 
RPL13 27.44 27.09 -0.35 0.165452 
VPS35 25.28 24.93 -0.35 1.14024 
COL12A1 34.19 33.84 -0.35 0.267216 
PPP2R1A 26.69 26.34 -0.35 0.478132 
EIF5A;EIF5AL1;EIF5A2 28.20 27.84 -0.36 0.534278 
RPL15 27.79 27.43 -0.36 0.165221 
HSPA1B;HSPA1A 28.25 27.89 -0.36 0.152895 
APP 26.35 25.98 -0.37 0.321732 
UBA1 26.51 26.11 -0.40 0.25028 
PLEC 27.87 27.46 -0.41 0.104266 
PTK7 25.46 25.04 -0.42 0.143122 
RPS3A 28.30 27.88 -0.42 0.223698 
NID1 33.55 33.13 -0.42 0.149754 
TUFM 25.67 25.25 -0.42 0.133356 
PDAP1 25.59 25.16 -0.42 0.182493 
SEPT9 26.67 26.24 -0.42 0.258776 
PGAM1 27.65 27.22 -0.43 0.541 
HPX 27.12 26.69 -0.43 0.330433 
LAMC1 32.53 32.09 -0.43 0.241862 
MAMDC2 26.11 25.67 -0.44 0.205415 
SFRP1 27.39 26.95 -0.44 0.178272 
307 
 
RPS2 28.73 28.28 -0.45 0.287787 
VAT1 28.81 28.35 -0.46 0.416918 
RPL10A 27.52 27.04 -0.49 0.304784 
ARPC2 25.52 25.03 -0.49 0.145361 
TUBB 31.76 31.27 -0.49 0.319678 
COTL1 28.98 28.49 -0.49 0.550463 
DSTN 27.01 26.52 -0.49 0.74662 
BANF1 28.59 28.09 -0.51 0.230091 
TXNDC17 26.78 26.27 -0.51 0.98271 
SDC4 28.17 27.67 -0.51 0.337291 
ACTB 33.90 33.39 -0.51 0.809917 
YWHAQ 28.47 27.95 -0.52 0.313292 
FKBP7 24.16 23.64 -0.52 0.186681 
RPL12 26.48 25.96 -0.52 0.189623 
GPC1 27.97 27.45 -0.52 0.893542 
RRBP1 25.92 25.40 -0.52 0.116676 
H2AFY 26.82 26.30 -0.53 0.0941237 
TAGLN2 26.70 26.17 -0.53 0.334707 
ALCAM 28.91 28.38 -0.53 0.550014 
RPS14 27.52 26.98 -0.54 0.296766 
RPS18 27.19 26.64 -0.55 0.240855 
YBX1;YBX3 26.80 26.24 -0.56 0.272284 
MDH1 26.75 26.19 -0.56 0.522118 
CLIC4 29.17 28.60 -0.57 0.867111 
RPL11 27.80 27.21 -0.59 0.469115 
RPL31 25.19 24.60 -0.60 0.149902 
RPS27A;UBA52;UBB;UBC 29.52 28.92 -0.60 0.236872 
DNAH17 28.00 27.39 -0.61 0.595612 
EDIL3 31.02 30.41 -0.61 0.298768 
ACTN1 29.70 29.08 -0.62 0.665388 
RPL36AL;RPL36A 26.55 25.93 -0.63 0.387084 
ACTC1;ACTA1 30.52 29.89 -0.63 0.309281 
SEPT2 27.10 26.47 -0.63 0.317794 
LAMP1 27.28 26.65 -0.64 0.162332 
AGRN 30.30 29.67 -0.64 0.274315 
RPL6 29.39 28.75 -0.64 0.382132 
FSCN1 26.86 26.23 -0.64 0.461361 
KIF5B 27.30 26.66 -0.64 1.4221 
RPS25 26.38 25.72 -0.65 0.173257 
NUCB1 28.38 27.72 -0.66 0.898929 
B2M 32.09 31.42 -0.67 0.766374 
HNRNPC 26.95 26.27 -0.68 0.18452 
PEBP1 28.80 28.11 -0.69 2.03048 
FABP1 28.86 28.16 -0.70 0.620114 
MMP2 31.27 30.56 -0.71 1.65032 
PDIA4 28.66 27.93 -0.73 0.209006 
308 
 
LASP1 28.22 27.48 -0.74 0.506788 
ANXA5 32.22 31.46 -0.76 0.751591 
RPS12 27.52 26.77 -0.76 0.396355 
VNN2 26.72 25.96 -0.76 0.595204 
DBI 26.92 26.16 -0.77 0.447709 
TMSB4X 31.15 30.38 -0.77 1.10001 
THBS4 27.51 26.74 -0.77 0.27164 
RPL18 27.28 26.50 -0.78 0.263544 
IGFBP5 33.13 32.35 -0.78 0.727898 
BCAP31 25.34 24.55 -0.79 0.525449 
RCN1 28.81 28.02 -0.79 0.410211 
RPL27A 26.85 26.05 -0.80 0.288423 
DSG1 27.45 26.64 -0.81 0.157441 
RPL4 28.72 27.91 -0.81 0.28423 
PCOLCE 29.70 28.86 -0.83 0.619049 
CALML5 27.38 26.55 -0.83 0.111215 
AHNAK 30.21 29.38 -0.84 0.484195 
HSPD1 29.44 28.60 -0.84 0.255136 
RPL3 28.50 27.66 -0.84 0.286434 
DSC1 26.51 25.66 -0.85 0.124729 
PSMB3 24.29 23.43 -0.85 0.721641 
IQGAP1 25.99 25.14 -0.85 0.269007 
MDH2 27.77 26.91 -0.85 0.194684 
CSTA 26.25 25.40 -0.85 0.172933 
RPS19 25.61 24.74 -0.87 0.199427 
RPS7 26.36 25.48 -0.88 0.431883 
VDAC1 26.06 25.18 -0.88 0.79143 
FLNA 31.08 30.20 -0.88 0.861366 
TXNDC5 27.21 26.32 -0.89 0.260203 
FLNC 29.14 28.23 -0.90 0.75825 
SEC13 24.33 23.43 -0.91 0.592841 
IGFBP4 29.73 28.82 -0.91 0.56565 
COL5A2 27.77 26.85 -0.92 2.42653 
COL11A1 29.40 28.48 -0.92 1.17939 
IGFBP7 29.08 28.14 -0.93 0.638886 
SERPINE1 27.41 26.46 -0.94 0.513643 
MVP 30.19 29.23 -0.96 0.690925 
SPARC 31.89 30.93 -0.96 0.707015 
RPL7 27.55 26.55 -1.00 0.313476 
PA2G4 24.04 23.02 -1.01 0.298036 
TIMP2 29.58 28.57 -1.01 1.88152 
VCAN 32.60 31.56 -1.04 0.323094 
PAICS 26.21 25.16 -1.05 0.569732 
PRKCSH 28.36 27.31 -1.05 0.66318 
FST 26.82 25.76 -1.06 0.875112 
SH3BGRL 24.66 23.61 -1.06 1.05193 
309 
 
P4HB 31.08 30.02 -1.06 0.431898 
FLNB 25.72 24.65 -1.07 0.284411 
MRC2 26.68 25.61 -1.07 0.494651 
HIST1H2BC;HIST1H2BM;HIST1H2BN;HIST1H
2BH;HIST2H2BF;HIST1H2BD 31.78 30.68 -1.10 0.328476 
PDIA3 30.81 29.71 -1.10 0.39672 
SUMO2 26.32 25.22 -1.10 1.7321 
GARS 26.61 25.47 -1.14 0.326518 
APOM 27.38 26.24 -1.14 0.366223 
PTMS 27.58 26.42 -1.15 0.513706 
NCAPG 27.72 26.56 -1.16 1.08891 
CALD1 28.26 27.09 -1.17 0.592184 
KPNB1 25.88 24.71 -1.17 0.620067 
MYH9 33.19 32.00 -1.20 0.619931 
GANAB 25.94 24.74 -1.20 0.320315 
MFGE8 33.28 32.04 -1.25 0.787162 
HSPA5 31.00 29.75 -1.25 0.53124 
CALU 30.64 29.38 -1.27 0.919994 
CAT 25.92 24.64 -1.28 0.521895 
AHCTF1 31.79 30.50 -1.30 0.732242 
PLS3 27.11 25.81 -1.30 1.0909 
QSOX1 27.96 26.65 -1.32 0.851985 
SPTAN1 27.65 26.32 -1.33 0.665678 
SERPINF1 27.45 26.11 -1.34 1.15211 
HSP90B1 30.52 29.16 -1.36 0.515026 
CALR 31.24 29.86 -1.38 0.756862 
PRDX2 27.12 25.72 -1.40 0.611713 
NID2 30.96 29.55 -1.41 1.40788 
MAP4 25.31 23.89 -1.42 0.39227 
LAMA5 27.41 25.98 -1.43 0.595859 
MYL6 29.86 28.40 -1.46 0.799571 
EZR 26.93 25.44 -1.49 0.730255 
NUCB2 25.16 23.61 -1.55 1.37034 
PPIB 29.66 28.11 -1.55 0.816317 
HNRNPD 25.66 24.08 -1.58 0.514541 
HIST1H4A 30.37 28.77 -1.59 0.490569 
GLUD1;GLUD2 26.65 25.05 -1.60 0.77539 
HSPG2 28.40 26.77 -1.63 0.88396 
MYL12A;MYL12B 27.38 25.75 -1.64 1.15024 
HNRNPA3 25.70 24.05 -1.65 0.50447 
ATP5B 28.42 26.77 -1.66 0.582229 
HIST3H2A;HIST1H2AD;HIST1H2AB 31.76 30.07 -1.69 0.673113 
CAV1 26.47 24.74 -1.73 0.898265 
HNRNPA1;HNRNPA1L2 27.26 25.53 -1.73 0.631412 
CLU 30.76 29.02 -1.74 1.65262 
XRCC6 26.79 25.01 -1.78 0.844014 
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ATP5A1 27.72 25.93 -1.79 0.551468 
MYOF 27.45 25.63 -1.82 0.817158 
PDIA6 27.01 25.16 -1.84 0.621581 
TPM4 32.05 30.19 -1.85 1.48177 
MDK 26.49 24.63 -1.86 1.24158 
RPN1 26.69 24.82 -1.86 0.789321 
LRRC59 25.84 23.98 -1.87 0.868473 
DSP 33.47 31.60 -1.87 1.27375 
PTX3 28.74 26.86 -1.88 0.321278 
HIST2H3A 29.64 27.75 -1.89 0.628059 
HNRNPU 26.68 24.75 -1.92 0.621967 
HNRNPA2B1 28.41 26.49 -1.92 0.660663 
LAMA1 30.30 28.38 -1.93 0.775132 
SERPINH1 29.45 27.50 -1.95 1.13188 
COL1A1 34.69 32.74 -1.95 2.07079 
GAS6 27.50 25.54 -1.96 0.956109 
HYOU1 25.51 23.54 -1.97 0.585456 
STMN1 27.52 25.48 -2.04 0.901188 
FSTL1 30.83 28.76 -2.07 2.15666 
COL3A1 31.03 28.91 -2.12 2.04479 
LMNA 28.96 26.84 -2.13 1.09973 
COL1A2 33.65 31.46 -2.19 2.63217 
CANX 28.69 26.43 -2.26 1.0445 
JUP 26.54 24.22 -2.32 0.357823 
LUM 26.34 23.91 -2.43 1.17689 
HIST1H1B 30.14 27.69 -2.45 0.824482 
HP1BP3 25.66 23.03 -2.63 0.801125 
CCBE1 26.69 24.04 -2.65 2.7338 
CKAP4 29.38 26.71 -2.67 0.804589 
MYH10 26.28 23.53 -2.75 0.623494 
C2orf16 29.03 26.27 -2.76 0.795121 
TAGLN 26.93 24.15 -2.78 1.73403 
C1R 29.79 26.95 -2.85 1.78667 
H2AFV;H2AFZ 26.31 23.46 -2.85 1.44313 
RELN 27.66 24.28 -3.37 1.3837 
C1S 29.62 26.20 -3.42 2.3826 
HIST1H1C 31.45 28.03 -3.42 1.23882 
ESYT1 28.27 24.24 -4.03 3.53476 
TPM1 27.71 23.66 -4.05 1.20751 
FBLN1 28.85 24.22 -4.63 1.42214 
SVEP1 29.50 24.26 -5.23 3.19075 





8.2 Mass Spectrometry 2: Proteomic assessment of Conditioned Media and  
EVs isolated by SEC from OIS IMR90s 
This data forms the basis of section 4.7 and is referred to throughout as MS2. Conditioned 
media (CM) and SEC fractions 8 (F8) and 20 (F20) were collected in triplicate from OIS 
IMR90s. These were analysed by mass spectrometry through collaboration with the CECAD 
proteomic facility (University of Cologne). Gene lists detailing the label-free quantitation 
intensities (LFQ) for each sample were produced and analysed according to section 2.13.2. 
Mean LFQ intensity values (Mean LFQ) from CM (blue), F20 (orange) and F8 (yellow) 
replicates are detailed. Localisation data designating each gene as intracellular (IC), 
membrane (M) or secreted (S) was determined via Protein Atlas (www.proteinatlas.org) with 
genes able to receive multiple designations.  




OIS F20  
Mean LFQ 
(Log2)  
OIS F8  
Mean LFQ 
(Log2)  
AAMDC IC     24.98371 
ABCA1 IC/M     29.68345 
ABCB1 IC/M     25.95742 
ABCC1 M     29.13849 
ABCC4 M     30.46293 
ABI1 IC     30.12145 
ABI2 IC     26.66569 
ABLIM3 IC     25.08053 
ABRACL IC 25.4159   25.28334 
ACAT2 IC 26.48094   27.13531 
ACE IC/M/S     27.38164 
ACO1 IC 26.53025   29.09845 
ACSL4 IC/M     30.85085 
ACVR1 IC/M/S     28.48284 
ADAM10 M/S   26.97185 32.19276 
ADAM17 M/S     29.22058 
ADAM19 M 26.90319     
ADAM9 M/S 27.90273 29.07207   
ADCY9 IC/M     25.57121 
ADGRL2;LPHN2 M     26.31223 
ADH5 IC     29.32701 
ADSS IC     28.22857 
AGRN IC/M/S 27.9858 28.53762 30.96894 
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AHCYL1;AHCYL2 IC     26.969 
AHSA1 IC     25.69364 
AIDA IC     29.13232 
AK1 IC     29.14786 
AKAP12 IC   25.9627 31.61564 
AKR1B1 IC 29.26335 28.62211 31.46519 
AKR7A2 IC     26.24693 
AKT1 IC     27.33822 
AKT2 IC     25.59523 
AKT3 IC     25.54323 
ALCAM M   27.83661 31.61411 
AMPD3 IC     25.80188 
ANGPTL3 S 27.08665     
ANGPTL4 IC/S 27.83144   27.25433 
ANO6 M     29.60783 
ANPEP M 24.66107 26.83289 33.60273 
ANTXR1 IC/M/S 27.02419     
ANTXR2 M     30.11047 
ANXA11 IC   25.948 32.23455 
ANXA3 IC     26.85678 
ANXA4 IC   26.9667 31.68801 
ANXA6 IC 27.77959 32.0543 35.55463 
ANXA7 IC     29.89894 
AOC3;AOC2 IC/S   24.82403   
AP3M1;AP3M2 IC     24.12766 
APOB S 26.47176     
APOM IC/S 29.55682 28.30869 28.67931 
APP IC/M 26.3001     
APPL1 IC     25.77723 
APPL2 IC     25.94381 
ARAF IC     27.03641 
ARCN1 IC/S     26.36757 
AREG M   27.94792 26.58249 
ARF6 IC     25.35626 
ARHGAP1 IC/M     26.34283 
ARHGAP17 IC     24.71077 
ARHGAP18 IC     26.78504 
ARHGEF7 IC     26.29087 
ARL3 IC     28.1471 
ARMT1 IC     25.87171 
ARPC1B IC 28.17091   29.08967 
ARPC1B IC 26.79546 25.70912 30.78283 
ARPC5 IC     29.14601 
ARPC5L IC     27.55116 
ARRB1 IC     25.02663 
ARVCF IC     27.14921 
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ASPH IC/M     26.47689 
ASS1 IC     25.03871 
ATOX1 IC     28.73419 
ATP10D M     24.19031 
ATP13A3 M     25.47157 
ATP1B1 IC/M     31.61045 
ATP1B3 IC/M     31.12847 
ATP2B1 M     31.25346 
ATP2B3 M     27.16579 
ATP2B4 IC/M   26.91019 33.17017 
ATP6AP2 IC/M/S 27.61471     
ATP6V0D1 IC     27.50479 
ATP6V1C1 IC     26.4347 
ATP6V1D IC     25.71886 
ATP6V1E1 IC     26.16209 
ATP6V1G1 IC     28.94606 
ATP6V1H IC     25.24715 
ATP7A M     27.24007 
ATRN M     26.68793 
AXL M 26.14645     
B2M M/S 32.31861 32.08738 32.72649 
B3GAT3;B3GAT2 IC/S 26.50131     
B4GAT1 S 27.39915   28.60696 
BAG3 IC/M     26.40843 
BAIAP2 IC     27.50806 
BAX IC     27.61296 
BCR;BCR/ABL fusion IC     25.98291 
BDKRB2 M     29.16384 
BGN S 26.82017 25.97856 25.41406 
BHMT IC       
BICD2 IC     24.50211 
BLVRA IC     25.68802 
BMP1 S 26.94628 27.91903   
BMP2 S 27.29726 27.68412 27.15996 
BPGM IC     29.54921 
BPNT1 IC     26.69035 
BRCC3 IC     24.49995 
BRK1 IC     29.78575 
BTN2A1 IC/M     31.14343 
BZW1 IC     25.88027 
C12orf10 IC/S     26.30164 
C12orf57 IC     26.579 
C12orf75;OCC1 IC     28.03858 
C1QTNF3-AMACR;C1QTNF3 S 26.04894 29.65673   
C1S IC/S 27.7316 27.42667   
C3 IC/S 27.4315     
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C8B IC/S 26.36645     
CA2 IC 28.85286     
CAB39 IC 27.85318   27.90122 
CACNA2D1 IC/M/S   27.82248 32.12043 
CADM1 IC/M     30.22755 
CALML5 IC     25.05173 
CAMK2D IC/M/S     26.7242 
CAPG IC     26.87971 
CAPN1 IC     28.18003 
CAPN5 IC     29.71995 
CAPNS1 IC 28.01178 27.45631 29.45722 
CARS IC 26.78809     
CASK IC/M     29.41138 
CASP3 IC     26.14507 
CASP7 IC     24.45428 
CAST IC     28.13098 
CAT IC 25.85399     
CAV1 M     27.8812 
CAV1 M     29.67712 
CCDC22 IC     23.41023 
CCDC50 IC     28.46891 
CCDC6 IC     25.80933 
CCM2 IC     27.58504 
CCNYL1 IC     24.53658 
CCS IC     25.64502 
CD109 M     26.30211 
CD151 M     32.04515 
CD248 M 26.57525     
CD276 M/S     30.92165 
CD4 IC/M/S     25.8651 
CD46 M     28.17717 
CD46 M     26.84842 
CD47 IC/M     28.91376 
CD63 M     26.86543 
CD81 M   31.23326 31.32081 
CD82 IC/M     28.26552 
CD9 M   30.90094 34.0278 
CD93 M 25.48963     
CD97 IC/M/S     30.23927 
CD99 M/S   27.02464 30.67723 
CDC42SE1 IC     27.39194 
CDCP1 M/S     32.29887 
CDH11 IC/M/S   25.79525 30.59884 
CDH13 IC/S 27.82877 26.9097 32.55167 
CDH2 IC/M     30.37734 
CDH6 M 24.18246 26.34989 29.43752 
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CDK4 IC     27.14127 
CDKN1A IC     24.4423 
CDV3 IC     27.09979 
CFD S 29.24857     
CFHR5 S 27.69297     
CHMP1A IC     28.27383 
CHMP1B IC     28.47134 
CHMP2A IC     26.77649 
CHMP2B IC     25.517 
CHMP3 IC     27.12865 
CHMP4A IC     27.40682 
CHMP4B IC     30.12222 
CHMP5 IC     30.144 
CHMP6 IC     27.07033 
CHORDC1 IC     25.0647 
CHRM2 M     26.67278 
CHST3 M 25.78254     
CLDND1 IC/M/S     25.95879 
CLEC11A S 29.52895 29.00702   
CLIC1 IC 29.66686 29.38579 33.06066 
CLIC4 IC 29.57108 29.56432 32.71655 
CLIP1 IC     24.55666 
CLIP2 IC     26.90825 
CLMP M     27.93701 
CLSTN1 M 30.7713 29.12313   
CLTB IC 25.72156   28.73788 
CLU IC/S 28.04072 28.73055 27.63376 
CMPK1 S     29.15157 
CNDP2 IC     28.17757 
CNNM4;CNNM3 M     24.39897 
CNPY2 IC/S     24.70247 
CNTN1 S 23.99595     
COL11A1 IC/S 27.33434 29.74854   
COL12A1 IC/S 30.65987 30.13416 30.21902 
COL18A1 IC/S 25.66949     
COL1A1 IC/S 32.15053 32.41099 31.33486 
COL1A2 S 30.91824 31.24826 30.00484 
COL2A1 S 25.5726     
COL3A1 IC/S 27.23291 27.37475 25.16726 
COL4A1 IC/S 27.35603 27.86335 27.80506 
COL4A2 IC/S 27.19336   27.0645 
COL5A1 IC/S 28.83933 30.584 26.08256 
COL6A1 S 34.07177 34.56767 36.72612 
COL6A2 IC/S 31.98974 33.15217 36.21564 
COL6A3 IC/S     28.05809 
COL6A3 IC/S 34.28388 35.57797 38.27821 
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COLEC10 S 27.7668     
COMT IC/M     26.68445 
COPS3 IC     25.50543 
COPS4 IC     26.2468 
COPS5 IC     25.55175 
COPZ1 IC     26.36827 
CORO2B IC     26.65162 
COTL1 IC 29.32716 28.88078 30.57866 
CPNE3 IC     30.27408 
CRIP2 IC 29.27649     
CRYZ IC     26.81033 
CSDE1 IC     26.1773 
CSF2 S 27.41924     
CSNK1E IC     25.76321 
CSPG4 M 25.07481 26.58626 31.97827 
CST1 S 30.76601 28.96765 27.69106 
CST3 S 30.87573 32.36263 28.28488 
CST4 S 30.79638 31.53749 28.79743 
CTGF S   27.61956 27.06057 
CTHRC1 IC/S 26.39175     
CTNNA2 IC     25.66694 
CTSA IC/S 28.98934     
CTSB S 31.65713 32.75062 30.14217 
CTSC IC/S   27.98556   
CTSD IC/S 30.6346   27.28583 
CTSL S 26.4262     
CTSV S   26.80951   
CUL1 IC     26.58388 
CUL3 IC     26.93611 
CUL5 IC     27.47835 
CXCL5 S 27.23754     
CXCL8 S 31.8142 31.91948 27.57283 
CYBRD1 M     26.91006 
CYFIP1 IC     30.38793 
CYFIP2 IC     25.47448 
DAB2 IC     24.96796 
DAG1 IC/M/S 28.25213     
DAP IC     29.47527 
DBI IC 28.72885     
DBNL IC/S     28.22904 
DCBLD1 M     27.99954 
DCBLD2 IC/M     30.29365 
DCC IC/M     24.69239 
DCTN3 IC     26.45367 
DCTN4 IC     25.88731 
DCUN1D3 IC     28.07937 
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DDAH1 IC 27.30423   27.39142 
DDAH2 IC     28.64048 
DDR2 IC/M/S     28.17837 
DDX19A;DDX19B IC     24.77679 
DIAPH1 IC     24.77697 
DIP2B IC     30.2913 
DIP2C IC/M     26.62871 
DKFZp566H1924;NPTN IC/M     31.68294 
DKFZp686J1372 IC   27.49322 28.75377 
DKK3 S 30.00006 28.31207   
DLG5 IC     25.5255 
DLGAP4 IC     26.80046 
DLL4 M     26.02678 
DMBT1 S     26.84736 
DMD IC     26.58968 
DNAJB1 IC     25.7483 
DNAJC13 M     26.17971 
DNAJC5 M     26.61899 
DNM2 IC     27.84312 
DOCK10 IC 34.13003     
DOCK11 IC     24.30023 
DOCK9 IC     24.96935 
DOS M/S     27.33366 
DPP3 IC     27.59288 
DPP4 IC/M     32.28726 
DPYSL2 IC 26.96145   29.25552 
DPYSL3 IC 27.46801   27.55248 
DTNA;DTNB IC/M     26.81714 
DUSP3 IC     26.29814 
DYNC1LI2 IC     26.16198 
ECE1 IC/M     30.21763 
ECM1 S 31.82385 32.79427 28.90761 
EDIL3 S     31.03648 
EEA1 IC     28.12463 
EFEMP1 IC/S 26.0604     
EFNB1 M     29.03488 
EFNB2 M     26.83809 
EGFR IC/M/S   26.03454 33.31243 
EHD1 IC 26.32652 24.69603 33.23429 
EHD2 IC 25.92414   30.64911 
EHD3 IC     28.25187 
EHD4 IC     29.62248 
EIF2B3 IC     24.95084 
EIF5 IC     25.77345 
ELFN2 M     27.5582 
ELMO2 IC     26.27871 
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EMILIN1 IC/S 29.66984 27.77475 31.03605 
ENG M   25.97461 32.00021 
ENOPH1 IC 26.21552     
ENPP1 M     30.42673 
ENPP2 IC/M 28.51252     
ENSA IC     27.07527 
EPB41L1 IC     26.91504 
EPB41L1 IC     26.38871 
EPB41L2 IC     30.713 
EPB41L5 IC     26.53978 
EPHA2 M   27.98501 32.92589 
EPHA4 IC/M/S     28.01286 
EPHB2 M/S     30.9764 
ERBB2 IC/M     24.61912 
EREG M     27.04767 
ERP44 S     26.65347 
ESD IC     28.90047 
ESR1 IC 30.8498 27.2496 31.78582 
ETF1 IC     26.77803 
ETHE1 IC     27.39024 
EVA1A IC     25.83162 
EVA1B IC     31.68921 
EXOC4 IC     26.56224 
EXOC5 IC     25.73983 
EXOC7 IC     26.10321 
EXOC8 IC     27.47053 
F10 S 27.06094 28.18829   
F11 IC/S   28.71773   
F2R M/S     27.74002 
F2RL1 M     25.44823 
F3 IC/M   29.05341 31.56602 
FABP1 IC 27.43231 28.40578   
FABP5 IC   26.08082 30.12982 
FAH IC 25.50598     
FAM114A1 IC     27.76194 
FAM126A IC     26.0311 
FAM129B IC 25.99097   30.59549 
FAM171A1 M/S     27.24642 
FAM171A2 M     26.09137 
FAM171B M/S     28.5339 
FAM49B IC     29.78369 
FAM65A IC     26.51711 
FAP IC/S     30.30211 
FAS M/S     31.19182 
FAT1 IC/M/S   26.36902 33.41288 
FAT4 M     28.47469 
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FBN1 S 28.3583     
FERMT2 IC     29.37856 
FGFR1 IC/M/S     24.34287 
FGG IC/S     25.62035 
FGL2 S   26.36622   
FH IC     25.32206 
FHL2 IC 28.6511   30.34355 
FKBP10 IC/S     26.56547 
FLRT3 M     29.59927 
FMNL3 IC     29.54856 
FMOD S 28.17123     
FN1 IC/S 35.76691 36.59223 34.29031 
FN3KRP IC     25.52515 
FRMD6 IC     26.70631 
FST IC/S   27.39367   
FSTL1 IC/S 30.69041 30.98313 28.16377 
FTH1 IC   27.73032 28.87451 
FTL IC     27.46605 
FZD6 M     26.94536 
G6PD IC 27.37021 25.97207 31.64911 
GABARAP IC     25.7994 
GALK1 IC     28.01353 
GALNT2 S     24.48103 
GAP43 IC     24.4749 
GBE1 IC 27.57513   28.23225 
GCLC IC/M     26.39736 
GDF15 IC/M 31.68923 30.19443 31.41039 
GFPT1 IC/M     28.53562 
GFPT2 IC/M/S     25.9191 
GGT1;GGT3P;GGT2 IC/M/S     28.74391 
GIT2 IC     26.32463 
GJA1 M     30.66711 
GLG1 IC/M/S     27.39026 
GLIPR1 IC/M/S     27.65705 
GLIPR2 IC     30.11239 
GLOD4 IC     28.05197 
GLRX IC     28.92269 
GLRX3 IC     28.45656 
GMFB IC     27.19947 
GMPPA IC     26.20434 
GMPR2 IC     25.71238 
GNA12 IC     26.07672 
GNA13 IC     30.48645 
GNG10 IC     27.85776 
GNG11 IC     27.49076 
GNG2 IC     30.39266 
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GNL1 IC     24.38264 
GOLGA7 IC     27.40664 
GOLIM4 M     26.83744 
GOT1 IC     27.85935 
GPC1 IC/M/S 26.92725 27.71591 27.74539 
GPR68 M     25.64909 
GPRIN1 IC     29.59752 
GPS1 IC     25.49782 
GPSM1 IC     26.21096 
GPX1 IC     26.72293 
GPX3;GPX6;GPX5 IC/S 28.1914   26.03492 
GRB2 IC     26.98962 
GREM1 S   28.83923 31.2571 
GRHPR IC     27.21482 
GRK5 IC     28.3494 
GRN IC/S   26.4658 26.17801 
GSK3A IC     25.45356 
GSK3B IC     26.50201 
GSR IC     26.69868 
GSS IC     26.57943 
GSTA3 IC 25.82863     
HABP2 IC/S   26.19092   
HAGH IC 27.98749 27.1981 28.23525 
hCG_2004507;CSNK1G1 IC/M     28.07493 
HEBP1 IC     26.7726 
HEBP2 IC 28.03107   27.96101 
HERC4 IC/M     25.60331 
HEXA S 25.66427     
HEXB IC/S 27.12904     
HGF IC/S 28.51953     
HGFAC S 29.46615 28.38275   
HGS IC 27.19999   27.67898 
HINT1 IC 29.27498 27.14992 30.67472 
HINT3 IC     27.12627 
HLA-B IC/M     28.97657 
HLA-B IC/M     28.61584 
HLA-B IC/M     31.19205 
HLA-B IC/M     28.87998 
HLA-C M/S 27.92785   28.24611 
HLA-C M/S 27.48148   30.023 
HN1 IC     26.94596 
HPCAL1;HPCA IC 27.27584   27.26928 
HPD IC       
HSP90AB2P IC     27.73611 
HSPB1 IC 28.80611 27.57506 30.95106 
HSPB6 IC     27.55946 
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HSPG2 IC/S 27.91846 28.57577   
HTRA1 IC/S 28.15631   27.53752 
ICAM1 M/S 26.37607 28.24003 34.83569 
ICAM5 IC/M     28.18847 
IDH1 IC 27.08106   27.89192 
IDI1 IC     26.53806 
IGF1R IC/M     25.83639 
IGF2 M/S 28.53118 29.47018   
IGF2R IC/M 28.78364 28.33133 28.24068 
IGFALS IC/M/S 27.59734     
IGFBP2 IC/S 32.40348 29.41945   
IGFBP3 IC/S   27.27775   
IGFBP4 S 32.04973 32.30362   
IGFBP5 S 33.34144 32.44885 30.93588 
IGFBP6 S 29.00944 28.49255   
IGFBP7 S 29.87992 31.20537 27.90544 
IGSF8 M/S   28.27907 31.6957 
IL1B IC     28.28831 
IL1RAP IC/M/S   26.89943 26.65693 
IL6 IC/S 28.80475 28.81594 29.03625 
IL6ST M/S     27.84342 
ILK IC     30.57864 
IMPA1 IC     26.6741 
IMPAD1 IC/M     25.22971 
INHBA S 31.73799 30.12643 27.19543 
INPP5A IC/S     27.85168 
IRGQ IC     27.2548 
ISG15 IC 24.76273     
IST1 IC     29.633 
ITCH IC     27.01664 
ITFG3 IC/M     29.72018 
ITGA1 M   26.9212 33.60386 
ITGA11 M     29.91783 
ITGA2 M   28.09908 30.9677 
ITGA2 M 28.438 31.33204 36.067 
ITGA3 IC/M   27.24644 33.6525 
ITGA4 M/S     29.6861 
ITGA5 M   27.72002 32.4898 
ITGA6 IC/M     32.19271 
ITGA7 IC/M     27.39176 
ITGAV IC/M 23.42509 26.80322 33.61011 
ITGB1BP1 IC     25.6733 
ITGB3 M/S     32.75568 
ITGB5 IC/M   26.51773 32.67752 
ITGB8 M     28.02858 
ITPA IC     25.47015 
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JAG1 IC/M     26.97356 
JAM3 IC/M     27.66632 
KIDINS220 IC/M     26.89654 
KIRREL M     29.56005 
KLC1 IC     29.06334 
KLC2 IC     26.79641 
KLKB1 IC/S   27.03479   
KPNA3 IC     25.42527 
KRIT1 IC     26.83184 
L1CAM IC/M/S     27.54319 
LAMA4 IC/S 26.85994 27.91092 28.43366 
LAMA5 IC/S   26.91411 28.55402 
LAMB1 IC/S 28.98191 28.48797 29.95112 
LAMC1 IC/S 29.55868 29.01692 29.93747 
LAMP1 M     29.20407 
LAMP2 M     26.10976 
LAMTOR1 IC     26.16793 
LAP3 IC 25.26046 25.65875 29.9574 
LASP1 IC 25.96213 27.67939 30.7955 
LGALS3 IC 29.00945   29.59699 
LHFPL2 M     27.45256 
LIF IC/S 29.03465     
LIMS1 IC     29.17086 
LIN7C IC     30.24314 
LLGL1 IC     27.64139 
LMAN2 IC/M/S 27.05191     
LOXL2 IC/S 30.13479 30.89556 28.46527 
LPAR1 IC/S     27.45228 
LPP IC 27.09394     
LPXN IC     26.55418 
LRPAP1 S     26.26091 
LRRC17 S 28.29987   30.65916 
LRRC47 IC     26.05596 
LRRC57 IC     29.06475 
LRRC8C M     26.21609 
LRRFIP1 IC     25.71015 
LRSAM1 IC     25.70578 
LTBP2 IC/S   26.09978   
LTBR IC/M     27.34736 
LXN IC     28.4361 
LYPLA1 IC/M     26.91693 
LYPLA2 IC     27.87896 
LYZ S 28.8453     
MAMDC2 S     27.23568 
MAN1A1 M 26.46734     
MAN2A1 M 25.75539     
323 
 
MAN2B1 S 25.99174     
MANBA S 26.64081     
MAP2K1 IC     28.29473 
MAP2K2 IC     27.36154 
MAP3K9 IC/S     30.37108 
MAP4K4 IC     31.46298 
MAPK1 IC 27.88615     
MAPK3 IC     26.76223 
MAPRE2 IC 26.27651     
MARK2 IC     28.00038 
MARK3 IC/M     26.9612 
MCAM M     30.49765 
MCFD2 IC/S 27.67528     
MDH1 IC 27.18726 27.368 30.75037 
ME1 IC     25.80486 
MEMO1 IC/M     27.21466 
METTL2B IC/M 28.13901     
MFGE8 S 27.74061   32.80285 
MGAT5 M 26.92599     
MGLL IC     28.12644 
MGRN1 IC     24.9537 
MICA M     27.15788 
MICAL1 IC     25.50143 
MIF IC 29.71797 27.77607 30.11083 
MINK1 IC     29.27495 
MME IC/M   26.14485 32.59869 
MMP1 S 34.51389 34.7442 30.61922 
MMP14 M/S 26.61133 27.17589 33.32472 
MMP2 IC/S 31.43456 31.55919 30.86856 
MMP3 IC/S 31.50699 29.1156 27.66794 
MOB1A;MOB1B IC     28.60301 
MPZL1 M/S     29.77025 
MRAS IC     27.38729 
MRC2 IC/M 27.96275 27.662 27.30278 
MSRA IC/S     26.08895 
MST1 IC/S 25.72193     
MT1F IC     26.14225 
MT2A IC 27.96712 31.34174 32.20433 
MVB12A IC     26.35701 
MVP IC 26.80424 26.65349 33.26288 
MXRA8 M 26.79608     
MYADM M     27.39237 
MYDGF IC/S   27.11068 27.77214 
MYLK IC/M     24.69938 
MYO10 IC     27.59087 
MYOF IC/M     32.58382 
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NAGK IC     26.00601 
NANS IC     27.46246 
NAPA IC     29.2588 
NAPG IC     28.75444 
NCKAP1 M     29.54234 
NCS1 IC     26.00949 
NCSTN IC/M/S     28.21193 
NDRG1 IC     29.62173 
NDRG3 IC     26.39334 
NEDD4 IC     25.49854 
NEDD8;NEDD8-MDP1 IC   27.32939 30.13923 
NEO1 M     27.73109 
NES IC     27.45899 
NF2 IC     28.93109 
NFKB2 IC     25.8123 
NID1 S 28.82867 29.00822 29.22574 
NID2 IC/S 28.96072 28.61428 28.15737 
NINJ1 M     27.812 
NIT2 IC     26.33196 
NOTCH1 M     28.4551 
NOTCH2 IC/M     30.49876 
NOTCH3 IC/M/S     27.07502 
NPC2 IC/S     26.22055 
NPTX1 S 27.10634     
NRG1 IC/M/S 27.16077   27.38026 
NRP1 IC/M/S     31.72999 
NRP2 M/S     28.84191 
NT5E IC/M/S 28.30493 31.75785 35.61343 
NTM IC/M/S   27.4291 29.63415 
NTSR1 M     27.61587 
NUCB1 S 31.42384 28.97977 26.32567 
NUCB2;Nucb2;HEL-S-109 IC/S       
NUDT5 IC 27.2056   28.00582 
NUMB IC     29.93208 
NUTF2 IC 27.19489   28.13441 
OGFR IC     23.93844 
OMD S   27.81899   
OPTN IC     25.54466 
ORAI1 M/S     27.77308 
OSBP IC     26.71679 
OSMR IC/M/S     26.58643 
OTUB1 IC 27.34647 26.0344 28.05048 
OXSR1 IC     27.14431 
P4HA1 S     26.31968 
PACSIN2 IC     29.84604 
PAFAH1B1 IC 27.99133   27.85709 
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PAFAH1B2 IC 26.55805     
PAFAH1B3 IC     24.91975 
PAG1 IC     29.32336 
PAK2 IC     28.41676 
PALLD IC     26.83318 
PAM IC/M/S 26.92196     
PAMR1 IC/S 26.62846     
PAPPA S 27.62469 28.62732 27.87462 
PAPSS2 IC     27.40706 
PARP4 IC     28.48363 
PARVA IC/M     29.03739 
PBXIP1 IC/M     29.22529 
PCBD1 IC 27.56312     
PCDH18 IC/M     27.61936 
PCDH7 IC/M     26.54544 
PCDH9 M     27.44591 
PCDHGA4;PCDHGA7 M     25.04758 
PCDHGB4 M     25.51563 
PCDHGB5 M     28.72165 
PCDHGC3 IC/M     26.52571 
PCOLCE S 28.19793 27.41966   
PDCD10 IC     28.59111 
PDCD6 IC     28.36998 
PDCD6IP IC   27.80326 33.89684 
PDGFC S     26.56183 
PDGFRB IC/S     30.66343 
PDLIM1 IC 28.42627 27.91281 30.79498 
PDLIM4 IC 27.32045   29.71059 
PDLIM5 IC/M     27.21206 
PDPK1;PDPK2P IC     26.58039 
PDXK IC     27.06145 
PEA15 IC     27.54073 
PFDN1 IC/M     28.46684 
PFDN2 IC     28.81587 
PFDN6 IC     28.67132 
PFKL IC     27.53484 
PFKM IC     25.70935 
PFN2 IC/M     29.62106 
PGLS IC 26.66479   27.80562 
PGM1 IC     26.22002 
PGM3 IC 27.98317     
PGRMC2 IC/M     25.37246 
PHLDA1 IC     29.58839 
PHLDA2 IC     29.27095 
PHLDA3 IC     27.76765 
PHLDB1 IC     30.4321 
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PHPT1 IC 27.1898   28.28097 
PI4K2A IC     25.50851 
PICALM IC     26.44003 
PIN1 IC     27.57633 
PIP4K2A IC     25.99935 
PIP4K2B IC     28.50235 
PIP5K1A IC     26.77896 
PITPNA IC     26.84418 
PITPNB IC     27.6188 
PLAT S 30.8295 30.04223 30.20124 
PLAU IC/S 34.51733 34.50888 32.6261 
PLAUR S     31.49907 
PLCB1 IC     24.80887 
PLCB3 IC     28.04281 
PLCB4 IC     26.73405 
PLCD1 IC     26.04067 
PLCD3 IC     26.41027 
PLD1 IC     25.90699 
PLD3 IC/M     25.81915 
PLEKHO2 IC     29.21452 
PLIN3 IC 28.00106   29.62529 
PLOD1 S 31.51486 28.23882 27.85483 
PLOD2 IC/M/S 26.52342     
PLOD3 IC/S 28.68864     
PLSCR3;TMEM256-PLSCR3 IC/M     29.20232 
PLTP IC/S 26.64294   26.86514 
PLXDC2 M       
PLXNA1 M     30.59561 
PLXNA3 M     26.975 
PLXNB1 M     27.50933 
PLXNB2 IC/M/S   26.22972 33.11894 
PMM2 IC     26.47054 
POSTN S 26.90807 27.09157   
POSTN S 32.02559 28.925 27.70921 
PPFIA1 IC/M     26.24058 
PPFIBP1 IC     29.24074 
PPP1R7 IC     27.55985 
PPP5C IC     27.28061 
PPP6C IC     25.31343 
PRDX5 IC 28.0387   28.58629 
PRKAA1 IC     28.63019 
PRKACA;PRKACB;KIN27 IC     26.34648 
PRKCA IC     29.74905 
PRKCDBP IC     26.97614 
PROCR IC/M 26.9131     
PRSS23 IC/S 28.30412 28.5858 30.29482 
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PSAP IC/S 30.5568 29.66366 29.05495 
PSD3 IC     26.94085 
PSEN1 IC/M     26.41718 
PSMD10 IC     27.91199 
PSMD5 IC     25.46802 
PSMD9 IC     27.94733 
PSME1 IC 26.40553   26.27871 
PTGFRN M     27.18141 
PTGR1 IC     26.71171 
PTK7 IC/M/S     31.0224 
PTMS IC   28.78505 25.49135 
PTP4A2 IC     28.08814 
PTPN11 IC     26.9426 
PTPRA M/S     29.23386 
PTPRD;PTPRS;PTPRF M/S     25.22142 
PTPRJ M/S     27.31277 
PTPRK IC/M     29.47702 
PTRF IC   29.44804 30.12986 
PTRHD1 IC     25.79263 
PTTG1IP M/S     27.63104 
PTX3 S 29.16739 30.04007 31.0676 
PVR IC/M/S 25.90889   30.49625 
PVRL2 IC/M     29.65869 
PVRL3 IC/M     28.3468 
PXDN IC/S 33.03299 30.29812 33.43946 
PXN IC     28.54941 
QDPR IC     26.81043 
QSOX1 IC/M/S 31.9553 27.79634 25.95287 
RAB10 IC     29.59976 
RAB11B;RAB11A IC 25.70887   31.50569 
RAB12 IC     25.12749 
RAB13 IC     31.56341 
RAB18 IC/M     26.25745 
RAB21 IC     27.87566 
RAB22A IC     28.12421 
RAB23 IC     28.39584 
RAB2A IC     28.48587 
RAB34 IC     28.25073 
RAB35 IC     30.301 
RAB3A IC     26.86904 
RAB3B IC     26.34081 
RAB6A IC     28.98685 
RAB8A IC     29.73833 
RAB8B IC     29.27504 
RAB9A;RAB9B IC     25.81714 
RAC2 IC     30.96855 
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RAD23B IC     28.3111 
RAF1 IC     27.55069 
RAP2B IC     28.08048 
RAP2C IC     29.61823 
RASA1 IC     24.14095 
RASA2 S     26.59295 
RASA3 IC     29.45251 
RBP4 IC/S 32.01303 30.53825 26.99356 
RCN3 IC/M/S 27.86834     
RECK M     28.61125 
REEP5 M     26.59033 
RELB IC 31.31446 31.70667   
RELL1 M     28.18362 
REPS1 IC     27.79677 
RGN IC 27.09418     
RGS17 IC     28.07308 
RHBDF1 IC/M     29.56479 
RHBDF2 IC/M     25.86072 
RHOG IC     32.07817 
RIN1 IC     27.42455 
RIT1 IC     25.95516 
RNASE4 S 29.72282     
RND3 IC     29.90227 
RNH1 IC 26.50662   28.76448 
RNPEP IC/S     26.10546 
ROBO1 IC/M     28.99611 
RTN4 IC/M   26.90816 28.92491 
S100A10 M 29.5999 27.19331 32.44305 
S100A13 IC 29.24237 29.64687 33.30081 
S100A16 IC   26.7179 31.56861 
S100A4 IC     24.86462 
S100A6 IC 31.42528 31.02325 32.75807 
SARS IC 26.60463   28.40783 
SBDS IC     26.08909 
SCAMP1 IC/M     25.34653 
SCRN1 IC     28.78911 
SDC2 M     27.06735 
SDC4 M   26.17773 26.2302 
SDCBP IC   28.12719 32.3221 
SEC13 IC     27.39036 
SEC22B IC/M     25.284 
SEC24C IC     26.65125 
SEC24D IC     26.3614 
SEC31A IC/S     28.63002 
SEMA3A IC/S 28.08983     
SEMA6D IC/M/S     25.54213 
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SEMA7A IC/M 30.38024 29.70479 28.13664 
SEPT11 IC 28.33396   29.56581 
SEPT2 IC 28.14288   28.83201 
SEPT7 IC 27.39129   29.66791 
SEPT9 IC/S 26.55942   29.86548 
SERPINB2;SERPINB10 S 26.31261   30.50017 
SERPINB6 IC 26.49354   27.30097 
SERPINB8 IC 25.98022   26.61186 
SERPINE1 S 32.54554 29.23792 28.82729 
SERPINE2 S     27.0296 
SGCD M     29.54357 
SGCE M     25.72324 
SGTA IC     27.48779 
SH3BGRL IC     27.97101 
SH3BP4 IC     29.36881 
SH3GL1 IC     29.75113 
SH3KBP1 IC     28.298 
SH3PXD2B IC     25.2054 
SHC1;SHC2 IC     25.82522 
SIRPA M     26.74977 
SLC12A2 M     28.83066 
SLC12A4 M     28.35339 
SLC12A7 M     26.60083 
SLC14A1 IC/M     26.55696 
SLC16A3 M     31.47539 
SLC16A6 M     31.15539 
SLC16A7 M     25.19583 
SLC1A3 M     26.3604 
SLC1A4 M     26.025 
SLC20A1 M     31.0752 
SLC20A2 M     27.76431 
SLC26A2 IC/M     26.74483 
SLC2A3;SLC2A14 M     31.1226 
SLC30A1 M     28.96439 
SLC38A1 IC/M     28.88247 
SLC38A2 M     30.95973 
SLC39A10 M/S     28.85957 
SLC39A14 M/S     28.83616 
SLC39A6 M     27.78814 
SLC3A2 IC/M 24.79139 29.06569 33.15626 
SLC3A2 IC/M     27.12538 
SLC44A1 M     28.43412 
SLC44A2 IC/M     27.34744 
SLC4A2 IC/M     25.51587 
SLC4A4 IC/M     28.65312 
SLC4A7 M     29.12876 
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SLC4A7 M     27.49761 
SLC6A15 IC/M     30.19182 
SLC6A8 IC/M     27.81127 
SLC7A11 M     26.8739 
SLC7A2 M     28.23259 
SLC7A5 M   25.22144 31.02608 
SLC7A6 IC/M     26.77516 
SLC9A1 M     30.62636 
SLC9A3R2 IC     27.55541 
SLITRK6 M     27.29312 
SLK IC     28.16278 
SMAD1 IC     26.74425 
SMAD3 IC     26.40895 
SMS IC     27.40994 
SMURF2 IC     28.92193 
SNAP29 IC     27.97128 
SNTB1 S     27.14639 
SNTB2 IC/S     29.2629 
SNX1 IC     26.11813 
SNX12 IC     26.51647 
SNX18 IC     25.74141 
SNX2 IC     25.70431 
SNX3 IC     29.54729 
SNX6 IC     26.65283 
SNX8 IC     24.89714 
SNX9 IC     28.70827 
SOD2 IC 27.68439     
SPARC IC/S 33.04401 33.29606 29.09241 
SPG20 IC     25.25945 
SPINK6 S   27.65162   
SPON2 IC/S 31.83777 29.15317 27.46104 
SPRED1 IC/M     25.46456 
SPRY4 IC/M     29.75602 
SQSTM1 IC     29.41323 
SRI IC     29.14304 
SRM IC     28.21769 
SRPX S 26.77399   26.57449 
SSC5D IC/S   27.42494 27.91464 
STAM IC     28.3395 
STAMBP IC     25.59631 
STAT1 IC     26.62911 
STAT3 IC     24.592 
STC1 IC/S 33.90657 30.39974 30.8288 
STC2 IC/S 30.68887 26.90369 27.23099 
STEAP3 M     29.40799 
STK10 IC     29.16569 
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STK24 IC     29.35902 
STOM M    27.66963 33.22626 
STRAP IC     28.27549 
STX12 IC/M     27.0022 
STX1B IC/M     26.46746 
STX2 M     27.33289 
STX3 IC/M     28.62357 
STX4 IC/M     31.71933 
STX7 IC/M     28.86139 
STXBP1 IC     30.63117 
STXBP3 IC     30.75911 
SUGT1 IC     27.05028 
SWAP70 IC     25.69716 
TALDO1 IC 27.14988     
TANC1 IC     26.13097 
TAOK1 IC     29.44247 
TAOK3 IC     29.35522 
TAX1BP3 IC     27.06298 
TBC1D10A IC     24.61668 
TBC1D10B IC     26.30486 
TBC1D24 IC     26.90921 
TCEB1 IC     30.14599 
TCEB2 IC     28.30707 
TENM3 IC/M     28.00556 
TENM4 IC/M     27.94677 
TFPI S   28.31768 27.09493 
TFPI2 IC/S 31.08841 29.37049 28.62438 
TFRC IC/M 26.17429   29.32796 
TGFBI IC/S 33.4858 33.57981 33.05596 
TGFBR2 M     28.52543 
TGM2 IC 29.69313 29.89197 32.62613 
TGOLN2 M     25.43608 
THBD M     29.35791 
THBS1 S 28.46822 30.83725 27.42927 
THBS3 IC/S   27.4583   
THBS4 IC/S   28.78571   
THOP1 IC     24.89549 
THSD4 M/S     26.62123 
THY1 M/S 27.45928   31.45987 
TIGAR IC     27.57929 
TIMP1 IC/S 34.69346 33.77536 31.34348 
TIMP2 IC/S 30.0822 30.43477 30.62524 
TIMP3 S     26.71011 
TIPRL IC     26.3464 
TLN2 IC     25.24303 
TMBIM1 IC/M     25.41109 
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TMEM132A IC/M 26.3662 25.97524 28.50434 
TMEM2 IC/M     29.70256 
TMEM200A M     26.19149 
TMEM237 M     24.73294 
TMEM30A IC/M     26.97923 
TMEM51 M     29.14249 
TMSB10 IC   31.38119 33.02569 
TMSB4X IC 28.41096 31.21314 33.6013 
TNC IC/S 31.30153 32.09578 33.71857 
TNFAIP2 IC     25.40051 
TNFRSF10B M     29.6686 
TNFRSF10C IC/M     26.54047 
TNFRSF10D M     28.96876 
TNFRSF11B S 29.10577 28.27824 27.62111 
TNFRSF12A M/S 27.38242 26.84709 27.63399 
TNFSF15 IC/S 27.12834     
TNIK IC/S     26.547 
TNKS1BP1 IC     28.49444 
TNPO1;TNPO2 IC     26.76284 
TNS1 IC     28.30429 
TOLLIP IC     27.84703 
TOM1 IC     28.52424 
TOMM34 IC     26.13038 
TP53I3 IC     27.51487 
TPBG M     31.56175 
TPD52L2 IC   26.03844 29.05898 
TPPP3 IC     27.31166 
TRAFD1 IC     24.71594 
TRHDE IC/M     27.37809 
TRIM25 IC     27.64602 
TRIO IC/S     26.58948 
TRIOBP IC     27.60303 
TRIP10 IC     27.58512 
TRMT112 IC     24.96111 
TRPA1 M     30.33752 
TRPV2 IC/M     26.28234 
TSG101 IC     28.79487 
TSPAN14 M   28.95794 29.47107 
TSPAN4 M     26.06594 
TSPAN5 M     28.06747 
TSPAN6 IC/M     27.55766 
TSPAN9 M     28.63957 
TSTA3 IC     26.16704 
TTC9C IC     25.63504 
TTYH3 M     29.878 
TUBB3 IC 27.97021 27.9849 30.39515 
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TWF2 IC 28.1489   28.1049 
TWSG1 S 27.99457     
TXNDC17 IC   28.66179 30.59118 
TXNDC5 IC/S     27.64334 
TXNL1 IC     28.49805 
TXNRD1 IC 29.11404   29.45654 
UBA6 IC     26.62518 
UBASH3B IC     25.59314 
UBE2D3;UBE2D2 IC     27.18207 
UBE2Z IC     25.54217 
UBFD1 IC     25.81768 
UBTD1 IC     29.73152 
UCHL3 IC     27.18223 
UFM1 IC     28.02705 
UGDH IC 26.72845   28.80932 
UGP2 IC 27.29395 25.58408 28.19581 
ULBP1 M     26.66503 
ULBP3 S     26.04796 
USO1 IC     26.41639 
UTRN IC     28.02263 
VAMP3 M     28.2984 
VANGL1 M     25.86647 
VASN M 28.55059     
VASP IC     30.82736 
VAT1L IC     27.38023 
VBP1 IC     27.38192 
VCAN IC/S 25.07668 28.20725 32.27998 
VEGFA IC/S 28.15244     
VEGFA IC/S   25.64606 25.31255 
VNN1 S 29.50603     
VNN2 IC/M/S       
VPS26A IC     26.21141 
VPS28 IC     28.67883 
VPS29 IC     26.81575 
VPS35 IC 27.61675   27.43072 
VPS37B IC     27.78124 
VPS45 IC     24.79123 
VPS4A IC     28.15415 
VPS4B IC     28.7188 
VTA1 IC     27.09741 
VWA5A IC     28.19843 
WASF2 IC     28.61473 
WDR48 IC     27.57496 
WLS IC/M     27.75981 
WNT5A S 29.76394 28.8759 31.56367 
WNT5B S 25.71335     
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XPNPEP1 IC     26.84565 
YKT6 IC     28.78298 
ZDHHC20 M     26.75799 





8.3 Mass Spectrometry 3: Proteomic assessment of Conditioned Media and  
EVs isolated by SEC from vector and OIS IMR90s 
This data forms the basis of section 4.8 and is referred to throughout as MS3. Conditioned 
media (CM) and SEC fractions 8 (F8) and 20 (F20) were collected in triplicate from vector and 
OIS IMR90s. These were analysed by mass spectrometry through collaboration with the 
CECAD proteomic facility (University of Cologne). Gene lists detailing the label-free 
quantitation intensities (LFQ) for each sample were produced and analysed according to 
section 2.13.2. Mean LFQ intensity values (Mean LFQ) from OIS CM (blue), OIS F20 (orange), 
OIS F8 (yellow), vector CM (green), vector F20 (grey) and vector F8 (dark grey) replicates are 
detailed.  
 Mean LFQ Intensity 


















AARS 24.99 25.76 26.03 23.79 25.60 26.92 
ABCA1 24.61 24.90 29.06 24.66 24.98 24.35 
ABCC4 23.74 25.08 26.61 24.16 24.74 24.48 
ABI2 24.12 25.46 25.13 24.33 25.68 24.08 
ACE 25.06 25.15 27.67 24.29 25.38 24.95 
ACLY 27.66 26.54 28.65 25.07 25.16 28.13 
ACOT7 24.16 25.08 26.29 24.55 25.05 25.00 
ACSL4 24.15 24.98 29.00 24.17 25.10 24.43 
ACTC1;ACTA
1 31.03 25.28 30.14 30.35 28.15 31.13 
ACTG1 35.15 34.50 35.81 35.09 34.59 36.22 
ACTN4 30.44 29.43 29.52 31.00 28.13 30.11 
ACTR2 27.93 27.83 29.00 27.32 28.58 27.69 
ADAM10 29.03 28.03 32.05 28.22 28.69 29.39 
ADAMTS7 25.70 24.50 24.28 24.77 24.47 25.34 
ADSS 24.20 24.73 26.46 24.92 25.11 24.09 
AGRN 32.33 32.86 32.74 31.49 32.33 33.91 
AHCYL1;AHC
YL2 23.59 25.16 27.06 24.61 25.28 25.07 
AHNAK 29.43 26.52 31.18 29.46 27.54 32.09 
AIMP2 24.14 24.87 26.51 24.16 25.14 24.28 
AKAP12 24.78 24.75 25.86 24.66 24.59 24.79 
ALCAM 28.88 26.85 31.25 28.45 29.87 30.14 
ANGPTL2 26.45 25.97 25.24 27.98 25.17 29.14 
ANKFY1 24.83 25.32 25.66 24.37 24.86 24.35 
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ANO6 24.06 24.62 27.39 24.38 25.21 26.68 
ANPEP 26.32 25.71 32.63 24.65 27.61 29.77 
ANTXR2 24.03 24.54 28.55 24.87 24.56 26.22 
ANXA2;ANX
A2P2 29.37 31.62 33.62 28.62 32.30 34.53 
ANXA5 26.41 31.80 32.30 24.28 32.00 33.96 
ANXA7 24.08 24.60 26.58 24.38 25.17 25.02 
AP1G1 24.30 24.49 25.24 23.36 25.15 24.12 
AP2B1 27.18 24.09 27.14 26.76 24.89 24.65 
AP2M1 25.03 25.09 26.64 24.47 24.89 24.82 
APOE 26.75 23.99 26.27 24.03 25.40 24.03 
ARG1 24.13 25.26 23.52 24.53 24.53 25.52 
ARHGAP1 24.62 24.55 23.74 25.18 24.79 25.55 
ARPC1B 29.49 27.70 29.27 27.89 26.95 27.94 
ARPC3 25.45 24.10 26.53 26.61 24.55 24.70 
ARPC4;ARPC
4-TTLL3 24.16 27.13 27.65 24.27 27.24 27.10 
ATP1A1 26.10 29.67 33.09 24.68 31.76 31.17 
ATP1B1 24.17 24.44 27.03 24.29 24.96 24.53 
ATP2A2 24.78 25.28 27.15 24.32 24.81 27.96 
ATP5A1 26.23 25.95 27.12 27.02 26.75 28.33 
ATP6V1G1 26.55 25.09 27.38 24.20 25.92 24.43 
B4GAT1 27.21 25.45 23.79 26.77 25.28 26.41 
BLVRB 24.95 25.14 25.27 25.08 25.35 24.80 
BMP1 28.30 27.48 27.87 28.40 27.48 24.41 
BMP2 30.51 24.79 26.70 24.68 25.23 24.43 
BSG 23.61 26.78 31.16 24.78 31.03 29.33 
BTN2A1 24.80 24.77 29.05 24.31 25.06 24.85 
C1QBP 25.21 24.93 24.78 25.89 24.80 23.86 
C1R 31.25 31.26 24.57 33.04 30.23 28.75 
C1S 31.69 31.57 24.35 33.03 30.21 27.87 
CAB39 24.26 24.65 26.70 24.04 24.83 24.64 
CACNA2D1 26.58 24.08 31.39 24.65 27.70 29.32 
CAMK2D 24.57 25.04 24.58 24.77 25.26 26.00 
CAP1 30.95 24.64 30.14 28.75 24.92 29.15 
CAPN1 24.19 25.17 23.99 24.15 24.57 26.08 
CARS 23.79 24.68 26.06 23.35 24.92 25.29 
CAT 24.30 26.27 23.81 24.25 25.10 25.66 
CAV1 24.06 25.19 27.15 24.46 24.91 29.07 
CBR1 26.84 24.34 27.05 25.34 25.79 26.21 
CCBE1 24.17 24.69 24.48 23.61 25.07 26.70 
CCDC80 25.03 25.14 24.01 28.70 25.05 27.85 
CCT2 27.97 25.27 29.75 27.67 27.26 27.72 
CCT3 26.02 27.22 29.78 25.88 26.69 28.37 
CCT6A 27.87 24.04 29.37 27.89 25.19 28.21 
CCT8 28.21 26.50 30.12 26.83 27.49 28.51 
CD109 25.08 24.58 25.71 24.53 25.82 24.98 
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CD151 27.21 27.45 33.29 24.18 28.27 30.07 
CD276 24.03 24.62 28.53 24.14 25.79 24.26 
CD44 32.88 32.36 35.17 31.16 32.96 34.21 
CD46 24.43 25.71 27.70 24.38 25.44 26.49 
CD47 24.19 24.73 27.40 24.77 25.05 25.35 
CD59 31.45 30.92 34.82 28.95 31.69 32.59 
CD81 28.27 31.80 32.20 25.74 33.60 31.38 
CD82 25.07 25.34 29.58 24.01 26.36 26.70 
CD9 29.17 25.18 33.46 28.18 28.46 30.36 
CD97 23.82 24.57 28.40 23.87 24.74 24.55 
CD99 24.09 23.84 31.08 24.56 28.44 30.12 
CDC37 25.79 24.79 25.85 24.62 24.82 24.19 
CDC42BPB 23.86 25.31 27.19 24.34 25.01 26.53 
CDC42SE1 24.65 24.21 26.00 24.47 25.36 24.00 
CDCP1 25.85 25.10 31.49 24.28 25.17 24.86 
CDH13 29.05 27.83 32.63 27.41 26.76 30.54 
CDH6 28.26 24.87 28.17 28.26 25.03 26.69 
CDK4 24.36 25.52 26.26 23.87 24.68 24.63 
CEMIP 25.40 25.99 24.44 24.32 24.91 27.43 
CHMP1B 23.88 25.97 24.03 24.28 24.93 27.41 
CHMP2A 24.74 25.09 28.45 24.37 24.32 25.03 
CKAP4 27.37 25.03 29.21 26.39 27.79 30.38 
CLDN11 24.33 24.59 24.37 24.24 24.83 29.14 
CLIC1 30.87 25.63 31.35 28.82 29.97 30.03 
CLIC4 30.68 24.45 31.21 29.59 25.18 30.74 
CLSTN1 31.38 27.35 23.99 30.87 24.87 27.24 
COL12A1 34.51 32.13 30.86 35.21 30.10 32.62 
COL15A1 25.21 24.56 23.86 27.22 24.98 27.55 
COL1A1 34.84 35.81 32.26 36.69 35.56 34.03 
COL1A2 34.44 34.84 31.44 37.21 34.69 33.46 
COL3A1 31.82 31.13 24.03 34.52 30.20 29.64 
COL6A1 35.94 36.27 38.52 35.55 37.05 35.61 
COL6A2 35.30 35.83 38.37 34.47 36.68 35.19 
COL6A3 24.77 24.40 30.76 24.02 24.91 24.36 
COL6A3 37.03 38.11 40.20 36.17 39.14 37.26 
COL7A1 28.26 24.35 28.86 25.48 25.41 25.00 
COMT 23.78 24.70 25.06 23.88 24.79 25.40 
COPB2 24.41 25.06 25.58 24.96 25.58 24.64 
CORO1B 27.90 25.43 27.84 25.53 25.28 26.76 
COTL1 29.12 28.45 29.36 29.32 24.59 28.44 
CPNE3 24.01 24.86 28.00 24.38 24.54 26.69 
CRIP2 27.95 25.06 29.35 25.07 25.41 28.07 
CRISPLD2 27.71 26.19 26.95 24.10 25.29 24.19 
CRK 25.72 25.53 27.97 24.55 24.88 24.61 
CS 25.85 25.11 24.57 24.87 24.88 26.28 
CSPG4 30.14 30.47 33.18 25.26 31.35 32.26 
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CTGF 31.42 28.01 28.70 28.49 25.98 24.90 
CTSZ 29.67 27.73 23.67 27.81 26.05 27.33 
CTTN 28.65 25.20 27.92 28.05 24.32 24.53 
CUL2 24.79 24.17 25.94 24.08 25.55 24.88 
CYB5R3 24.48 25.49 26.92 24.47 25.26 24.88 
CYBRD1 25.08 25.42 23.89 24.41 24.54 28.01 
DAP 28.76 27.82 27.66 26.84 25.68 26.57 
DBN1 28.21 24.98 27.35 26.90 25.46 26.55 
DBNL 26.29 25.12 26.92 24.55 24.64 26.28 
DCBLD2 27.89 23.81 28.49 24.54 24.70 24.86 
DCN 30.41 28.66 24.10 36.41 30.02 31.20 
DCTN1;DKFZ
p686E0752 26.57 25.82 26.60 24.56 24.95 25.71 
DDAH1 24.22 24.40 26.99 24.05 25.27 28.23 
DDAH2 27.24 24.80 27.81 26.75 24.89 28.95 
DDR2 24.94 25.00 26.55 23.68 25.09 24.16 
DDX17 24.71 24.77 23.71 23.86 24.15 25.45 
DDX3X;DDX
3Y 23.97 25.06 26.68 24.54 25.15 24.25 
DKFZp566H
1924;NPTN 23.99 24.62 28.38 25.15 24.98 28.94 
DLL4 25.15 24.84 26.68 23.74 24.19 25.01 
DMBT1 25.34 27.45 25.90 23.84 27.46 26.95 
DNAJA1 24.82 24.61 27.34 24.40 24.88 24.54 
DNAJA2 23.59 24.96 26.63 23.74 25.01 24.55 
DNAJC13 24.23 25.45 25.14 24.36 25.57 24.16 
DNASE1L1 24.75 24.39 28.25 23.91 24.74 24.84 
DOCK10 23.10 24.68 26.18 24.31 24.66 24.72 
DPP4 24.45 24.35 28.57 25.27 27.93 27.87 
DPYSL3 26.64 25.70 26.80 26.50 25.22 27.87 
DSTN 29.50 25.41 29.85 27.90 24.97 29.22 
DYNC1H1 27.54 28.50 30.97 25.72 27.35 29.80 
DYNC1I2 27.27 26.42 27.72 25.83 26.94 26.99 
ECE1 24.77 24.51 29.59 24.02 25.98 27.19 
ECM1 34.13 32.51 28.87 33.20 31.11 30.37 
EEF1G 27.93 27.03 27.21 26.39 24.79 28.08 
EFEMP1 26.04 24.54 24.22 29.95 24.57 26.55 
EFNB1 26.43 25.27 27.41 24.05 25.02 26.68 
EGFR 25.36 25.41 32.92 25.21 26.63 30.23 
EHD2 24.83 24.47 28.52 24.37 24.80 29.12 
EIF2S3;EIF2S
3L 25.67 24.83 26.64 23.60 25.05 24.60 
EIF3E 23.67 24.28 25.92 24.75 25.42 24.57 
EIF3I 27.18 25.28 27.52 24.97 24.78 24.01 
EIF4A1;EIF4
A2 29.49 25.79 29.61 27.58 27.00 28.56 
EIF4B 25.60 26.12 26.16 24.10 25.42 24.51 
EIF5A;EIF5A
L1;EIF5A2 29.07 26.34 27.59 29.06 27.53 28.69 
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ELFN2 24.51 24.88 26.14 24.34 24.92 24.87 
EMILIN1 31.37 31.48 32.78 28.77 31.97 30.78 
ENG 26.65 24.83 31.85 23.80 26.22 27.84 
ENPP1 24.60 24.89 28.69 24.18 24.36 24.88 
EPB41L2 24.38 24.73 25.33 24.85 24.80 27.71 
EPB41L2 26.29 24.11 29.87 27.80 26.72 32.05 
EPB41L3 24.70 25.18 26.31 24.62 24.66 27.31 
EPHA2 23.49 25.62 32.05 24.38 28.59 28.62 
EPHB2 25.72 25.33 30.33 24.28 24.95 28.56 
EPHB4 24.70 24.64 27.11 24.24 25.76 24.36 
ERBB2IP 24.36 24.97 26.12 24.81 25.26 24.83 
ESR1 27.27 24.79 30.04 24.40 24.48 24.53 
ESYT1 24.77 25.47 23.77 25.06 24.87 27.12 
EXT2 25.77 24.89 24.31 27.08 25.40 24.65 
F2RL1 23.74 25.35 25.24 24.76 25.48 24.20 
F3 27.35 29.02 32.69 24.28 30.74 30.73 
FABP5 26.05 24.59 24.11 26.84 25.03 25.06 
FAM129B 27.57 25.08 29.40 26.26 24.92 27.14 
FAM171A2 24.16 25.04 24.25 23.85 25.07 26.23 
FAM49B 24.62 25.96 23.83 24.63 24.51 26.14 
FAP 24.61 25.13 28.11 24.67 25.63 25.54 
FARP1 24.34 25.16 30.19 25.04 25.08 31.14 
FARSB 23.74 24.60 25.93 24.39 24.99 24.43 
FAS 24.09 25.36 29.71 24.33 24.87 28.01 
FASN 27.78 28.33 30.05 24.52 24.88 27.95 
FAT1 29.08 27.39 31.94 26.30 27.07 30.88 
FAT4 24.26 25.23 24.25 24.34 24.54 26.66 
FBLN1 28.50 25.16 30.23 31.04 24.82 28.66 
FBN1 32.56 29.43 25.64 33.00 24.85 26.72 
FBN2 30.82 27.52 23.33 32.98 27.59 26.53 
FERMT2 24.17 25.77 25.94 24.16 25.15 26.89 
FHL2 24.84 24.24 27.71 23.89 24.89 28.52 
FHL3 24.65 24.75 25.69 24.41 24.55 24.60 
FKBP10 26.49 24.64 26.79 26.56 25.71 24.86 
FLNB 27.76 24.75 24.08 27.54 24.67 27.01 
FLOT1 24.20 24.46 27.38 24.79 25.04 29.57 
FLOT2 24.17 24.36 23.50 24.27 24.23 27.18 
FLRT3 24.27 24.82 27.65 24.49 25.08 24.70 
FLT1 29.49 25.93 27.74 23.82 25.05 24.27 
FMNL3 24.46 25.03 26.52 24.30 25.25 24.49 
FN3KRP 23.39 24.65 26.41 23.63 24.86 24.00 
FSTL1 33.13 29.57 24.71 34.44 29.30 29.31 
FTH1 24.22 25.85 23.40 24.78 25.12 24.70 
FZD6 24.78 24.48 25.84 23.94 25.05 25.24 
GAS6 27.80 27.30 26.72 30.32 26.85 28.42 
GDF15 32.54 29.56 31.51 26.47 30.17 29.64 
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GDI1 28.03 24.78 27.72 27.09 27.14 24.82 
GFPT1 23.87 24.59 25.86 24.56 24.52 24.62 
GGT1;GGT3
P;GGT2 23.89 25.10 26.85 24.55 25.39 24.74 
GIPC1 23.74 25.44 26.65 25.62 25.39 25.13 
GJA1 24.31 25.17 31.25 23.84 24.09 29.19 
GLI2 23.91 24.50 24.08 24.58 25.27 25.46 
GLIPR1 23.77 25.13 25.52 24.29 25.24 24.81 
GLIPR2 24.92 25.19 28.55 24.66 25.86 29.88 
GLO1 26.78 24.80 23.57 25.81 25.06 24.84 
GNAI1 24.53 24.40 27.11 24.45 24.96 24.21 
GNAI3 24.11 24.96 28.72 23.98 24.92 24.25 
GNAQ 24.34 24.66 26.09 24.29 25.11 24.78 
GNB1 26.89 27.06 31.78 24.20 28.93 30.77 
GNB2 25.43 24.92 31.91 24.16 26.77 30.54 
GNB2L1 26.64 26.12 26.80 25.85 25.38 24.66 
GNB4 24.64 25.14 29.01 24.50 25.35 26.11 
GNG5 24.30 25.40 29.43 23.96 25.12 27.62 
GNS 26.46 25.93 23.90 25.37 25.03 26.52 
GPC1 30.29 28.51 28.36 30.80 28.20 29.92 
GPC6 23.92 24.07 24.77 24.32 24.32 28.80 
GPRC5B 24.28 25.39 24.73 24.78 25.10 28.28 
GPRIN1 24.66 24.48 25.98 23.95 24.82 24.82 
GRB2 24.04 24.50 26.71 24.28 24.78 25.00 
GRK5 24.28 24.84 26.31 24.97 25.30 24.29 
GRN 29.08 28.42 24.16 28.04 27.07 27.86 
GSK3B 24.32 25.27 25.68 24.25 24.86 24.33 
GSTO1 30.20 25.92 28.54 28.01 24.63 24.87 
GSTP1 29.22 25.20 28.51 28.70 25.48 29.47 
H2AFV;H2AF
Z 24.63 24.48 24.53 24.54 24.77 27.63 
H2AFY 24.52 24.88 23.85 24.49 24.61 28.37 
H3F3B;H3F3
A 24.33 28.53 25.39 25.36 28.12 31.82 
HAPLN3 23.39 24.19 29.52 24.47 25.35 24.60 
HEG1 24.90 24.96 25.99 24.78 24.35 28.16 
HGF 33.05 28.91 31.57 30.13 28.18 29.04 
HGFAC 27.83 24.77 23.78 29.06 24.82 24.77 
HGS 24.16 24.91 26.93 24.53 25.20 27.93 
HIST1H1B 26.14 26.83 24.12 28.07 25.67 31.01 
HIST1H1C;HI




ST1H2AA 24.69 25.56 23.79 24.50 25.04 29.16 
HIST1H2BC 24.79 30.80 24.53 24.21 27.93 33.16 
HIST1H2BD 27.19 29.95 28.37 30.10 29.83 35.68 
HIST1H2BH;




H2BFS 24.43 25.27 23.41 24.20 25.19 31.19 
HIST1H4A 26.27 27.16 25.16 27.83 28.49 31.50 
HIST2H2AC;
HIST2H2AA3 25.21 28.24 26.12 29.49 29.15 33.75 
HLA-A 30.00 29.12 33.30 27.04 29.89 31.66 
HLA-B 24.03 24.74 29.19 24.79 25.67 24.23 
HLA-B 23.85 25.06 30.11 24.21 25.76 27.44 
HLA-B 28.61 28.63 31.57 24.22 28.28 29.04 
HLA-B 26.11 25.43 29.56 23.99 25.39 27.59 
HLA-C 24.91 24.82 28.95 24.65 25.60 24.76 
HLA-C 24.59 24.32 26.87 24.06 25.22 24.80 
HLA-C 29.72 24.22 30.04 27.58 24.96 24.73 
HMGB1;HM
GB1P1 29.13 25.33 23.66 29.34 25.51 27.44 
HMGN4 23.62 29.60 24.36 27.35 25.69 29.55 
HNRNPA1;H
NRNPA1L2 28.34 28.53 27.10 29.15 27.73 28.50 
HNRNPA2B1 29.53 27.82 26.65 30.53 28.20 28.13 
HNRNPA3 26.92 25.73 24.74 27.71 26.75 27.62 
HNRNPH1;H
NRNPH2 25.24 25.02 24.28 24.12 24.66 26.10 
HNRNPK 26.87 26.09 26.77 27.38 27.05 27.22 
HNRNPM 25.85 24.56 23.88 24.43 25.16 26.02 
HP1BP3 24.42 24.86 23.38 24.74 24.83 28.02 
HPCA;HPCA
L1;NCALD 24.06 25.21 25.88 23.87 24.38 24.32 
HRAS 32.05 32.91 35.76 24.40 34.35 30.29 
HSP90B1 29.29 27.02 29.70 29.11 27.15 30.45 
HSPA1B;HSP
A1A 27.84 27.29 27.88 27.96 24.69 29.15 
HSPA4 28.38 25.45 28.54 27.25 25.85 27.27 
HSPA8 23.72 25.36 26.70 24.76 24.78 24.05 
HSPG2 30.12 30.12 29.88 32.25 30.62 35.38 
HSPH1 27.05 24.88 27.17 24.20 25.24 24.97 
ICAM1 30.76 29.79 34.76 24.39 32.32 28.83 
ICAM5 28.11 25.80 28.24 25.02 24.85 24.74 
IGFBP3 30.86 26.35 27.71 30.64 24.81 23.84 
IGFBP4 34.37 32.37 27.12 34.41 30.73 29.68 
IGFBP6 31.27 28.72 23.65 30.46 26.30 25.13 
IGSF8 23.77 28.18 31.69 24.32 30.67 31.10 
IL1RAP 24.38 25.08 26.73 24.85 24.16 24.47 
IL6ST 24.45 24.94 30.44 23.82 25.17 24.87 
ILK 24.72 24.90 28.30 24.16 24.93 27.49 
IRGQ 25.13 25.39 26.63 24.30 24.70 24.41 
ITCH 24.47 25.70 25.68 24.57 25.84 24.34 
ITFG3 23.33 24.77 29.89 24.30 25.60 27.42 
ITGA1 25.85 26.50 33.63 24.66 29.77 31.82 
ITGA2 24.40 25.33 30.13 24.21 24.54 25.06 
ITGA2 30.98 30.49 35.51 25.58 31.51 31.03 
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ITGA3 24.36 26.72 32.32 24.28 27.50 31.31 
ITGA4 24.51 25.56 30.53 24.34 24.76 27.31 
ITGA5 25.16 27.78 31.96 23.76 30.47 29.20 
ITGA6 24.36 25.26 31.44 24.19 27.91 24.80 
ITGA8 24.49 25.09 27.95 24.51 25.19 24.63 
ITGAV 25.34 25.34 33.11 24.45 29.09 30.12 
ITGB1 30.92 31.68 35.41 27.24 33.02 32.97 
ITGB3 24.47 24.78 31.59 24.07 28.72 29.85 
ITGB5 26.18 26.77 32.84 23.95 28.00 26.52 
JAK1 24.57 25.64 27.17 24.74 24.58 24.32 
JAM3 24.27 24.97 28.10 24.79 24.95 23.71 
KHDRBS1 26.34 24.89 23.72 26.12 25.55 24.88 
KIRREL 24.10 24.69 29.23 24.02 25.28 28.03 
KLC1 24.64 25.34 26.32 23.69 24.42 24.68 
LAMA2 25.04 26.87 24.40 26.53 26.69 25.88 
LAMA4 29.70 30.55 30.40 32.61 30.64 33.78 
LAMA5 28.58 29.75 30.90 28.24 29.08 32.21 
LAMB1 31.94 31.83 31.76 32.76 31.20 33.85 
LAMB2 23.84 24.64 24.25 23.33 25.31 29.94 
LAMC1 32.49 33.25 32.73 33.14 32.47 34.54 
LAMP1 23.84 25.58 27.73 24.44 25.36 29.18 
LAP3 23.75 25.15 27.00 23.83 25.29 24.64 
LEPRE1 27.09 26.92 26.60 26.96 25.55 24.87 
LLGL1 24.67 24.93 26.69 24.82 25.34 24.46 
LMAN1 23.37 25.24 25.51 23.79 25.57 24.18 
LMNA 30.73 26.59 24.33 32.09 24.86 29.50 
LOXL2 33.81 31.99 30.01 31.99 30.50 32.71 
LPAR1 24.53 25.08 27.71 23.89 24.16 29.69 
LRRC17 26.88 24.84 30.81 25.61 24.64 26.15 
LRRC32 24.82 25.22 25.43 24.48 25.11 24.17 
LRRC47 23.98 25.24 25.82 24.53 24.96 24.90 
LRRC59 27.64 25.17 23.85 26.36 25.58 25.20 
LTBP2 31.73 29.35 26.50 31.95 27.45 29.48 
LUM 29.89 25.21 23.97 33.01 24.61 27.93 
MAP1B 28.08 24.55 23.46 27.24 25.38 24.79 
MAP4K4 25.49 25.08 29.37 24.55 25.62 27.80 
MAPRE1 24.00 24.78 24.28 23.99 25.28 25.27 
MARCKS 27.47 24.51 29.39 29.24 24.70 30.22 
MARCKSL1 24.81 27.75 30.13 25.53 28.88 28.89 
MDK 30.22 24.85 26.78 31.27 24.90 29.39 
MFGE8 31.36 28.99 33.51 32.30 30.68 35.19 
MICA 24.41 25.03 27.60 24.22 25.62 25.16 
MME 24.75 26.14 31.00 24.38 28.45 24.52 
MMP14 30.62 27.08 31.16 26.23 24.70 28.02 
MPZL1 23.61 24.99 28.01 24.63 25.39 24.89 
MRC2 27.80 27.02 28.81 26.94 25.34 27.30 
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MRGPRF 24.17 24.44 25.19 24.57 25.38 28.33 
MT2A 28.63 27.27 30.34 24.78 24.66 26.55 
MXRA8 24.29 25.02 24.39 24.09 25.78 27.23 
MYOF 24.72 24.70 30.30 25.12 24.62 31.33 
NAPA 24.96 24.67 27.35 24.50 25.31 25.04 
NAPG 24.37 24.87 27.68 24.26 24.86 24.29 
NARS 24.64 25.00 23.45 24.24 24.72 25.81 
NCKAP1 24.77 24.61 27.57 24.83 25.17 25.60 
NDRG1 24.55 25.13 28.41 24.34 25.28 25.09 
NES 29.29 26.66 29.02 26.93 25.42 26.86 
NID1 32.16 32.21 31.47 31.95 31.50 33.20 
NID2 32.07 30.87 30.22 33.04 30.77 33.50 
NOTCH1 24.51 24.79 29.15 24.22 25.26 23.58 
NOTCH3 25.06 24.29 27.68 23.91 25.02 26.75 
NPM1 30.58 25.12 23.96 30.67 25.25 28.53 
NRG1 31.80 24.09 28.26 25.34 24.85 26.10 
NRP2 23.91 24.67 27.13 23.84 25.12 25.10 
NT5E 29.74 29.02 33.84 23.87 32.11 31.14 
NTM 28.96 27.99 29.97 25.34 28.94 25.86 
NTN4 24.70 25.54 24.46 28.78 24.98 29.61 
NTSR1 23.81 25.07 28.29 25.17 24.62 25.18 
NUMB 24.20 25.36 28.37 23.83 25.08 24.48 
NUTF2 24.83 25.44 26.55 24.21 24.58 27.66 
OTUB1 25.77 25.19 26.45 24.15 24.68 24.42 
P4HA1 23.99 26.36 28.31 24.31 25.08 26.49 
P4HA2 26.53 25.17 27.60 24.81 25.08 24.60 
PABPC1;PAB
PC3 27.48 25.30 23.40 26.04 25.52 24.83 
PACSIN2 24.97 24.55 26.22 24.46 25.35 24.70 
PACSIN3 24.27 25.28 23.97 24.07 24.75 25.92 
PALLD 24.58 25.22 26.84 24.46 24.66 27.65 
PALM2-
AKAP2;PAL
M2 24.81 25.16 26.20 24.43 25.53 24.69 
PAM 25.38 25.63 23.72 26.16 24.72 24.54 
PAMR1 30.94 28.23 28.93 28.93 25.75 26.01 
PBXIP1 24.52 24.79 26.10 24.82 24.79 27.26 
PCDH7 24.79 25.63 26.03 23.99 25.34 24.30 
PCDHGB4 24.49 25.02 25.56 23.83 25.49 24.77 
PCDHGB5 23.70 24.82 28.10 24.56 25.70 24.77 
PCDHGC3 23.88 24.52 28.35 24.38 25.54 26.58 
PCMT1 26.70 24.55 27.50 24.69 25.05 24.06 
PCOLCE 32.86 31.70 27.58 32.95 30.24 30.88 
PDCD10 24.66 24.39 25.91 23.77 24.28 24.53 
PDCD6IP 26.67 27.19 31.64 24.57 26.60 32.79 
PDGFC 24.62 25.43 26.35 24.71 25.63 24.06 
PDGFRA;FIP
1L1 24.54 25.19 23.88 24.36 25.32 26.67 
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PDGFRB 25.85 25.69 31.36 24.47 28.09 30.69 
PDLIM1 29.03 24.83 28.85 28.04 24.91 28.27 
PDLIM4 27.80 24.37 28.31 23.21 24.75 24.66 
PEBP1 28.42 25.03 27.29 28.39 24.14 28.12 
PFDN1 24.68 25.00 26.42 23.76 25.33 25.80 
PFDN2 27.07 24.87 26.84 24.03 24.63 25.07 
PFKL 24.38 25.13 27.78 23.91 25.50 24.11 
PGRMC1 23.98 24.72 24.26 24.06 25.27 27.00 
PHB 24.92 25.01 25.90 23.96 25.03 24.68 
PHGDH 24.86 25.00 27.17 23.77 25.60 30.23 
PHLDA1 24.75 25.79 28.68 23.78 25.56 25.84 
PHLDA3 24.67 24.77 24.41 24.27 24.61 24.85 
PHLDB1 24.18 25.06 29.04 24.45 24.56 23.94 
PI4KA 24.18 24.43 25.77 24.07 25.20 24.45 
PLAT 33.94 30.35 31.31 30.15 27.49 28.82 
PLAUR 24.97 25.91 32.58 24.18 27.62 25.73 
PLIN3 28.95 24.58 28.01 27.45 24.50 27.26 
PLOD2 26.97 24.48 26.41 25.34 24.34 25.03 
PLS3 27.79 25.07 27.83 27.05 25.48 27.01 
PLXNA1 24.68 25.21 29.44 24.90 27.50 26.82 
PLXNB1 24.23 25.07 26.09 24.41 25.32 24.33 
PLXNB2 27.08 24.78 31.40 26.46 27.47 29.24 
PLXND1 24.09 24.76 26.32 24.28 24.70 24.82 
POSTN 30.76 27.53 27.98 29.22 25.02 25.04 
PPP1CA;PPP
1CC 24.77 24.47 27.82 24.37 25.17 27.03 
PRDX4 25.25 26.05 23.93 24.40 25.76 25.47 
PRDX6 29.26 27.71 29.44 28.39 29.00 30.17 
PRKAR2A 24.01 24.75 26.16 24.31 24.71 24.47 
PRKCA 24.18 25.16 26.31 23.95 24.22 25.25 
PRSS23 28.74 26.75 30.26 27.64 27.86 27.19 
PSAT1 24.40 25.48 23.77 23.83 25.25 25.31 
PSMA2 23.57 27.69 23.86 24.48 26.48 24.67 
PSMA7;PSM
A8 24.42 29.00 26.77 24.10 28.03 24.15 
PSMB5 24.15 27.39 24.14 24.81 24.96 24.83 
PSMC1 24.45 24.55 26.51 23.65 24.53 25.10 
PSMC3 23.99 24.67 26.72 24.17 24.27 24.94 
PSMC4 24.13 24.95 26.41 23.60 25.04 24.75 
PSMC5 25.03 25.20 26.16 24.86 25.41 25.74 
PSMD1 24.44 25.01 25.84 24.60 25.61 24.54 
PSMD3 24.77 25.21 23.89 24.55 24.85 25.45 
PSMD4 23.88 24.67 26.67 24.49 25.96 24.18 
PSMD6 24.46 24.48 27.55 24.39 24.60 24.42 
PSME2 27.62 24.26 26.62 24.87 24.99 24.19 
PTGFRN 24.80 25.07 28.29 24.06 25.68 24.22 
PTK7 28.72 25.27 30.21 28.02 28.44 31.06 
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PTMA 26.20 24.45 23.67 25.46 24.60 25.39 
PTN 30.26 24.12 23.11 31.69 25.79 28.54 
PTPRG 24.02 24.53 26.57 23.75 25.11 24.39 
PTPRJ 24.37 24.92 25.23 25.02 25.09 24.40 
PTPRK 28.01 25.15 28.74 26.28 25.41 27.80 
PTRF 28.85 25.11 28.28 28.60 25.49 29.58 
PTTG1IP 24.79 25.25 24.70 24.77 24.78 26.35 
PTX3 32.06 33.43 37.21 30.69 34.75 33.64 
PVR 28.13 25.46 29.58 28.42 26.99 28.25 
PVRL2 24.51 24.84 28.72 24.79 24.95 27.56 
PVRL3 24.44 24.33 28.10 23.92 24.70 25.12 
PXDN 34.26 34.15 35.44 33.10 34.22 33.58 
PXN 24.60 25.24 26.15 24.10 24.68 25.41 
PYGB 26.81 25.16 27.70 25.78 24.69 26.34 
QSOX1 30.72 30.56 27.76 32.96 30.25 29.59 
RAB10 24.47 25.26 28.14 24.02 24.92 26.67 
RAB13 23.94 25.06 29.38 24.36 25.00 28.45 
RAB14 24.37 25.45 27.42 24.09 24.86 28.10 
RAB1A 26.55 25.58 29.23 25.62 24.68 28.54 
RAB1B;RAB
1C 24.22 24.54 28.47 23.60 25.97 24.50 
RAB34 24.08 25.44 26.39 24.38 24.97 24.36 
RAB35 24.56 25.61 29.10 25.13 24.82 27.55 
RAB5B 24.36 24.04 26.70 24.56 24.93 24.58 
RAB6A 24.41 24.61 26.45 24.88 24.68 24.23 
RAB8A 24.27 25.07 27.28 24.02 24.81 24.88 
RAC1 26.45 25.25 30.91 25.14 26.67 29.76 
RAC2 24.07 25.40 28.05 24.55 25.10 24.14 
RALB 23.81 25.03 29.84 24.17 24.73 28.90 
RAP1A 24.40 24.92 26.56 24.30 25.05 24.68 
RBP4 29.74 29.00 27.11 29.06 24.50 28.81 
RELN 23.95 25.08 23.41 24.35 24.77 27.39 
RFTN2 25.17 24.62 25.91 23.43 24.98 24.28 
RHOA 23.85 25.02 29.81 24.36 27.53 28.43 
RHOB 24.48 24.52 28.39 24.36 24.48 26.64 
RHOC 28.00 25.61 29.74 26.98 26.04 28.03 
RPL10A 29.34 25.07 26.06 28.14 24.98 27.41 
RPL18 24.06 25.09 27.95 24.25 25.11 24.86 
RPL23A 23.79 24.63 26.61 23.89 24.80 27.34 
RPL26 23.90 24.92 27.71 23.98 24.72 26.29 
RPL31 23.79 25.72 26.45 24.29 24.79 24.22 
RPL32 26.45 24.62 24.43 23.69 25.25 27.50 
RPL35A 24.47 25.17 26.76 24.16 24.58 24.02 
RPL9 24.12 23.92 25.72 24.40 25.37 24.75 
RPS12 28.82 23.85 26.92 27.16 25.02 25.15 
RPS27;RPS2




;UBC;UBA52 27.35 30.19 30.49 28.03 29.75 32.47 
RPS7 24.94 24.48 27.08 24.45 25.19 24.91 
RRAS 25.04 25.10 26.46 23.80 24.72 23.96 
RTN4 26.81 25.20 26.71 24.31 24.67 25.70 
RUVBL1 25.38 24.93 26.92 24.04 25.29 24.20 
S100A10 27.49 24.59 27.81 27.96 24.90 28.67 
S100A13 24.21 24.86 28.53 25.24 24.69 27.20 
S100A16 24.55 24.82 30.12 23.51 24.94 28.50 
S100A6 28.94 28.88 30.06 29.14 29.89 31.01 
SCARB2 25.39 25.53 24.28 24.43 24.76 27.63 
SCRIB 23.82 25.47 27.56 23.93 24.85 25.00 
SCUBE3 29.94 25.81 29.83 25.06 26.02 25.05 
SDCBP 24.45 28.73 29.97 23.88 28.82 31.66 
SEC13 24.53 25.44 26.63 24.60 25.25 25.59 
SEC22B 24.66 24.84 26.20 23.67 24.90 27.20 
SEC23A 23.92 25.44 27.97 24.45 25.34 25.88 
SEMA5A 28.03 27.71 23.76 24.34 25.89 24.93 
SERBP1 26.78 26.38 26.37 26.02 25.50 25.01 
SERPINB2 25.79 24.78 29.02 23.86 25.03 25.44 
SERPINE1 29.61 28.94 28.65 28.91 27.97 24.22 
SERPINH1 29.01 27.68 29.08 30.55 25.19 30.04 
SFPQ 25.20 25.16 23.44 25.68 25.36 25.38 
SGCB 24.46 24.92 23.53 24.69 25.87 26.37 
SGCD 24.72 25.54 27.30 24.98 25.48 28.22 
SH3BGRL3 31.95 31.24 31.37 31.69 30.84 30.98 
SHMT2 24.22 24.96 24.56 23.80 25.51 27.39 
SIRPA;SIRPB
1 24.25 24.78 27.30 24.69 25.20 24.00 
SLC12A2 24.17 24.89 26.54 23.75 25.31 25.91 
SLC16A3 23.50 24.86 30.96 25.14 25.69 29.20 
SLC16A6 24.13 26.03 30.49 24.84 27.53 24.96 
SLC20A1 23.71 24.71 29.86 24.24 24.69 24.50 
SLC25A3 24.41 25.33 23.75 23.91 25.66 26.68 
SLC2A3;SLC2
A14 24.38 24.63 28.10 24.81 24.96 24.97 
SLC35F6 25.12 24.52 24.39 23.81 24.34 26.13 
SLC39A14 24.64 24.43 27.44 23.67 25.02 24.90 
SLC3A2 26.30 25.15 30.99 24.48 26.70 29.53 
SLC44A1 24.40 25.04 26.75 24.22 25.26 25.16 
SLC4A7 24.23 25.12 26.58 24.17 24.93 24.50 
SLC4A7 24.04 25.37 26.79 23.70 25.04 24.30 
SLC5A3 23.80 25.01 25.62 23.16 24.41 24.38 
SLC6A15 24.41 25.01 26.12 24.16 24.79 24.85 
SLC6A6 24.10 24.77 25.72 24.62 25.02 24.11 
SLC7A2 23.96 25.19 27.40 24.51 25.23 23.85 
SLC9A1 24.29 24.03 28.18 24.07 25.52 26.02 
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SMURF2 23.93 24.33 26.36 24.25 25.50 25.12 
SNAP29 24.20 24.74 26.23 23.75 25.27 24.28 
SNTB2 24.64 25.17 25.77 23.97 24.67 24.49 
SNX18 24.16 24.70 25.09 23.95 24.87 24.68 
SOD1 30.44 28.77 28.53 29.00 28.33 29.53 
SPARC 34.87 32.34 29.31 33.56 32.41 32.50 
SPRY2 24.46 25.24 26.02 24.60 24.80 24.40 
SPRY4 24.91 25.01 27.97 24.17 24.94 24.26 
SPTBN1 24.72 25.28 23.70 24.51 24.43 26.31 
SRGAP1 24.94 24.37 25.51 23.95 24.89 24.97 
SRGAP2;SRG
AP2B 25.05 25.15 27.68 24.28 25.66 26.51 
SRI 24.10 24.76 26.15 24.66 25.26 24.54 
SRPX 30.97 25.86 29.75 28.05 25.62 28.39 
SRPX2 30.08 26.72 29.14 25.27 25.95 25.28 
SRSF2 24.97 24.68 24.12 24.86 24.96 26.93 
SRSF3 24.07 25.11 23.65 24.89 25.06 26.97 
STC2 29.78 24.11 23.98 30.49 24.63 28.79 
STEAP3 24.92 24.61 26.65 24.71 24.72 24.38 
STIP1 30.58 25.55 29.21 27.79 25.71 27.68 
STK10 23.96 25.00 25.50 23.92 24.89 25.06 
STMN1 29.39 27.73 27.17 30.34 26.70 28.34 
STOM 25.09 25.24 31.19 24.20 28.84 33.84 
STUB1 24.61 24.96 28.15 24.33 25.94 24.44 
STXBP1 24.30 23.65 27.72 24.38 24.93 27.08 
STXBP3 24.46 24.16 27.72 25.36 24.72 24.76 
SUSD2 25.37 25.33 29.76 24.31 29.45 24.07 
SVEP1 26.09 25.11 23.40 33.20 24.85 30.20 
TAGLN 24.52 24.48 23.96 24.29 25.10 27.33 
TAOK1 24.22 24.61 26.08 24.30 24.83 24.38 
TCEB1 27.54 24.71 26.62 25.78 25.40 24.20 
TCP1 27.48 24.52 29.30 26.84 24.83 27.75 
TENM3 24.45 25.25 27.66 24.10 25.25 24.03 
TFPI 29.45 28.07 28.76 29.15 25.38 27.75 
TGFB1 27.55 25.76 27.18 23.78 24.46 24.71 
TGFBI 34.43 33.16 35.38 34.59 33.72 33.24 
TGM2 28.02 26.67 29.93 25.56 27.80 28.36 
THBD 25.13 24.75 27.72 23.68 25.48 25.03 
THBS1 34.16 32.81 31.48 32.17 31.10 30.43 
TIMP1 34.97 32.44 30.67 32.99 31.71 33.58 
TIMP2 32.55 32.13 31.03 32.95 31.28 29.20 
TJP1 24.19 25.38 29.21 24.83 25.42 25.07 
TMED10 23.92 24.79 26.02 24.16 25.48 26.77 
TMEM119 24.66 25.52 28.06 24.10 24.81 29.75 
TMEM132A 27.85 25.05 28.07 24.77 24.71 25.30 
TMEM2 25.42 26.11 28.78 24.82 25.33 24.53 
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TMEM30A 24.32 25.51 26.46 24.35 25.25 25.17 
TMEM51 24.96 25.22 27.05 24.32 25.02 25.09 
TMEM59 25.05 24.96 26.02 24.17 24.85 24.80 
TNC 31.86 30.15 31.94 31.05 30.51 30.63 
TNFRSF10B 25.12 25.18 29.01 24.75 25.83 24.01 
TNFRSF10D 28.07 24.97 27.11 23.99 24.92 23.87 
TNFRSF12A 29.36 27.62 27.76 27.21 26.83 25.67 
TOLLIP 24.65 24.98 27.03 24.53 25.54 23.48 
TPBG 24.78 24.91 30.98 24.46 25.45 26.20 
TPD52L2 28.06 25.00 27.88 26.39 25.72 24.63 
TRPA1 24.54 24.61 28.06 24.23 24.79 26.31 
TSG101 24.89 24.72 23.65 24.15 25.64 28.04 
TSPAN14 25.03 24.45 29.86 24.28 23.96 25.37 
TSPAN4 24.65 24.70 27.36 24.76 24.77 24.72 
TSPAN5 24.54 25.41 29.92 24.42 25.08 27.10 
TSPAN9 23.90 25.12 27.79 24.33 25.22 24.19 
TTYH3 23.35 25.21 29.04 24.59 27.49 30.23 
TUBA1A;TU
BA3C;TUBA
3E 31.77 32.87 32.33 31.47 32.65 33.06 
TUBA1B 24.81 24.68 27.59 23.95 25.26 24.31 
TUBA4A 24.62 25.40 25.89 24.86 24.42 25.00 
TUBB 28.55 30.55 30.71 27.91 30.83 31.68 
TUBB2A 25.59 28.55 27.11 25.77 27.02 28.31 
TUBB6 24.15 24.00 27.56 24.24 24.87 29.00 
TXN 30.05 25.52 24.25 31.78 25.84 28.91 
TXNL1 26.17 24.81 23.85 25.48 25.44 26.27 
UACA 24.62 25.23 26.56 23.69 24.94 25.00 
UBTD1 24.75 24.71 27.23 24.24 24.45 25.62 
USP14 23.86 24.79 25.22 24.12 24.95 23.73 
USP5 23.99 24.01 26.56 25.09 24.89 24.56 
UTRN 24.12 25.27 23.62 24.58 25.39 26.79 
VAPA 26.90 25.54 23.94 25.72 25.16 25.14 
VASN 28.67 25.21 26.26 28.02 24.76 24.70 
VASP 27.58 25.06 28.16 26.92 25.09 27.52 
VAT1 28.35 24.97 28.73 27.34 25.00 30.30 
VCAN 31.65 32.70 35.94 31.46 34.60 34.27 
VCL 29.91 28.32 30.13 30.25 28.50 31.14 
VDAC2 24.30 24.91 24.17 24.35 24.79 26.29 
VPS35 24.79 25.59 26.95 23.80 25.41 24.40 
VPS37B 23.83 24.74 23.57 24.21 25.39 27.21 
VWA5A 24.38 25.48 26.08 24.37 25.66 24.48 
WARS 27.41 26.27 26.95 27.04 25.11 28.33 
WDR64 23.85 25.36 30.33 24.57 24.82 24.98 
WLS 24.24 24.13 27.55 24.36 25.26 24.97 
WNT5A 30.18 28.66 32.20 26.60 26.55 30.37 
WNT5B 24.04 25.41 29.09 24.14 25.09 27.25 
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XRCC5 24.15 25.20 24.02 24.55 24.82 26.32 
XRCC6 24.87 26.22 24.51 23.56 24.13 28.35 
YWHAB 30.46 28.42 30.71 29.07 28.89 29.97 
ZC3HAV1 23.63 25.05 27.72 23.40 24.07 24.75 
ZDHHC20 24.65 24.64 28.04 23.93 24.94 24.68 
A2M 24.02 27.97 23.88 26.63 27.55 24.67 
AAMDC 25.05 25.24 24.79 24.62 24.74 24.91 
ABCC1 23.65 25.35 26.61 24.44 25.53 26.99 
ABI1 24.79 25.30 27.60 23.62 25.07 27.47 
ABLIM3 24.36 24.91 24.90 25.10 25.09 24.47 
ACAT2 24.41 24.47 24.34 25.61 25.16 24.25 
ACTB 24.46 30.96 30.08 23.84 31.35 30.99 
ACTN1 29.35 28.22 29.19 29.91 27.29 29.44 
ACTR1A 25.06 25.70 27.25 24.71 25.66 26.65 
ACTR3 28.51 28.32 29.67 27.27 27.71 29.10 
ADAM17 24.85 24.14 27.98 23.84 25.65 27.36 
ADAM19 28.57 25.06 24.56 26.28 24.90 24.13 
ADAM9 29.23 24.89 29.74 29.82 24.95 29.86 
ADAMTS1 28.67 24.93 26.43 27.07 25.16 27.34 
ADAMTS12 28.17 25.63 25.86 25.51 25.08 24.98 
ADD1 24.89 25.48 28.47 24.34 25.42 27.95 
ADD3 24.91 24.44 27.41 23.46 25.16 27.30 
ADH5 25.53 26.48 27.99 23.68 24.51 27.96 
ADM 25.99 26.15 24.27 29.43 29.31 24.70 
AEBP1 28.78 24.71 27.73 28.94 24.84 27.27 
AFP 27.54 25.47 24.38 28.20 24.64 24.99 
AHCY 26.78 24.44 26.76 28.05 24.70 27.01 
AKR1A1 26.24 25.68 25.55 24.62 24.44 24.63 
AKR1B1 30.17 25.51 28.61 28.26 25.74 27.94 
AKR7A2 24.42 24.17 25.83 24.57 25.53 25.72 
ALDH9A1 25.08 25.22 24.81 24.76 25.17 24.66 
ALDOA 32.90 33.40 33.04 32.41 32.64 32.59 
ANXA1 25.70 29.54 32.26 24.68 29.51 32.85 
ANXA11 24.78 25.50 30.61 24.61 26.68 30.11 
ANXA4 24.85 27.11 28.14 23.69 27.02 29.02 
ANXA6 27.23 29.10 33.42 24.61 30.88 33.03 
AP2A1 24.55 25.10 27.84 24.47 25.80 27.34 
APEX1 25.32 25.22 24.98 25.47 24.88 24.78 
APLP2 27.17 24.90 24.31 25.15 25.19 24.37 
APOM 26.55 24.24 24.61 26.61 25.70 26.54 
APP 31.85 27.88 24.98 30.80 25.44 25.22 
AREG 31.63 27.66 28.36 24.76 27.07 28.85 
ARHGDIA 29.80 25.84 29.06 29.07 26.05 29.15 
ARL3 24.60 24.97 25.35 24.00 24.76 25.03 
ARPC2 27.04 24.83 25.02 26.83 25.02 24.37 
ARPC5 24.87 24.70 27.75 23.99 27.22 25.32 
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ATIC 24.93 25.35 27.70 23.66 24.75 27.77 
ATP1B3 24.68 25.60 27.86 24.53 25.89 25.68 
ATP2B1 24.38 24.37 31.15 24.49 28.02 30.56 
ATP2B4 24.07 27.06 29.83 24.76 28.73 30.12 
ATP5B 28.38 27.13 28.98 27.63 27.39 28.90 
ATP6AP1 26.09 25.08 24.33 24.76 25.15 24.75 
ATP6AP2 28.16 24.22 24.57 26.48 25.22 24.65 
ATP6V1A 25.56 26.17 27.73 24.63 26.01 27.64 
ATP6V1B2 25.40 24.02 28.01 24.70 24.58 26.99 
ATP6V1E1 23.87 25.00 26.60 24.28 24.25 24.99 
ATRN 25.26 24.50 25.17 26.35 25.22 24.76 
AXL 27.25 25.25 24.11 27.20 25.40 23.79 
B2M 34.39 32.61 32.67 34.36 32.11 32.14 
BANF1 25.35 24.99 23.48 24.22 25.39 24.11 
BASP1 28.44 27.07 32.06 28.82 25.96 32.24 
BAX 25.07 25.24 24.95 24.72 24.80 24.80 
BCAM 24.26 25.40 27.63 24.86 26.72 27.30 
BDKRB2 24.83 24.61 28.47 24.22 24.79 28.16 
BGN 32.58 29.35 27.38 31.80 27.54 27.17 
BRK1 24.80 25.17 26.73 23.75 25.34 27.26 
C12orf75;OC
C1 24.22 24.28 27.40 24.02 24.11 27.16 
C1QTNF3-
AMACR;C1Q
TNF3 26.38 26.71 23.89 28.00 25.87 24.31 
C8B 26.04 25.51 24.09 25.99 25.23 24.73 
CAD 25.37 25.18 26.11 24.26 25.12 25.85 
CADM1 24.55 25.44 28.42 24.07 26.85 28.01 
CALD1 25.63 25.32 24.78 28.71 25.44 24.71 
CALD1 29.76 28.61 28.41 30.07 27.68 29.24 
CALM2;CAL
M1 24.44 28.76 30.71 25.74 29.76 30.88 
CALR 29.64 27.50 28.10 28.98 26.41 28.29 
CALU 30.71 27.16 23.55 30.88 25.76 25.43 
CAND1 26.44 25.65 27.36 26.69 26.06 27.54 
CANX 24.18 24.15 28.16 24.53 25.81 28.26 
CAPG 24.58 24.51 25.19 23.77 25.30 25.40 
CAPN2 27.28 25.29 27.15 24.98 25.22 27.47 
CAPN5 24.46 25.22 28.52 23.30 24.56 26.49 
CAPNS1 25.97 25.30 27.36 25.64 25.36 25.93 
CAPZA1 29.93 26.93 28.84 28.76 29.24 29.26 
CAPZA2 26.31 25.18 26.84 24.64 25.19 26.25 
CAPZB 28.47 26.24 29.39 27.46 24.76 29.27 
CASK 24.35 25.31 26.53 24.26 24.74 27.53 
CAST 25.93 24.58 24.29 25.93 25.21 24.58 
CCDC50 23.93 25.59 28.57 24.72 24.73 29.01 
CCL2 27.64 24.81 23.51 25.85 25.19 25.04 
CCNY 24.69 24.60 24.44 23.99 24.82 25.09 
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CCT4 29.03 29.04 30.30 27.41 28.22 29.74 
CCT5 28.27 27.48 28.93 27.87 29.22 28.41 
CCT7 27.88 26.21 29.26 25.10 26.55 28.56 
CD248 30.34 29.66 29.66 29.32 28.81 29.57 
CD55 24.60 24.70 26.09 23.27 25.14 24.40 
CDC42 26.77 25.62 30.84 25.69 26.69 30.05 
CDH11 27.69 25.86 29.46 28.15 24.53 28.88 
CDH2 24.11 25.85 28.08 23.91 24.92 27.71 
CFH 29.12 27.41 24.00 29.61 24.99 24.55 
CFL1 33.03 31.32 32.61 32.10 31.93 33.06 
CFL2 28.44 24.97 27.21 27.57 25.19 28.37 
CHID1 26.39 25.25 24.82 26.16 25.21 24.79 
CHMP4B 23.94 24.87 27.03 24.72 25.08 27.71 
CHMP6 24.52 25.24 24.99 24.00 25.25 25.36 
CHP1 25.36 25.36 26.34 24.76 25.34 24.85 
CKB 26.73 26.58 27.35 26.25 26.67 27.45 
CLEC11A 30.96 26.81 26.28 27.91 25.17 25.98 
CLMP 24.12 24.69 27.44 24.61 25.23 25.97 
CLTA 25.13 25.49 29.97 24.54 24.81 30.01 
CLTB 23.97 24.88 27.19 24.70 25.08 26.15 
CLTC 29.66 29.33 32.44 29.12 30.08 32.65 
CLU 32.40 31.10 30.34 33.67 29.72 31.27 
CNKSR3 25.98 25.22 24.11 27.27 25.24 24.40 
CNP 24.59 24.90 29.44 23.87 25.50 29.29 
COL11A1 27.87 26.26 24.91 28.42 24.78 24.85 
COL16A1 27.50 25.31 23.49 27.50 24.90 24.54 
COL18A1 29.99 26.62 28.74 28.04 27.75 27.50 
COL4A1 31.10 26.65 29.28 31.18 24.87 28.00 
COL4A2 32.40 29.13 27.65 32.64 26.89 27.51 
COL5A1 31.69 29.13 26.86 31.48 28.58 27.91 
COL5A2 30.49 29.87 24.36 33.32 29.75 26.20 
COL8A1 24.75 24.82 24.29 27.55 24.75 24.99 
COLEC10 28.85 25.34 23.64 27.49 24.95 24.55 
COLGALT1 24.36 24.85 25.81 24.37 24.62 25.54 
COMP 27.80 24.81 24.39 28.54 24.70 24.60 
COPA 24.50 25.46 27.51 24.34 24.93 27.70 
COPE 24.66 24.84 24.84 24.69 24.54 24.35 
COPG1 24.69 24.90 26.74 24.03 25.21 26.05 
COPS3 24.61 25.22 24.92 24.39 24.85 24.59 
CORO1C 30.73 25.63 30.00 29.52 25.96 29.55 
CORO2B 24.78 24.39 25.55 24.51 24.44 24.90 
CPA4 26.50 24.36 25.02 29.10 24.99 24.72 
CPE 24.98 24.66 23.84 27.16 24.66 24.89 
CPNE1 23.41 25.79 26.89 24.26 24.94 27.50 
CSF3 28.17 24.71 24.83 24.82 24.80 24.80 
CSRP1 28.76 24.80 28.64 28.93 28.27 29.21 
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CST3 34.05 31.71 27.88 31.01 30.33 31.24 
CTHRC1 29.09 25.06 24.36 28.45 25.25 24.27 
CTNNA1 24.45 25.04 30.42 23.69 27.93 30.19 
CTNNB1 24.29 25.07 28.47 24.21 25.12 29.21 
CTNND1 24.65 24.33 30.38 24.52 25.08 30.19 
CTSA 26.51 24.13 24.05 26.06 25.17 24.89 
CTSB 33.77 31.28 29.22 30.54 28.95 31.65 
CTSC 26.08 24.72 24.24 27.50 25.46 24.93 
CTSD 29.12 24.99 24.14 26.32 25.52 24.47 
CTSL 29.78 26.81 24.06 26.57 25.60 24.40 
CXCL8 34.78 29.64 28.42 25.69 26.97 30.28 
CYFIP1 24.97 24.57 27.87 24.32 25.59 28.11 
CYR61 30.68 28.11 29.11 28.01 25.42 29.16 
DAG1 27.82 24.72 24.17 28.17 24.78 24.48 
DCD 24.48 27.25 26.41 24.91 27.78 26.42 
DCHS1 24.95 25.30 25.72 24.19 25.38 25.86 
DCTN2 27.31 25.03 23.81 25.46 24.62 24.66 
DDX1 26.60 25.42 24.32 25.58 24.41 25.01 
DIP2B 23.78 25.24 27.19 24.95 24.80 27.77 
DKFZp686J1
372 28.43 25.32 24.41 27.08 25.72 24.77 
DKK3 31.18 29.22 26.91 29.71 26.61 28.26 
DLG1 24.81 25.41 25.58 24.29 25.52 25.66 
DNM2 23.93 24.94 26.52 24.41 25.28 26.05 
DPYSL2 26.89 27.83 28.72 26.32 27.44 29.63 
DSG1 24.41 24.62 25.30 23.97 25.21 25.32 
DSP 26.55 24.68 24.27 28.37 24.96 24.30 
DYNC1LI2 25.04 24.32 24.92 24.45 25.03 25.51 
EDIL3 29.42 29.08 34.28 28.76 31.44 33.56 
EEA1 25.87 25.04 23.78 25.95 24.98 23.57 
EEF1A1;EEF1
A1P5 32.39 31.26 31.93 31.27 31.40 31.98 
EEF1B2 24.69 25.01 26.49 24.71 25.68 26.44 
EEF1D 27.25 25.30 27.11 26.09 24.35 27.69 
EEF2 30.69 28.86 30.83 29.64 29.11 30.17 
EFEMP2 29.27 29.67 27.57 29.90 25.98 28.10 
EHD1 25.53 25.55 31.00 24.43 24.14 30.64 
EHD3 23.98 24.51 26.73 24.41 24.65 26.98 
EHD4 24.27 24.84 28.21 24.26 24.90 27.96 
EIF1 26.29 24.85 24.12 25.05 24.67 24.42 
EIF3A 24.80 25.65 25.02 23.61 24.82 25.04 
EIF3B 24.98 24.55 24.56 24.29 25.39 25.47 
EIF3C;EIF3CL 24.48 24.75 25.38 24.21 25.08 25.30 
EIF3D 23.65 25.74 25.98 24.11 24.61 26.37 
EIF4H 24.77 24.95 26.67 24.53 24.65 25.00 
EIF6 25.88 25.28 25.43 24.19 25.67 25.02 
ENAH 25.28 24.86 24.05 25.10 25.32 23.73 
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ENO1 33.23 31.94 32.53 32.39 32.58 32.63 
ENPP2 24.30 24.81 23.50 26.32 25.48 24.28 
EPRS 26.72 25.28 26.91 26.56 25.22 26.35 
ERAP1 26.54 24.43 23.73 24.49 24.84 24.87 
ERP29 24.62 24.71 23.66 24.36 25.50 24.54 
ESD 24.18 24.17 26.32 24.93 25.03 25.73 
EVA1A 24.30 24.58 27.04 24.50 24.74 27.59 
EVA1B 24.43 28.05 30.12 24.21 27.22 30.22 
EXT1 25.32 26.86 24.29 26.36 26.01 25.15 
EZR 27.56 25.35 28.33 28.41 24.86 28.99 
F10 25.75 24.96 23.95 27.36 26.06 24.10 
F11 24.93 25.24 24.05 29.15 24.30 24.52 
F2R 23.96 25.05 27.76 24.89 25.02 27.18 
FAM20C 24.68 25.27 23.96 25.22 25.50 24.28 
FAM3C 29.15 24.84 23.54 27.36 25.22 24.07 
FAU 24.52 25.08 26.32 24.84 25.60 25.13 
FBLN1 31.67 31.40 33.19 32.73 31.76 32.61 
FBLN5 26.15 25.00 23.44 28.66 25.73 24.37 
FDPS 24.45 25.84 26.21 24.89 24.51 25.01 
FGL2 26.72 24.50 23.85 24.96 25.17 24.73 
FKBP1A 28.94 28.46 28.10 27.77 27.06 28.09 
FLII 24.14 25.28 25.08 24.19 24.99 24.53 
FLNA 32.33 30.31 31.30 32.42 29.05 31.93 
FLNC 30.51 28.14 29.15 30.03 28.51 29.35 
FN1 36.35 36.45 34.54 36.19 35.59 35.19 
FSCN1 30.19 29.29 30.58 29.17 29.28 30.53 
FST 28.78 27.89 23.71 30.06 27.31 24.81 
FSTL3 27.02 25.45 23.61 27.44 25.33 24.54 
FZD2 24.32 24.87 27.00 24.49 24.89 27.48 
G6PD 27.86 24.91 28.81 27.08 26.78 28.49 
GALK1 25.13 25.04 26.33 24.49 24.40 26.57 
GALNT2 28.17 25.15 24.17 28.35 25.61 24.71 
GALNT5 28.32 24.94 24.00 29.04 24.30 24.76 
GANAB 28.56 25.21 28.43 27.70 25.01 28.50 
GAPDH 33.06 31.94 33.59 31.19 31.23 33.29 
GARS 24.19 25.83 26.97 24.74 24.72 27.59 
GBE1 25.14 24.58 25.62 24.10 26.02 26.28 
GCN1L1 25.15 24.99 25.41 24.05 24.30 24.30 
GDI2 30.44 28.61 30.44 29.92 28.41 30.38 
GLG1 29.02 25.04 24.95 24.82 25.22 24.66 
GNA11;GNA
14 24.28 24.66 27.39 23.39 25.13 27.27 
GNA13 24.24 24.90 26.91 24.86 25.10 25.12 
GNAI2 25.68 27.33 31.94 23.37 30.55 31.31 
GNAS 25.07 25.08 30.08 24.15 24.96 30.19 
GNG12 23.95 25.09 29.86 24.29 27.82 29.77 
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GNG2 24.06 25.62 28.95 24.32 25.25 28.34 
GNPTG 26.08 25.07 23.83 25.97 24.93 24.65 
GOLM1 26.74 24.71 24.01 29.14 24.93 25.18 
GPI 30.10 27.24 28.46 28.46 26.32 27.87 
GPR124 24.02 24.75 25.23 24.19 24.42 26.16 
GREM1 27.90 26.11 29.60 29.06 24.70 29.58 
GRHPR 24.64 24.57 24.55 24.44 26.22 25.68 
GSN 31.11 30.93 31.35 31.98 30.35 31.32 
HEL-S-
109;NUCB2;
Nucb2 29.34 25.22 24.04 28.98 25.09 25.47 
HEXB 28.05 25.07 24.08 27.84 24.87 24.75 
HINT1 29.02 25.86 29.06 28.57 26.99 28.79 
HMGA1 31.24 29.89 28.59 29.48 28.80 28.15 
HMGA2 26.61 25.01 23.72 25.63 25.04 24.64 
HMOX2 24.26 24.65 25.39 24.64 25.25 24.93 
HN1 26.84 25.72 26.26 25.96 24.67 26.39 
HNRNPC 28.53 25.18 24.10 29.23 24.93 26.33 
HNRNPD 26.20 24.34 25.11 25.52 24.98 24.77 
HNRNPDL 25.68 24.63 23.90 25.90 25.50 24.46 
HNRNPL 25.53 25.63 24.62 25.91 25.57 24.63 
HNRNPU 27.28 25.87 23.97 27.77 24.61 24.71 
HSP90AA1 30.29 28.52 29.34 29.60 28.12 28.87 
HSP90AB1 31.65 29.48 31.00 31.16 30.36 31.10 
HSPA5 31.40 31.02 30.58 30.30 29.27 30.98 
HSPA6;HSPA
7 24.95 24.93 26.69 23.83 25.12 26.02 
HSPA8 23.54 24.31 26.25 24.07 25.01 26.00 
HSPA8 33.22 31.71 33.02 31.98 31.75 33.15 
HSPA9 27.71 24.27 27.79 26.41 24.51 28.28 
HSPB1 29.41 26.50 29.73 29.85 28.87 30.82 
HSPD1 28.87 29.74 29.46 27.97 29.08 29.88 
HSPE1;HSPE
1-MOB4 29.82 24.74 26.99 28.30 25.24 27.17 
HTRA1 30.41 26.01 29.08 29.59 24.93 29.29 
HYOU1 24.18 24.82 25.07 24.09 24.99 25.16 
IDH1 26.53 24.79 25.08 25.99 25.38 25.58 
IFT74 24.32 24.88 24.10 25.27 26.15 25.10 
IGF2 30.80 28.89 24.02 30.22 24.46 23.98 
IGF2BP1 24.35 24.53 26.64 24.60 25.23 25.24 
IGF2R 27.38 27.72 27.23 27.48 25.97 27.41 
IGFBP2 32.08 27.24 23.98 31.03 24.30 26.58 
IGFBP5 35.70 33.49 31.60 35.98 33.23 32.12 
IGFBP7 33.45 32.13 28.73 33.37 31.01 29.64 
ILF3 26.61 24.14 24.72 26.81 25.27 25.07 
IMPDH2 24.60 24.68 25.34 24.12 25.23 25.61 
INHBA 33.12 28.32 27.76 24.10 26.70 27.50 
IPO5 25.17 24.93 25.94 24.05 24.89 25.46 
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IQGAP1 28.10 25.08 28.29 26.58 24.75 27.93 
IST1 25.21 24.64 26.99 23.77 25.10 27.46 
ITGA11 24.00 25.14 27.82 24.84 24.32 27.84 
JUP 23.17 27.87 27.71 24.70 27.41 28.17 
KIF5B 28.42 24.66 28.28 26.40 24.33 27.66 
KPNB1 28.47 25.68 28.95 27.41 24.93 28.76 
KPRP 24.32 27.20 26.58 24.52 26.98 26.95 
KRAS 24.38 25.26 27.72 24.50 24.83 28.09 
L1CAM 23.69 25.29 25.07 23.65 25.64 24.34 
LAMA1 26.62 28.38 29.39 27.13 26.79 30.01 
LASP1 29.34 24.03 28.66 30.01 24.91 28.72 
LDHA 30.91 29.21 29.67 30.18 26.90 29.79 
LDHB 30.77 29.07 30.19 29.57 27.60 29.61 
LGALS1 33.49 31.24 33.55 33.58 33.18 33.34 
LGALS3 27.32 25.09 23.66 26.96 25.22 24.52 
LGALS3BP 29.50 32.91 30.52 29.35 31.87 30.22 
LHFPL2 23.77 25.60 25.68 24.48 24.63 25.28 
LIMS1;LIMS
2 24.30 25.36 24.87 23.72 25.01 24.74 
LIN7C 24.12 25.09 27.46 23.78 24.14 27.71 
LMAN2 27.69 24.87 24.56 27.42 24.46 24.40 
LOX 28.76 28.68 24.48 28.83 25.54 26.65 
LOXL1 26.41 24.93 23.77 27.72 24.38 24.03 
LPP 24.59 24.69 26.15 23.52 25.17 26.44 
LPXN 25.41 24.93 25.09 24.26 25.63 24.79 
LRP1 29.33 30.91 30.15 28.89 29.97 30.49 
LTBP1 33.24 29.14 30.76 31.94 27.11 29.66 
LTBP3 29.65 25.63 25.27 26.67 25.11 24.69 
LTBP4 28.35 26.81 24.17 30.16 24.53 24.94 
LTF 27.84 25.09 24.08 28.68 25.56 24.07 
LUC7L2 24.34 25.39 24.26 24.04 24.67 24.18 
MAMDC2 23.83 25.57 25.95 24.32 24.91 26.22 
MAN1A1 25.09 24.63 24.40 25.80 25.15 24.08 
MAN2A1 27.56 24.78 24.70 24.78 25.37 25.47 
MAP1LC3B;
MAP1LC3B2 24.46 24.85 25.80 23.81 25.10 24.76 
MAP4 28.87 25.53 24.14 29.37 25.66 24.55 
MAPK3 24.24 25.24 24.15 24.26 25.55 23.92 
MARK3 24.48 25.28 25.96 23.50 25.48 25.51 
MASP1 24.21 25.10 23.49 29.93 24.71 24.89 
MCAM 24.74 25.82 29.65 24.64 27.47 29.86 
MDH1 29.34 27.79 27.98 28.46 25.22 27.54 
MDH2 29.70 25.35 27.75 28.66 25.41 27.55 
MEMO1 23.94 25.25 23.63 25.25 25.28 24.35 
MFAP2 27.38 24.26 24.44 26.82 25.16 23.68 
MGAT5 27.36 25.32 24.23 26.98 24.57 24.62 
MIF 28.80 27.22 28.74 27.24 27.17 29.00 
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MINK1 24.38 25.67 27.69 24.41 25.19 27.22 
MMP1 36.68 34.36 31.99 30.95 32.78 33.54 
MMP2 32.62 31.92 30.06 33.41 31.40 30.15 
MOXD1 24.56 25.26 26.16 23.93 24.90 26.36 
MSN 33.02 31.16 33.78 32.07 30.21 33.14 
MST1 25.60 24.34 25.01 25.89 25.00 24.75 
MT1E;MT1L 24.78 24.63 25.59 24.05 25.00 24.80 
MTAP 25.58 25.23 25.07 24.86 24.67 24.47 
MTHFD1 24.26 24.55 27.66 24.59 24.69 27.04 
MTPN 29.04 25.89 27.14 27.62 25.12 27.89 
MVP 28.29 25.67 31.62 26.45 29.26 31.67 
MYDGF 25.58 26.53 25.53 25.27 25.08 25.92 
MYH9 33.23 29.85 33.04 33.28 30.20 33.18 
MYL12A;MY
L12B 27.74 24.88 26.42 27.13 25.22 27.71 
MYL6 31.00 28.96 30.52 30.07 27.76 30.72 
MYO1B 24.07 24.89 28.97 24.21 24.52 28.65 
MYO1C 24.51 24.58 30.84 24.70 25.58 30.66 
MYO6 23.93 24.65 25.99 24.59 25.11 24.69 
NANS 24.40 25.28 25.29 24.27 24.95 24.88 
NAP1L1 24.82 25.72 26.77 23.70 24.17 26.45 
NCAM1 26.83 25.06 24.87 27.73 24.60 24.52 
NCL 29.19 25.41 24.19 29.61 25.05 27.15 
NEDD8;NED
D8-MDP1 27.05 24.99 27.36 26.23 25.07 27.18 
NEO1 27.20 24.57 27.19 27.84 24.95 27.62 




E2P1 29.67 27.26 29.12 29.14 26.61 27.77 
NOTCH2 24.41 25.31 29.53 24.60 24.90 28.88 
NPC2 29.29 24.81 23.89 29.42 24.71 25.05 
NPEPPS 24.69 25.03 26.87 24.09 25.34 26.67 
NPTX1 30.30 27.68 23.80 27.64 25.45 25.14 
NRAS 25.16 24.43 27.18 24.76 24.86 27.34 
NRP1 27.08 25.99 29.65 24.68 24.98 29.21 
NUCB1 32.95 28.34 26.04 32.16 24.56 27.91 
OAF 28.08 25.29 24.02 26.96 25.39 24.68 
OLFML2A 25.27 25.49 24.50 26.69 25.02 24.50 
OLFML3 27.74 24.84 23.80 30.46 24.84 25.28 
OMD 26.37 24.67 24.15 26.88 24.44 25.16 
OS9 26.26 25.34 23.61 25.36 24.68 24.55 
P4HB 31.22 30.60 30.33 30.77 30.47 30.17 
PA2G4 28.07 24.54 23.50 26.35 25.34 24.43 
PAICS 24.31 24.85 26.66 24.47 24.63 26.42 
PAK2 24.71 25.07 26.25 24.78 25.35 25.91 
PAPPA 28.71 27.28 26.38 26.72 25.65 24.92 
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PARK7 29.81 25.76 28.05 28.95 25.63 28.08 
PCBP1 27.37 26.23 28.72 26.78 24.64 28.21 
PCBP2 24.23 25.00 26.18 25.23 25.54 25.92 
PCDH18 25.19 24.96 26.93 26.07 24.68 26.70 
PDAP1 25.56 25.16 24.23 25.16 24.81 24.88 
PDCD5 26.07 25.19 24.12 25.81 25.31 24.19 
PDCD6 24.72 25.05 24.42 24.02 24.89 23.98 
PDGFD 24.19 24.73 26.65 25.21 24.64 27.14 
PDIA3 30.64 30.22 29.62 30.05 28.47 30.20 
PDIA4 28.13 27.62 26.57 27.66 26.84 27.45 
PDIA6 26.69 25.09 26.43 26.82 24.85 27.02 
PDLIM7 25.58 25.39 25.87 26.88 24.99 26.70 
PFDN6 24.42 24.50 25.99 24.51 24.68 25.84 
PFKP 24.08 25.21 27.90 24.81 25.22 27.68 
PFN1 32.70 30.36 32.01 32.22 30.29 31.61 
PFN2 27.40 24.99 26.93 27.44 25.37 27.27 
PGAM1;PGA
M4 30.30 29.32 31.13 29.02 28.94 30.44 
PGD 29.28 26.30 28.67 28.16 24.98 29.13 
PGK1 32.18 28.86 30.35 30.23 28.27 30.60 
PHPT1 27.44 25.55 26.89 27.42 24.65 27.12 
PI4K2A 24.68 24.38 24.52 24.24 25.31 23.77 
PKM 33.15 32.61 33.90 31.62 32.83 33.53 
PLAU 36.38 32.55 33.03 31.63 31.95 32.76 
PLD3 24.37 24.37 26.63 25.23 24.93 25.91 
PLEC 31.43 28.80 30.19 29.89 27.48 29.75 
PLEKHO2 24.29 24.96 25.36 24.20 25.22 24.84 
PLOD1 30.74 30.27 29.68 29.26 29.33 28.75 
PLOD3 28.29 27.27 27.25 26.00 27.32 26.68 
PLTP 28.15 25.35 24.97 27.83 25.03 26.12 
PLXNA3 23.79 25.32 25.84 23.61 25.15 24.91 
POSTN 34.54 30.34 31.45 32.15 29.26 31.12 
PPIA 32.97 30.70 32.07 32.19 30.82 32.07 
PPIB 28.40 25.09 27.24 27.42 25.13 26.53 
PPP1CB 24.64 25.47 24.43 24.66 25.07 25.06 
PPP1R12A 24.90 25.11 24.13 25.03 24.98 24.63 
PPP2CA 27.24 25.40 27.70 27.44 24.92 27.57 
PPP2R1A 27.41 24.28 27.72 25.69 25.48 28.01 
PRDX1 31.22 29.62 30.73 30.62 30.44 31.18 
PRDX2 26.96 24.94 27.53 27.80 25.21 27.53 
PRDX3 24.79 24.55 24.61 26.44 25.06 24.36 
PRDX5 26.84 25.00 23.54 25.62 24.67 24.54 
PRKAR1A 26.63 24.93 26.43 24.99 25.27 26.94 
PRKCDBP 24.99 24.73 26.70 23.77 25.81 27.33 
PRKCSH 27.22 27.62 27.26 26.35 26.28 27.67 
PROS1 27.33 25.59 23.23 27.49 24.89 24.42 
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PSAP 32.11 27.13 26.65 29.70 25.51 27.96 
PSG4 26.00 24.97 24.30 27.95 25.04 24.16 
PSMA1 24.82 31.54 27.12 24.18 30.34 27.10 
PSMA3 24.31 27.46 24.10 23.78 25.47 24.40 
PSMA5 24.60 29.24 27.21 24.16 28.23 27.31 
PSMA6 24.81 28.62 25.82 24.58 26.81 24.06 
PSMB2 24.03 27.11 23.76 24.82 26.10 24.05 
PSMB7 24.20 28.51 23.74 24.27 26.70 24.83 
PSMC2 25.63 25.40 27.32 24.12 24.89 27.39 
PSMC6 24.74 24.97 26.07 24.13 25.09 24.42 
PSMD11 24.72 25.02 26.36 23.39 25.22 26.09 
PSMD2 24.30 26.55 27.50 24.74 24.78 27.63 
PTGDS 27.38 24.72 23.81 29.56 24.97 24.68 
PTGES3 27.18 25.02 26.99 25.15 24.71 27.23 
PTMS 25.99 24.98 23.80 27.61 24.67 24.39 
QPCT 28.10 24.52 24.01 25.50 25.21 24.27 
RAB11B;RA
B11A 27.90 24.84 28.55 25.62 24.93 28.16 
RAB21 24.31 25.15 25.48 24.91 25.83 25.10 
RAB2A 25.62 25.22 25.85 24.19 24.41 26.72 
RAB5C 24.27 24.89 28.40 24.49 23.86 27.68 
RAB7A 23.85 24.41 28.09 24.25 25.36 28.81 
RAB8B 24.24 25.30 27.37 24.47 24.75 26.04 
RAD23B 25.72 24.75 24.16 26.61 24.67 25.01 
RAF1 24.80 24.96 25.36 23.25 25.32 24.63 
RALA 24.30 24.41 28.12 24.03 25.27 27.16 
RAN 28.51 25.66 28.64 28.52 25.28 28.49 
RANBP1 24.62 24.21 26.55 23.78 25.15 26.57 
RAP1B 24.45 24.84 30.42 24.51 28.53 29.54 
RAP1GDS1 25.43 24.67 24.26 24.46 25.63 25.21 
RAP2C 24.83 24.83 26.28 24.21 25.12 24.97 
RARRES2 25.24 26.04 24.16 28.23 25.37 24.93 
RARS 25.00 25.27 25.33 24.15 25.50 24.94 
RASA2 23.90 24.84 24.76 24.57 25.39 25.25 
RASA3 23.94 24.83 25.60 23.98 24.49 26.05 
RBMX;RBM
XL2 26.80 25.14 24.42 27.21 25.11 24.43 
RCN1 28.45 24.81 24.54 29.13 24.59 24.87 
RCN3 26.89 25.35 24.03 27.58 24.86 24.45 
RDX 24.37 24.57 27.82 23.36 24.40 28.02 
RECK 24.87 25.50 28.40 24.16 24.74 29.18 
RFTN1 23.82 24.79 30.63 24.93 25.46 31.08 
RHBDF1 24.95 24.07 27.08 24.60 25.35 26.99 
RHOG 24.17 26.22 29.33 24.00 24.93 29.11 
RIN1 24.31 25.06 25.84 24.54 26.08 25.02 
RNASE4 27.38 24.91 24.51 28.22 24.58 24.15 
RNASET2 25.10 24.29 23.92 25.47 25.06 25.04 
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RND3 24.11 25.20 26.18 24.42 24.94 26.60 
RNH1 27.16 25.00 27.03 24.69 25.08 27.00 
ROCK2 24.20 25.01 26.67 24.14 25.06 26.17 
RP2 23.70 25.08 28.13 24.15 25.08 27.80 
RPL10 24.71 24.88 26.98 24.66 25.05 26.37 
RPL11 30.20 30.16 31.65 29.18 25.08 31.52 
RPL12 27.11 27.70 28.45 25.91 25.04 28.12 
RPL13 27.07 26.66 28.42 27.66 25.88 28.79 
RPL14 24.25 25.20 27.03 23.44 24.85 27.22 
RPL15 24.65 25.64 28.61 24.77 24.85 28.27 
RPL17;RPL1
7-C18orf32 24.18 25.20 27.63 24.40 28.48 28.05 
RPL18A 24.40 25.11 27.13 25.43 24.92 26.43 
RPL19 27.56 26.96 27.89 27.94 25.06 28.31 
RPL21 24.25 25.42 26.13 24.24 24.83 24.96 
RPL23 24.34 25.01 25.37 23.62 25.25 24.00 
RPL24 24.42 24.90 25.81 25.26 25.44 26.14 
RPL27A 24.40 25.76 27.24 24.60 25.75 27.67 
RPL28 24.71 24.33 27.11 23.79 25.23 27.23 
RPL29 24.78 24.59 26.97 24.48 25.51 27.57 
RPL3 27.34 26.36 28.33 25.90 25.46 27.95 
RPL30 27.03 24.74 27.09 24.82 25.33 27.02 
RPL34 23.85 25.51 25.79 24.87 25.16 26.20 
RPL36AL;RP
L36A;RPL36
A-HNRNPH2 23.83 24.95 25.16 24.43 24.59 24.63 
RPL4 28.10 26.58 28.67 28.62 27.51 28.81 
RPL5 28.40 24.75 28.07 27.42 25.00 28.16 
RPL6 28.83 26.14 29.09 26.51 26.46 28.86 
RPL7 24.30 25.13 28.84 24.78 24.92 28.61 
RPL7A 25.90 25.34 27.40 25.03 25.14 27.44 
RPL8 25.86 25.95 28.62 25.88 24.89 28.86 
RPLP0;RPLP
0P6 26.16 25.10 26.13 26.38 25.67 25.21 
RPLP1 25.95 25.08 26.96 24.37 26.98 26.49 
RPLP2 27.51 24.99 25.31 26.66 25.08 26.13 
RPN1 27.04 24.97 27.29 23.95 24.93 27.65 
RPS11 26.16 25.91 28.22 24.48 26.36 28.58 
RPS14 24.37 26.05 28.63 24.61 24.54 28.71 
RPS15 25.06 25.61 25.57 24.04 24.72 25.11 
RPS16;ZNF9
0 23.82 25.02 27.30 23.84 25.02 27.38 
RPS17 24.60 24.51 27.10 24.97 24.70 26.86 
RPS18 24.42 24.43 27.37 24.12 24.37 26.63 
RPS19 27.06 24.59 26.70 25.20 24.43 25.20 
RPS2 26.15 24.27 28.61 24.12 25.25 28.39 
RPS20 27.16 24.99 28.41 26.71 25.76 28.36 
RPS21 27.19 29.48 26.76 26.57 28.36 26.82 
360 
 
RPS23 26.63 25.12 27.56 24.01 24.84 27.98 
RPS25 24.08 24.86 27.38 24.60 24.99 27.56 
RPS26;RPS2
6P11 24.12 24.82 25.69 24.20 25.04 26.88 
RPS28 26.60 25.38 24.42 26.07 24.75 24.67 
RPS29 24.57 24.86 24.06 25.14 25.40 24.66 
RPS3 25.60 24.22 25.99 26.20 24.53 25.17 
RPS3A 26.47 26.91 28.69 27.86 26.07 28.77 
RPS4X 26.23 26.33 29.09 25.48 24.75 29.09 
RPS5 27.32 24.98 27.97 25.63 23.79 27.40 
RPS6 27.10 24.47 28.79 24.91 24.89 28.58 
RPS8 26.34 26.35 28.73 24.32 24.57 29.02 
RPS9 24.07 25.70 25.90 24.44 25.12 25.55 
RPSA 27.34 27.66 27.95 24.53 24.59 27.40 
RRAS2 25.00 25.08 25.94 23.99 25.12 26.35 
RRBP1 29.21 24.81 24.72 28.96 24.41 25.69 
RSU1 26.02 25.16 24.37 25.25 25.23 24.83 
RTCB 24.53 25.12 27.42 24.03 25.54 26.90 
RUVBL2 24.33 24.35 26.26 25.06 24.55 25.84 
S100A11 27.02 24.94 31.13 28.35 25.83 30.65 
SARS 24.42 25.03 24.25 24.36 24.82 25.57 
SCAMP3 24.27 24.86 27.37 24.51 25.34 26.51 
SCRN1 26.91 25.59 27.16 25.99 24.95 27.59 
SDC4 29.23 28.81 26.87 29.59 25.90 27.98 
SDF4 31.08 25.57 24.51 29.89 25.15 27.25 
SEC31A 24.19 25.42 26.91 24.31 24.80 25.78 
SEMA7A 33.40 29.41 27.53 26.59 27.19 28.99 
SEPT11 28.25 25.35 28.15 27.10 24.93 27.40 
SEPT2 26.47 25.27 28.55 24.50 24.95 27.58 
SEPT7 28.08 25.11 28.65 27.67 25.35 28.12 
SEPT9 27.39 24.98 28.34 27.19 24.80 27.75 
SERPINF1 31.38 24.84 24.87 30.49 25.57 25.63 
SH3BGRL 24.64 25.16 24.19 26.43 24.62 24.39 
SH3GL1 26.54 24.99 27.17 25.02 24.92 27.27 
SLC14A1 24.07 25.22 25.49 24.23 24.38 24.38 
SLC16A1 24.47 25.48 28.54 24.28 24.66 28.09 
SLC1A5 24.08 25.24 30.87 24.42 25.78 31.51 
SLC2A1 24.34 24.74 27.61 24.51 24.07 27.95 
SLC38A2 24.83 25.25 27.76 24.45 25.16 26.96 
SLC39A10 24.74 24.67 28.50 23.90 24.50 27.94 
SLC39A6 24.27 24.62 26.85 23.34 25.62 26.60 
SLC7A5 24.41 25.00 28.91 24.63 25.48 29.95 
SLC9A3R2 24.89 24.26 25.81 24.46 25.24 26.55 
SLK 24.43 24.01 24.91 24.44 25.39 24.13 
SMAD5;SM
AD1;SMAD2
;SMAD9 25.29 25.36 24.96 24.33 25.35 24.65 
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SNAP23 24.57 25.06 28.38 23.39 24.79 28.70 
SND1 28.05 24.65 28.08 26.52 25.38 27.49 
SNX6 23.96 24.50 25.50 24.91 25.05 25.85 
SNX9 24.57 25.24 26.44 24.97 25.08 25.54 
SPCS2 23.45 25.04 24.32 24.56 25.11 24.44 
SPINK6 26.05 24.63 24.31 26.36 24.44 23.92 
SPON2 32.63 26.87 27.54 30.60 29.32 29.08 
SPTAN1 24.41 25.14 24.41 25.79 24.43 24.05 
SQSTM1 23.98 24.95 28.10 24.49 24.20 28.34 
SRM 24.72 24.30 23.93 23.57 24.11 24.04 
SRSF1 24.86 24.53 24.65 25.67 25.94 24.80 
SSC5D 28.29 28.38 30.74 27.00 28.04 30.29 
ST13;ST13P5
;ST13P4 25.57 24.38 23.71 25.89 24.06 25.19 
STC1 36.01 30.87 31.55 28.47 31.20 32.30 
STPG2 27.12 24.71 24.53 27.64 25.03 25.20 
STRAP 26.34 24.65 26.49 24.84 25.99 25.12 
STX4 24.64 24.99 29.53 24.29 25.25 29.22 
STX7 24.80 25.36 25.53 24.82 24.62 26.88 
SUMO2 24.67 24.99 23.85 26.23 25.41 24.16 
SYNCRIP 25.29 25.05 25.21 24.80 24.69 25.71 
TAGLN2 27.57 24.73 26.60 28.05 24.90 27.52 
TALDO1 28.33 26.19 27.10 28.67 25.68 27.76 
TARS 26.78 24.15 25.78 24.78 25.27 26.23 
TBCA 29.57 27.45 26.98 27.24 25.38 27.63 
TEK 23.98 25.23 27.72 24.99 24.89 27.12 
TENM4 24.39 24.93 25.47 24.23 24.28 24.71 
TFPI2 30.65 27.56 28.65 23.77 26.54 27.96 
TFRC 24.85 25.07 28.38 23.87 25.91 28.16 
TGFBR2 24.50 24.93 23.97 24.09 25.90 25.21 
TGOLN2 23.97 24.87 24.42 26.21 25.19 25.03 
THBS4 24.61 25.05 24.08 26.08 24.49 24.63 
THY1 23.89 26.10 31.44 24.17 26.91 30.15 
TIMP3 24.36 24.50 26.06 23.91 24.61 24.74 
TKT 29.60 29.84 30.03 29.36 28.96 30.58 
TLDC1 23.76 24.56 28.44 24.63 24.77 27.85 
TLN1 31.94 28.68 32.55 30.97 30.70 32.45 
TLN2 24.46 25.02 25.01 24.35 25.82 24.63 
TMSB10 32.88 32.27 31.46 32.47 31.62 31.64 
TMSB4X 32.06 31.25 30.77 32.70 30.84 31.43 
TNFAIP3 24.86 25.39 25.68 24.52 24.49 24.72 
TNFRSF11B 30.58 25.50 25.11 25.53 24.70 24.60 
TNPO1 25.12 25.75 24.84 24.61 24.68 24.69 
TPI1 31.53 30.00 31.35 30.78 28.52 31.12 
TPM1 26.39 25.35 24.67 28.65 24.23 25.55 
TPM2 29.43 26.71 27.79 29.18 24.31 26.60 
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TPM3 31.13 29.55 30.28 29.83 28.80 29.67 
TPM4 31.71 30.81 31.49 32.39 30.27 31.38 
TPP1 27.38 25.21 25.56 24.10 25.04 26.51 
TPP2 23.77 28.95 27.98 24.27 28.29 27.45 
TPT1 31.81 25.80 28.46 30.59 25.32 28.62 
TRHDE 24.52 24.83 24.33 24.03 24.94 26.42 
TSPAN6 24.77 25.43 26.25 24.30 24.92 26.47 
TUBB3 28.29 28.73 29.78 26.83 28.84 29.00 
TUBB4B 31.47 31.43 32.13 31.42 31.50 32.28 
TUBB8 24.66 24.66 26.66 24.32 28.82 24.96 
TUFM 24.83 25.43 26.42 24.46 25.67 26.63 
TWF1 24.47 24.88 26.74 24.20 24.38 26.25 
TWF2 24.50 24.50 26.21 25.73 25.28 24.55 
TWSG1 29.85 27.86 24.45 29.88 24.64 24.97 
TXNDC17 27.82 25.45 26.34 26.34 25.54 26.39 
TXNDC5 26.80 25.43 26.69 27.30 26.90 26.71 
TXNRD1 26.42 25.11 26.30 26.40 24.18 26.89 
UBA1 28.19 24.79 29.07 26.96 25.29 29.40 
UBE2L3 28.07 24.45 23.58 26.75 25.58 24.70 
UBE2NL;UBE
2N 27.80 24.59 28.06 27.23 25.17 27.95 
UBE4B 27.20 25.23 24.71 25.90 24.92 24.35 
UBR4 23.63 24.26 24.36 24.57 25.29 24.48 
UCHL1 31.81 27.95 30.52 30.74 28.21 31.17 
UGDH 26.08 25.21 27.16 24.13 24.28 27.51 
UGP2 25.29 24.78 25.36 23.77 24.91 25.23 
VAMP3 23.96 24.75 27.26 24.17 25.66 27.39 
VAMP5 24.56 25.02 25.31 24.14 25.53 27.85 
VARS 24.44 24.00 26.98 24.36 25.36 26.50 
VBP1 24.25 25.09 24.80 24.72 25.30 24.60 
VCP 29.81 31.29 29.87 28.62 30.64 30.35 
VEGFC 29.97 24.78 24.26 28.44 24.48 24.99 
VIM 35.66 33.57 34.22 34.55 32.98 34.35 
VPS28 23.51 25.46 27.23 23.62 24.63 27.99 
VPS37C 24.26 25.13 25.59 24.29 24.64 25.82 
VPS4A 24.48 24.94 26.65 24.67 24.84 27.03 
WDR1 31.12 28.86 30.93 30.24 30.30 31.20 
WFDC1 24.84 24.92 24.59 26.45 25.40 24.94 
YARS 24.77 24.95 26.51 24.08 25.54 26.38 
YBX1 25.15 26.66 24.06 24.32 25.48 25.74 
YES1;FYN 24.64 25.59 26.99 24.26 25.59 26.36 
YWHAE 29.95 29.80 30.74 30.83 29.72 30.81 
YWHAG 30.56 29.33 31.42 30.03 29.44 30.95 
YWHAH 27.89 28.09 29.01 27.75 28.09 29.70 
YWHAQ 29.15 29.07 30.52 28.81 28.95 30.88 
YWHAZ 31.57 31.64 32.64 31.68 31.05 32.50 
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ZDHHC5 23.33 25.59 28.58 23.84 25.13 28.56 










8.4 Genes Uniquely Present at Increased Levels in OIS Fraction 8 (MS3) 
This data describes genes identified in MS3 that are uniquely present at increased levels in 
OIS Fraction 8 compared to the vector condition (see Figure 4.23). The fold change (FC) in 
mean label free quantitation intensities (LFQ) are detailed. Unpaired Student’s t-tests were 
also performed with the p-value described in the final column (-Log10 p-value).      
Gene Names 
FC 
Mean LFQ  
(Log2) 
-Log10 p-value 
PLAUR 7.6796 2.55668 
COL6A3 6.68073 3.91471 
MME 6.47649 3.37821 
ITGA6 6.24975 2.13407 
SLC16A6 5.73359 4.54713 
IL6ST 5.44257 3.44419 
NOTCH1 5.44209 2.18692 
SLC20A1 5.18488 2.19877 
TNFRSF10B 5.18328 2.56654 
ABCA1 5.12311 2.59873 
WDR64 5.08365 3.23384 
PHLDB1 5.06077 4.17423 
TSPAN14 4.98351 4.29193 
TPBG 4.94208 2.67139 
GNAI3 4.85355 3.6341 
TMEM2 4.78101 2.64556 
CD276 4.65514 4.76923 
BTN2A1 4.58885 2.35384 
HAPLN3 4.50395 3.75333 
SERPINE1 4.29867 2.64861 
ACSL4 4.27189 2.96307 
TJP1 4.20534 2.96967 
ZC3HAV1 4.14844 3.69103 
JAM3 4.13358 2.95375 
PTGFRN 4.11049 3.61435 
SPRY4 4.10961 2.74152 
NDRG1 4.07997 2.54307 
RAB1B;RAB1C 3.94292 3.77417 
NUMB 3.88735 2.62617 
CD97 3.86316 2.28264 
RAC2 3.82144 2.29388 
PFKL 3.7465 2.32777 
ENPP1 3.73056 2.25033 
BMP1 3.66694 2.68924 
TSPAN9 3.62629 2.37894 
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NAPG 3.61952 3.66181 
CTTN 3.6054 3.05456 
EPHA2 3.51458 4.02505 
ITGA4 3.48856 2.31438 
STUB1 3.4845 2.14515 
GNB4 3.47477 0.902115 
TENM3 3.4554 3.15951 
PCDHGB5 3.42782 2.26536 
TOLLIP 3.41366 3.4679 
SLC7A2 3.39634 2.60314 
ZDHHC20 3.37914 3.15789 
TSPAN5 3.35236 1.17905 
TUBA1B 3.32676 2.12674 
FAP 3.26517 3.22314 
DNASE1L1 3.25913 4.03387 
FLRT3 3.21466 3.12342 
SIRPA;SIRPB1 3.21077 2.13076 
ITGA8 3.20778 1.92631 
TSPAN4 3.1748 2.40633 
COL6A2 3.15788 3.11707 
GDI1 3.14982 2.54865 
RPL18 3.13923 2.24503 
CHMP2A 3.13665 2.73555 
PVRL3 3.05107 3.50906 
ITGAV 3.0411 5.11119 
RPL35A 3.01795 2.41491 
CD9 3.01167 3.74771 
PSMD6 3.0116 2.14091 
SCRIB 2.87608 3.37354 
SLC2A3;SLC2A14 2.86767 1.82592 
COL6A1 2.85609 3.10533 
MPZL1 2.84544 2.3047 
PHLDA1 2.82451 1.70019 
NTSR1 2.81992 3.5321 
ACE 2.78342 2.08311 
ADAM10 2.71384 2.2816 
ADSS 2.68018 1.25487 
DNAJA1 2.67708 2.43995 
STXBP3 2.66525 3.50934 
SEC23A 2.66452 0.815143 
EGFR 2.64836 3.16499 
RAB6A 2.62549 3.02636 
ATP1B1 2.61197 3.07656 
PLXNA1 2.60759 2.24137 
GNAI1 2.60092 2.43566 
SLC9A1 2.5432 1.57151 
366 
 
EPHB4 2.53763 1.11309 
LLGL1 2.53646 1.73707 
SLC4A7 2.52244 2.26717 
MICA 2.52186 1.86503 
IL1RAP 2.51204 1.78571 
GNB2L1 2.46013 1.91351 
VPS35 2.43916 2.50103 
CCT2 2.43419 1.35335 
ABCC4 2.43253 3.11678 
WLS 2.42312 1.90593 
PSMA7;PSMA8 2.41712 2.16082 
PTPRG 2.40755 2.68977 
GRK5 2.38766 2.60299 
STEAP3 2.36968 2.26696 
PSMD4 2.36763 1.37465 
ECE1 2.35283 1.57568 
RAB5B 2.31844 1.43067 
SLC6A6 2.31229 1.31949 
GJA1 2.29579 2.38953 
ERBB2IP 2.28741 1.96108 
VCAN 2.28056 1.39945 
RPL31 2.27152 1.17849 
PDGFC 2.25882 1.9385 
ANTXR2 2.25609 2.66749 
FN3KRP 2.25392 1.73616 
RHOB 2.25003 0.990751 
AP2B1 2.23767 2.42289 
SLC39A14 2.22836 1.0092 
LAP3 2.19396 1.76322 
ARPC5 2.1862 0.567269 
DDX3X;DDX3Y 2.17222 3.60387 
RAB8A 2.16456 2.18382 
DNAJA2 2.16182 1.23935 
ITFG3 2.15813 1.50676 
NRP2 2.12714 2.34148 
ATP1A1 2.11211 1.97527 
FMNL3 2.11001 3.62628 
AIMP2 2.09155 1.27184 
IRGQ 2.09077 1.69763 
FBLN1 2.08506 1.02505 
NAPA 2.05218 2.97395 
VWA5A 2.05159 2.0003 
RAP1A 2.0474 2.92753 
USP5 2.03383 1.64219 
PLXNB2 2.01075 1.82948 
SNAP29 2.00953 1.81389 
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TGFBI 2.00163 2.65473 
PSMC4 1.95624 2.25435 
VASN 1.95312 1.04699 
PRKAR2A 1.94531 1.65253 
CDC42SE1 1.93943 2.35904 
AP2M1 1.93367 4.61808 
CD47 1.87813 1.41043 
ITGB3 1.87526 2.60301 
RPS7 1.87456 1.29156 
BSG 1.87375 2.97944 
CLMP 1.86995 0.830849 
FKBP10 1.86835 1.01497 
CYB5R3 1.86549 3.46359 
KLC1 1.85554 1.37981 
PLXND1 1.83354 3.11717 
AHCYL1;AHCYL2 1.82073 2.29318 
PSMC3 1.80164 1.47158 
WNT5B 1.76577 1.47224 
GGT1;GGT3P;GGT2 1.76363 2.00666 
TMEM51 1.75379 1.62402 
SERBP1 1.7407 1.69608 
SLC16A3 1.74033 1.84086 
CAB39 1.73775 1.42601 
PCDHGC3 1.73653 2.06266 
ANXA7 1.73301 3.03918 
GNG5 1.73292 2.33973 
CDH6 1.7252 0.946123 
FAS 1.71904 2.31658 
MRC2 1.71884 1.79488 
RAB34 1.69932 2.10225 
PLXNB1 1.69311 1.80324 
TRPA1 1.67866 1.10524 
TIMP2 1.67653 1.86387 
RAB8B 1.67582 0.82785 
UACA 1.67176 2.43022 
RPL23 1.60843 0.738344 
UBTD1 1.60343 1.35182 
CHP1 1.59725 0.647464 
PCDH7 1.5838 1.16672 
TCP1 1.57169 1.68061 
SCAMP3 1.55414 0.537675 
MAP4K4 1.54029 2.53706 
SRGAP2;SRGAP2B 1.51 2.60919 
PSMC6 1.49591 0.586429 
CDK4 1.49422 2.15823 
PI4KA 1.48227 1.09335 
368 
 
RAB10 1.47144 2.56314 
PVR 1.46146 1.85576 
TWF2 1.45752 0.815344 
DOCK10 1.44564 1.37543 
SEC31A 1.43601 0.855749 
PDCD10 1.43336 1.46114 
KIRREL 1.43132 2.44106 
GRB2 1.42724 2.08198 
HPCA;HPCAL1;NCALD 1.42145 0.920769 
RAB35 1.41979 2.47248 
TAOK1 1.40958 1.93306 
PSMD1 1.40841 1.01377 
GIPC1 1.40534 1.63444 
GNA13 1.40525 0.886101 
CLTB 1.40359 0.898419 
SRI 1.40201 1.52057 
LRRC32 1.39978 2.55451 
FARSB 1.39716 1.36658 
CCT3 1.38705 1.32099 
SMURF2 1.37768 1.1602 
GSK3B 1.36992 1.5521 
STK10 1.36789 2.50896 
PYGB 1.36677 1.03747 
SEC13 1.35857 1.8437 
ATP1B3 1.34978 0.514662 
CCT6A 1.34959 1.46888 
CPNE3 1.34335 2.28665 
GPRIN1 1.33938 1.24623 
ARPC3 1.33055 1.43437 
PACSIN2 1.33005 2.37013 
LRRC47 1.32921 1.71494 
GFPT1 1.32172 1.97383 
ANKFY1 1.31703 2.54787 
PVRL2 1.30703 2.52715 
IGF2BP1 1.29961 0.91818 
ACTR2 1.29668 1.76523 
FAU 1.29117 0.553239 
ITCH 1.29057 2.13185 
PSMC1 1.28701 3.1405 
SLC44A1 1.28419 1.64 
RPL21 1.27289 0.861075 
PHB 1.27264 1.463 
SNTB2 1.27083 1.35238 
SPRY2 1.24954 1.76841 
S100A13 1.24878 2.12282 
NCKAP1 1.24653 2.31313 
369 
 
GNAQ 1.24471 1.52943 
ATP6V1E1 1.23178 0.808747 
ABI2 1.22631 2.08991 
CUL2 1.22187 0.954673 
ALCAM 1.21272 2.13899 
EIF3E 1.20523 4.13211 
PALM2-AKAP2;PALM2 1.19488 2.70462 
ESD 1.18923 0.629283 
LMAN1 1.18353 1.28796 
MARCKSL1 1.18266 1.72357 
ELFN2 1.18246 1.75968 
MYO6 1.17885 0.795197 
EIF4H 1.17583 0.938533 
ACOT7 1.17069 1.04149 
SLC5A3 1.15463 1.60193 
PSMC5 1.14733 1.10291 
SLC6A15 1.1413 1.04577 
RHOA 1.13762 1.4499 
RAP2C 1.13596 0.555552 
TNC 1.13123 1.97589 
TMEM30A 1.11866 1.18861 
AP1G1 1.11528 1.39952 
CD46 1.10855 1.76414 
CD99 1.10554 1.75064 
PFDN1 1.09018 1.08421 
COPG1 1.0874 0.816108 
RPL36AL;RPL36A;RPL36A-HNRNPH2 1.08523 0.616868 
ATP6V1B2 1.08295 0.954361 
RPL26 1.07784 1.66214 
ITGA3 1.06872 1.99092 
CD109 1.0459 1.83189 
DNAJC13 1.03705 1.12784 
CAPNS1 1.02416 0.627633 
PRKCA 1.02354 1.11611 
F2RL1 1.02096 2.05256 
SLC14A1 1.00803 0.939625 
PXN 1.00606 1.71754 
 
 
 
